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Abstract	
	
Chemical	biology	may	provide	useful	 small	molecule	probes	 that	can	contribute	 to	
advancing	 stem	 cells	 therapeutic	 application	 and	 the	 still	 challenging	 GPCR	 drug	
research	field.	In	this	context,	in	this	thesis	we	focus	on	the	development	of	chemical	
probes	 to	 the	 modulation	 of	 neural	 stem	 cells	 (NSCs)	 and,	 in	 parallel,	 to	 the	
characterization	of	the	recently	discovered	P2Y14	receptor	(P2Y14R).		
Particularly,	the	first	application	deals	with	pursuing	a	knowledge-based	phenotypic	
approach	(i)	and	a	functionalized	congeners	approach	(ii).	Strategies	(i)	and	(ii)	have	
been	 conducted	 in	 parallel	 with	 the	 deliberate	 aim	 of	 identifying	 critical	
targets/pathways	 involved	 in	 NSCs	 differentiation	 and	 starting	 points	 for	 the	
development	 of	 new	 drugs.	 Particularly,	 a	 focused	 library	 of	 chemical	 probes	 has	
been	 designed	 and	 synthesized.	 An	 experimental	 pipeline,	 evaluating	 hepato-	 and	
neuro-toxicity,	 neuroprotection	 and	 proliferation	 in	 cell	 lines	 and	 primary	 neurons	
has	 been	 used	 for	 prioritizing	 compounds	 with	 better	 chances	 to	 be	 further	
investigated	 in	 the	 NCS	 phenotypic	 assay	 (i).	 In	 parallel,	 the	 application	 of	 the	
functionalized	 congener	 approach	 has	 allowed	 to	 design	 fluorescent,	 multi-target	
and	polyamine	congeners	of	the	selected	chemical	scaffold	(ii).		
Regarding	 the	 chemical	 biological	 approach	 towards	 P2Y14R,	 we	 have	 recently	
achieved	promising	results	that	could	aid	in	unveiling	its	pharmacological	potential	in	
diabetes	 and	 inflammation.	 In	 particular,	 we	 have	 used	 structural	 insights	 of	 the	
recently	 obtained	 structural	 information	 of	 P2Y14R	 to	 discover	 a	 new	 scaffold	 for	
P2Y14R	 antagonists.	 In	 addition,	 two	 fluorescent	 probes	 (agonist	 and	 antagonist)	
have	 been	 developed	 and	 their	 utility	 to	 detect	 P2Y14R	 using	 fluorescence	
microscopy	and	flow	cytometry	has	been	also	successfully	demonstrated.	
Collectively,	 these	 results	 provide	 initial	 clues	 to	 our	 understanding	 of	 stem	 cell	
biology	and	P2Y14R	pharmacology,	and	could	inspire	powerful	pharmacological	tools.		
	 I	
Preface	
	
As	 elegantly	 discussed	 by	 Arrowsmith	 et	 al.,1	 efforts	 in	 chemical	 biology	 and	 drug	
discovery	 by	 academic	medicinal	 chemists	 have	 increased	 substantially	 in	 the	 last	
ten	years.	These	efforts	occurred	in	part	because	of	the	availability	of	large	numbers	
of	 uncharacterized	 potential	 drug	 targets	 emerging	 from	 genome	 sequencing	
studies,	from	the	development	of	sophisticated	screening	technologies	and	from	the	
possibility	 of	 inventing	 new	 medicines.1	 Some	 of	 these	 efforts,	 probably	 due	 the	
complexity	 and	 unreliability	 of	 drug	 discovery,	 resulted	 in	 a	 more	 measured	
objective:	 to	 generate	 small	 molecule	 tools	 to	 help	 elucidate	 the	 roles	 of	 the	
targeted	proteins	in	healthy	and	diseased	processes.	On	this	basis,	chemical	biology	
has	matured	 as	 a	 scientific	 discipline	 spanning	 the	 fields	 of	 chemistry	 and	 biology	
and	 that	 is	 centered	on	 the	application	of	 chemical	 tools	 (i.e.	 chemical	probes),	 to	
the	study	and	manipulation	of	biological	systems.1		
In	the	years	high-quality	chemical	probes	have	been	developed	and	the	have	served	
both	 as	 powerful	 research	 tools	 and	 as	 seeds	 to	 spur	 the	 development	 of	 new	
medicines.2	
A	chemical	probe	is	defined	as	a	small-molecule	modulator	of	proteins	function	that	
allows	 asking	mechanistic	 and	 phenotypic	 questions	 about	 its	 molecular	 target	 in	
biochemical,	cell-based	or	animal	studies.2	Chemical	probes	have	proven	to	be	very	
impactful	not	only	because	they	are	complementary	to	genetic	approaches,	but	also	
because	 they	 have	 unique	 advantages.	 They	 can	 rapidly	 and	 reversibly	 inhibit	 a	
protein	 in	 living	 cells	 or	 animals,	 can	 be	 used	 in	 almost	 any	 cell	 type	 and	 reveal	
temporal	features	of	target	inhibition.1	
Thus,	chemical	biology	has	been	equally	successfully	used	in	different	areas	such	as	
isolated	receptor	and	single-cell	characterization	studies.3	
Following	 this	 thread,	 in	 this	 thesis	we	 propose	 and	 foster	 two	 different	 chemical	
biology	 approaches	 in	 two	 distinct	 endeavors.	 Particularly,	 we	 focus	 on	 the	
development	of	chemical	probes	to	the	modulation	of	neural	stem	cells	(NSCs)	and,	
in	parallel,	to	the	characterization	of	the	recently	discovered	P2Y14	receptor	(P2Y14R).	
Accordingly,	the	following	two	parts	of	this	thesis	deal	with	the	two	approaches.	
In	detail,	in	part	I,	we	report	on	the	main	PhD	project,	conducted	at	the	University	of	
Bologna	 within	 the	 regional	 project	 Spinner-NovaMolStam,	 and	 related	 to	 the	
development	 of	 chemical	 probes	 for	 NSCs	 application.	 Stem	 cell	 research	 has	
attracted	great	attention	and	gained	strong	momentum	in	the	past	15	years	due	to	
new	 breakthroughs	 in	 the	 stem	 cell	 field,	 availability	 of	 new	 and	 powerful	
techniques,	 and	 its	 vast	 potential	 in	 regeneration	 of	 tissues	 damaged	 by	 injury	 or	
disease.4	 Although	 the	 modulation	 of	 NSC	 by	 small	 molecules	 is	 an	 emerging	
regenerative	 strategy	 for	 treating	 currently	 incurable	 neurodegenerative	 disorders	
(e.g.	 Alzheimer’s	 disease),	 this	 field	 still	 present	 unsourmountable	 challenges	 to	
medicinal	chemists.4	Despite	a	variety	of	signaling	pathways	have	been	shown	to	be	
critically	 involved	 in	 NSCs	 self-renewal	 and	 differentiation,5	 a	 validated	 druggable	
target	 is	 far	 from	 being	 identified.	 To	 overcome	 this	 limitation,	 we	 envisioned	 a	
chemical	biology	approach	to	 the	 identification	of	novel	chemical	probes	 for	NSCs.	
Toward	 this	 aim	 we	 exploited	 a	 knowledge-based	 phenotypic	 approach	 (i)	 and	 a	
functionalized	congeners	(ii)	approach.	As	discussed	in	detail	in	Par.	4.2	of	part	I	and	
Par.	1.2	of	part	II,	the	functionalized	congener	approach	has	been	proposed	by	Dr.	K.	
	 II	
A.	Jacobson	as	a	chemical	biology	platform	to	the	study	of	the	different	proteins,	in	
particular	belonging	to	the	GPCR	superfamily.6	Functionalized	congeners,	in	which	a	
chemically	 functionalized	 chain	 is	 introduced	 at	 a	 structurally	 permissive	 site	 on	 a	
pharmacophore,	 have	 been	 designed	 from	 the	 agonist	 and	 antagonist	 ligands	 of	
various	 GPCRs.6	 However,	 its	 versatility	 for	 other	 applications	 has	 been	
demonstrated.7	
Strategies	 (i)	 and	 (ii)	 have	 been	 conducted	 in	 parallel	 with	 the	 deliberate	 aim	 of	
identifying	critical	targets/pathways	in	NSCs	differentiation	and	ultimately	unlocking	
the	 regenerative	 potential	 of	 endogenous	 NSCs.	 Particularly,	 a	 focused	 library	 of	
chemical	 probes	 has	 been	 developed	 to	 be	 tested	 in	 NSCs-based	 phenotypic	
screening	 assay	 (i).	 In	 parallel,	 the	 application	 of	 the	 functionalized	 congener	
approach	has	allowed	to	design	fluorescent,	multi-target	and	polyamine	congeners	
of	the	selected	chemical	scaffold	(ii).		
In	part	II	of	this	thesis,	we	report	on	a	7-months	project	conducted	in	the	laboratory	
of	Molecular	Recognition	Section,	headed	by	Dr.	Jacobson,	at	the	National	Institutes	
of	Health	(Bethesda,	US).	
In	this	second	application,	the	exploited	chemical	biology	approach	could	count	on	
the	 recently	 obtained	 structural	 information	 of	 the	 P2Y14	 receptor	 (P2Y14R).8	 The	
P2Y14R	 is	 a	 Gi/o-coupled	 receptor,	 which	 belongs	 to	 the	 P2Y	 family	 of	 purinergic	
receptors	 and	 it	 is	 the	most	 recently	 discovered	 among	members	 of	 P2Y	 family.9	
Despite	emerging	as	an	attractive	 therapeutic	 target,10	 to	date,	 the	P2Y14R	has	not	
been	widely	explored	from	a	medicinal	chemistry	perspective	and	its	pharmacology	
has	not	been	fully	disclosed.	Additionally,	few	selective	radioligands	are	available,11	
thus	 improved	 and	 more	 versatile	 chemical	 probes	 are	 needed.	 To	 this	 end,	 by	
applying	the	functionalized	congener	approach,	high-affinity	antagonist	and	agonist	
fluorescent	probes	have	been	synthesized	and	biologically	evaluated.	Moreover,	we	
have	 used	 the	 recently	 obtained	 structural	 insights	 of	 P2Y14R	 to	 discover	 a	 new	
scaffold	 for	 developing	 P2Y14R	 antagonists.	 Thus,	 the	 development	 of	 potent	 and	
selective	agonists	and	antagonists	of	P2Y14	 receptor	 is	 a	major	achievement,	 given	
the	 potential	 critical	 role	 of	 this	 signaling	 protein	 in	 inflammatory,	 endocrine,	 and	
immune	processes.10			
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1.	Introduction	
	
	
1.1 The	stem	cell	era		
	
In	 1981	 the	 establishment	 of	 embryonic	 stem	 cells	 (ESCs)	 in	 culture	 isolated	 from	
mouse	blastocysts	by	two	independent	groups,1	initiated	a	flurry	of	studies	into	the	
stem	 cells	 (SCs)	 field.	 Then,	 growth	 of	 the	 field	 has	 been	 rapid,	 and	 it	 has	 been	
increasing	steadily	since	about	2001.	Figure	1	graphically	depicts	this	growth	rate.	In	
fact,	 in	 the	 late	 1990s,	 for	 the	 first	 time	 a	 method	 to	 derive	 ESCs	 from	 human	
embryos	 and	 to	 grow	 these	 cells	 in	 laboratory	was	developed.2	More	 importantly,	
this	 raised	 new	 awareness	 of	 their	 therapeutic	 potential,	 which	 appeared	 to	 be	
“limitless”.3	 Furthermore,	 in	 2007,	 the	 discovery	 by	 the	 stem	 cell	 pioneers	
Yamanaka4	 and	 Thomson5	 that	 human	 somatic	 cells	 can	 be	 reprogrammed	 to	 a	
pluripotent	 state	 (i.e.	 induced	pluripotent	 stem	cells,	 iPSCs)	has	 revolutionized	 cell	
biology,	earning	them	the	2012	Nobel	Prize.6	
From	that	moment	on,	successful	achievements	and	promises	about	SCs	cures	have	
been	well	documented	in	the	literature.	Nowadays,	the	remarkable	potential	of	SCs	
to	develop	into	many	different	cell	types	throughout	the	life	and	to	serve	as	internal	
repair	 system	 to	 replenish	 other	 cells,	 has	 been	 widely	 recognized.6	 Actually,	 SCs	
take	 on	 great	 importance	 because	 they	 are	 distinguished	 from	other	 cell	 types	 by	
two	 important	 features.	 First,	 they	 are	 unspecialized	 cells	 capable	 of	 renewing	
themselves	through	cell	division,	even	after	long	periods	of	inactivity.	Second,	under	
certain	 physiologic	 or	 experimental	 conditions,	 they	 can	 be	 induced	 to	 become	
tissue-	or	organ-specific	cells	with	special	functions.7	
	
												
Figure	 1.	 Number	 of	 published	 articles	 on	 stem	 cell	 research	 between	 1951	 and	 2015.	 After	 the	
isolation	of	hESCs	 in	1998,	the	number	of	stem	cell	articles	 increased	and	has	continued	an	upward	
progression	 (csv	 file	downloaded	 from	PubMed	database	http://www.ncbi.nlm.nih.gov/	on	Feb.	20,	
2016). 	
	
Indeed,	 SCs	 are	 defined	 as	 cells	 that	 have	 clonogenic	 and	 self-renewal	 capabilities	
and	that	differentiate	 into	multiple	cell	 lineages	 in	response	to	appropriate	signals.	
		 3	
Consequently,	 SCs	 have	 been	 classified	 into	 categories	 according	 to	 their	
developmental	status	and	their	capacity	to	differentiate	in	different	types	of	cells,	or	
by	 their	 degree	 of	 plasticity7	 (see	 Table	 1).	 In	 general,	 adult	 stem	 cells	 (ASCs)	 are	
unspecialized	 cells	 found	 in	 differentiated	 tissues,	 which	 can	 self-renew	 for	 long	
periods	of	time	and	differentiate	into	specialized	cell	types	of	the	tissue	from	which	
they	originate	(multipotent	cells);	ESCs	are	derived	from	mammalian	embryos	in	the	
blastocyst	stage	and	have	the	ability	to	generate	any	terminally	differentiated	cell	of	
the	body	(pluripotent	cells).7	On	the	other	hand,	cancer	stem	cells	(CSCs)	are	cancer	
cells	found	within	solid	tumors	or	hematological	cancers.	CSCs	may	generate	tumors	
through	the	stem	cell	processes	of	self-renewal	and	differentiation	into	multiple	cell	
types,	which	 reflects	 the	heterogeneity	normally	 associated	 to	a	particular	 type	of	
cancer.	CSCs	are	therefore	tumorigenic	cells	and	undergo	to	an	aberrant	and	poorly	
regulated	process	of	proliferation	within	a	tissue,	analogous	to	what	normal	SCs	do.8	
Conversely,	 iPSCs	 are	 a	 particular	 type	 of	 adult	 cells	 that	 have	 been	 genetically	
reprogrammed	 to	 an	ESCs–like	 state	by	being	 forced	 to	 express	 genes	 and	 factors	
important	for	maintaining	the	defining	properties	of	pluripotency.7	
	
		 CLASSIFICATION	 FEATURES	
Sources/types	 Embryonic	stem	
cells	
are	pluripotent	stem	cells	derived	from	the	inner	cell	mass	
of	the	blastocyst	and	can	give	rise	to	cells	derived	from	all	
three	germ	layers	(endoderm,	mesoderm,	and	ectoderm).		
Adult	stem	cells		 endodermal	origin:	intestinal	and	pulmonary	epithelial	SCs	
pancreatic	SCs,	mammary,	thyroid	and	prostatic	gland	SCs	
mesodermal	origin:	subdivided	in	hematopoietic	SCs	and	
mesenchymal	SCs	that	give	rise	to	blood	cells,	urogenital	
system,	skeletal	and	smooth	muscles,	connective	tissues.	
ectodermal	origin:	neural	SCs,	epidermis	SCs,	ocular	SCs.	
Cancer	stem	cells	 identified	in	cancers	and	tumor,	such	as	acute	myeloid	
leukemic	SCs,	brain	tumor	SCs,	breast	cancer	SCs	etc.	
Induced	pluripotent	
stem	cells	
artificially	derived	pluripotent	stem	cells	from	a	non-
pluripotent	cell,	typically	an	adult	somatic	cell,	by	inducing	a	
forced	expression	of	specific	genes.	
Degree	of	
plasticity	
Totipotent	cells	 zygote,	spore,	morula;	they	give	rise	to	all	the	cells	and	
tissues	that	make	up	an	embryo	and	that	support	its	
development	in	utero.	
Pluripotent	cells	 embryonic	stem	cells;	they	give	rise	to	cells	derived	from	all	
three	germ	layers,	but	cannot	give	rise	to	an	entire	
organism.	
Multipotent	cells		 progenitor	cell,	such	as	hematopoietic	SCs;	they	give	rise	to	
a	limited	range	of	cells	within	a	tissue	type.	
Unipotent	cells	 precursor	cells;	they	give	rise	to	just	one	cell	type.	
Table	1.	Classification	of	SCs.	
	
Given	their	peculiar	properties,	SCs	hold	great	promises	for	developmental	biology,	
disease	modeling,	drug	discovery,	and	for	regenerative	medicine.	Accordingly,	some	
of	the	applications	involve	the	study	of	human	development.	In	fact,	recent	reports	
showed	how	SCs	 form	and	 repair	 tissues	 and	organs,9	 how	aging	 impacts	 on	 their	
function,	 and	 their	 role	 in	 various	 diseases.10	 In	 addition,	 the	 discovery	 of	 iPSCs	
widened	 the	 range	 of	 applications	 in	 drug	 discovery,	 and	 disease	 modeling.11	 By	
exposing	a	patient’s	skin	cells	to	growth	factors,	signaling	molecules,	and/or	genetic	
manipulation,	 it	 has	 been	 found	 a	 scalable	 and	 low-cost	 method	 to	 link	 human	
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disease	 to	 drug	 discovery,	 providing	 an	 improved	 model	 system	 to	 study	 disease	
biology.	 Indeed,	 iPSCs	 retain	 the	 genetic	 characteristics	 of	 their	 donors,	 which	
enables	genotype-dependent	pathophysiology	to	manifest	at	the	cellular	 level	and,	
thereby,	 shedding	 new	 light	 on	 phenotypic	 traits	 and	 cellular	 mechanisms	 of	 a	
certain	 disease.11	 Hence,	 this	 approach	 capitalizes	 on	 the	 idea	 of	 personalized	
medicine	by	using	the	patient’s	own	cells	to	discover	new	drugs	and	thus	increasing	
the	 likelihood	of	a	 favorable	outcome.	The	 search	 for	 compounds	 that	 can	correct	
disease	 defects	 in	 such	 culture	 dish	 (the	 so	 called	 disease-in-a-dish)12	 is	 now	
becoming	a	tangible	reality.		
The	 current	 advances	 in	 SCs	 field	 may	 also	 make	 possible	 new	 regenerative	
approaches	 for	 the	 treatment	 of	 incurable	 diseases,	 such	 as	 neurodegenerative	
diseases.13 These	approaches	could	involve	cell	replacement	therapy	(also	patient-
specific	 derived	 iPSCs)	 and/or	 drug	 treatment	 to	 stimulate	 the	 body's	 own	
regenerative	capabilities	by	promoting	survival,	migration/homing,	proliferation,	and	
differentiation	of	endogenous	stem/progenitor	cells.		
If	stem	cell	replacement	therapy	is	already	in	the	clinics,	small	molecules	modulating	
SCs	 are	 just	 approaching	 the	 clinical	 applications. Indeed,	 in	 2012,	 the	 SCs	
replacement	 therapy	 field	 hit	 a	 milestone,	 reaching	 a	 total	 of	 1	 million	
hematopoietic	 stem	 cell/bone	 marrow	 transplants	 worldwide.14	 In	 2015,	 the	
European	Medicines	Agency	(EMA)	has	approved	another	successful	cellular	therapy	
based	on	epithelial	SCs	(Holoclar®)15	for	the	treatment	of	limbal	stem	cell	deficiency,	
a	rare	eye	condition	that	can	result	in	blindness.		
However,	gaps	 in	our	understanding	of	SCs	and	 their	maturation/engraftment	 into	
differentiated	 tissues	 have	 presented	 substantial	 barriers	 to	 regeneration	 of	 other	
tissues/organs,	as	in	the	case	of	spinal	cord	injury	(SCI).	SCI	currently	lacks	therapy,	
although	 the	 transplantation	of	human	central	nervous	 system-derived	SCs	at	9	or	
30	days	post-SCI	has	shown	some	therapeutic	promise	in	rodent	models.16	However,	
there	 is	 no	 preclinical	 evidence	 supporting	 either	 the	 safety	 or	 efficacy	 of	 SCs	
transplantation	in	chronic	SCI	yet.17	
Nonetheless,	cell	therapies	showed	a	number	of	technical	obstacles	to	their	practical	
use.	 In	 contrast	 to	 the	 other	 cell	 types,	 SCs	 are	 particularly	 sensitive	 to	 soluble	
biochemical	 factors,	 extracellular	matrixes	 (ECMs),	 and	a	 variety	of	 stimuli	 such	as	
chemical,	mechanical,	 optical,	 and	 electrical	 cues,	 resulting	 in	 unpredictability	 cell	
culture	 and	 generation	 of	 heterogeneous	 population	 of	 cells.	 This	 arises	 from	 the	
fact	 that	 “cocktails”	 of	 growth	 factors,	 signaling	 molecules,	 and/or	 genetic	
manipulation	generally	 control	 SCs	expansion	and	differentiation	ex	vivo.18	Clearly,	
there	is	a	need	for	more	efficient	and	selective	methods	to	control	the	proliferation	
and	the	differentiation	of	SCs	to	produce	homogenous	populations	of	particular	cell	
types.	 In	 fact,	 the	 ability	 to	maintain	 pluripotency	without	 compromising	 genomic	
integrity,	and	efficiently	directing	differentiation	is	of	particular	importance	because	
undifferentiated	 cells	 can	 generate	 tumor.18	 Thus,	 only	 a	 precise	 control	 of	 such	
relevant	exogenous	and	micro-environmental	 factors	may	enable	 the	 regulation	of	
cell	phenotype,	function,	differentiation,	and	integration	after	implantation.18			
Based	 on	 this,	 the	 enthusiasm	 surrounding	 the	 clinical	 potential	 of	 both	 ESCs	 and	
iPSCs	as	cell	 replacement	 therapy	 is	hardened	by	key	 issues	 regarding	 their	 safety,	
efficacy,	and	genome	integrity.19	
By	contrast,	small	molecules	that	precisely	modulate	SCs	fate	can	potentially	relieve	
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these	problems,	as	the	major	convergence	of	SCs	biology	and	regenerative	therapy.	
The	modulation	of	SCs	with	both	naturally	occurring	and	synthetic	small	molecules	is	
being	played	an	 integral	part	 in	 the	advancement	of	SCs	research	 and,	 in	a	certain	
way,	is	being	preferred	to	cell-based	therapy.19,20	
The	final	goal	is	to	design	compounds	able	to	act	at	a	particular	stage	of	one	or	more	
pathways,	 leading	 to	 specific	 responses,	 which	 can	 be	minutely	 controlled	 by	 the	
concentration	 of	 the	 compound	 itself.	 The	 ability	 to	 act	 selectively	 on	 the	 desired	
pathways,	 and	 in	 a	 controlled	 manner,	 may	 enable	 to	 finely	 regulate	 SCs	
proliferation	and	differentiation.	This	is	important	in	the	formation	of	new	cells	and	
tissues	 for	 use	 in	 basic	 research,	 disease	 modeling	 and	 drug	 discovery,	 and,	
ultimately	 in	 the	 clinic.21	Moreover,	 this	 is	 equally	 important	 for	 chemical	 biology	
applications.	 There	 is	 a	 compelling	 need	 not	 only	 of	 small	 molecules	 with	
regenerative	potential,	but	also	able	to	characterize	signaling	pathways	 involved	 in	
the	regulation	of	SCs	biology.21-22	 In	this	context,	during	the	last	years,	the	rising	of	
chemical	 biology	 as	 a	 nascent	 discipline	 of	 regenerative	medicine	 is	 undeniable.19	
And	 in	 fact,	 it	 has	 already	 demonstrated	 useful	 at	 dissecting	 the	 role	 of	 specific	
pathways	 in	 a	 variety	 of	 SCs	 processes	 including	 self-renewal,	 proliferation	 and	
differentiation.23	 Perhaps,	 the	most	 striking	 improvement	 in	 our	 understanding	 of	
SCs	biology	came	indeed	from	the	application	of	chemical	biology	approaches	to	SCs.	
As	 its	 name	 implies,	 chemical	 biology	 is	 a	multidisciplinary	 discipline	 that	 involves	
the	 study	 and	 perturbation	 of	 biological	 systems	 with	 chemical	 probes.	 Probes	
targeting	one	or	several	of	 the	SCs	processes	can	be	 identified	either	 in	a	targeted	
approach	based	on	 known	mechanisms	 and	 signaling	 pathways,	 or	 in	 an	unbiased	
fashion	 using	 cell-based	 high-throughput	 screening	 (HTS)	 approaches.24	 The	 first	
strategy	mainly	includes	the	use	of	molecules	that	target	epigenetic	modifications	or	
specific	 canonical	 signaling	 pathways	 involved	 in	 SCs	 biology.	 The	 target-based	
approach	has	provided	several	 insights	 into	the	complex	regulatory	mechanisms	of	
SCs	 fate.	 On	 the	 contrary,	 the	 second	 strategy	 relies	 on	 unbiased	 phenotypic	 or	
pathway-based	 cellular	 screens	 of	 chemical	 libraries	 with	 the	 goal	 of	 identifying	
small	 molecules	 agnostic	 for	 specific	 targets/mechanisms,	 but	 showing	 a	 desired	
phenotypic	effect.	A	number	of	such	screening	strategies	have	been	established,	and	
among	 them,	 high-content	 cell-based	 approaches	 are	 rapidly	 emerging	 as	
particularly	 effective.25	 The	 major	 challenge	 with	 unbiased	 cell-based	 screens,	
however,	 is	 the	 need	 for	 subsequent	 identification	 of	 the	 specific	 target(s)	 and/or	
biological	pathway(s)	through	which	the	small	molecule	exerts	its	effects.24a 	
	
 
1.2 Neural	stem	cells	(NSCs)	
	
The	 application	 of	 chemical	 tools	will	 be	 instrumental	 for	 the	 discoveries	 of	 novel	
therapies	based	on	the	knowledge	and	application	of	powerful	SCs,	that	are	neural	
stem	cells	(NSCs).26	
	
	“Once the development was ended, the founts of growth and regeneration of the 
axons and dendrites dried up irrevocably. In the adult centers, the nerve paths are 
something fixed, ended, and immutable. Everything may die, nothing may be 
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regenerated. It is for the science of the future to change, if possible, this harsh 
decree”	(Ramon	y	Cajal,	1913)	
	
One	of	the	longest	standing	dogmas	in	neuroscience	was	that	the	brain	was	a	static	
organ	 lacking	 regenerative	 capacity,	 as	 suggested	 in	 1913	 by	 the	 Spanish	 neuro-
anatomist	 Ramony	 y	 Cajal.	 Decades	 afterwards,	 investigation	 into	 anatomical	
changes	occurring	 in	 the	central	nervous	system	(CNS)	of	 female	songbird	canaries	
challenged	this	long-standing	assumption.27	This	groundbreaking	work	proved	that	a	
remodeling	process,	which	involve	both	cell	proliferation	(assessed	via	[3H]thymidine	
incorporation	 experiments)	 in	 discrete	 regions	 of	 the	 songbird	 brain	 (i.e.	 the	
ventricular	 zones),	 and	 cell	 migration/differentiation	 into	 newly	 grafted	 neurons	
(neurogenesis)	continue	throughout	life.28	 
Despite	changing	the	scientific	community’s	standpoint	on	adult	neurogenesis,	only	
in	1992	Reynolds	and	Weiss	 showed	that	multipotent	NSCs	could	be	 isolated	 from	
the	 CNS	 of	 adult	 and	 embryonic	mice	 and	 propagated	 in	 vitro	 in	 the	 presence	 of	
mitogens	 to	 give	 rise	 to	 large	 spheres	 of	 cells	 termed	 “neurospheres”.29	 These	
neurospheres	are	composed	of	both	differentiated	neurons	and	glial	cells,	but	also	
by	 immature	 SCs.	 Moreover,	 they	 demonstrated	 that	 a	 neurosphere	 could	 be	
produced	from	a	single	cell	and	that	this	neurosphere	could	be	subsequently	split	to	
generate	 a	 new	one,	which	preserves	 the	previous	 cell	 heterogeneity.	 Thus,	 these	
cells,	 being	 capable	 to	 produce	 neurosphere,	 recapitulate	 the	 properties	 of	 SCs,	
behaving	 as	multipotent	 cells	 able	 to	 self-renew.30	Next,	 the	 identification	of	 such	
cells	also	in	vivo	in	adult	brain	confirmed	certainly	the	existence	of	NSCs	in	defined	
regions.31	Indeed,	it	is	now	well-established	that	neurogenesis	occurs	throughout	life	
in	 the	“neurogenic	niches”	of	 the	adult	brain:	 the	 subventricular	 zone	 (SVZ)	of	 the	
forebrain	 and	 the	 subgranular	 zone	 (SGZ)	 of	 the	 dentate	 gyrus	 (DG)	 within	 the	
hippocampus.32	The	neurogenic	niches	 represent	a	unique	micro-environment	 that	
determines	 NSCs	 survival	 and	 fate	 by	 a	 multitude	 of	 effects,	 such	 as	 cell–cell	
contacts	 and	 interactions	 with	 specific	 factors.32	 By	 definition,	 NSCs	 are	
undifferentiated	 precursor	 cells	 described	 by	 their	 capacity	 for	 self-renewal	 and	
multipotency.	 Through	 proliferation	 and	 division,	 NSCs	 generate	 clonally	 related	
progeny	 that	 differentiate	 to	 form	all	 the	major	 cell	 types	of	 the	CNS	 (Figure	2).33	
These	 cells	 include	 neurons,	 astrocytes	 and	 oligodendrocytes.	 The	 symmetric	
division	of	NSCs	underlies	their	ability	to	self-renew	and	serves	to	maintain	the	NSCs	
population.	 In	 contrast,	 asymmetric	 mitosis	 produces	 one	 NSCs	 and	 one	 neural	
progenitor	 cell	 (NPCs),	 daughter	 cells	 with	 restricted	 differentiation	 capacity	 for	
neuronal	 or	 glial	 lineages.	 In	 addition,	 terminal	 asymmetric	 division	 generates	 two	
NPCs,	but	does	not	contribute	to	maintaining	the	NSCs	pool	(Figure	2).	Although	the	
gross	 anatomical	 location	 of	 proliferating	 immature	 cells	 has	 been	well	 identified,	
the	exact	 identity	of	the	precursor	cells	 is	not	well	defined.	They	should	be	able	to	
give	 rise	 to	 all	 cell	 types	 of	 all	 regions	 of	 the	 CNS	 during	 development,	 as	well	 as	
reconstitute	 those	 regions	 following	 damage.	 Furthermore,	 it	 has	 been	
demonstrated	 that	 different	 subpopulations	 of	 neural	 precursors	 exist	 that	 are	
regionally	specified	to	respond	to	certain	cues	related	to	their	neighboring	cells	and	
precise	anatomical	location.34		
In	 fact,	 despite	 SVZ	 and	 SGZ	 niches	 share	 several	 key	 characteristics,	 a	 high	
heterogeneity	 of	 adult	 NSCs	 have	 been	 highlighted	 between	 the	 two	 neurogenic	
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regions.	 Notably,	 adult	 SVZ	 NSCs	 (also	 named	 type	 B	 cells)	 give	 rise	 to	 transient	
amplifying	 progenitors	 (C	 cells),31	 which	 divide	 just	 few	 times	 before	 becoming	
neuroblasts	(A	cells);	radial	glia-like	NSCs	(named	RGLs	or	type	1	cells)	in	the	SGZ	give	
rise	 to	 intermediate	 progenitor	 cells	 (IPCs)	 also	 exhibiting	 limited	 rounds	 of	
proliferation	 before	 generating	 neuroblasts.	 Then,	 these	 neuroblasts	 migrate	
tangentially	along	the	SGZ,	develop	into	immature	neurons	in	the	granule	cell	layer,	
and	 differentiate	 into	 dentate	 granule	 neurons.35	While	 in	 contrast,	 A	 cells	 in	 SVZ	
radially	migrate	into	the	olfactory	bulb	where	differentiate	into	different	subtypes	of	
interneurons.36	
Even	 though	 recent	 advances	 on	 deriving	 or	 inducing	NSCs	 from	different	 sources	
have	 been	 achieved,	 no	 direct	 and	 thorough	 comparison	 of	 their	 biological	 and	
molecular	properties	or	of	their	physiological	relevance	and	possible	relationship	to	
endogenous	 NSCs	 has	 yet	 been	 performed.37	 Indeed,	 NSCs	 are	 still	 lacking	 of	
established	marker	 proteins,	 resulting	 in	 difficult	 characterization	 and	 isolation	 of	
bona	 fide	 NSCs.	 However,	 some	 level	 of	 consensus	 is	 recognized	 in	 terms	 of	
characterization	of	differentiating	or	differentiated	cells,	based	on	a	combination	of	
markers	 for	 immature	 and	 mature	 phenotypes,	 such	 as	 nestin	 and	 β-tubulin	 III,	
respectively	(see	Figure	2).33	
In	 the	 next	 paragraph,	 a	 general	 overview	 of	 molecular	 hallmarks	 characterizing	
NSCs	will	be	provided.	
	
Figure	2.	Graphic	representation	of	NSCs	differentiation	fate	and	related	markers.	
 
 
1.3	Molecular	hallmarks	of	NSCs	 
 
As	previously	anticipated,	the	establishment	of	specific	markers	for	both	mature	and	
immature	 phenotypes	 is	 far	 to	 be	 complete.33	 Their	 identification	 would	 be	 of	
fundamental	importance	not	only	to	detect	and	enable	prospective	isolation	of	bona	
fide	 NSCs,	 but	 also	 to	 understand	 how	 these	 intrinsic	 regulators	 (transcription	
factors,	 cytoskeleton	 proteins	 etc.)	 affect	 gene	 expression	 and/or	 cell	 function.	 To	
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date,	 only	 a	 handful	 of	 proliferation/differentiation	 markers	 have	 been	 identified	
and	 then	 confirmed	 by	 the	 recent	 advances	 in	 reprogramming	 somatic	 cells.38	
However,	some	of	them	result	to	be	non-specific	for	adult	NSCs	and	are	often	shared	
by	other	cell	types.	This	problem	is	particularly	evident	in	the	case	of	distinguishing	
activated	 adult	 NSCs	 from	 quiescent	 NSCs,	 which	 do	 not	 express	 many	 unique	
antigens.39		
Following	 the	 introduction	 of	 5-bromodeoxyuridine	 (BrdU),40	 a	 nucleotide	 analog	
that	 non-selectively	 labels	 proliferating	 cells	 in	 the	 adult	 brain,	while	 avoiding	 the	
use	 of	 [3H]thymidine	 and	 autoradiographic	 techniques,	 the	 field	 witnessed	 an	
explosion	of	studies	aimed	at	establishing	specific	and	reliable	methods	to	track	both	
quiescent	 and	 proliferating	 cells.	 One	 of	 the	 first	markers	 to	 be	 identified	 for	 the	
immature	 NSCs	 was	 nestin,	 a	 class	 VI	 intermediate	 filament	 protein.41	 Originally	
described	as	the	marker	distinguishing	progenitor	SCs	from	differentiated	cells	both	
in	 vitro	 and	 in	 vivo,29	 nestin	was	 also	 found	 to	 be	 expressed	 in	 CNS	 tumor	 cells.42	
Furthermore,	endothelial	 cells	within	CNS	 tumor	have	been	 reported	 to	be	nestin-
postive,	 but	 also	 a	 variety	 of	 adult	 human	 non-CNS	 cells,	 such	 as	 newly	 formed	
human	blood	vessels	cells,	have	been	showed	to	express	nestin.43	Thus,	even	though	
nestin	 is	 generally	 recognized	 as	 a	marker	 protein	 of	 undifferentiated	NSCs	 at	 the	
stage	 that	 precedes	 the	 commitment	 of	 the	mature	 progeny	 to	 a	 specific	 lineage,	
recent	evidences	suggest	that	nestin	is	also	a	marker	for	angiogenesis.44	
On	the	other	hand,	Pax6	emerged	as	transcription	factor	identified	during	embryonic	
development	in	precursor	cells.	Further	studies	revealed	that	Pax6	might	represent	a	
suitable	 marker	 for	 newly	 generated	 cells	 in	 the	 DG	 during	 the	 differentiation	
phase.45	 However,	 it	 should	 be	 noted	 that	 a	 small	 subpopulation	 of	 hilar	 mature	
neurons	and	certain	astrocytes	of	 the	adult	hippocampus	also	express	Pax6,	hence	
confirming	its	differential	expression	in	regionally	restricted	areas	of	adult	brain.45	
Another	candidate	for	immature	neuronal	markers	is	NeuroD,	which	is	a	basic	helix–
loop–helix	 transcription	 factor	 specifically	 expressed	 in	 later	 stages	 of	 neuronal	
commitment.45	In	addition	to	NeuroD,	doublecortin	(DCX)	is	a	protein	that	promotes	
microtubule	 polymerization	 and	 is	 present	 in	 migrating	 neuroblasts	 and	 young	
neurons.	In	general,	DCX-expressing	cells	are	temporally	in-frame	with	polysialylated	
neural	 cell	 adhesion	 molecule	 (PSA-NCAM),	 highly	 expressed	 in	 neural	 and	 glial	
progenitor	 cells.	However,	not	 all	 newly	 formed	neurons	within	 the	brain	 seem	 to	
express	 DCX.	 Its	 expression	 is	 known	 to	 occur	 in	 newly	 generated	 hippocampal,	
striatal	 and	olfactory	neurons,	but	within	 the	neocortex,	newly	generated	neurons	
lack	DCX.46	Thus,	DCX	can	be	used	to	label	the	post-mitotic	neuronal	progenitor	cells	
and	early	immature	neurons	only	in	defined	brain	regions.38	
Regarding	mature	 phenotype	markers,	 glial	 fibrillar	 acidic	 protein	 (GFAP)	 is	widely	
known	 as	 a	 marker	 for	 mature	 astrocytes	 in	 the	 adult	 brain.	 However,	 striking	
evidences	 supported	 the	 fact	 that	 it	 is	highly	expressed	by	 radial	 glial	 cells,	whose	
heterogeneity	 raises	 doubts	 about	 GFAP	 specificity.47	 Indeed,	 these	 GFAP-positive	
cells	have	been	demonstrated	to	express	not	only	the	functional	 features	common	
to	astrocyte,	but	also	the	functional	characteristics	intermediate	between	astrocytes	
and	radial	glia,	that	may	direct	the	migration	or	the	formation	of	new	neurons.48		
Conversely,	neuron-specific	class	III	beta-tubulin	(Tuj-1)	is	used	as	a	neuron-specific	
marker	 of	 newly	 generated	 cells.38	 It	 is	 expressed	 in	 early	 post-mitotic	 and	
differentiated	neurons	and	in	some	mitotically	active	neuronal	precursors.	Thus,	it	is	
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considered	 as	 one	 of	 the	 most	 specific	 marker	 for	 labeling	 the	 neuronal	 lineage.	
Additionally,	NeuN,	a	soluble	nuclear	protein,	is	observed	in	most	neuronal	cell	types	
throughout	 the	 CNS,	 with	 the	 exception	 of	 some	 neuronal	 populations	 (e.g.	
cerebellar	Purkinje	cells).	In	this	context,	NeuN	results	to	be	very	useful	thanks	to	its	
ability	to	discriminate	between	neuronal	and	non-neuronal	cells.45		
On	 the	 other	 hand,	 OLIG2	 is	 a	 basic	 helix-loop-helix	 transcription	 factor	 that	 has	
been	described	 in	 the	ventral	 spinal	 cord	 in	a	 subpopulation	of	neural	progenitors	
that	give	rise	first	to	motor	neurons	and	then	oligodendrocytes.49	Indeed,	it	has	been	
considered	as	suitable	oligodendroglial	lineage	marker.50	In	this	respect,	it’s	worth	to	
note	that	OLIG2	is	guiltily	limited	to	normal	oligodendroglia	and	their	progenitors	in	
human	brain.	Accordingly,	 spatiotemporal	differences	 in	OLIG2	expression	 indicate	
that	 it	 is	 critical	 not	 only	 for	 initial	 oligodendroglial	 specification,	 but	 also	 for	 the	
development	of	other	neural	cell	types.50	Moreover,	OLIG2	expression	is	associated	
with	all	gliomas,	implying	its	usefulness	as	marker	of	diffuse	gliomas.51	
	
	
1.4	Stemistry:	the	control	of	stem	cells	using	chemistry	
	
Already	 in	2013,	Angela	Russell	dealt	with	 the	concept	of	 targeting	 resident	SCs	 in	
situ	 using	 chemistry,	 which	 was	 elegantly	 defined	 as	 “regenerative	 medicinal	
chemistry”.52 Soon	 after,	 in	 2014,	 Davies	 and	 Russell	 coined	 the	 neologism	
“stemistry”	 referring	 to	 the	 contraction	 of	 “stem	 cell	 chemistry”,	 which	 directly	
interfaces	 SCs	 biology	 and	 chemistry.53	 Since	 its	 inception,	 the	 prospect	 of	
developing	new	chemical	entities	capable	of	targeting	the	regenerative	processes	in	
vivo,	 represents	 an	emerging	approach	 in	medicine	and	drug	discovery.53	Actually,	
the	 demonstration	 that	 an	 agent	 targeting	 the	 own	 regenerative	 capability	 of	 the	
body	would	have	profound	effects	on	diseases	dates	back	to	1989,	with	the	use	of	
erythropoietin.52	 This	 hormone	 is	 currently	 in	 clinical	 use	 for	 patients	with	 severe	
anemia,	 being	 able	 to	 modulate	 the	 production	 of	 red	 blood	 cells	 from	
hematopoietic	progenitor	cells.	Moreover,	after	the	identification	of	the	critical	role	
played	by	another	hormone	(thrombopoietin)	in	the	production	of	platelets,	several	
thrombopoietin	mimetics	were	developed,	 culminating	 in	 2005	 in	 the	discovery	of	
eltrombopag,	 marketed	 for	 the	 treatment	 of	 thrombocytopenia54	 and,	 more	
recently,	approved	for	aplastic	anemia.55	
In	 parallel,	 several	 reports	 retrospectively	 demonstrated	 that	 also	 existing	 drugs	
exert	 some	 of	 their	 effects	 by	 modulating	 SCs	 fate.	 This	 is	 the	 case	 for	 the	
antidepressant	drug	fluoxetine.56		
In	 general,	 small	 molecules	 are	 particularly	 attractive	 because	 can	 be	 delivered	
efficiently	 into	 the	 cell,	 can	 be	 targeted	 to	 specific	 tissues	 and,	more	 importantly,	
their	 effects	 are	 reversible.	 The	 compounds	 doses	 can	 be	 changed	 for	 maximum	
benefit,	 and,	 from	 a	 medicinal	 chemistry	 perspective,	 molecules	 can	 be	 further	
modified	 to	 increase	 potency,	 selectivity,	 safety,	 or	 stability.	 Importantly,	 small	
molecules	 can	 play	 several	 roles	 within	 the	 SCs	 field,	 according	 to	 the	 following	
objectives:	
	
i. maintaining	 pluripotent	 and	multipotent	 ESCs	 in	 an	 undifferentiated	 state	
while	preserving	self-renewal	capacity;	
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ii. identifying	the	signaling	pathways	implicated	in	regulating	the	different	SCs	
types	 and	 the	 different	 SCs	 stages	 (self-renewal,	 proliferation,	
differentiation,	migration,	engraftment),	in	order	to	disclose	their	biological	
roles	and	their	potential	as	druggable	targets;	
iii. reprogramming	adult	stem	and	other	differentiated	cells.	
	
Below,	objective	(i)	applied	to	ESCs	will	be	briefly	discussed,	whereas	for	objectives	
(ii)	and	(iii)	significant	examples	in	the	field	of	NSCs	will	be	addressed.		
	
	
1.4.1	Maintaining	pluripotent	and	multipotent	SCs	with	small	molecules	
	
Objective	(i)	refers	to	the	development	of	those	molecules	able	to	maintain	ESCs	in	a	
continuous	 proliferative	 circle	 in	 growth	 and	 transcription	 factors-free	 conditions.	
This	is	of	notable	importance	because	it	avoids	genome	integrity	issues	and	the	risk	
of	 tumorigenicity	 associated	with	 feeder-conditioned	medium.	 In	 this	 respect,	 the	
main	contribution	in	this	field	came	from	the	work	published	by	Chen	and	colleagues	
in	 2006.57	 The	 authors	 successfully	 implemented	 an	 unbiased	 cell-based	 screen	 of	
50,000	 compounds	 library	 (5	 µM)	 to	 identify	 small	molecules	 able	 to	 regulate	 the	
self-renewal	 of	 ESCs.	 From	 the	 small	 (~	 30)	 set	 of	 compounds	 resulting	 from	 the	
primary	 screen,	 a	 class	 of	 3,4-dihydropyrimido[4,5-d]pyrimidines	 was	 identified.	 A	
focused	 library	 of	 second-generation	 3,4-dihydropyrimido[4,5-d]pyrimidines	 was	
synthesized,	 aiming	 at	 exploring	 the	 structure-activity-relationships	 (SAR).	Notably,	
the	analog	SC1,	also	called	pluripotin	 (Figure	3),	was	 identified	with	10-fold	higher	
activity	and	 relatively	 low	cellular	 toxicity	 compared	 to	 the	 starting	hit.	To	 identify	
the	cellular	 target(s)	of	SC1,	affinity	chromatography	was	performed	revealing	that	
SC1	 acts	 simultaneously	 on	 two	 targets:	 ERK1	 and	 Ras	 GTPase-activating	 protein. 
Such	 proteins,	 which	 have	 previously	 been	 shown	 to	 play	 a	 critical	 role	 in	 SCs	
differentiation,58	could	also	represent	targets	for	designing	new	drugs. 
Thus,	SC1	successfully	addresses	objective	(i),	allowing	the	propagation	of	ESCS	in	an	
undifferentiated	 pluripotent	 state	 under	 chemically	 defined	 conditions.	 It	 also	
addresses	 objective	 (ii),	 as	 it	 allowed	 the	 identification	 of	 two	 signaling	 pathways,	
which	could	themselves	represent	potential	druggable	targets.		
	
	
1.4.2	Identifying	signaling	pathways	regulating	NSCs	fate	with	small	molecules	
	
The	 discovery	 of	 small	 molecules	 to	 promote	 the	 proliferation,	 survival,	
differentiation,	 and/or	 migration	 of	 neural	 stem/progenitor	 cells	 (objective	 ii)	
represents	an	attractive	 strategy	 to	 tackle	neurodegenerative	diseases.	One	of	 the	
first	 molecules	 discovered	 to	 cause	 differentiation	 towards	 NSCs	 of	 ESCs	 is	
represented	by	retinoic	acid	 (Figure	3).59 This	ability	have	been	widely	exploited	to	
directly	 differentiate	 ESCs,	 even	 though	 it	 is	 relatively	 nonspecific	 in	 targeting	
specific	 cell	 lineage	 and	 its	 effects	 are	 hampered	 by	 chemical	 and	 metabolic	
instability.59		
With	 the	 aim	 of	 understanding	 the	 processes	 that	 regulate	 neuronal	 specification	
and	 identifying	 specific	 molecules,	 in	 2003,	 Ding	 et	 al.	 set	 up	 a	 high-throughput	
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phenotypic	 cell-based	 screen	with	 a	 luciferase	 reporter	 by	 inserting	 Tα1	 tubulin,	 a	
specific	 neuronal	 marker.60	 Starting	 from	 the	 hypothesis	 that	 kinases	 affect	 the	
differentiation	 processes,	 a	 kinase-focused	 combinatorial	 library	 (>105	compounds)	
was	 tested	 leading	 to	 the	 discovery	 of	 TWS119	 (Figure	 3),	 a	 4,6-disubstituted	
pyrrolopyrimidine	 that	 induces	neural	differentiation	of	ESCs.	By	means	of	affinity-
based	and	biochemical	experiments,	the	target	of	TWS119	was	shown	to	be	GSK-3β.	
These	 findings	 provided	 evidence	 that	 GSK-3β	 is	 involved	 in	 mammalian	
neurogenesis,	thereby	emerging	as	an	attractive	target	for	clinical	intervention.60		
The	 importance	of	GSK-3β	 in	 controlling	 neurogenesis	 emerged	 also	 from	another	
recent	 report.61	 In	 this	 case,	 the	authors	 implemented	a	high-content	 screen	using	
human	NPCs	to	systematically	characterize	the	effects	of	more	than	5,000	bioactive	
compounds	 (2	 µM)	 on	 both	 the	 neuronal	 differentiation	 and	 further	 the	midbrain	
dopamine	 (mDA)	 neuron	 specification.	 From	 the	 primary	 screening	 aimed	 at	
promoting	 neuronal	 differentiation,	 a	 certain	 number	 of	 hits	 were	 selected	 for	
further	testing.	Of	the	promoting	compounds,	following	experiments	confirmed	the	
effects	of	21	small	molecules,	among	which	 two	pharmacological	classes	emerged:	
the	 GSK-3	 inhibitors	 (exemplified	 by	 kenpaullone,	 Figure	 3) and	 the	 statins	
(exemplified	by	mevastatin,	Figure	3).	Then,	the	effects	of	compounds	on	promoting	
the	mDA	 neuron	 specification	 were	 evaluated.	 Re-testing	 of	 the	 selected	 hits	 (21	
compounds)	 confirmed	 the	 effect	 on	 mDA	 specification	 of	 human	 NPCs	 by	 two	
pharmacological	classes:	 the	TGF-β	receptor	 inhibitors	 (exemplified	by	LY364947	 in	
Figure	 3)	 and	 the	 statins	 as	 well	 (mevastatin).	 Thus,	 this	 study	 disclosed	 three	
pharmacological	classes	that	effectively	 increase	the	rates	of	neuronal	and/or	mDA	
differentiation	of	human	NPCs.	It	also	provided	molecular	insights	into	the	signaling	
network	governing	the	differentiation	of	NPCs,	which	may	be	potentially	valuable	for	
the	study/treatment	of	PD.61	
Recently,	 it	 has	 been	 also	 showed	 the	 potential	 of	 natural-derived	 compounds	 to	
affect	neurogenesis.	 Starting	 from	the	neurotrophic	activity	displayed	 in	 cell-based	
assays	 by	 the	 novel	 nature-inspired	 2-oxa-spiro[5.5]-undecane	 scaffold,62	 two	
compounds	 (comp#1	and	comp#2	 in	Figure	3)	were	selected	 to	 further	 investigate	
their	 neurotrophic,	 neurogenic	 and	 neuroprotective	 potential	 in	 ex	 vivo	 mouse	
primary	 neurosphere,	 in	 brain	 slice	 cultures,	 and	 in	 vivo	 zebrafish	 and	 mouse	
models.63	While	from	the	ex	vivo	experiments,	no	significant	differences	among	the	
two	compounds	have	been	observed,	the	results	obtained	from	in	vivo	investigations		
	
	
Figure	3.	Small	molecule	probes	modulating	SCs	fate.	
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suggest	 that	 comp#2	 is	 more	 neurotrophic	 than	 neurogenic,	 whereas	 comp#1	
exhibits	the	opposite	profile.	This	difference	became	particularly	evident	in	an	acute	
ischemic	 stroke	 mouse	 model,	 revealing	 that	 comp#2	 exhibits	 remarkable	
neuroprotective	 effects	 compared	 to	 the	 comp#1.	 Additionally,	 the	 molecular	
mechanisms	 of	 action	 of	 comp#2	 appear	 to	 be	 linked	 to	 the	 modulation	 of	 the	
complex	 pathway	 involving	 TrkB-MEK-ERK-CREB-BDNF.	 This	 is	 because	 treatment	
with	 neurotrophin	 receptor	 TrkB	 inhibitor	 (ANA-12,	 N-[2-[[(Hexahydro-2-oxo-1H-
azepin-3-yl)amino]carbonyl]phenyl]-benzo[b]thiophene-2-carboxamide)	 and	 MEK	
inhibitor	 (PD98059,	 2-(2-Amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)	
significantly	reduce	the	neurotrophic	action	of	the	compound.63		
	
	
1.4.3	 Reprogramming	 adult	 stem	 and	 other	 differentiated	 cells	 to	 neural/glial	
lineages	
	
As	mentioned	 above,	 the	 possibility	 to	 directly	 reprogramming	 SCs	 by	 using	 small	
molecules	is	particularly	attractive	(objective	iii).64		
Accordingly,	 it	was	hypothesized	that	chemicals	known	to	promote	reprogramming	
could	facilitate	the	cells	to	enter	into	a	“plastic”	state,	which	could	allow	them	to	be	
converted	to	NPCs	under	neural-specific	conditions.65		
To	achieve	this	goal,	Cheng	et	al.66	 identified	a	chemical	cocktail	that	 induces	NPCs	
from	 terminally	 differentiated	 cells	 under	 hypoxic	 condition.	 Particularly,	 the	
combination	 of	 Valproic	 acid	 (histone	 deacetylase	 inhibitor	 (HDACi),	 Figure	 4),	
CHIR99021	(GSK-3β	 inhibitor)	and	Repsox	(TGF-β	 inhibitor),	named	VCR,	was	found	
to	induce	the	transition	of	mouse	embryonic	fibroblasts	to	NPCs	only	under	hypoxic	
conditions,	 and	 not	 under	 normoxic	 conditions.	 Thus,	 hypoxia,	 as	 a	 peculiar	
characteristic	 of	 in	 vivo	 SCs	 niches,	 combined	with	 VCR	 cocktail	 that	 up-regulates	
Sox2	expression,	play	a	major	role	in	NPCs	reprogramming.	Given	that,	the	authors	
further	 characterized	 the	 obtained	 chemical-induced	 NPCs	 by	 comparing	 their	
proliferation	 and	 self-renewal	 abilities	 in	mouse	 brain-derived	 NPCs.	 Interestingly,	
they	 showed	 a	 high	 degree	 of	 similarity	 both	 in	 transcription	 profiles	 and	 their	
multipotency	properties	 in	vitro	and	 in	vivo,	corroborating	the	 idea	that	the	use	of	
lineage-specific	culture	conditions	(VCR	and	hypoxia)	allowed	to	obtain	reliable	NPCs	
from	 somatic	 cells.	Moreover,	 the	 feasibility	 of	 generating	 chemical-induced	NPCs	
from	fibroblasts	by	using	VCR	has	been	significantly	confirmed	by	the	successful	use	
of	 alternative	 inhibitors	 targeting	 HDACs,	 GSK-3β	 and	 TGF-β	 kinases.	 This	 also	
supports	the	central	role	of	these	pathways	in	the	direct	conversion	of	fibroblast	into	
NPCs.66		
Just	 one	 year	 later,	 the	 same	 group	 exploited	 a	 slightly	 modified	 version	 of	 the	
previous	 identified	 drugs	 cocktail	 VCR	 to	 directly	 convert	 mouse	 astrocytes	 into	
neuronal	cells.67	By	optimizing	the	concentration	of	valproic	acid,	the	authors	were	
able	 to	 induce	 neurons	 maturation	 from	 cultured	 astrocytes	 without	 generating	
Sox2-positive	 NPCs.	 Furthermore,	 additional	 screens	 revealed	 that	 removal	 of	
valproic	 acid	 from	 the	 cocktail	 drastically	 abrogated	 the	 induction	 of	 neuroblasts	
from	astrocytes,	whereas	excluding	CHIR99021	or	repsox	showed	minimal	effects	on	
neuroblast	 generation.	 Intriguingly,	 the	 conversion	 induced	 by	 VR	 combination	
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(valproic	 acid	 and	 repsox)	 displayed	 a	 similar	 efficiency	 compared	 to	VCR	 cocktail.	
While,	neuroblasts	generation	from	astrocytes	was	maintained	by	using	valproic	acid	
alone,	even	displaying	a	 lower	effectiveness	compared	with	VR,	neither	CHIR99021	
or	 repsox	 alone	 nor	 their	 combination	 produced	 any	 neuroblast.	 These	 findings	
suggest	that	small	molecules	can	directly	convert	astrocytes	into	neurons	in	vitro	in	a	
concentration-	and	time-dependent	manner.67	However,	the	practical	implication	of	
such	 chemical-induced	 conversion	 in	 vivo	 has	 not	 been	 confirmed	 yet,	 and	 the	
potential	 effects	of	 these	 chemicals	on	other	 cells	 types	need	 to	be	 systematically	
and	 carefully	 evaluated.	 To	 this	 end,	 the	 same	 group	 tested	 whether	 VCR	 in	
combination	with	other	small	molecules	known	to	promote	neural	differentiation	of	
NPCs,	 might	 facilitate	 the	 conversion	 of	 human	 fibroblasts	 into	 neuronal	 cells.68	
Thus,	they	screened	~	25	compounds	reported	to	 induce	neural	cells	differentiation	
and	they	found	that	additional	4	small	molecules	[i.	e.	Forskolin	(cAMP	activator,	F,	
in	 Figure	 4);	 SP600125	 (JNK	 inhibitor,	 S);	 GO6983	 (PKC	 inhibitor,	 G)	 and	 Y-27632	
(ROCK	 inhibitor,	 Y)]	 are	 required	 to	 efficiently	 improve	 the	 neuronal	 conversion.	
Thus,	 they	optimized	 a	 chemicals	 cocktail	 comprising	 a	 total	 of	 7	 small	molecules,	
defined	 as	 VCRFSGY.	 Such	 neural-promoting	 molecules	 include	 compounds	 with	
significantly	 different	 mechanisms	 of	 action,	 so	 that	 the	 precise	 regulatory	
mechanisms	 of	 this	 VCRFSGY	 cocktail	 remain	 to	 be	 understood.	 Despite	 that,	 this	
approach	 was	 successfully	 applied	 to	 generate	 human	 chemical-induced	 neuron	
from	 skin	 fibroblasts	 derived	 from	 familial	 AD	 patients,	 further	 supporting	 the	
feasibility	to	generate	patient-specific	neuronal	cells	by	chemical	tools.68	
Interestingly,	 in	 the	 same	 issue	of	Cell	 Stem	Cell	 journal,	 another	 similar	work	has	
been	reported	by	Li	et	al.69	In	this	case,	by	performing	two	screening	assays	for	small	
molecules	(~	5,000	and	1,500	compounds,	respectively)	able	to	convert	mouse	skin	
cells	 into	 neurons,	 the	 authors	 first	 identified	 CHIR99021,	 forskolin,	 ISX9,	 and	
SB431542	 (TGF-β	 inhibitor,	 in	 Figure	 4)	 for	 their	 ability	 to	 increase	 the	 number	 of	
TUJ1-positive	 cells	 and,	 secondly,	 they	 found	 an	 additional	 small	 molecule	 (i.e.	 I-
BET151,	 a	 BET-family	 bromodomain	 inhibitor)	 that	 facilitate	 neuronal	
reprogramming	and	maturation.	Accordingly,	further	experiments	demonstrated	
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Figure	4.	Small	molecule	probes	modulating	adult	SCs	reprogramming.	
	
that	 the	 ISX9	molecule	was	 essential	 for	 activating	 neuron-specific	 genes,	while	 I-
BET151	for	affecting	chromatin	remodeling,	which	leads	to	erase	the	initial	cell		
identity,	 while	 allowing	 the	 acquisition	 of	 converted	 fates.	 Moreover,	 co-culture	
assays	with	astrocytes	or	primary	neurons	revealed	that	the	newly	chemical-induced	
neurons	were	 capable	 of	 forming	 functional	 synaptic	 connections	 reciprocally	 and	
with	existing	neurons.69	Lately,	one	of	the	most	recent	examples	of	small	molecules-
based	reprogramming	provided	the	demonstration	that	the	conversion	of	astrocytes	
to	 fully	 functional	 neurons	 can	 be	 achieved	 also	 with	 human	 cells.70	 Unlike	 the	
previously	 discussed	 chemical	 cocktail	 VCR	 used	 for	 mouse	 astrocytes	
reprogramming,	 the	 authors	 identified	 a	 cocktail	 of	 9	 small	 molecules	 (including,	
valproic	acid,	CHIR99021,	SB431542,	thiazovivin	(ROCK	inhibitor),	LDN193189	(ROCK	
inhibitor),	TTNPB	(retinoic	acid	analogue),	DAPT	(γ-secretase	inhibitor),	Smoothened	
agonist	 (SAG))	able	 to	 induce	human	astrocytes	 reprogramming	 into	neuronal	cells	
with	a	specific	sequence.	70	
Collectively,	 these	 results	 indicate	 that	 direct	 chemical	 conversion	 may	 offer	 an	
alternative	 path	 for	 generating	 cell	 types	 other	 than	 neurons,	 providing	 disease	
models	and	possibilities	for	regenerative	therapy.71		
Even	 though	 small	 molecules	 probing	 NSCs	 function	 are	 highly	 desirable,	 their	
discovery	has	proven	 challenging	because	of	 the	extremely	high	 complexity	of	 the	
mammalian	 neurogenesis.	 This	 raises	 many	 important	 questions:	 is	 there	 any	
validated	 target	 that	modulate	 neurogenesis	 for	 druggable	 purposes?	What	 is	 the	
best	approach	to	gain	information	at	molecular	level	of	NSCs	regulation?	
In	 the	 following	 paragraph,	 we	 provide	 an	 overview	 of	 the	 intricate	 and	 complex	
signals	orchestrating	neurogenesis.	Again,	 the	chemical	modulation	represents	one	
of	the	most	suitable	approaches	to	study	such	complexity.	
	
	
1.5	Pathways	modulating	adult	neurogenesis	
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The	study	of	neurogenesis	in	the	adult	brain	is	among	the	most	exciting	and	fastest	
moving	areas	of	neuroscience	today.72	However,	the	study	of	its	mechanisms	is	still	
matter	 of	 intense	 debate,	 due	 to	 the	 lack	 of	 specific	 tools	 and	markers.72	 Several	
mechanisms	underlying	neurogenesis	have	been	advanced	and	have	been	properly	
reviewed	 elsewhere.36,	 73	 Remarkably,	 what	 attracts	 our	 attention	 is	 that	 many	
mechanisms	 implicated	 in	 neurogenesis	 have	 been	 identified	 thanks	 to	 the	 use	 of	
chemicals	or	drugs.	This	supports	 the	working	hypothesis	 that	small	molecules	can	
indeed	 play	 a	 major	 role	 as	 chemical	 probes	 to	 dissect	 new	 targets	 and	 new	
pathways	underlying	the	neurogenesis	and	to	open	the	way	to	the	development	of	
new	drugs.			
Among	 the	 most	 accredited	 mechanisms	 orchestrating	 neurogenesis,	 nuclear	
receptors74	and	epigenetic	regulators75	play	a	crucial	role	in	intrinsically	modulating	
neurogenesis.	 For	 example,	 rising	 evidences	 suggest	 that	 the	 activation	 of	 PPARγ	
pathway	 promotes	 neuronal	 differentiation	 and	 axon	 polarity.	 This	 has	 been	
demonstrated	 by	 the	 fact	 that	 PPARγ	 agonist	 pioglitazone	 (Figure	 5),	 stimulated	
NSCs	 proliferation	 via	 ERK	 pathway	 by	 phosphorylating	 and	 up-regulating	 the	
epidermal	growth	factor	(EGF)	receptor	and	cyclin	B	protein	levels.76		
Moreover,	 the	 fundamental	 role	 played	 by	 the	 orphan	 nuclear	 receptor	 Tlx	 in	 the	
regulation	of	NSCs	proliferation	has	been	 recently	highlighted.77	Particularly,	 it	has	
been	shown	that	Tlx	 is	able	 to	maintain	NSCs	 in	a	proliferative	state	 thanks	 to	 the	
activation	 of	 the	 Wnt/β-catenin	 pathway78	 and	 the	 recruitment	 of	 histone	
deacetylases	 (HDACs).79	 Importantly,	 the	 effects	 of	 HDACs	 activation	 led	 to	 the	
transcriptional	 repression	 of	 Tlx	 target	 genes,	 such	 as	 the	 cyclin-dependent	 kinase	
inhibitor,	 p21.79	 Additionally,	 the	 critical	 role	 of	 p21	was	 further	 established	 after	
chronic	 treatment	 with	 antidepressants	 imipramine,	 desipramine	 and	 fluoxetine	
(Figure	 5)	which	 decrease	 p21	 expression,	 and	 this	was	 associated	with	 increased	
neurogenesis	 in	 vivo.80	 In	 addition	 to	 histone	modifications,	 DNA	methylation	 has	
emerged	as	an	 important	 regulator	of	 synaptic	plasticity	via	modulation	of	 specific	
gene	 expression.81	 The	 different	 expression	 of	 three	 DNA	 methyltransferases	
(DNMT1-3)	 in	 various	 stages	 and	 anatomical	 locations	 associated	 to	 neurogenesis,	
clearly	 demonstrate	 the	 peculiar	 roles	 of	 DNA	 methylation	 in	 this	 process.	 For	
instance,	DNMT1	is	highly	expressed	in	proliferative	cells	 in	the	adult	DG	and	plays	
an	 important	 role	 in	 the	 survival	 of	 newly	 generated	 neurons.	 However,	 DNMT1	
deletion	in	adult	NSCs	and	precursor	cells	resulted	in	a	decrease	of	newly	generated	
mature	neurons,	while	not	influencing	post-mitotic	neurons	survival.82		
In	 addition	 to	 nuclear	 receptors	 and	 epigenetic	 regulators	 mentioned	 above,	 the	
Hippo	 signaling	 pathway	 appears	 to	 be	 critical	 in	 maintaining	 NSCs	 quiescence.83	
Indeed,	 its	 transcriptional	 co-activator	 YAP	 protein	 is	 highly	 expressed	 in	 neural	
tubes	 and	 in	 the	 cerebellum,	 co-localizing	 with	 Sox2,	 a	 neural	 progenitor	marker.	
Loss	 of	 downstream	 kinases	Mst1/2	 or	 Lats1/2	 of	 Hippo	 pathway,	 corresponding	
with	the	YAP	activation,	leads	to	a	marked	expansion	of	neural	progenitors,	partially	
due	to	an	up-regulation	of	stemness	genes.	Conversely,	YAP	loss-of-function	results	
in	 increased	 cell	 death	 and	 precocious	 neural	 differentiation.83	 As	 confirmed	 in	
Drosophila,	 Ding	 and	 coworker	 showed	 that	 the	 Hippo	 pathway	 is	 modulated	 via	
inter-cellular	 trans-membrane	 proteins	 (crumbs	 and	 echinoid)	 that	 are	 both	
expressed	 in	 a	 nutrient-dependent	 way	 by	 niche	 glial	 cells	 and	 NSCs	 in	 order	 to	
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maintain	quiescence	and	suppress	cell	growth.	Indeed,	their	deletion	resulted	in	the	
reactivation	 of	 NSCs,	 thus	 providing	 evidence	 that	 the	 Hippo	 pathway	 activity	
discriminates	 quiescent	 from	 non-quiescent	 NSCs	 in	 the	 Drosophila	 nervous	
system.84	 Collectively,	 these	 findings	 support	 that	 the	Hippo	pathway	plays	 crucial	
roles	 in	regulating	NPCs	number	and	suggest	the	possibilities	for	discovering	useful	
pharmacological	tools	targeting	specific	players	of	this	pathway.85		
In	 addition	 to	 these	 intrinsic	 factors,	 adult	 neurogenesis	 is	 further	 finely	 tuned	 by	
many	 extrinsic	 molecular	 players,	 including	 morphogens,	 growth	 factors	 and	
neurotransmitters	 (reviewed	 in	 86).	 Such	 signals	 form	 a	 complex	 network	 of	
interactions	that	regulate	NSCs	in	terms	of	proliferation,	migration,	 integration	and	
plasticity	maintenance.	For	example,	bone	morphogenetic	proteins	(BMPs)	promote	
glia	differentiation87	and	NSCs	quiescence,88	while	inhibiting	neural	differentiation	in	
the	 adult	 brain.	 Other	 known	 extrinsic	 regulators	 include	 Notch	 and	 Wnt	
pathways.86b	While	Notch	signaling	is	responsible	for	regulation	of	identity	and	self-
renewal	of	NSCs,	Wnt	play	a	fundamental	role	in	adult	hippocampus.	Notably,	Wnt	
promotes	 proliferation	 and	neuronal	 fate	 commitment	 of	 neural	 precursors	 in	 the	
adult	 SGZ,	 and	 its	 overexpression	 increased	 neurogenesis	 from	 adult	 progenitors	
both	 in	 vitro	 and	 in	 vivo.89	 By	 contrast,	 blockade	 of	 Wnt	 signaling	 decreases	
neurogenesis	 of	 adult	 progenitors	 in	 vitro	 and	 abrogates	 almost	 completely	
neurogenesis	 in	 vivo.89	 Additionally,	 glycogen	 synthase	 kinase-3β	 (GSK-3β),	 a	
downstream	 regulator	 of	 Wnt	 pathway,	 has	 been	 demonstrated	 to	 be	 critical	 in	
many	 processes	 during	 neurodevelopment.	 Indeed,	 the	 level	 of	 GSK-3β	 activity	
influences	 NPCs	 proliferation/differentiation	 during	 repairing	 processes,	 as	well	 as	
efficient	neurotransmission	in	differentiated	adult	neurons.	Understanding	how	GSK-
3β	 signaling	 controls	 neurogenesis,	 neuronal	 polarization	 and	 axon	 growth	 during	
brain	 development	 is	 particularly	 challenging	 due	 to	 the	 broad	 range	 of	 GSK-3β	
substrates.90	 Indeed,	 recent	 advances	 suggest	 that	 GSK-3β	 is	 a	 central	 node	 for	
multiple	 signaling	 pathways	 and,	 in	 this	 complex	 scenario,	 it	 orchestrates	 the	
proliferation	and	differentiation	of	neural	progenitors.	Moreover,	the	essential	role	
of	 GSK-3β	 signaling	 in	 neurogenesis	 has	 been	 confirmed	 by	 considering	 the	
involvement	in	neurodegenerative	disorders,	such	as	Alzheimer’s	disease	(AD).91		
Although	the	source	of	most	niche	signals	remains	to	be	fully	characterized,	it	is	clear	
that	multiple	morphogens	 are	 concomitantly	 acting	 on	 adult	 neural	 precursors	 to	
fine-tune	the	number	of	quiescent	precursors	and	the	amount	of	new	neurons	and	
astrocytes	in	the	adult	brain.	
In	 addition,	 four	 neurotrophic	 factors	 have	 been	 identified,	 namely	 nerve	 growth	
factor	 (NGF),	brain-derived	neurotrophic	 factor	 (BDNF),	neurotrophin	3	 (NT-3),	and	
neurotrophin	 4/5	 (NT-4/5)	 and	 their	 fundamental	 role	 in	modulating	neurogenesis	
has	 been	 widely	 recognized.92	 Neurotrophins	 bind	 to	 receptor	 tyrosine	 kinases	
known	as	Trk	receptors	(TrkA-C)	and	their	co-receptor	p75NTR,	displaying	different	
binding	affinities	for	the	different	neurotrophin.	Interestingly,	BDNF	is	known	for	its	
survival-promoting	effects	on	new	neuroblasts	through	the	TrkB	receptor,93	whereas	
the	proliferative	effect	of	NGF	on	NSC	proliferation	was	firstly	reported	by	Cattaneo	
and	McKay.94	Soon	after,	following	studies	revealed	that	NGF	promotes	proliferation	
through	the	phosphorylation	of	ERK1/2	in	NSCs	by	interacting	with	TrkA	receptor.95		
Accumulating	evidences	also	suggest	crucial	roles	of	neurotransmitters	in	regulating	
adult	NSCs	proliferation,	differentiation,	and	synaptic	integration,	as	well	as	activity-
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dependent	 adult	 neurogenesis.	 For	 example,	 GABA,	 the	 major	 inhibitory	
neurotransmitter	 of	 the	 brain,	 promotes	 NSC	 quiescence	 by	 blocking	 cell-cycle	
progression.96	 Also	 the	 dopamine	 receptor	 D2	 antagonist	 haloperidol	 (Figure	 5)	
increases	 SVZ	 NSCs	 division,	 suggesting	 that	 dopamine	 promotes	 quiescence	 as	
well.97	 In	 contrast,	 serotonin	 (5HT)98	 and	 acetylcholine	 (ACh)99	 activate	 SVZ	 NSCs.	
Interestingly,	serotonergic	axons,	a	small	set	of	neurons	originating	from	the	raphe,	
have	 been	 recently	 reported	 to	 critically	 modulate	 SVZ	 neurogenesis.	 Indeed,	
electron	 microscopy	 revealed	 that	 5HT	 axons	 form	 contacts	 between	 ependymal	
cells/NSCs	 expressing	 the	 5HT	 receptors	 2C	 and	 5A	 in	 the	 SVZ.	 To	 test	 this	
hypothesis,	 the	 authors	 evaluated	 the	 ability	 of	 5HT2C	 agonists	 (RO-60-0175)	 or	
antagonists	 (SB206553,	 in	 Figure	 5)	 to	 increase	 or	 decrease	 SVZ	 proliferation,	
respectively.98	 Paez-Gonzalez	 et	 al.	 disclosed	 an	 unknown	 population	 of	 choline	
acetyltransferase	(ChAT)	neurons	residing	and	regulating	the	SVZ	neurogenic	niche.	
In	contrast	to	neighboring	neurons,	ChAT	neurons	appear	to	be	functionally	different		
as	 they	 release	ACh	 locally	 in	an	activity-dependent	manner	 to	 control	neurogenic	
proliferation.	Following	experiments	revealed	that	SVZ	NSCs	directly	respond	to	local	
ACh	release,	synergizing	with	fibroblast	growth	factor	receptor	(FGFR)	activation	to	
	
	
Figure	5.	Small	molecules	modulating	specific	targets/pathways	of	NSCs.	
	
increase	neuroblast	production.99	These	results	suggest	an	unknown	ChAT-mediated	
pathway	 controlling	 SVZ	 neurogenesis	 and	 thus,	 may	 open	 new	 possibilities	 for	
modulating	neuroregenerative	capacities	in	health	and	disease.100		
However,	 it	 is	 worth	 to	 note	 that	 it	 is	 not	 always	 clear	 whether	 pharmacological	
manipulations	 act	 by	 directly	 affecting	 neural	 precursors	 and	 newborn	 neurons	 or	
through	 indirect	modulation	 of	 the	 niche.101	 Intriguingly,	 antidepressants	 (such	 as	
imipramine	 and	 fluoxetine,	 in	 Figure	 5)	 used	 in	 clinics,	 should	 increase	 neural	
progenitor	proliferation,	accelerate	dendritic	development,	and	enhance	survival	of	
newborn	 neurons	 in	 the	 adult	 hippocampus	 through	 changes	 in	 5HT	 and	
norepinephrine	levels.102  
In	parallel	to	cellular	players,	the	demonstration	that	stress	levels	negatively	affected	
the	 numbers	 of	 proliferating	 cells	 in	 the	 DG103	 fueled	 a	 plethora	 of	 studies	 to	
investigate	how	neurogenesis	can	be	also	significantly	 influenced	by	other	external	
stimuli.	For	example,	van	Praag	et	al.	demonstrated	that	physical	exercise	increases	
S
HN
O
O O
N
	Pioglitazone N R
N
R	=	CH₃	Imipramine
 R = H  Desipramine
N
H
O
FF
F
Fluoxetine
O
F
N
OH
Cl
	Haloperidol
N
F
Cl
NH2
RO-60-0175
N
N
NHO
N
SB206553
		 18	
cell	 proliferation	 in	 DG,104	while	 Gould	 and	 colleagues	 showed	 how	 learning	 tasks	
modulate	 adult	 neurogenesis	 in	 a	 complex	 and	 specific	 fashion,	 depending	
essentially	on	hippocampus.105	Conversely,	changes	in	neurogenesis	were	shown	to	
be	associated	with	age	and	pathological	conditions,	as	in	the	case	of	AD.	Particularly,	
the	effect	of	neurodegeneration	on	adult	neurogenesis	is	significantly	very	complex	
(reviewed	 in	 106).	 During	 neurodegeneration,	 activation	 of	 resident	 microglia,	
astrocytes,	and	infiltrating	peripheral	macrophages	causes	the	release	of	cytokines,	
chemokines,	neurotransmitters,	and	reactive	oxygen	species	(ROS),	which	differently	
affect	 various	 aspects	 of	 neurogenesis.106	 For	 example,	 in	 animal	 models	 of	 AD,	
aberrant	 GABA	 signaling	 influences	 differentiation	 of	 neural	 progenitors	 and	
dendritic	growth	of	newly	neurons	 in	the	SGZ.107	Another	major	negative	regulator	
of	 adult	 neurogenesis	 is	 inflammation,	 induced	 by	 injuries,	 degenerative	 and	
neurological	 diseases.108	 In	 addition	 to	 decrease	 the	 proliferative	 capacity	 and	
neuronal	 fate	 commitment	 of	 neural	 progenitors	 in	 the	 adult	 SGZ,	 inflammation	
disrupts	 the	 niche	microenvironment	 by	 increasing	 the	 number	 of	microglia	 cells,	
that	result	in	an	impaired	neurogenesis.109	
From	 the	 data	 discussed	 so	 far,	 it	 is	 evident	 that	 every	 single	 phase	 of	 adult	
neurogenesis	 can	 be	 regulated	 by	 different	 stimuli	 and	 each	 stimulus	 can	 have	
multiple	targets.	Furthermore,	different	stimuli	interact	with	each	other	and	impact	
the	final	outcome	of	adult	neurogenesis.	In	general,	regulation	of	adult	neurogenesis	
by	 external	 stimuli	 is	 complex	 and	 the	 effect	 depends	 on	 timing,	 dose/duration,	
specific	 paradigms,	 animal	models	 (age,	 sex,	 genetic	background),	 and	methods	of	
analysis.	 The	 major	 challenge	 is	 to	 identify	 intrinsic	 cellular	 and	 molecular	
mechanisms	underlying	different	stages	of	adult	neurogenesis.	What	are	targets	of	
particular	 stimulation-quiescent	 putative	 stem	 cells,	 their	 specific	 progeny,	 or	
mature	cell	types	from	the	niche?	Are	SGZ	and	SVZ	niches	differentially	regulated	by	
the	same	stimuli?		
Unfortunately,	we	 still	 have	 a	 lot	 of	 questions	 to	 answer	 about	 the	 application	 of	
NSCs	 in	 a	 therapeutic	 context.	 Further	 and	 concerted	 research	 is	 needed	 to	 fully	
disclose	 the	 therapeutic	 potential	 of	 regenerative	 medicine.	 In	 the	 following	
paragraph,	significant	examples	will	be	described.	
	
	
1.6	 New	 therapies	 for	 regenerative	 medicine:	 challenging	 and	 opportunities	 for	
neurodegenerative	diseases	
	
Traditionally,	 the	 term	 “regeneration”	 describes	 the	 processes	 that	 properly	
maintain	cell	number	(homeostasis)	and	replace	damaged	cells	after	injury	(repair).	
In	 almost	 all	 tissues,	 regenerative	 potential	 is	 determined	 by	 the	 presence	 of	 a	
dedicated	 population	 of	 stem	 and	 progenitor	 cells,	 which	 respond	 to	 endogenous	
and	exogenous	cues	to	produce	cells	replacement	as	needed.110	Given	the	ability	of	
SCs	 to	 become	 different	 cell	 types	 in	 the	 body,	 regenerative	medicine	 offer	 great	
promise	 in	 treating	 currently	 incurable	 diseases.13	 Particularly,	 the	 establishment	
that	 neurogenesis	 occurs	 continually	 throughout	 adults’	 life	 hold	 tremendous	
promise	for	treating	neurodegenerative	diseases,	such	as	AD	and	Parkinson’s	(PD).		
These	and	other	neurodegenerative	diseases	share	common	mechanisms	leading	to	
neuronal	dysfunction	and,	eventually,	neuronal	death.111	Current	therapies	address	
the	symptoms,	but	are	yet	not	effective	for	rescuing	cellular	function	or	even	halting	
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the	 neuronal	 death	 process.112	 As	 exemplified	 by	 AD	 clinical	 trials,	 AD	 drugs	 keep	
failing,	having	a	99.6	%	failure	rate.	Indeed,	a	recent	study	highlighted	that,	between	
2002	 and	 2012,	 only	 memantine	 (3,5-dimethyladamantan-1-amine)	 over	 244	
compounds	in	413	clinical	trials	for	AD,	was	approved	in	2003.113	Reasons	for	these	
failures	 are	 numerous,	 ranging	 from	 insufficient	 understanding	 of	 mechanisms	
underlying	 such	 diseases	 to	 poor	 diagnosis	 techniques.	 For	 example,	
neurodegeneration	 in	AD	 is	 determined	by	 a	 complex	 and	 intertwined	network	 of	
neurotoxic	 events	 that	 include	 oxidative	 stress,	metals	 dyshomeostasis,	 glutamate	
excitotoxicity,	 inflammatory	 process,	 proteins	 (Aβ	 and	 tau)	 misfolding	 and	
aggregation.	 Such	multifactorial	 nature	 of	 AD	 contributes	 in	 the	 failure	 of	 existing	
pharmacological	approaches	to	alter	the	disease	course.114	Furthermore,	the	current	
diagnosis	 relies	 on	 performing	 cognitive	 tests	 and	 looking	 for	 the	 presence	 of	
amyloid	plaques	and	neurofibrillary	tangles	 in	the	brain.	However,	 it	has	now	been	
recognized	 that	 the	 plaque	 stage	 of	 AD	 is	 a	 much-too-late	 phase	 at	 which	 to	
commence	 treatment.	 In	 addition,	 no	 single	 biomarker	 is	 reliable	 and	 valid	 for	
determining	 the	 true	 stage	 of	 AD	 advancement,	 further	 aggravated	 by	 the	 high	
variability	 of	 biomarker	 expression	 and	 disease	 progression	 in	 different	 AD	
patients.115		
The	depicted	scenario	is	not	different	from	that	seen	for	PD116	or	amyotrophic	lateral	
sclerosis	(ALS)117	 (see	cited	review	for	a	more	detailed	description).	In	all	cases,	this	
can	 be	 also	 ascribed	 to	 the	 models	 employed	 in	 vitro	 and	 in	 vivo,	 not	 truly	
representing	 the	 complexity	 of	 such	 diseases	 and	 lacking	 of	 clinical	 translation.115	
These	 findings	 are	 further	 exacerbated	 by	 the	 growing	 incidence	 of	 ageing	 and	
consequently	 of	 neurodegenerative	 diseases.	 According	 to	 Alzheimer's	 Disease	
International,	there	were	an	estimated	46.8	million	people	with	dementia	worldwide	
in	2015.118	
Against	 this	 backdrop,	 regenerative	 approaches	 involving	 both	 SCs	 replacement	
therapy	 and	 the	 modulation	 of	 SCs	 using	 small	 molecules	 have	 the	 potential	 to	
revolutionize	neurodegenerative	diseases	treatment	in	the	future.	
	
	
1.6.1	New	regenerative	cellular	therapies	for	neurodegenerative	diseases	
	
To	date,	 the	 therapeutic	potential	of	NSCs	has	been	already	demonstrated	 in	vitro	
and	 also	 in	 vivo	 in	 various	 animal	 models	 of	 diseases,	 and	 some	 of	 them	 have	
entered	the	clinical	trials.	Starting	from	the	outstanding	paper	by	Blurton-Jones	and	
coworkers,119	where	NSCs-injection	rescued	the	cognitive	phenotype	and	 increased	
synaptic	 density	 in	 triple	 transgenic	mouse	model	 of	 AD,	 the	 beneficial	 effects	 of	
NSCs	 transplantation	 in	 neurodegenerative	 states	 seem	 to	 be	 a	 dream	 becoming	
reality.120 Indeed,	 Stemedica	 International	 recently	 provided	 the	 means	 to	 bring	
allogeneic	human	mesenchymal	stem	cells	 (MSCs)	 in	clinical	 trial.120	Accordingly,	 in	
2015	 the	US	Food	and	Drug	Administration	 (FDA)	granted	approval	 for	a	phase	2A	
trial	 using	 intravenous	 administration	 of	 MSCs	 to	 treat	 patients	 with	 mild	 to	
moderate	dementia	caused	by	AD.121	
An	 additional	 biopharmaceutical	 company,	 Neuralstem	 Inc.,	 actively	 working	 on	
NSCs	technology	and	harnessing	the	benefits	of	combining	cellular	and	growth	factor	
therapies,	reported	on	the	possibility	to	implement	human	cortical	NSCs	expressing	
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insulin-like	growth	factor-1	as	a	novel	cellular	therapy	for	AD.122	As	a	consequence,	
the	observed	beneficial	effect	arises	from	the	synergistic	actions	of	both	cell	therapy	
and	 growth	 factor	 implementation.	 Even	 though	 this	 study	 is	 still	 in	 its	 infancy	
lacking	 of	 clinical	 translation,	 Neuralstem	 also	 pioneered	 human	 fetal	 NSC	
transplants	 for	 ALS	 patients,	 already	 in	 clinical	 trials.123	 However,	 to	 date,	 clinical	
applications	of	NSCs	based	on	cell	 replacement	 therapy	has	 shown	 limited	success	
due	 to	 inefficient	 survival,	 increased	 risk	 of	 tumorigenicity	 and	 possible	 immune	
responses124	 (as	 previously	mentioned	 for	 SCI	 in	 Par.	 1.1).	 In	 addition,	 the	 use	 of	
human	ESCs	or	fetal	SCs	as	SCs	sources	has	raised	numerous	ethical	issues.125		
	
	
1.6.2	New	neuroregenerative	 therapeutic	 small	molecules	 for	 neurodegenerative	
diseases	
	
By	 contrast,	 adult	 SCs	 and	 the	 recently	 discovered	 iPSCs	 are	 exempted	 from	
unwanted	ethical	controversy,	thus	emerging	as	alternative	SCs	source	not	only	for	
cell	therapy	but	also	for	disease	modeling	and	phenotypic	drug	discovery.11	In	fact,	a	
recent	application	focused	on	modeling	AD	using	both	familial	and	sporadic	patient-
derived	 iPSCs.	 This	 study	 revealed	 stress	 phenotypes	 and	 differential	 drug	
responsiveness	associated	with	 intracellular	amyloid	beta	oligomers	 in	AD	neurons	
and	astrocytes.126	 In	PD,	a	prominent	work	aimed	to	model	disease,	to	 identify	the	
corresponding	hallmarks,	and	to	screen	drugs	has	been	recently	reported	by	Chung	
et	al.127	Once	confirmed	the	connection	between	α-Synuclein	(α-Syn)	and	nitrosative	
stress	in	both	yeast	and	rat	models	involving	cortical	neurons,	the	authors	generated	
cortical	 neurons	 from	 iPSCs	 of	 PD	 patients	 with	 α-Syn	 mutations	 to	 screen	 for	
compounds	 that	 rescue	 α-Syn	 toxicity.	 Implementing	 a	 copper	 complex	 as	 a	
fluorescent-based	sensor	for	the	screening	assay,	they	showed	that	the	nitric	oxide	
level	was	higher	in	PD-neurons	compared	to	control.	Interestingly,	they	found	that	a	
small	molecule	NAB2	(Figure	6)128	is	able	to	rescue	yeast	from	α-Syn	toxicity	and	to	
decrease	nitric	oxide	level	in	PD-neurons.		
Concerning	ALS,	Yang	et	al.	performed	an	innovative	small	molecules	survival	screen,	
using	motor	neurons	(MNs)	from	both	wild-type	and	mutant	SOD1	mESCs.	From	the	
screening,	the	multikinases	(GSK-3β	and	mitogen-activated	protein	kinase	4	(MAP4K)	
kinases)	 inhibitor	 kenpaullone	 (Figure	 3)	 was	 identified.	 It	 showed	 an	 impressive	
ability	to	prolong	the	healthy	survival	of	both	types	of	MNs	that	can	be	attributed	to	
its	dual	 inhibition.	Furthermore,	kenpaullone	also	strongly	 improved	the	survival	of	
human	MNs	 derived	 from	 ALS	 patient-iPSCs,	 resulting	more	 active	 than	 reference	
compounds	(olesoxime	and	dexpramipexole).129	
Collectively,	 these	 findings	 clearly	 demonstrate	 that	 patient-derived	 iPSCs	 would	
enable	 drug	 evaluation	 in	 reliable	 models,	 able	 to	 recapitulate	 all	 the	 molecular	
features	underlying	neurodegeneration.	Moreover,	due	to	the	high	variability	and	to	
the	lack	of	standardized	protocol	to	generate	iPSCs,	iPSCs-based	cell	therapy	is	being	
blemished	by	reprogramming	iPSCs	from	patient’s	cells.	These	emerge	as	innovative	
platforms	 for	 developing	 disease-relevant	 cellular	 phenotypes	 suitable	 for	 drug	
discovery	purposes.11	
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Figure	6.	Small	molecules	with	regenerative	therapeutic	potential.	
	
Thus,	an	exciting	alternative,	which	avoids	SCs-based	therapy,	is	rapidly	emerging	in	
the	field	of	neuroregenerative	medicine:	the	activation	of	endogenous	neurogenesis	
and	 neuroprotection	 via	 chemical	 modulation.13	 Small	 molecules	 triggering	
neurogenesis	 are	 particularly	 interesting	 not	 only	 because	 of	 their	 enormous	
therapeutic	 implications,	 but	 also	because	 they	 can	 serve	 as	 tools	 to	 decipher	 the	
biological	mechanisms	of	neurogenesis.		
The	 chemical	 stimulation	 of	 endogenous	 SCs-based	 repair	 mechanisms	 has	 been	
successfully	 exploited	 to	 treat	major	 depressive	 disorder	 (MDD)	by	Neuralstem.	 In	
this	case,	the	company	has	completed	Phase	Ia	and	Ib	trials	evaluating	safety	doses	
and	pharmacokinetic	 (PK)	of	 its	 first	neurogenic	small	molecule	product	candidate,	
the	 benzylpiperazine-aminopyridine	 NSI-189	 (Figure	 6).130	 At	 this	 time,	 NSI-189’s	
mechanism	of	action	remains	elusive.	As	clinical	trials	progress,	it	is	expected	that	an	
increasing	amount	of	data	will	appear	discussing	how	NSI-189	elicits	 its	neurogenic	
effect	in	hippocampus	and	its	neuroprotective/nootropic	properties.	
Although	 this	 paragraph	 reported	 on	 the	 first	 proof-of-concept	 of	 regenerative	
strategy,	unfortunately	there	is	not	a	general	streamlined	approach	to	identify	small	
molecules	with	these	intriguing	regenerative	features.		
In	 the	 next	 paragraph,	 the	 basic	 strategies	 to	 discover	 new	 chemical	 probes	 and	
drugs	targeting	NSCs	will	be	described,	with	a	special	emphasis	on	the	peculiarities	
of	target-based	vs.	phenotypic-based	approaches.	
	
	
1.7	Target-based	vs.	phenotypic	based	approaches	in	NSCs	
	
Several	 target-based	 approaches	 have	 yielded	 small-molecule	modulators	 of	 HSCs	
self-renewal,	as	previously	mentioned	in	Par.	1.4.2.	In	the	case	of	NSCs,	the	situation	
appears	more	complicate	due	to	the	lack	of	well-characterized	pathways	involved	in	
a	 specific	 process	 of	NSCs	 fate.	Despite	 that,	 epigenetic	 alteration	 is	 an	 important	
determinant	 in	 lineage	 specification	 of	 NSCs,131	 making	 epigenetic	 enzymes	
attractive	 targets.132	 Among	 these,	 the	 HDACi	 have	 been	 widely	 studied.132	 For	
example,	 valproic	 acid	 (Figure	 4)	 induced	 neuronal	 differentiation	 of	 adult	
hippocampal	 neural	 progenitors.	 In	 addition,	 valproic	 acid	 inhibited	 astrocyte	 and	
oligodendrocyte	 differentiation,	 by	 up-regulating,	 neuron-specific	 genes,	 such	 as	
NeuroD,	 resulting	 in	 the	 induction	 and	 suppression	 of	 neuronal	 and	 glial	
differentiation,	 respectively.	 These	 results	 suggest	 that	 valproic	 acid	 promotes	
neuronal	 fate	 and	 inhibits	 glial	 fate	 simultaneously	 through	 the	 induction	 of	
neurogenic	 transcription	 factors	 including	 NeuroD.133	 Similarly,	 a	 following	 report	
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demonstrated	 that	 epigenetic	 mechanisms	 regulate	 timing	 of	 progenitor	 cell	
differentiation	 into	 myelin-forming	 oligodendrocytes	 in	 vivo.134	 In	 this	 context,	
histone	deacetylation	was	shown	to	be	essential	during	a	specific	temporal	window	
of	 oligodendrocytes	 differentiation	 and	 myelin	 gene	 expression.	 Indeed,	
administration	of	valproic	acid	resulted	in	significant	hypomyelination	with	delayed	
expression	of	oligodendrocytes	markers,	while	maintaining	expression	of	progenitor	
markers.	 Taken	 together,	 these	 data	 identify	 modifications	 of	 histones	 critical	 for	
controlling	 neuronal	 versus	 oligodendrocyte	 differentiation.	 Interestingly,	 another	
report	 supported	 the	hypothesis	 that	HDAC	 inhibition	promotes	neuronal	 fate	and	
simultaneously	 inhibits	 glial	 fate	 through	 the	 direct	 induction	 of	 neurogenic	
transcription	 factors,	 such	 as	 NeuroD.135	 In	 detail,	 starting	 from	 the	 unexpected	
results	 that	 a	 subset	 of	 small	 molecules	 screened	 for	 cardiogenic	 differentiation	
induced	 a	 neuronal	 phenotype,136	 Schneider	 et	 al.	 counter-screened	 these	 hits	 for	
their	 neurogenic	 potential	 and	 identified	 five	 3,5-disubstituted	 isoxazole	 hits	 that	
selectively	 convert	 NSCs	 into	 neurons	 expressing	 NeuroD.135	 In	 search	 of	 a	 more	
potent	 and	 soluble	 lead,	 the	 authors	 synthesized	 a	 focused	 library	 of	 3,5-
disubstituted	isoxazoles	(75	analogues)	that	 led	to	the	identification	of	 ISX9	(Figure	
4).	Additional	experiments	showed	that	it	activates	CaMKII	(the	major	HDAC	kinase),	
which	 in	 turn	 led	 to	 sequestration	of	HDAC5	 from	 the	nucleus,	 thus	de-repressing	
neurogenic	 transcription	factors,	 including	NeuroD.	These	studies	provide	evidence	
that	blockade	of	HDAC	activity	plays	a	major	role	 in	neuronal	 lineage	specification.	
Indeed,	Hao	et	al.137	also	demonstrated	that	HDAC	inhibition	promotes	neurogenesis	
in	vivo;	however,	they	suggested	that	the	effect	observed	with	valproic	acid	did	not	
result	 exclusively	 from	 HDAC	 inhibition.	 It	 is	 well	 known	 that	 valproic	 acid,	 in	
addition	 to	 modulating	 HDAC	 activity,	 inhibits	 GSK-3β	 and	 activates	 the	 mitogen-
activated	protein	kinase	(MEK)/ERK	pathway.	Intriguingly,	the	selective	inhibition	of	
GSK-3β,	HDACs,	 or	 both	GSK-3β	 and	HDACs	did	not	 produce	 the	 same	neurogenic	
activity	as	that	produced	by	valproic	acid,	indicating	that	activation	of	MEK/ERK	may	
also	 be	 proneurogenic	 in	 vivo.	 Further	 evidence	 that	 the	 inhibition	 of	 HDAC	 is	
neurogenic	came	from	the	work	of	Fischer	et	al.	who	demonstrated	that	this	applies	
also	 in	 vivo.	 In	 fact,	 treatment	of	mice	with	 the	HDACi	 sodium	butyrate	 (Figure	7)	
promoted	dendrites	propagation,	 increased	synapse	number,	and	restored	learning	
behavior	and	long-term	memories.138		
Collectively,	 these	 data	 demonstrate	 that	 HDAC	 mediated	 gene	 regulation	 is	 an	
important	determinant	of	neural	 lineage	progression	and	maintenance	 in	the	brain	
and	 that	 inhibition	 of	 HDACs	 may	 serve	 as	 a	 means	 to	 stimulate	 the	 brain’s	
regenerative	mechanisms	in	vivo.139	
Another	strategy	to	develop	small	molecules	for	regeneration	is	to	focus	on	defined	
molecular	targets	or	pathways,	such	as	Wnt-mediated	signalling,	which	is	implicated	
in	 specific	 regenerative	 processes	 as	 already	 shown.	 One	 potential	 concern	 about	
activating	a	regenerative	pathway	is	the	risk	of	causing	certain	genetic	alterations	or	
abnormal	 gene	expressions	 that	 lead	 to	 the	 activation	of	 some	of	 those	pathways	
that	 have	 been	 associated	 with	 cancer.	 Strategies	 such	 as	 temporal	 and/or	
synergistic	 activation	may	 provide	 a	 viable	 solution.	 To	 discover	 novel	 compounds	
and	 pathways	 that	 interact	 with	 the	 canonical	 Wnt–β-catenin	 signalling	 pathway,	
Zhang	 et	 al	 set	 up	 a	 reporter	 based	 high-throughput	 screen	 for	 small	 molecules	
(100,000	compounds)	that	synergistically	with	Wnt3A	ligand	activate	the	reporter.140	
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A	2,6,9-trisubstituted	purine	 compound,	QS11	 (Figure	7),	 has	been	 selected	 for	 its	
ability	 to	 synergize	with	 canonical	Wnt	 proteins	 both	 in	 vitro	 and	 in	 vivo.	 Affinity	
chromatography	identified	the	GTPase	activating	protein	of	ADP-ribosylation	factor	1	
(ARF-GAP)	as	a	target	of	QS11.	Additional	biochemical,	genetic	and	functional	studies	
have	 confirmed	 that	 QS11	 inhibits	 ARF-GAP,	 suggesting	 that	 QS11	 interacts	 with	
Wnt/β-catenin	signaling	through	modulating	ARF	activity	and	β-catenin	localization.		
Although	targeted	modulation	of	known	pathways	and	the	epigenome	has	identified	
a	 variety	 of	 operative	 mechanisms	 in	 NSCs,	 the	 field	 still	 lacks	 a	 complete	
understanding	of	how	to	selectively	control	NSCs	fate.	Thus,	designing	unbiased	cell-
based	 screens	 to	 identify	novel	mechanisms	 that	 control	NSCs	 fate	 is	 an	emerging	
strategy.	The	promising	outcomes	provided	by	this	approach	led	to	the	discovery	of	
a	2-substituted	aminothiazol	(neuropathiazol,	Figure	7).141	Warashina	and	colleagues	
used	an	imaging-based	screen	with	neuronal	(Tuj-1)	and	astroglial	(GFAP)	markers	to	
identify	 compounds	 that	 direct	 the	 differentiation	 of	 adult	 NPCs	 into	 neurons	 or	
astrocytes,	 respectively.141	 Notably,	 neuropathiazol	 induced	 up	 to	 80%	 of	 cells	 to	
differentiate	 into	 Tuj-1-positive	 neurons	 with	 characteristic	 neuronal	 morphology. 
But	 also,	 it	 increased	 the	 expression	 of	 NeuroD,	 concomitantly	 decreasing	 the	
expression	 of	 Sox2.	 Importantly,	 unlike	 retinoic	 acid,	 neuropathiazol	 blocked	 the	
proliferation	 and	 BMP-induced	 astrocyte	 differentiation	 of	 NSCs.141	 Following	 SAR	
study	 identified	 a	 molecule,	 KHS101	 (Figure	 7),	 which	 displayed	 improved	
neurogenic	 activity	 in	 vitro	 and	 brain	 penetration	 compared	 to	 neuropathiazol.142	
KHS101	 also	 increased	 neuronal	 differentiation	 in	 adult	 rats	 and	 affinity	
chromatography	 revealed	 the	 transforming	 acidic	 coiled-coil	 containing	 protein	 3	
(TACC3)	 as	 a	 putative	 target.	 Genetic	 modifications	 of	 cultured	 NPCs	 aimed	 at	
reducing	TACC3	expression	produced	a	neuronal	differentiation	phenotype	similar	to	
cells	 treated	with	KHS101.	 Interestingly,	 treatment	with	KHS101	also	 increased	the	
nuclear	 localization	 of	 the	 nervous	 system–specific	 transcription	 factor	 aryl	
hydrocarbon	 receptor	 nuclear	 translocator	 2	 (ARNT2),	 whose	 overexpression	 also	
promotes	neuronal	differentiation.	Altogether,	these	evidences	indicate	that	KHS101	
modulates	neurogenesis	by	interacting	with	TACC3	and	supporting	the	existence	of	a	
functional	link	between	TACC3-ARNT2.153		
To	discover	novel	signaling	pathways	involved	in	NSCs	self-renewal,	Diamandis	et	al.	
designed	an	unbiased	chemical-genetic	cell-based	screen	with	the	goal	of	identifying	
those	that	inhibit	neurosphere	proliferation	in	mouse	NSCs.143	The	authors	screened	
pharmacologically	 active	 compounds	 (1,267	 compounds)	 and	 after	 filtering	 out	
cytotoxic	 molecules,	 the	 selected	 hit	 compounds	 with	 promising	 effects	 on	 NSC	
cultures	were	subjected	to	additional	studies.	These	studies	revealed	that	these	hits	
(such	 as	 dihydrocapsaicin,	 an	 agonist	 of	 the	 vanilloid	 receptor;	 apomorphine,	 an	
agonist	of	the	dopamine	receptor;	and	PAPP	(Figure	7),	a	serotonin	agonist,	as	well	
as	numerous	other	modulators	of	the	serotonin,	opioid	and	glutamate	pathways	143)	
are	 neuromodulatory.	 In	 understanding	 the	 mechanisms	 of	 action	 of	 these	
compounds,	one	important	question	is	whether	they	are	acting	on	replicative	NSCs	
or	differentiated	cells.	Diamandis	et	al.	addressed	this	point	by	testing	whether	the	
compounds	 prevented	 treated	 neurosphere	 cells	 from	 giving	 rise	 to	 new	
neurospheres	 after	 a	 period	 of	 culture	 without	 the	 compound.	 New	 neurosphere	
formation	 was	 indeed	 inhibited	 by	 many	 of	 the	 compounds,	 indicating	 that	 the	
replicative	SCs	capable	of	re-establishing	neurospheres	had	been	depleted.	Notably,	
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many	 of	 the	 compounds	 identified	 as	 anti-proliferative	 for	 neurospheres	 also	
inhibited	 tumor	 spheroid	 growth	 in	 vitro,	 including	 those	 known	 as	modulators	 of	
the	 dopamine,	 N-methyl-D-aspartate	 (NMDA),	 opioid,	 vanilloid	 and	 serotonin	
pathways.143		
Similarly,	 Kim	 et	 al.	 designed	 a	 chemical	 genomics	 screen	 with	 the	 aim	 of	
understanding	 genes	 and	 pathways	 that	 modulate	 neural	 stem/precursor	 cell	
differentiation.144	A	quantitative	whole-cell	immunofluorescence	assay	was	set	up	to	
screen	tool	compound	collections	with	the	goal	of	 identifying	small	molecules	able	
to	 increase	NSCs	 differentiation	 toward	 neuronal	 lineage	 in	mouse	NPCs.	Notably,	
among	the	42	proneurogenic	molecules	identified,	27	compounds	are	known	GSK-3β	
inhibitors.	To	further	validate	such	screening	by	confirming	the	effect	of	GSK-3β	hit	
compounds	 on	 neural	 specification,	 one	 representative	 GSK-3β	 inhibitor	 hit	
compound	 (SB627772)	 was	 confirmed	 in	 human	 NSCs	 culture.	 Additionally,	
SB627772	was	also	shown	to	promote	endogenous	neurogenesis	in	the	SVZ	region	in	
vivo.	 This	 study	 clearly	 demonstrates	 that	 a	 phenotypic	 assay	 using	
immunofluorescent	markers	can	be	used	for	compounds	screen	to	discover	targets	
and	 pathways	 related	 to	 the	 differentiation	 of	 lineage-restricted	 precursor	 cells	
toward	specific	lineages.144	
Finally,	 the	 implementation	 of	 a	 SCs-based	 model	 of	 motor	 neurons	 (MNs)	
degeneration	 induced	 by	 microglial	 activation	 has	 been	 recently	 reported.145	 In	
contrast	 to	 the	 previous	 examples,	 this	 assay	 has	 been	 designed	 looking	 for	
neuroprotective	small-molecules	using	SCs-derived	MNs	and	activated	microglia	as	a	
stress	 paradigm.	 From	more	 than	 10,000	 small	molecules	 tested	 at	 10	 µM,	 12	 hit	
compounds	were	selected	for	further	testing.	These	compounds	act	through	diverse	
pathways,	including	the	inhibition	of	nitric	oxide	production	by	microglia,	activation	
of	 the	Nrf2	 pathway	 in	microglia	 and	 astrocytes,	 and	direct	 protection	 of	 neurons	
from	 nitric-oxide-induced	 degeneration.	 Hierarchical	 clustering	 of	 the	 data	 from	
expression	profiling	revealed	a	tight	association	of	four	hit	compounds	E5,	E14,	E19,	
and	 E20,	 whose	 activity	 was	 confirmed	 using	 human	 neurons.	 Considering	 that	
microglial	cells	are	activated	in	many	neurodegenerative	disorders,	the	identified	hit	
compounds	 could	 be	 suitable	 starting	 points	 for	 the	 development	 of	 new	
neuroprotective	drugs	to	treat	various	neurodegenerative	diseases.145		
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Figure	 7.	 Small	 molecule	 probes	 of	 NSCs	 discovered	 by	 target-based	 and	 phenotypic	 based	
approaches.	
	
Although	 these	 examples	 are	 only	 few	 demonstrating	 unique	 roles	 of	 small	
molecules	 in	 NSCs	 biology,	 systematic	 screens	 to	 identify	 previously	 uncovered	
pathways	 in	 neural	 precursors	 in	 an	 unbiased	 manner	 are	 being	 performed.	 For	
example,	 many	 of	 the	 small	 molecules	 screens	 designed	 to	 identify	 chemical	
regulators	of	SCs	biology	have	been	biased	to	particular	pathways	(i.e.	Wnt)	already	
known	to	be	involved	in	SCs	biology.	Although	these	screens	have	helped	discovering	
new	 agents	 that	 regulate	 NSCs	 biology,	 the	 screen	 design	 precludes	 the	
identification	 of	 novel	 pathways	 regulating	 NSCs	 function.	 Although	 investigations	
into	these	pathways	will	undoubtedly	 lead	to	new	insights	and	potential	 therapies,	
parallel	work	into	identifying	novel	pathways	and	targets	is	also	necessary	to	move	
the	field	forward.	Unbiased	screening	of	novel	pathways	regulating	NSCs	processes	
will	help	further	our	understanding	of	the	NSCs	biology	and	of	the	complete	network	
of	signals	regulating	their	self-renewal	and	multi-lineage	differentiation	potential.		
In	the	following	paragraph,	an	exemplificative	unbiased	in	vivo	screening	to	discover	
molecules	with	neuroregenerative	potential	will	be	discussed.	
	
	
1.7.1	An	innovative	unbiased	phenotypic	approach	toward	the	discovery	of	P7C3	
	
An	 ever-increasing	 number	 of	 screens	 for	 small	 molecules	 that	 can	modulate	 the	
proliferation	 and	 differentiation	 of	 NSCs	 have	 been	 successfully	 described	 in	 the	
previous	 paragraph	 (and	 reviewed	 in	 24).	 However,	 it	 should	 be	 noted	 that	 such	
screening	assays	have	been	limited	to	cell	lines	and	ex	vivo	assays,	and	hits	in	many	
cases	display	unfavorable	pharmacokinetics	for	in	vivo	application.	
A	brilliant	work	 recently	published	 in	Cell	 reported	on	a	novel,	unbiased	 screen	 to	
identify	 compounds	 that	 selectively	 enhance	 production	 of	 neurons	 from	 NSCs	 in	
living	 mice.146 This	 approach	 proposed	 by	 Pieper	 et	 al.	 elegantly	 bypasses	 the	
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above-discussed	 roadblocks,	 leading	 to	 the	 discovery	 of	 a	 previously	 unknown	
compound	 with	 direct	 translational	 and	 clinical	 potential	 for	 neurodegenerative	
diseases.147 First	of	all,	 the	authors	performed	an	 in	silico	screen	to	 identify	about	
1,000	 compounds	 with	 favorable	 pharmacokinetic	 properties	 that	 were	 clustered	
into	groups	of	10.	Then,	the	effects	on	cell	proliferation	and	survival	within	the	SGZ	
were	 detected,	 and	 re-testing	 individual	 compounds	 from	 the	 identified	 groups	 of	
molecules	 led	to	the	 identification	of	8	proneurogenic	compounds	selected	 for	 the	
desired	pharmacological	profile.	Particularly,	an	aminopropylcarbazole	(P7C3,	Figure	
8)	exhibited	highly	 favorable	pharmacological	and	PK	profiles,	being	able	to	readily	
cross	 the	 BBB	 and	 to	 prevent	 the	 death	 of	 newborn	 neurons.	 To	 examine	 this	
further,	 the	 authors	 used	 a	mouse	model	with	 impaired	 SGZ	 neurogenesis	 due	 to	
elevated	 apoptosis	 of	 newborn	 neurons.	 P7C3	 is	 able	 to	 restore	 normal	 SGZ	
neurogenesis	 in	 this	 model	 by	 inhibiting	 apoptosis,	 perhaps	 regulated	 in	 part	 by	
maintaining	mitochondrial	integrity.146	As	a	further	step,	a	series	of	P7C3	derivatives	
were	designed	to	explore	the	SAR	around	P7C3	scaffold	with	the	goal	of	identifying	
compounds	 that	 promoted	 survival	 and	 proliferation	 of	 newborn	 neurons	 with	
improved	 potency	 and	 drug-like	 properties.	 	 In	 addition,	 chemical	 probes	 were	
purposely	 developed	 to	 provide	 insights	 into	 its	mechanism	 of	 action.	 In	 the	 first	
case,	 the	 chemical	 optimization	 of	 P7C3	 allowed	 the	 identification	 of	 two	
compounds,	 P7C3-A20	 (Figure	 8)148	 and	 then	 (-)-P7C3-S243	 (Figure	 8),149	 with	
improved	drug-like	properties,	while	preserving	the	neurogenic	activity.	On	the	basis	
of	 SAR	 studies,	 a	 suitable	 site	 that	 tolerates	 substitution	 without	 affecting	 the	
activity	was	 identified.	 In	particular,	by	modifying	 the	amine	 function	of	P7C3,	 the	
probes	 P7C3-S324	 (Figure	 8)147	 and	 P7C3-S326	 (Figure	 8)	 have	 been	 developed.150	
Specifically,	 P7C3-S324	 was	 decorated	 with	 a	 biotin	 moiety	 to	 use	 in	 affinity	
chromatography,	while	P7C3-S326	with	a	benzophenone	photo-crosslinker	modified	
with	an	alkyne	functionality	to	use	for	post-crosslinking	click	conjugation	to	biotin,	a	
fluorescent	dye	or	a	solid	support.	Although,	 the	precise	mechanism(s)	of	action	 is	
still	 undisclosed,	 P7C3-S326	 allowed	 to	 identify	 nicotinamide	
phosphoribosyltransferase	(NAMPT),	as	putative	target.	Interestingly,	P7C3	seems	to	
act	 by	 enhancing	 the	 activity	 of	 this	 protein,	 which	 represents	 the	 rate-limiting	
enzyme	 involved	 in	 the	 conversion	 of	 nicotinamide	 into	 nicotinamide	 adenine	
dinucleotide	 (NAD).	 These	 results	 are	 in	 line	with	 the	 initial	 hypothesis	 that	 P7C3	
class	of	proneurogenic	compounds	affects	mitochondrial	integrity	or	signaling.147	
Based	 on	 these	 encouraging	 findings	 and	 having	 established	 the	 structural	
requirements	underlying	the	neurogenic	activity,	the	authors	also	assessed	the	P7C3	
neurogenic	and	neuroprotective	efficacy	 in	different	mouse	models	of	neurological	
disorders.	Consistently,	it	has	been	showed	that	P7C3	is	effective	in	a	mouse	model	
of	 PD	 protecting	 against	 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine	 (MPTP)-
mediated	 cell	 death	 of	 dopaminergic	 neurons	 in	 the	 substantia	 nigra.151	
Furthermore,	 derivative	 (-)-P7C3-S243	 was	 also	 evaluated	 in	 the	 rat	 6-
hydroxydopamine	 model	 of	 PD,	 showing	 a	 promising	 neuroprotective	 profile.152	
Similarly,	 P7C3-A20	 has	 been	 showed	 to	 protect	 ventral	 horn	 spinal	 cord	 motor	
neurons	 from	 cell	 death	 in	 the	 G93A-SOD1	 mutant	 mouse	 model	 of	 ALS.153	
Additionally,	 P7C3	 derivatives	 preserve	 axonal	 integrity	 after	 injury	 in	 a	 rodent	
model	of	blast-mediated	traumatic	brain	injury	(TBI)154	and	also	rescue	neurons	and	
improve	 functional	 outcomes	 following	 peripheral	 nerve	 injury.155	 Furthermore,	 it	
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has	been	reported	on	the	ability	of	P7C3	to	restore	the	neurogenic	deficits	observed	
in	 the	 Ts65Dn	 mouse	 model	 of	 Down	 syndrome.156	 Finally,	 considering	 the	
convergence	of	evidence	 linking	neurogenesis	with	depressive-like	behavior,	P7C3-
A20	demonstrated	greater	proneurogenic	efficacy	than	a	wide	spectrum	of	currently	
marketed	antidepressant	drugs	in	depression-prone	Ghsr-null	mice.157		
	
Figure	8.	P7C3-based	development	of	lead	compounds	and	chemical	probes.	
	
All	 in	 all,	 this	 is	 a	 truly	 landmark	 study,	 providing	 several	 important	 advances:	 a	
formidable	 new	 screening	 approach	 in	 living	 mice	 and	 the	 related	 biological,	
biochemical	 and	 animal	 studies.	 Indeed,	 it	 offers	 benchmarks	 and	 methods	 for	
future	 in	 vivo	 small-molecule	 screening	 in	 mammals,	 incomparable	 to	 previous	
whole-organism	screening	in	invertebrates	and	non-mammalian	vertebrates	such	as	
zebrafish.158	 In	 this	 in	vivo	“target-agnostic”	screen,	hits	are	biased	toward	desired	
phenotypic	 and	 pharmacological	 profiles,	 thereby	 permitting	 to	 ad	 hoc	 filter	 out	
compounds	 with	 unfavorable	 PK.	 Moreover,	 the	 in	 vivo	 setting	 allows	 the	
modulation	of	SCs	 in	 their	natural	microenvironment,	 thus	avoiding	 false	positives,	
possibly	 arising	 from	 ex	 vivo	 SCs	 culture	 or	 from	 SCs	 lines.	 To	 note,	 P7C3	 has	
favorable	 pharmacokinetics,	 low	 toxicity	 and	 no	 teratogenicity.	 Thus,	 as	 P7C3	 is	
highly	 promising	 in	 promoting	 survival	 of	 newborn	 neurons	 and	 maintaining	
mitochondrial	integrity,	P7C3	derivatives	may	be	very	effective	in	the	clinical	setting	
of	neurodegenerative	disease.	
Of	note,	this	approach,	which	aims	at	discovering	new	neuroregenerative	drugs,	also	
represents	 a	 valuable	 example	 of	 chemical	 biology	 platform	within	 academia	 (i.e.	
University	 of	 Texas	 Southwestern	 Medical	 Center).159	 Indeed,	 this	 brilliant	 study	
would	 not	 take	 place	 without	 the	 remarkable	 integration	 of	 a	 high-throughput	
screening	facility,	a	medicinal	chemistry	laboratory,	and	a	structural	biology	core,	all	
supporting	the	mission	of	understanding	and	harnessing	interactions	between	small	
molecules	and	biology.159	
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2.	Aims	and	objectives	
	
The	 power	 of	 small	 molecules	 to	 address	 questions	 in	 cell	 biology	 has	 fueled	 an	
explosion	 of	 interest	 in	 chemical	 biology	 during	 the	 last	 two	 decades.160	 The	
development	of	chemical	probes	–	i.e.	small	molecules	that	specifically	and	potently	
modulate	 the	 activities	 of	 cellular	 targets	 -	 is	 an	 established	 strength	 of	 chemical	
biology.160	 Indeed,	 such	 chemical	 probes	 represent	 valuable	 tools	 for	 the	 study	 of	
biological	 systems	 at	 the	 molecular	 level	 and	 also	 contribute	 to	 drug	 discovery.	
Particularly,	 chemical	 biology	 has	 already	 tackled	 challenges	 in	 several	 incurable	
diseases,	 especially	 in	 the	 field	 of	 neurodegeneration.161	 In	 this	 context,	 chemical	
probes	offer	significant	potential	as	tools	for	perturbing	and	understanding	relatively	
unexplained	 targets	and	pathways	 involved	 in	 the	neurodegenerative	processes.161	
For	example,	the	main	chemical	biology	approach	towards	understanding	the	causes	
of	Alzheimer’s	disease	 (AD)	was	and	 still	 is	 largely	directed	 to	 the	development	of	
chemical	probes	for	amyloid	β	(Aβ).161 This	has	allowed	to	gain	significant	insights	on	
its	 formation,	structure,	and	 interactions	with	metals,	membranes,	proteins	and	to	
develop	 potential	 drug	 and	 imaging	 agent	 candidates.162	 Despite	 the	 significant	
advances,	however	the	development	of	chemical	tools	and	drugs	for	AD	is	an	urgent	
need.113	 Indeed,	 the	 absence	 of	 effective	 treatments	 in	 general	 against	 the	
neurodegenerative	 diseases	 provides	 an	 opportunity	 for	 innovative	 approaches,	
especially	 within	 academia.163	 In	 this	 respect,	 an	 emerging	 strategy	 relies	 on	 the	
activation	 of	 endogenous	 neural	 stem	 cells	 (NSCs)	 within	 our	 brain,	 as	 well	
neurogenesis	 and	 neuroprotection	 mechanisms,	 via	 chemical	 modulation.53	
Although	it	is	a	relatively	young	approach,	the	so-called	“neuregenerative	approach”	
has	already	proven	useful	at	dissecting	the	role	of	specific	pathways	 in	a	variety	of	
NSCs	processes	including	self-renewal,	proliferation	and	differentiation19	that	can	be	
useful	 for	 the	 treatment	 of	 neurodegenerative	 diseases. In	 fact,	 the	 examples	
illustrated	in	Chapter	1	account	for	the	significant	role	played	by	chemical	biology	to	
discovery	 and	 develop	 small	molecules	 able	 to	modulate	NSCs	 fate	 in	 the	 field	 of	
neurodegeneration.	Davies,	the	pioneer	of	the	“stemistry” approach24b	clearly	states	
that	 “This	 emerging	 area	 of	 stemistry	 has	 unbelievable	 potential,	 through	 the	
stimulation	 of	 endogenous	 stem	 cell	 based	 repair	 mechanisms,	 to	 revolutionise	
human	therapies.	As	always	Chemistry	is	the	key”.164	
However,	 the	 use	 of	 chemical	 probes	 is	 not	 exempt	 from	 fundamental	 risks,	 and	
objective	guidelines	to	the	appropriate	development	of	high-quality	probes	continue	
to	be	a	matter	of	much	concern	and	discussion.165 At	 this	point,	a	question	arises:	
how	to	discover	new	chemical	probes	for	NSCs?	
As	 anticipated	 in	 the	 previous	 chapter,	 the	 main	 approaches	 to	 generating	 small	
molecules	 that	 control	 NSCs	 fate	 involves	 the	 use	 of	 target-based	 or	 cell-based	
phenotypic	screens	of	small	molecules	libraries.	
In	 general,	 the	 target-based	 approach	 begins	 with	 a	 druggable	 target	 that	 is	 a	
protein	 or	 pathway	 considered	 to	 be	 relevant	 for	 the	 disease	 or	 process	 under	
investigation.166	An	in	vitro	assay	is	then	established	against	a	purified	target	protein.	
Target-based	strategy	ideally	identifies	high-affinity	compounds	with	a	known	target	
and	 mechanism	 of	 action.166	 Nevertheless,	 the	 limitations	 and	 drawbacks	 of	 this	
strategy	are	numerous.	First,	targets	must	be	identified	and	validated,	and	validated	
targets	 for	 NSCs,	 especially	 for	 neurodegenerative	 diseases,	 have	 been	 elusive.166	
		 29	
Second,	the	approach	is	unable	to	identify	new	targets	and	the	available	druggable	
target	 space	 for	NSCs	has	been	constrained	 to	certain	classes,	 such	as	kinases	and	
epigenetic	enzymes.24a	Third,	compounds	identified	through	in	vitro	assays	can	have	
chemical	 liabilities	 (for	 example,	 solubility	 or	 reactivity),	 and	 insurmountable	 off-
target	effects.	Finally,	compounds	in	target-based	assays	are	selected	for	their	ability	
to	 inhibit	 or	 activate	 an	 individual	 biological	 target.	 However,	 when	 the	 hit	
compounds	 from	 target-based	 approaches	 are	 tested	 in	 a	 cellular	 context,	 the	
capacity	of	cells	to	re-route	signaling	pathways	and	to	activate	other	compensatory	
mechanisms	is	huge,	and	remains	highly	unpredictable.166				
In	 contrast,	 cell-based	phenotypic	 screening	 involves	 the	unbiased	 identification	of	
compounds	that	modify	a	specific	phenotype	within	the	physiological	context	of	an	
intact	 cell	 or	 organism.166	 In	 the	 context	 of	 neurodegenerative	 diseases,	 large	
chemical	 libraries	 (in	 the	 order	 of	 a	 million	 compounds)	 are	 screened	 on	 cellular	
models	with	relevant	phenotypes	such	as	overt	cell	death,	altered	 localization	of	a	
disease-relevant	 protein	 and	modification	 of	 specific	 cellular	 stress	 responses	 that	
have	 been	 linked	 to	 neurodegeneration.166	 The	 key	 to	 any	 unbiased	 phenotypic	
screen	is	a	robust	and	consistent	phenotype	that	can	be	modulated	and	scored	for	
an	effect	that	is	directly	connected	to	disease	pathology.	The	main	advantage	of	the	
phenotypic	 screen	 is	 that	 it	 takes	 place	 within	 a	 living	 cell,	 and	 accesses	 the	
complexity	of	in	vivo	biology.	The	screen	itself	filters	out	compounds	that	fail	due	to	
various	 chemical	 liabilities,	 such	 as	 toxicity,	 lack	 of	 permeation	 and	 efficacy.	
Moreover,	various	features	that	influence	the	function	of	a	protein	target	within	the	
cell,	including	binding	partners,	subcellular	localization,	contribute	to	the	success	of	
phenotypic	 versus	 target-based	 approaches.167	 Despite	 these	 advantages,	
phenotypic	screens	also	have	limitations,	which	can	be	overcome	by	the	use	of	NSCs.	
In	the	context	of	neurodegenerative	disease,	where	established	in	vitro	models	are	
limited	by	weak	and	variable	phenotypes,	NSCs	provide	a	valuable	model	to	screen	
chemical	 libraries.11	 Indeed,	 with	 the	 inception	 of	 induced	 pluripotent	 stem	 cells	
(iPSCs)	 cells	 derived	 from	 living	 patients,	 new	 relevant	 in	 vitro	 models	 can	 be	
obtained,	 which	 retain	 the	 genetic	 characteristics	 of	 their	 donors,	 enabling	 to	
recapitulate	pathological	features	of	a	certain	disease.11	
Furthermore,	NSCs-based	chemical-biological	phenotypic	approaches	are	particularly	
suitable	 for	 studying	 the	 complex	 network	 of	 intertwined	 molecular	 targets	 and	
pathways	 orchestrating	 the	 functional	 ground	 state	 of	 NSCs.26	 Indeed,	 such	
complexity	 limited	our	understanding	 in	 the	 field	and	greatly	hampered	the	use	of	
target-based	 approaches	 to	 identify	 small	molecules	modulating	 NSCs.	 Indeed,	 no	
single	validated	target	with	neuroregenerative	potential	has	been	identified,	thus	a	
phenotypic	approach	emerges	as	particularly	promising.		
On	these	premises,	this	part	of	my	PhD	project	aims	to	identify	new	chemical	probes	
for	modulating	NSCs,	with	a	focus	in	the	field	of	neuroregeneration.	To	achieve	this	
goal,	 we	 exploit,	 in	 parallel,	 knowledge-based	 phenotypic	 (i)	 and	 functionalized	
congener	(ii)	chemical	biology	approaches.	As	depicted	 in	Figure	9,	the	knowledge-
based	phenotypic	approach	(i)	can	be	outlined	as	follows:	designing	and	synthesizing	
a	 focused-chemical	 library	 (a),	 testing	 this	 library	 in	 a	 phenotypic	 screen	 (b),	 and	
identifying	the	target(s)	of	the	identified	hit	compounds	(c).	Toward	objective	(a),	we	
focus	on	a	priori	knowledge	that	some	existing	drugs	and	P7C3	drug	candidate	have	
been	 shown	 to	 display	 neuroregenerative	 effects.	 Hence,	 looking	 for	 suitable	
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scaffolds	 amenable	 to	 chemical	 manipulation,	 we	 realized	 that	 both	 tricyclic	
antidepressants	 (TCAs,	 e.g.	 imipramine	 see	 Par.	 4.1.1	 for	 a	 detailed	 discussion)168	
and	P7C3	(see	Par.	1.7.1)163	share	intriguing	structural	features,	i.e.	a	tricyclic	moiety	
linked	to	an	amino	function	via	a	propyl	alkyl	chain	(Figure	9).	Accordingly,	these	two	
compounds	 may	 be	 considered	 as	 suitable	 starting	 points	 to	 develop	 chemical	
libraries	 with	 neurogenic	 potential.	 Additionally,	 being	 these	 molecules	 already	
characterized	for	their	pharmacokinetic	profiles,	a	chemical	library	inspired	by	these	
compounds	may	have	the	chance	to	identify	compounds	with	high	drug-likeness.169	
Thus,	 building	on	 these	 strong	premises,	we	aim	 to	 synthesize	 a	 focused	 chemical	
library	inspired	by	TCAs	and	P7C3	(a),	which	would	allow	to	explore	the	neurogenic-	
and	 neuroprotective-structure	 activity	 relationships	 around	 the	 selected	 scaffolds.	
Once	 the	 focused	 chemical	 library	 have	been	developed,	 before	 submitting	 to	 the	
full-scale	compounds	screening	in	the	NSCs	assay,	the	preliminary	evaluation	of	their	
safety	profiles	in	different	cell	lines	will	be	performed	as	primary	screening	(b).	This	
would	 improve	 the	drug-likeness	of	 synthesized	 compounds,	 filtering	out	 the	 toxic	
ones.	 As	 a	 second	 step,	 the	 evaluation	 of	 neuroprotective	 and	 proliferation	
(neurogenesis)	capabilities	of	the	most	promising	compounds,	will	be	performed	in	
primary	neurons.	As	illustrated	in	Figure	9,	those	that	show	no	sign	of	toxicity	and	a	
neuroprotective/neurogenic	profile	will	be	progressed	to	the	phenotypic	NSCs-based	
assay,	 in	 order	 to	 evaluate	 their	 neurogenic	 potential,	 in	 terms	 of	 differentiation	
ability	 to	 modulate	 NSCs	 toward	 a	 given	 lineage	 (i.e.	 neurons,	 astrocytes	 and	
oligodendrocytes)	 (b).	 The	 last	 step	 of	 this	 knowledge-based	 approach	 relies	 on	
target	identification	studies	(c),	perhaps	the	most	problematic	issue	in	the	proposed	
pipeline.	
	
	
Figure	9.	Knowledge-based	chemical	biology	phenotypic	pipeline.	
	
In	 parallel,	 different	 sets	 of	 functionalized	 congeners	 (ii)	 inspired	 by	 TCAs	 will	 be	
developed.	As	medicinal	chemists,	the	possibility	to	conjugate	a	selected	compound	
to	 functionalized	 chains	 with	 different	 chemical	 and	 biological	 properties	 (i.e.	
functionalized	 congener	 approach)	 is	 particularly	 attractive.170	 To	 this	 end,	 as	
depicted	in	Figure	10,	we	synthesized	appropriate	functionalized	congeners	inspired	
by	 TCAs	 that,	 depending	 on	 the	 strategy	 of	 functionalization,	 have	 provided:	
fluorescent	(a),	dual-acting	(multi-target)	(b),	polyamine	congeners	(c).		
Among	them,	a	small	set	of	fluorescent	probes	inspired	to	TCAs	will	be	synthesized	
by	 conjugating	 the	 imipramine	 pharmacophore	 to	 a	 fluorescent	 dye	 through	
different	 linkers	 (a).	 This	 will	 be	 used	 to	 potentially	 identify	 the	 subcellular	
localization	 of	 the	 targets	 whereby	 the	 selected	 hit	 compounds	 elicit	 the	 desired	
effects.	On	the	other	hand,	given	the	complexity	of	NSCs	landscape,	the	possibility	to	
modulate	such	intricate	signaling	network	by	combining	in	a	single	chemical	entities	
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Figure	10.	Design	of	functionalized	congeners	of	TCAs.	
	
two	 pharmacophoric	 fragments	 belonging	 to	 two	 molecules	 with	 different	
neurogenic	mechanisms	of	action	(i.e.	multi-target	compound)171	may	be	particularly	
promising.	To	this	goal,	we	aim	to	conjugate	some	of	the	compounds	of	the	focused	
library	with	compounds	able	to	modulate	NSCs	(i.e.	valproic	acid).	The	last	strategy	
relies	 on	 conjugation	 of	 TCA	 imipramine	 with	 a	 polyamine	 carrier	 (Figure	 9).	 As 
polyamine	conjugation	has	already	showed	to	increase	the	cationic	character	of	the	
starting	molecule	and	to	promote	its	accumulation	directly	into	the	mitochondrion,	
additional	 neuroprotective	 effects	 can	 be	 achieved	 following	 this	 functionalization	
strategy.172	Moreover,	since	putrescine	in	neurosphere	stimulates	neural	progenitor	
proliferation,	 the	 appended	 polyamine	 to	 imipramine	may	 also	 provide	 secondary	
favorable	interactions	underlying	the	neurogenic	effects.173 	
Collectively,	 this	 strategy	 may	 provide	 new	 insights	 into	 the	 regulation	 of	
neurogenesis	 by	 the	 use	 of	 TCAs-	 and	 P7C3-inspired	 focused	 library	 and	
functionalized	congeners	for	discovering	chemical	probes	of	key	signaling	pathways	
implicated	in	NSCs	proliferation/differentiation.		
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3.	Chemistry		
3.1	Synthesis	of	the	focused	chemical	library	inspired	by	TCAs	and	P7C3	
	
The	TCAs	chemical	syntheses	present	in	the	literature	were	obsolete	and	hazardous	
procedures,	and,	moreover,	optimized	as	industrial	process	more	than	half	a	century	
ago.174	Thus,	 they	 result	of	 limited	applicability	 to	establish	 the	SAR	within	a	given	
targeted	 library.	 In	fact,	the	reported	route	for	the	synthesis	of	 imipramine	started	
with	 the	 alkylation	 of	 10,11-dihydro-5H-dibenz[b,f]azepine	 1a	 with	 3-
dimethylaminopropylchloride	 in	 presence	 of	 NaNH2	 as	 strong	 base	 in	 refluxing	
xylene	(Figure	1).175	Hence,	the	main	synthetic	challenge	to	obtain	the	TCAs-focused	
chemical	library	relies	on	finding	a	procedure,	with	the	required	following	features:	
characterized	by	a	simplified	work-up,	amenable	to	a	parallel	synthesis	application,	
while	avoiding	the	use	of	hazardous	substances.		
	
	
Figure	11.	Reported	route	for	the	synthesis	of	drug	imipramine	31.	
	
In	an	effort	to	find	out	a	general	synthetic	method,	which	would	involve	a	common	
intermediate	 for	 obtaining	 the	 primary,	 secondary,	 and tertiary	 amines	 of	 the	
selected	 tricyclic	 rings,	we	 followed	a	procedure	previously	 reported	by	Righi	et	 al	
for	similar	scaffold.176	It	 involves	a	direct	one-pot	reductive	N-alkylation	reaction	of	
tricyclic	 aromatic	 amines	 1a-6a	 with	 acetals	 67	 and	 69,	 in	 the	 presence	 of	
triethylsilane	 (TES)	 as	 nontoxic	 and	 stable	 reducing	 agent	 (Scheme	1).177	 Thus,	 the	
synthetic	route	started	with	the	synthesis	of	the	proper	acetal	intermediates	67	and	
69.	 In	 detail,	 the	 synthesis	 of	 67	 has	 been	 accomplished	 by	 using	 trifluoroacetic	
anhydride	 (TFAA)	 to	 protect	 the	 amino	 functionality	 of	 compound	 66	 as	
trifluoroacetamide	derivative.		
For	 the	 reduction	of	 the	nitrile	group	of	68,	 several	 reaction	conditions	have	been	
tested	before	obtaining	69	(Table	2).	Particularly,	the	first	attempts	involved	the	use	
of	LiAlH4	as	reducing	agent	 (conditions	A-C).	However,	if	condition	A	did	not	lead	to	
the	desired	compound	and	allow	to	recover	almost	60%	of	the	starting	material	68,	
condition	 B	 appeared	 to	 be	 too	 drastic,	 not	 allowing	 either	 to	 afford	 69	 and	 to	
recover	68.	Looking	for	a	compromise	between	the	two	above	conditions,	we	tested	
if	 an	 increase	of	number	of	equivalents	of	 LiAlH4	and	a	 reduction	of	 reaction	 time	
(condition	 C),	 could	 work.	 Also	 in	 this	 case,	 we	 did	 not	 get	 69,	 leading	 to	 a	 very	
complex	mixture	of	several	products,	extremely	difficult	to	purify.		
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Scheme	1.	Reagents	and	conditions:	
a.	TFAA,	TEA,	THF,	N2,	 r.t.;	b.	NaBH4,	NiSO4,	Ac2O,	MeOH,	r.t;	c.	TES,	TFA,	 	DCM,	N2,	 r.t.,	d.	
K2CO3,	MeOH/H2O,	r.t.;	e.	KOH,	MeOH/H2O,	MW,	150W,	160°C;	 	 f.	HCOH,	K10-clay,	NaBH4,	
MeOH,	MW	30',	80°C;g.	HCOOH,	HCOH,	H2O,	MW,	50W,	100°C;	h.	HCOOH,	HCOH,	H2O,	80°C.	
	
Table	2.	Reaction	conditions	explored	to	target	compound	69.	
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Once	 experienced	 that	 LiAlH4	 was	 not	 effective,	 we	 turned	 our	 attention	 to	 a	
different	reducing	agent,	i.e.	NaBH4.	To	overcome	its	limited	reducing	ability	toward	
the	nitrile	group,	we	have	modified	the	procedure	proposed	by	Caddick	et	al.178	 In	
particular,	it	involves	the	use	of	a	large	excess	of	NaBH4	(7	eq.)	and	Ni2+	as	catalyst,	
which	dramatically	improves	the	reactivity	of	hydride	donors.	Moreover,	to	prevent	
dimerization	 reaction,	 a	 well-known	 side	 reaction	 that	 often	 occurs	 during	 the	
reduction	of	nitriles	to	primary	amine,	the	use	of	a	trapping	agent	(acetic	anhydride	
or	 di-tert-butyl	 dicarbonate)	 was	 required.	 Thus,	 we	 initially	 tested	 different	 Ni2+	
salts	 (NiCO3	 and	NiSO4),	 and	 acetic	 anhydride	 as	 trapping	 agent	 (corresponding	 to	
conditions	D	and	E,	respectively).	Surprisingly,	only	NiSO4	(conditions	E)	affords	the	
target	 compound	69	 in	 50%	 yield.	 A	 following	 attempt	 (condition	 F)	 to	 obtain	 the	
trifluoroacetamide	(in	homology	to	67),	involved	the	use	of	trifluoroacetic	anhydride	
as	trapping	agent,	while	maintaining	NiSO4	as	catalyst.	Nevertheless,	in	this	case	just	
traces	of	69	were	observed,	due	to	the	 instability	of	 trifluoroacetamide	derivatives	
under	strong	reducing	conditions.	
With	the	acetals	67	and	69	 in	hands,	the	reductive	N-alkylation	reaction	of	tricyclic	
aromatic	amines	1a-6a	with	67	 or	69	was	performed.176	This	provided	 the	 tricyclic	
scaffolds	 6,5,6	 or	 6,6,6	 or	 6,7,6	 (carbazole,	 10,11-dihydro-dibenzazepine,	
dibenzazepine	and	differently	substituted	phenothiazines)	as	alkyl-amide	derivatives	
1b-12b	in	very	good	yields	(62%-95%).	Probably,	the	trend	of	yields	for	7b-12b	(62%-
82%)	reflects	the	lower	reactivity	of	acetamide	derivative	69,	compared	to	yield	for	
1b-6b	 (70%-95%),	 obtained	 starting	 from	 trifluoroacetamide	 67.	 The	 subsequent	
cleavage	of	the	amide-protecting	group	to	afford	primary	amines	1-12	involved	two	
different	procedures.	In	the	first	route,	the	removal	of	trifluoroacetamide	protecting	
group	of	1b-6b	under	mild	reaction	conditions	(K2CO3	in	H2O/MeOH)	led	to	primary	
amine	 derivatives	 1-6	 in	 quantitative	 yield.	 Coversely,	 the	 cleavage	 of	 acetamide	
protecting	 group	 of	7b-12b	 under	microwave	 (MW)	 irradiation	with	 a	 strong	 base	
(KOH	in	H2O/MeOH)	gave	the	primary	amines	7-12	only	in	good	yield	(72%-98%).	For	
comparison	 purposes,	 we	 also	 carried	 out	 the	 above-mentioned	 reaction	 under	
conventional	 reflux	 conditions	 (see	 Table	 3).	 Dramatic	 differences	 have	 been	
observed	 in	 terms	 of	 both	 yields	 (45%-67%	 with	 the	 conventional	 method)	 and	
decreased	reaction	time	(from	2	days	to	90	min).		
	
Table	3.	Comparison	between	conventional	and	MW	procedures.	
Compounds	 Reaction	type	 Conventional	conditions	
(reaction	time	and	yield)	
MW	conditions	(reaction	
time	and	yield)	
7b-12b	 Amide	
hydrolysis	
2	days	 45%-67%	 90	min	 72%-98%	
1-3	and	7-9	 Reductive	
alkylation	
10	h	 40%-58%	 30	min	 63%-74%	
	
Then,	compounds	1-12	were	converted	to	their	corresponding	secondary	amines	13-
24.	Our	first	attempt	was	based	on	a	one-pot	procedure	involving	the	N-methylation	
of	 amides	 1b-12b	 with	 NaH	 (as	 base),	 and	 MeI	 (as	 methylating	 agent)	 and	 the	
subsequent	 removal	 of	 the	 amide-protecting	 group	 using	 the	 same	 procedures	
described	for	1-12.	However,	searching	for	an	alternative	and	greener	procedure	to	
obtain	the	secondary	amines	13-24,	while	avoiding	the	use	of	highly	 toxic	MeI,	we	
developed	 a	 modified	 version	 of	 a	 MW-assisted	 reductive	 amination	 reaction	
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proposed	 by	Varma.179	 This	 contemplates	 the	 use	 of	 paraformaldehyde	 and	 acidic	
clay	montmorillonite	K-10	as	green	catalyst,	under	solvent-free	conditions.	However,	
reproducing	 the	 solvent-free	 conditions	 with	 our	 derivatives	 did	 not	 yield	 any	
product,	maybe	due	to	the	formation	of	a	non-homogeneous	the	reaction	mixture.	
This	has	been	overcome	by	adding	MeOH	as	solvent	and	by	harnessing	the	capability	
of	K-10	 to	act	 as	 solid	acid	 catalyst.	 It	 determines	 the	protonation	of	 the	 carbonyl	
oxygen	 of	 paraformaldehyde	 in	 order	 to	 facilitate	 the	 nucleophilic	 attack	 by	 the	
primary	amines	1-12	and,	additionally,	as	supporting	agent	for	NaBH4,	increasing	its	
reducing	ability	of	in	situ	generated	Schiff	bases.	In	detail,	this	reaction	involves	two	
steps.	 The	 first	 is	 based	on	 the	 activation	of	 paraformaldehyde	with	K-10	 catalyst,	
followed	 by	 the	 addition	 of	 the	 primary	 amine	 that	 leads	 to	 the	 formation	 of	 the	
imine	 intermediate	 using	 microwave	 irradiation	 at	 80°C	 for	 30	 min.	 Then,	 the	
addition	of	a	mixture	of	K-10	catalyst	and	NaBH4	and	further	microwave	 irradiation	
at	80°C	for	10	min	led	to	13-24	in	acceptable	yield	(24%-44%).		
To	achieve	the	tertiary	amines	25-36,	the	Eschweiler–Clarke	reaction	was	exploited.	
This	 reductive	amination	 involved	 the	use	of	 formaldehyde	and	 formic	acid,	which	
acts	as	hydride	donor	to	reduce	the	imine	generated	by	reaction	of	primary	amines	
with	 the	 formaldehyde.180	Despite	 the	wide	 synthetic	utility	of	 this	 reaction,	 it	has	
received	 only	 limited	 critical	 investigation.	 An	 improved	methodology181	 exploited	
the	 thermal	 decomposition	 in	 solvent-free	 conditions	 of	 oxalic	 acid	 under	 MW	
irradiation	into	the	intermediate	formic	acid	as	the	actual	reducing	agent.	However,	
efforts	 to	 obtain	 the	 desired	 compounds	 by	 using	 these	 conditions	 (both	
conventional	 and	microwave	 synthesis)	 did	 not	work	with	 our	 derivatives.	 On	 the	
other	hand,	 it	 is	worth	 to	note	 that	conventional	heating	procedures	 for	 the	same	
transformation	required	reflux	for	more	than	10	h,	affording	1-3	and	7-9	in	40%-58%	
yields	 (Table	 3).	 On	 the	 other	 hand,	 the	MW-assisted	 procedure	 developed	 by	 us	
revealed	consistent	increases	in	yields	(ranging	from	63%	to	74%)	and	shortening	of	
reaction	time	(from	10	h	to	30	min).	However,	the	choice	of	microwave	 irradiation	
failed	 in	 the	 case	 of	 phenothiazines	 derivatives	 4-6	 and	 10-12.	 Indeed,	 such	
compounds	displayed	an	excessive	reactivity	under	these	microwave	conditions	that	
provided	 the	 poly-methylated	 (both	 –N	 and	 –S	 atoms)	 analogue	 as	 only	 reaction	
product.	Thus,	a	conventional	procedure	was	used	at	controlled	temperature	(80°C)	
for	8-10	h,	leading	to	compounds	28-30	and	34-36	in	satisfactory	yield	(45%-84%).				
3.2	Synthesis	of	TCA-functionalized	fluorescent	congeners		
To	 obtain	 TCA-functionalized	 fluorescent	 congeners	 48-51,	 we	 exploited	 a	 click	
reaction	protocol	(Scheme	2).		
We	 started	 with	 the	 synthesis	 of	 the	 10-(3-Azidopropyl)-5,5-difluoro-1,3,7,9-
tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-f][1,3,2]diazaborinine,	 i.e.	 the	 core	 of	
BODIPY	azide	40.	Particularly,	its	synthesis	was	rapidly	achieved	by	the	condensation	
of	2,4-dimethylpyrrole	37	with	two	equivalents	of	acyl	chloride	38	 (Scheme	2).	The	
resulting	intermediate	dipyrrin	was	not	isolated,	as	application	of	base	and	boron		
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Scheme	2.	Reagents	and	conditions:	
a.	DCM,	r.t.,	30	min;	b.	TEA,	BF3.OEt2	,	r.t.,	14	h;	c.	NaN3,	DMF,	50	°C,	36	h;	d.	NaOH,	CHCl3:	
H2O,	MW,	200W,	140	°C,	10';		e.	K2CO3,	DMF,	70	°C,	72	h;	f.	40,	CuSO4.5	H2O	(15	mol%),	Na	
ascorbate	(45	mol%),	DCM:	t-BuOH:	H2O,	r.t.,	1-2	h		
trifluoride	 etherate	 yields	 the	 BODIPY	 chloride	 39.	 Next,	 nucleophilic	 substitution	
with	NaN3	provided	the	clickable	azide	40.	
The	introduction	of	the	linker	bearing	the	alkyne	group	on	desipramine	19	and	on	its	
corresponding	primary	amine	7	has	been	performed	using	two	different	procedures.	
In	the	case	of	secondary	amine	19,	a	nucleophilic	substitution	with	42	or	43	has	been	
performed.	This	reaction,	conducted	under	conventional	heating	condition,	resulted	
to	proceed	very	slowly,	requiring	72	h	to	appreciate	significant	amount	(40%-63%)	of	
target	 compounds	 45	 and	 47.	 However,	 the	 increase	 of	 the	 temperature,	 as	 well	
microwave	conditions	did	not	improve	both	the	reaction	time	and	the	yield.	
Regarding	 the	 primary	 amine	 7,	 several	 attempted	 have	 been	 accomplished	 to	
obtain	the	corresponding	functionalized	secondary	amine	44	(Table	4).		
First,	 we	 tried	 to	 obtain	 44	 starting	 from	 the	 corresponding	 trifluoroacetamide	
derivative	of	7	(conditions	A-F).	Following	a	classic	protocol	(condition	A),	involving	a	
weak	base	(K2CO3)	to	deprotonate	the	amide,	followed	by	the	addition	of	the	alkynyl	
linker	chain	bearing	a	good	leaving	group	(-Br),	did	not	lead	to	any	product	and	the	
starting	 material	 was	 recovered.	 Thus,	 supposing	 that	 K2CO3	 was	 not	 sufficiently	
strong	base	to	deprotonate	the	amide,	we	tried	with	a	stronger	base	(NaH,	condition	
B).	However,	also	in	this	case,	we	did	not	observe	any	product.	Then,	we	tested	if	the	
addition	of	a	catalyst	could	be	successful	 (conditions	C-E).	Although	we	tried	three	
catalysts	 with	 different	 mechanisms,	 such	 as	 KI	 (condition	 C),	
benzyltriethylammonium	 chloride	 (TEBA,	 condition	 D)	 and	 18-crown-6	 ether	
(condition	E),	we	again	did	not	get	any	product.	The	last	attempt	involved	the	use	of	
a	 different	 halogen	derivative,	 bearing	 an	 iodide	 as	 leaving	 group	 (condition	 F).	 In	
this	case,	we	observed	only	traces	of	the	desired	compound.		
As	 a	 second	 strategy,	 we	 tried	 if	 we	 could	 obtain	 the	 desired	 functionalized	
secondary	amine	44	by	directly	reacting	the	primary	amine	7	with	43	(condition	G).	
Employing	 a	 similar	 protocol	 seen	 for	 45	 and	 47,	 this	 nucleophilic	 substitution	
afforded	only	traces	of	44.	Finally,	as	reported	in	Scheme	2,	we	successfully	achieved	
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44	and	46,	by	exploiting	a	procedure	involving	a	biphasic	solvent	system	(CHCl3/H2O	
3:7)	and	microwave	irradiation	at	high	temperature	and	potency	(140	°C	and	200	W,	
respectively),	which	 led	 to	 the	 titles	 compounds	 in	 satisfying	yield	 (53%-58%).	This	
procedure	allows	to	“activate”	the	nucleophile	by	forming	organic	micelles	in	water	
that	 favors	 the	nucleophilic	attack	 towards	poor	 reactive	electrophiles,	 like	42	 and	
43.	
	
Table	4.	Reaction	conditions	explored	to	target	compound	44.	
	
		
Next,	copper(I)-catalyzed	[3+2]	cycloaddition	between	the	terminal	azide	40	and	the	
alkynes	44-47	afforded	the	TCAs-related	fluorescent	probes	48-51	only	in	acceptable	
yield	 (33%-39%)	due	 to	 the	 formation	of	 several	 side-products.	Efforts	 to	minimize	
the	excessive	reactivity	under	these	reaction	conditions,	by	shortening	the	reaction	
time,	 by	 using	 an	 ice	 bath	 and	 by	 producing	 an	 inert	 nitrogen	 atmosphere,	
unfortunately	failed	to	improve	the	reaction	yield.	
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3.3	Synthesis	of	TCAs-functionalized	multi-target	congeners	
	
As	depicted	 in	Scheme	3,	 to	obtain	TCAs-functionalized	multi-target	 congeners	53-
58,	we	have	exploited	an	amide	coupling	reaction.	It	involves	the	primary	amines	1-3	
and	7-9,	and	 the	carboxylic	 function	of	valproic	acid	52,	which	were	coupled	using	
EDCI	and	HOBt,	and	NEt3	(as	base).	This	procedure	provided	the	compounds	23-28	in	
very	good	yield	(73%-97%),	without	need	to	further	improve	the	reaction	conditions.	
	
 
Scheme	3.	Reagents	and	conditions:	
a.	EDCl,	OHBt,	NEt3,	DCM,	rt,	overnight.				
3.4	Synthesis	of	TCAs-functionalized	polyamine	congener	
The	synthesis	of	TCAs-functionalized	polyamine	congener	has	been	accomplished	as	
showed	in	Scheme	4.	Particularly,	before	incorporating	the	polyamine	backbone	into	
the	structure	of	desipramine	19,	it	has	been	functionalized	with	3-bromopropan-1-ol	
61	 through	 the	 nucleophilic	 substitution	 in	 the	 biphasic	 system	 (CHCl3/H2O	 3:7)	
previously	developed	(140	°C	and	200	W,	respectively).	Then,	the	conversion	of	the	
hydroxyl	group	of	62	 to	a	good	 leaving	group	was	first	attempted	by	 introducing	a	
tosyl	 functionality.	 However,	 this	 procedure	 failed,	 even	 employing	 pyridine	 as	
solvent.	 Thus,	 we	 decided	 to	 convert	 the	 hydroxyl	 group	 of	 62	 by	 using	 thionyl	
chloride,	which	afforded	63,	bearing	a	chloride	as	 leaving	group.	This	was	essential	
to	the	next	substitution	reaction,	which	involved	the	mono-Boc-protected	putrescine	
60	and	63.	To	achieve	64,	we	developed	a	MW-assisted	procedure	that	led	after	1	h	
at	110	°C	the	title	compound	in	good	yield	(65%).	The	following	deprotection	of	the	
Boc-protected	 amino	 function	 of	64	was	 performed	 under	 classical	 conditions	 (10	
equivalents	of	TFA	in	DCM),	leading	to	the	TCAs-functionalized	polyamine	congener	
65	as	trifluoroacetate	salt,	in	quantitative	yield.	
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Scheme	4.	Reagents	and	conditions:	
a.	Boc2O,	CHCl3,	0	°C,	3	h;	b.	NaOH,	CHCl3:	H2O,	MW,	200W,	140	°C,	10';	c.	SOCl2,	CHCl3,	rt,	4h;	
d.	CH3CN,	MW,	50W,	110	°C,	1h;	e.	TFA,	DCM,	3	h.	
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4.	Results	and	discussion	
	
In	 this	 part	 of	 thesis,	 we	 advocated	 a	 chemical	 biology	 approach	 to	 develop	 new	
chemical	 probes	 for	 NSCs.	 In	 particular,	we	 followed	 two	 parallel	 strategies,	 i.e.	 a	
knowledge-based	 phenotypic	 approach	 and	 a	 functionalized	 congener	 strategy.	 In	
both	approaches,	we	obtained	 interesting,	albeit	preliminary,	results,	which	will	be	
discussed	in	the	following.	
	
	
4.1	A	knowledge-based	phenotypic	approach	for	NSC	stemistry	application	
	
Despite	 recent	 medicinal	 chemistry	 strategy	 relies	 on	 target-based	 approach,	 we	
already	 pointed	 out	 that	 the	 knowledge	 in	 NSCs	 field	 is	 still	 incomplete	 and,	
according	 to	 the	 recent	 literature,	 validated	 targets/pathways	 are	 far	 from	 being	
identified.182	Thus,	for	the	reasons	highlighted	in	Chapter	2,	we	decided	to	follow	a	
phenotypic	approach.	However,	phenotypic	approaches	in	big	pharma	mostly	rely	on	
huge	 collection	of	 compounds	 (in	 some	cases	>400.000),183	 exploiting	 facilities	not	
available	 in	 academic	 environment.	 In	 our	 case,	 the	 project	 should	 be	 tailored	 to	
academic	 settings	where	cost-effectiveness	 is	a	major	consideration.	Our	attention	
was	therefore	drawn	to	a	strategy	that	can	yield	molecules	with	high	hit	rates	and	a	
concomitant	 reduced	 library	 size.169	 We	 reasoned	 that	 starting	 from	 compounds	
biologically	pre-validated	and	with	established	physicochemical	properties	to	design	
a	 focused-chemical	 libraries	 may	 be	 particularly	 suitable	 in	 an	 academic	
environment.169		
In	this	respect,	we	envisioned	to	follow	a	knowledge-based	approach.	On	this	basis,	
we	 looked	 for	 chemotypes	 already	 reported	 to	 modulate	 NSCs	 and,	 at	 the	 same	
time,	 amenable	 for	 further	 chemical	 development.	 Herein,	 we	 discuss	 the	 design	
rationale	underlying	the	focused	chemical	library.	
	
	
4.1.1	Design	rationale	of	the	focused	chemical	library	inspired	by	TCAs	and	P7C3	
	
It	 is	 an	 intriguingly	 postulated	 that	 existing	 drugs	 might	 exert	 their	 effects	 by	
promoting	 neurogenesis.	 Specifically,	 the	 relationships	 between	 neurogenesis	 and	
the	effect	of	antidepressants	have	been	widely	recognized	since	1999.184	Duman	et	
al	 showed	 that	 the	 atrophy	 and	 death	 of	 stress-vulnerable	 neurons	 in	 the	
hippocampus,	 as	 well	 as	 decreased	 neurogenesis	 of	 hippocampal	 neurons	 are	
reversed	 following	 antidepressant	 treatment	 in	 animal	 models	 of	 depression.184 
Later	 studies,	 in	 2009,	 confirmed	 these	 results	 showing	 that	 subjects	 with	 major	
depressive	 disorder	 (MDD)	 treated	 with	 antidepressants	 (imipramine	 and	
fluoxetine),	displayed	an	increase	of	both	neural	progenitor	and	dividing	cells	in	the	
DG.185 Importantly,	 antidepressants	 from	different	 classes	 have	 all	 been	 shown	 to	
induce	 neurogenesis	 in	 vivo,	 including	 the	 non-selective	 monoamine	 reuptake	
inhibitors	(NSRI)	imipramine185	and	amitriptyline186	(belonging	to	the	class	of	tricyclic	
antidepressants,	 TCAs);	 the	 selective	 serotonin	 reuptake	 inhibitors	 (SSRI)	
fluoxetine168	 and	 citalopram;187	 and	 the	 mood-stabilizers	 lithium,188	
carbamazepine189	 and	 valproic	 acid	 (Figure	 12).137	 Starting	 from	 the	 2000s,	 the	
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mechanisms	underlying	the	neurogenic	effect	of	antidepressants	have	attracted	the	
interest	of	several	researchers,	and	advances	that	have	been	made	in	the	field	have	
been	exhaustively	reviewed	in	102.	
	
	
Figure	12.	Antidepressant	drugs	with	neuroregenic/neuroprotective	effects.	
	
However,	 it	 should	 be	 noted	 that	 the	 association	 between	 neurogenesis	 and	
antidepressant	 action	 remains	 still	 controversial.	 Several	 mechanistic	 hypotheses	
have	 been	 advanced	 supporting	 the	 neurogenic	 effects	 of	 antidepressants.	 These	
proposed	 mechanisms	 include	 those	 directly	 mediated	 by	 NSCs	 and	 the	
astrocytes/oligodendrocytes-mechanisms	 that	 indirectly	 affect	 their	 fate.	 For	
example,	 Santarelli	 et	 al.	 in	 2003	 published	 a	 groundbreaking	 paper	 showing	 that	
fluoxetine	 and	 imipramine	 exert	 neurogenic	 effects	 by	 acting	 at	 ventral	
hippocampus	and	require	5HT1A	receptor	for	their	effect.168 	
It	 has	 been	 advanced	 that	 blocking	 the	 inhibitory	 control	 of	 GSK-3β	 on	 Wnt	
pathways	 potentiates	 neurogenesis.	 Accordingly,	 a	 recent	 study	 reported	 on	 the	
enhanced	neurogenesis	promoted	by	chronic	exposure	of	valproic	acid	(VPA)	in	the	
DG	of	the	hippocampus.	Particularly,	similar	to	neurotrophic	factors,	VPA	enhanced	
ERK	 pathway-dependent	 cortical	 neuronal	 growth.	 Although	 VPA	 affects	 the	
functions	 of	 GSK-3β	 and	 HDAC,	 its	 effects	 on	 the	 ERK	 pathway	 were	 not	 fully	
mimicked	 by	 selective	 inhibitors	 of	 GSK-3β	 or	 HDAC.	 Together,	 these	 data	
demonstrate	 that	 VPA	 activates	 the	 ERK	 pathway	 and	 induces	 ERK	 pathway-
mediated	neurotrophic	actions.137 	
In	accordance	with	what	suggested	by	the	previous	study,	it	has	been	proposed	that	
the	 neurogenic	 effect	 of	 antidepressants	 is	 mediated	 by	 neurotrophic	 activities.	
Intriguingly,	 impaired	 progenitor	 proliferation	 and	 neurogenesis	 were	 observed	 in	
transgenic	mice	 lacking	 TrkB	 in	 hippocampal	NPCs,	 even	when	exposed	 to	 chronic	
antidepressants	 (fluoxetine	and	 imipramine)	 treatment.190	Conversely,	mice	 lacking	
TrkB	 only	 in	 differentiated	 DG	 neurons	 display	 typical	 neurogenesis	 and	 respond	
normally	 to	 chronic	antidepressants.	The	authors	 suggest	 that	 chronic	exposure	 to	
antidepressants	 increase	 BDNF	 level	 implicating	 the	 subsequent	 TrkB	 activation	 as	
an	indirect	downstream	event	from	the	acute	accumulation	of	monoamine,	such	as	
serotonin	and	noradrenaline.190	Interestingly,	in	another	study,	the	TCA	amitriptyline	
was	shown	to	bind	the	extracellular	domains	of	TrkA	and	TrkB	and	induce	TrkA/TrkB	
heterodimerization,	which	does	not	occur	with	imipramine.186	Such	ability	of	tricyclic	
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antidepressants	 to	 bind	 Trk	 receptors	 and,	 in	 the	 case	 of	 amitryptiline	 to	 induce	
heterodimerization,	 is	 encouraging	 for	 the	 development	 of	 small	molecule	 ligands	
targeting	 these	 receptors	 for	 the	 treatment	 of	 neurodegenerative	 disorders.191	
Indeed,	this	approach	proposed	by	Longo	led	to	the	development	of	the	first	small	
molecule,	 referred	 to	 as	 LM11A-31	 (Figure	 12),	 targeting	 the	 p75	 neurotrophin	
receptor	 that	 is	 just	 now	 in	 phase	 II	 clinical	 trials	 for	 patients	 with	 Alzheimer’s	
disease	(AD).192 	
Regarding	 the	 indirect	 mechanisms	 controlling	 the	 neurogenic	 effect	 of	
antidepressant,	it	has	recently	proposed	that	amitriptyline	significantly	increased	the	
expression	of	fibroblast	growth	factor-2,	brain-derived	neurotrophic	factor,	vascular	
endothelial	growth	factor	and	glial	cell	line-derived	neurotrophic	factor	mRNA	with	a	
different	time	course	in	astrocyte	cultures,	but	not	in	neuron-enriched	cultures.193 	
Another	intriguing	indirect	mechanism	has	been	proposed,	which	involves	the	effect	
of	antidepressant	on	microglia	with	both	pro-	and	anti-inflammatory	properties.194	
Particularly,	 one	 group	 recently	 demonstrated	 that	 fluoxetine	 at	 10	 µM	 inhibited	
microglial	tumour	necrosis	factor-α	(TNF-α)	and	nitric	oxide	(NO)	production	 in	LPS	
treated-microglial	cells.	They	also	found	that	exposure	over	24	h	at	concentrations	<	
5	 µM	 actually	 created	 a	 pro-inflammatory	 environment.195	 Interestingly,	 another	
study	showed	that	fluoxetine	can	significantly	inhibit	the	synaptotoxicity,	as	well	as	
reduced	dendritic	complexity	and	axonal	branching	of	hippocampal	neurons	induced	
by	astrocytes	from	APP/PS1	mice.	These	astrocytes	produced	high	 levels	of	soluble	
β-amyloid	(Aβ),	which	could	be	significantly	inhibited	by	fluoxetine	via	activation	of	
serotonin	 5-HT2	 receptors.	 Indeed,	 fluoxetine	 inhibited	 activation	 of	 astrocytes,	
decreased	 Aβ	 level,	 ameliorated	 neurotoxicity,	 and	 improved	 behavioral	
performance.	 These	 findings	 may	 provide	 a	 basis	 for	 the	 clinical	 application	 of	
fluoxetine	in	AD	patients,	and	may	also	lay	the	foundation	for	novel	astrocyte-based	
therapies	of	AD.196	
On	the	basis	of	all	 the	reports	showing	that	antidepressants	 increase	neurogenesis	
and	exert	neuroprotective/neurotrophic	effects,	it	has	been	suggested	that	they	may	
be	 effective	 in	 the	 treatment	 of	 AD.197	 Since	 antidepressants	 are	 already	 in	 the	
market,	 the	 costs	of	new	drug	development	 for	AD	will	 be	dramatically	 reduced	 if	
they	 can	 be	 used	 as	 prevention	 or	 treatment	 tools.	 Some	 preclinical	 and	 clinical	
studies	have	shown	that	antidepressants	treatment	improved	the	cognitive	skills	and	
clinical	 symptoms	 of	 AD	 pathology.	 Interestingly,	 a	 recent	 article	 showed	 that	
antidepressants,	such	as	amitriptyline,	can	completely	reverse	the	symptoms	of	AD	
in	 a	 triple-transgenic	mouse	model	 of	 AD	 (3xTg	AD).198	Not	 only	 treating	 AD	mice	
with	amitriptyline	significantly	reversed	AD	pathology	by	reducing	reduction	toxic	Aβ	
amyloid	 aggregates,	 but	 also	 improved	 their	 cognitive	 skills	 in	 behavioral	 tests.	
Remarkably,	 amitriptyline	 treatment	 was	 able	 of	 forming	 new	 neurons	 in	 the	
hippocampus	and	cortical	regions	as	shown	by	a	variety	biochemical	assays.198	
This	has	 further	been	confirmed	by	another	 study	using	SSRI	 citalopram.187	Rather	
than	 increasing	 neurogenesis,	 citalopram	 is	 suggested	 to	 function	 to	 reduce	 Aβ	
accumulation	 in	 mice	 and	 human.187	 Indeed,	 citalopram	 reduced	 brain	 interstitial	
fluid	Aβ	levels	in	a	mouse	model	of	AD.	Infusion	of	serotonin	into	the	hippocampus	
also	 reduced	 Aβ	 levels	 and	 this	 effect	 was	 blocked	 by	 administration	 of	 ERK	
inhibitors,	suggesting	an	important	role	of	ERK	in	Aβ	metabolism.187	To	validate	the	
effects	 of	 antidepressants	 on	 AD	 treatment	 in	 human,	 the	 same	 research	 group	
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performed	 a	 retrospective	 comparison	 analysis	 and	 identified	 that	 healthy	
individuals	 who	 were	 treated	 with	 antidepressants	 showed	 significantly	 reduced	
levels	 of	 Aβ	 than	 those	 who	 took	 no	 antidepressants.199	 Therefore,	 there	 is	
indication	that	antidepressants	can	be	used	to	prevent	or	limit	plaque	accumulation	
to	reduce	the	risk	of	developing	AD.	
In	addition,	another	recently	discovered	small	molecules,	P7C3	(widely	discussed	in	
Par.	 1.7.1),	 attracted	 our	 attention	 for	 its	 outstanding	 proneurogenic	 and	
neuroprotective	 profile	 in	 various	 neurodegenerative	 conditions.147	 Moreover,	
looking	at	 its	 structure	 (aminopropylcarbazole)	and	comparing	 it	with	 that	of	TCAs	
(shown	 in	Figure	13),	we	realized	 that	 these	molecules,	not	only	possess	 the	same	
effect	on	neurogenesis,	but	also	contain	common	structural	features. Indeed,	both	
the	 compounds	 share	 similar	 chemical	 motifs:	 a	 tricyclic	 moiety	 connected	 to	 an	
amino	 functionality	 through	 an	 alkyl	 linker.	 Thus,	 both	 TCAs	 and	 P7C3	 may	 be	
considered	 as	 validated	 starting	 points	 for	 the	 design	 of	 focused	 libraries	 with	
neuroregenerative	potential.		
The	idea	of	designing	such	focused	library	either	starting	from	FDA-approved	drugs	
or	those	(i.e.	P7C3)	for	which	the	drug-like	properties	have	been	already	established,	
aims	to	increasing	the	library’s	hit	rate.169,	200	Furthermore,	our	scaffold	selection	is	
reinforced	 by	 the	 fact	 that	 these	 structures	 are	 highly	 recurrent	 in	 CNS-directed	
drugs	and	can	be	considered	“privileged”	for	the	synthesis	of	CNS-focused	libraries.	
To	 this	 end,	 recent	 screening	 of	 140	 FDA-approved	 CNS	 drugs	 suggested	 the	
effectiveness	 of	 the	 tricyclic	 group	 of	 antidepressants	 against	 three	 major	 AD	
targets:	acetylcholinesterase	(AChE),	β-secretase	(BACE-1),	and	Aβ	aggregation,	with	
one	 member,	 protriptyline,	 showing	 highest	 inhibitory	 activity.171 This	 finding	
prompted	 us	 to	 consider	 the	 tricyclic	 scaffold	 as	 prototypical	 structure	 for	
constructing	 our	 focused-chemical	 library	 that,	 in	 principle,	 should	 have	 good	
physicochemical	properties	to	act	at	the	CNS	level.	Furthermore,	given	the	additional	
activities	 displayed	 as	 disease-modifying	 agents	 against	 AD,	 we	 strongly	 believed	
that	TCAs	can	be	considered	optimal	starting	point	for	library	generation.	
	
Figure	13.	Design	of	the	focused-chemical	library	inspired	by	TCAs	and	P7C3.	
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Once	the	general	scaffold	has	been	selected,	(Figure	13),	to	explore	structure-activity	
relationships	(SAR)	a	focused-chemical	library	of	36	entries	has	been	created:	(1)	by	
varying	the	tricyclic	core,	(2)	by	changing	the	number	of	the	linker’s	methylene	units,	
(3)	by	replacing	the	amino	group	with	a	primary,	secondary,	or	tertiary	amine.		
As	 illustrated	 in	 Table	 5,	 we	 selected	 different	 tricyclic	 scaffolds	 carrying	 6,5,6	 or	
6,6,6	or	6,7,6	structures.	They	include	the	6,5,6	carbazole	moiety,	which	not	only	is	
present	 in	 the	 structure	 of	 P7C3,	 but	 its	 utility	 against	 AD	 has	 been	 widely	
demonstrated.201 The	choice	of	the	10,11-dihydro-dibenzazepine	and	dibenzazepine	
as	6,7,6	structures	has	been	motivated	by	the	fact	these	two	moieties	belong	to	the	
widely	 used	 antidepressants	 imipramine	 and	 mood	 stabilizer	 carbamazepine,	
respectively.	 Lastly,	 we	 also	 included	 differently	 substituted	 6,6,6	 phenothiazines	
(phenothiazine,	 2-(trifluoromethyl)phenothiazine	 and	 2-chlorophenothiazine	
respectively).	 Despite	 phenothiazines	 are	 not	 classified	 as	 antidepressants,	 but	 as	
antipsychotics,	 a	 recent	 patent	 claimed	 that	 phenothiazine-based	 compounds	
promote	 regeneration	 and	 survival	 of	 neurons,	 and	 could	 be	 useful	 to	 treat	
neurodegenerative	 diseases.202	 Interestingly,	 phenothiazine	 derivatives	 have	 been	
showed	 to	 inhibit	 butyrylcholinesterase,	 a	 co-regulator	 of	 cholinergic	
neurotransmission,	whose	activity	is	increased	in	AD.203		
	
Table	5.	Chemical	structure	of	compounds	1-36	of	the	focused	chemical	library.	
	
Compound	
number	
X	 R1	 R2	 R3	 n	
1	 CH2CH2	 H	 H	 H	 1	
2	 CH=CH	 H	 H	 H	 1	
3	 bond	 H	 H	 H	 1	
4	 S	 H	 H	 H	 1	
5	 S	 Cl	 H	 H	 1	
6	 S	 CF3	 H	 H	 1	
7	 CH2CH2	 H	 H	 H	 2	
8	 CH=CH	 H	 H	 H	 2	
9	 bond	 H	 H	 H	 2	
10	 S	 H	 H	 H	 2	
11	 S	 Cl	 H	 H	 2	
12	 S	 CF3	 H	 H	 2	
13	 CH2CH2	 H	 CH3	 H	 1	
14	 CH=CH	 H	 CH3	 H	 1	
N
NR2R3
X
R1
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15	 bond	 H	 CH3	 H	 1	
16	 S	 H	 CH3	 H	 1	
17	 S	 Cl	 CH3	 H	 1	
18	 S	 CF3	 CH3	 H	 1	
19	 CH2CH2	 H	 CH3	 H	 2	
20	 CH=CH	 H	 CH3	 H	 2	
21	 bond	 H	 CH3	 H	 2	
22	 S	 H	 CH3	 H	 2	
23	 S	 Cl	 CH3	 H	 2	
24	 S	 CF3	 CH3	 H	 2	
25	 CH2CH2	 H	 CH3	 CH3	 1	
26	 CH=CH	 H	 CH3	 CH3	 1	
27	 bond	 H	 CH3	 CH3	 1	
28	 S	 H	 CH3	 CH3	 1	
29	 S	 Cl	 CH3	 CH3	 1	
30	 S	 CF3	 CH3	 CH3	 1	
31	 CH2CH2	 H	 CH3	 CH3	 2	
32	 CH=CH	 H	 CH3	 CH3	 2	
33	 bond	 H	 CH3	 CH3	 2	
34	 S	 H	 CH3	 CH3	 2	
35	 S	 Cl	 CH3	 CH3	 2	
36	 S	 CF3	 CH3	 CH3	 2	
	
With	the	aim	to	explore	the	impact	of	linker	length,	we	also	generated	two	different	
alkyl	 linkers	constituted	by	two	and	three	methylenes,	respectively.	Thus,	two	sub-
sets	 of	 functionalized	 tricycles,	 carrying	 2-	 or	 3-methylenes	 chains,	 have	 been	
developed.	Furthermore,	to	assess	the	influence	of	amine	substitution,	each	sub-set	
is	composed	by	primary,	secondary	and	tertiary	amines,	 leading	to	1-12,	13-24	and	
25-36,	respectively.	
As	already	showed	in	Chapter	3,	the	developed	synthetic	strategy	allowed	to	obtain	
compounds	1-36	(Table	5).	
The	obtained	 focused	 chemical	 library	has	been	 submitted	 to	 the	 screening	assay,	
which	will	be	described	in	the	following.		
	
	
4.1.2	Towards	the	phenotypic	approach	for	NSCs	
	
Small	molecules	screening	using	NSCs	is	an	important	research	area	whose	objective	
it	 is	 to	 identify	molecules	either	capable	of	maintaining	self-renewal	of	NSCs,	or	of	
driving	 their	 differentiation	 toward	 specific	 fates.	 This	 emerging	 approach	 is	 also	
propelled	 by	 the	 lack	 of	 understanding	 of	 NSCs	 biology.25	 In	 this	 respect,	 high-
content	 screening	 (HCS)	 is	 particularly	 well	 suited	 for	 NSCs-based	 phenotypic	
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approaches.25	 When	 a	 defined	 molecular	 target	 is	 unavailable,	 the	 simultaneous	
analysis	 of	 morphology	 and	 biomarker	 expressions	 in	 such	 highly	 heterogeneous	
cultures	as	NSCs	after	compounds	treatment,	may	allow	to	identify	hits.	
Generally,	 in	 the	 identification	 of	 early	 hits,	 the	 major	 goal	 relies	 on	 the	
identification	 of	 potent	 compounds	 underlying	 the	 desired	 phenotype	 (i.e.	 NSCs	
proliferation/differentiation).	However,	hit	selection	based	on	potency	often	leads	to	
molecules	 from	 which	 it	 proves	 very	 difficult	 to	 eliminate	 toxicity	 or	 other	
unfavorable	 properties,	 such	 as	 lack	 of	 cell	 membrane	 permeability	 and	 chemical	
reactivity.204	In	fact,	many	good	drugs	are	not	very	potent	against	their	targets,	but	
rather	 show	 very	 low	 toxicity	 and	 good	 pharmacokinetic	 properties.	 For	 example,	
the	benzodiazepine	clonazepam	displays	an	IC50	of	23	µM	against	 its	target,	GABAA	
receptor,205	 which	 would	 most	 likely	 not	 be	 considered	 a	 hit	 in	 compounds	
screening.	Nonetheless,	this	drug	is	very	effective	and	is	on	the	market	since	many	
years.	 Such	discrepancy	between	 selecting	 the	most	 potent	molecule	 that	 induces	
the	desired	phenotype	and	 the	actual	 clinical	endpoint,	 suggests	considering	other	
parameters	over	the	selection	of	more	effective	compounds	when	choosing	the	hits	
from	library	screening.	Accordingly,	the	development	of	in	vitro	screens	to	facilitate	
prioritization	of	compounds	for	 further	testing	was	recently	cited	as	a	critical	need	
for	 toxicity	 testing	 by	 the	 National	 Research	 Council’s.206	 In	 this	 respect,	 before	
assessing	 the	 activity	 of	 small	 molecules	 in	 phenotypic	 screening	 program,	 the	
determination	of	cytotoxicity	leads	to	a	significant	improvement	in	the	effectiveness	
of	hit	compounds	 in	a	 timely	and	cost-effective	manner.	 Indeed,	although	the	HCS	
allows	 to	 analyze	 cells	 with	 a	 simultaneous	 readout	 of	 multiple	 phenotypic	
parameters,207	several	 factors	 limit	 the	extensive	use	of	cellular	 imaging	 in	primary	
screening,	such	as	the	high	cost	of	reagents,	complex	assay	development	and	data-
management	issues.208	This	is	of	especially	importance	in	an	academic	environment	
where,	due	to	the	limited	resources,	only	a	limited	number	of	hit	structures	can	be	
monitored.204		
On	these	bases,	before	embarking	in	full-scale	NSCs-based	screening	of	the	focused	
chemical	 library,	 we	 envisioned	 to	 preliminary	 evaluate	 cytotoxicity	 of	 the	
compounds	as	a	primary	screening.	
In	 particular,	 to	 potentially	 highlight	 hits	 from	 the	 focused	 chemical	 library	 with	
optimized	 physicochemical	 properties,	 a	 screening	 pipeline	 has	 been	 defined	 (see	
Figure	XX),	whose	main	goals	are:	(i)	 to	make	a	preliminary	screening	of	molecules	
for	 neuronal	 and	 hepatic	 viabilities;	 (ii)	 to	 evaluate	 neuroprotection	 (low-serum	
assay)	in	rat	primary	neurons;	iii)	to	assess	the	most	promising	compounds	for	their	
neurogenic	activity	(proliferation,	BrdU	assay)	in	rat	primary	neurons;	vi)	to	evaluate	
the	 differentiation	 of	 the	 best	 phenotypic	 compounds	 in	 a	 NSCs-based	 assays	 by	
using	HCS.	
While	the	objectives	(ii)	and	(iii)	are	still	ongoing,	in	the	following	paragraphs	we	will	
focus	 on	 discussing	 the	 screening	 of	 the	 focused	 chemical	 library	 for	 assessing	
neuronal	 and	 hepatic	 viabilities	 (i)	 and	 the	 set-up	 of	 NSCs-based	 phenotypic	
screening	(iv).	
	
	
4.1.2.1	Screening	of	molecules	for	neuronal	and	hepatic	viabilities	
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With	 the	 aim	 to	 identify	 small	 molecules	 with	 an	 optimal	 drug-like	 profile,	 we	
decided	in	collaboration	with	the	laboratory	of	Prof.	Monti	(University	of	Bologna)	to	
first	 filter	 out	 the	 potential	 cytotoxic	 compounds	 by	 evaluating	 cell	 viability	 in	
different	cell	lines.		
As	 first	 screening,	we	 tested	 compounds	on	primary	 rat	 cerebellar	 granule	neuron	
(CGNs),	 in	 order	 to	 proceed	 only	with	 those	molecules	 that	 do	 not	 show	 signs	 of	
neurotoxicity.	Since	cerebellum	is	also	engaged	in	cognition	and	learning	and	affects	
AD	patients’	 bodily	 control,	 CGNs	have	been	used	 as	model	 for	 studying	 neuronal	
death	and	apoptosis	 in	AD.209	To	examine	cell	toxicity,	CGNs	primary	neurons	were	
exposed	to	compounds	1-36	for	24	h	at	concentrations	ranging	from	0	to	50	μM,	and	
cell	 viability	 was	 measured	 by	 MTT	 assay	 (Figure	 14).	 As	 expected,	 being	 these	
compounds	inspired	by	FDA-approved	drugs,	only	at	the	higher	concentrations	(25-
50	µM),	the	compounds	started	to	show	signs	of	toxicity,	whereas	at	concentrations	
below	 to	 25	 µM,	 only	 some	 phenothiazines,	 including	 5-6	 and	 12,	 reduced	 cell	
viability.		
Intriguingly,	It	should	be	noted	that	CGNs	primary	neurons	treated	with	7-8,	15-16,	
19-20,	29	and	33	at	the	range	of	concentrations	tested	showed	a	slight	increment	in	
cell	 viability	 compared	 to	 untreated	 cells,	 potentially	 suggesting	 a	 proliferative	
effect.		
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Figure	 14.	 Toxicity	 of	 1−36	 to	 differentiated	 CGNs	 after	 24	 h	 treatment.	 Results	 are	
expressed	as	percentage	of	controls	and	are	the	mean	±	SE	of	four	different	experiments	run	
at	least	in	quadruplicate.		
	
In	 addition	 to	 neurotoxicity,	 the	 assessment	 of	 hepatotoxicity	would	 be	 of	 critical	
importance	 for	 the	 drug-likeness	 of	 library	 compounds.	 Indeed,	 although	 data	 on	
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antidepressant-induced	 liver	 injury	 are	 scarce,	 antidepressants	 can	 induce	
hepatotoxicity	in	elderly	patients.210		
To	this	end,	preliminary	experiments	were	performed	in	a	human	hepatoma	cell	line	
(HepG2)	 using	 those	 compounds	 that	 show	 no	 sign	 of	 neurotoxicity	 from	 the	
previous	screening	(Figure	15).	Compounds	3-4,	7-8,	10,	15-21,	23-24,	26,	29-31,	and	
33-34	 were	 incubated	 at	 0−50	 μM	 for	 24	 h.	 A	 decrease	 in	 the	 cell	 viability	 was	
observed	 for	 compound	3-4,	7,	 15,	17-18,	 23-24,	26	 and	 34	whereas	 no	 dramatic	
variation	was	found	for	8,	10,	16,	19-21,	29,	31	and	33,	even	at	high	concentrations	
(25-50	µM).	
	
	
	
Figure	15.	Toxicity	of	3-4,	7-8,	10,	15-21,	23-24,	26,	29-31,	and	33-34	to	HepG2	cells	after	24	
h	treatment.	Results	are	expressed	as	percentage	of	controls	and	are	the	mean	±	SE	of	three	
different	experiments	run	at	least	in	quadruplicate.		
	
Considering	 both	 in	 vitro	 neurotoxicity	 and	 hepatotoxicity	 assays	 as	 a	 primary	
screenings	of	the	series,	we	have	selected	16,	19-21,	29	and	33,	which	are	the	less	
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neurotoxic	and	hepatoxic	derivatives,	 to	 investigate	 in	 the	 further	neuroprotection	
assay.		
Particularly,	a	 low-serum	assay	 is	being	performed	 in	CGNs.	Since	 this	 test	 induces	
substantial	 oxidative	 stress	 leading	 to	 partial	 ATP	 depletion,	 K+	 loss,	 and	 the	
apoptotic	cascade	in	neurons,	it	represents	a	useful	model	of	neuronal	cell	death,	as	
well	 as	 neuronal	 senescence.211	 Thus,	 screening	 such	 compounds	 in	 this	 in	 vitro	
model	may	highlight	potential	neuroprotective	molecules	that	will	be	progressed	to	
the	BrdU-based	proliferation	assay	and	then,	to	the	NSCs-based	assay.	
	
	
4.1.2.2	Set-up	of	NSCs-based	phenotypic	screening	for	neurodegenerative	diseases	
	
In	 parallel,	 we	 started	 the	 set	 up	 of	 the	 NSCs	 (neural	 stem/precursor	 cells)-based	
phenotypic	 screening,	 in	 collaboration	with	 the	 CIRI-SDV	 laboratory	 of	 Prof.	 Laura	
Calzà	 (University	 of	 Bologna).	 Despite	 the	 high	 potential,	 this	 step	 is	 particularly	
challenging	 especially	 for	 NSCs,	 because	 often	 cellular	 phenotypes	 differentiation	
caused	by	small	molecules	result	in	a	continuum	of	responses,	and	a	clear	definition	
of	 a	 relatively	 narrow	 phenotype,	 is	 difficult	 to	 reach.212	 Indeed,	 factors	 such	 as	
cellular	 heterogeneity	 of	 cells	 culture	 (e.g.	 neurospheres),	 the	 inability	 to	 easily	
expand	or	freeze	down	such	cells,	and	the	complex	generation	protocols	 introduce	
prohibitive	 constraints.213	 Additionally,	 the	 culture	 might	 be	 in	 a	 state	 of	 chronic	
stress	owing	to	the	in	vitro	environment	—	for	example,	as	a	result	of	higher	oxygen	
tension	and	passaging.	Furthermore,	differentiated	NSCs	might	be	developmentally	
immature	and	might	not	represent	the	true	physiological	situation.213	Accordingly,	as	
in	vitro	model,	the	functional	connectivity	between	the	neurogenic	niches	within	the	
brain	 is	 lost	 in	NSCs,	precluding	detailed	analysis	of	 the	phenotype	within	a	neural	
network.213	 As	 a	 consequence,	 despite	 the	 potential	 of	 NSCs,	most	 physiologically	
relevant	 cellular	 assays	 exploit	 oxidative	 stressors	 (such	 as	 1-methyl-4-
phenylpyridinium	(MPP+))	or	proteins	overexpression	(such	β-amyloid	for	AD	and	γ-
synuclein	for	PD)	to	mimic	disease.214		
Among	the	available	NSCs	systems,	the	neurosphere	cultures,	which	are	identified	as	
floating	multicellular	clusters	that	proliferate	in	the	presence	of	growth	factors,	have	
been	 demonstrated	 valuable	 in	 compounds	 screening.143	 However,	 some	 of	 the	
characteristics	 of	 the	 neurospheres	 make	 them	 not	 the	 elective	 method.	 In	 fact,	
their	 composition	 is	 highly	 heterogeneous,	 being	 the	 growing	 cell	 population	
characterized	 by	 progenitor	 cells,	 glioblasts,	 neuroblasts	 and	 differentiated	
progeny.193	In	this	respect,	an	alternative	source	of	NSCs	for	drug	screening	studies	is	
represented	 by	 NSCs	 derived	 from	 mouse	 SVZ.215	 Indeed,	 these	 NSCs	 can	 be	
efficiently	cultured	as	both	neurosphere	and	adherent	monolayer,	and,	when	grown	
as	 monolayers,	 these	 cells	 better	 recapitulate	 neurogenesis	 in	 vitro	 than	
neurospheres	culture.215	Because	of	the	neurospheres’s	ability	to	expand	both	stem	
and	 non-stem	 cell	 populations,	 NSCs	 derived	 from	 SVZ	 preserved	 all	 the	 in	 vivo	
features	 of	 NSCs,	 being	 able	 to	 proliferate	 giving	 rise	 to	 other	 neural	 stem	 cells	
or/and	 to	 differentiate	 into	 different	 lineages	 (neurons,	 astrocytes	 and	
oligodendrocytes).	Thus,	the	availability	of	a	relevant	NSCs	culture	system,	together	
with	 the	 ability	 to	 maintain	 multipotency	 without	 producing	 non-stem	 cells	
population,	 make	 this	 germinal	 zone	 particularly	 suitable	 for	 compounds	
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screening.216	 Moreover,	 the	 wide	 use	 of	 mouse	 NSCs	 derived	 from	 SVZ	 in	 high-
throughput	screening	programs	prompted	us	to	consider	NSCs	from	mouse	SVZ	as	a	
well-characterized	in	vitro	model	to	perform	our	phenotypic	screening.192,	217		
Once	the	cell	source	has	been	selected	and	before	embarking	in	full-scale	screening	
of	 the	 chemical	 library,	 another	 critical	 step	 relies	 on	 validating	 the	 phenotypic	
assay.	To	this	end,	screening	programs	suggest	that	a	small	set	of	compounds	with	
known	activities	 should	be	 screened	 first.	 Screens	of	 these	compounds	can	 indeed	
validate	 the	 strategy	 by	 identifying	 positive	 control	 compounds	 with	 the	 desired	
phenotypes.212		
In	our	case,	as	positive	control	compounds,	we	have	focused	on	those	for	which	the	
desired	phenotypic	effects	have	been	already	demonstrated	both	in	vivo	and	in	vitro	
(Figure	16a).80,	185,	218	They	included	antidepressant	drugs	with	different	mechanisms	
of	 action:	 the	 non-selective	 monoamine	 reuptake	 inhibitors	 (NSRI)	 imipramine185	
and	amitriptyline;186	 the	 selective	 serotonin	 reuptake	 inhibitors	 (SSRI)	 fluoxetine168	
and	 citalopram;187	 and	 the	 mood-stabilizers	 lithium188	 and	 valproic	 acid.137	 The	
molecular	mechanisms	underlying	NSCs	modulation	of	these	drugs	are	still	unclear.	
In	addition,	a	direct	comparison	among	them	in	a	single	cellular	system	has	not	been	
made	 yet.	 To	 assess	 whether	 the	 observed	 NSC-effects	 may	 be	 ascribed	 to	 the	
antidepressant	 molecular	 mechanism	 of	 action	 (e.g.	 inhibition	 of	 monoamine	
transporters),	we	also	added	the	enantiomers	of	citalopram	and	fluoxetine.	In	detail,	
we	chose	the	S-enantiomer	of	citalopram	(escitalopram),	which	has	been	recognized	
as	the	most	selective	marketed	serotonin	transporter	(SERT)	inhibitor.219 In	addition,	
we	 included	 both	 the	 R-	 and	 S-	 enantiomers	 of	 fluoxetine,	 which	 display	 similar	
potency	 at	 human	 SERT,	 whereas	 the	 resulting	 nor-metabolites	 display	 in	 vivo	
different	profiles,	being	R-norfluoxetine	basically	inactive.219 	
	
a.		
	
	
b.	
O
N
F
N
O
N
F
N
N
H
O
FF
F
N
H
O
FF
F
N
H
O
FF
F
O
OH Li2CO3
Valproic acid (VPA)
Lithium carbonate
Citalopram (CIT) Escitalopram (ESC)
Fluoxetine (FLU) R-Fluoxetine (R-FLU) S-Fluoxetine (S-FLU)
N
N
N
Imipramine (IMI) Amitriptyline (AMI)
		 52	
	
Figure	 16.	 Antidepressants	 compounds	 tested	 on	 NSCs	 assay	 (a)	 and	 NSCs-based	 assay	
design	(b).	
	
Then,	we	 set	up	our	 screening	assay	based	on	NSCs	derived	 from	 the	 forebrain	of	
mouse	embryos	at	14-15	days	(Figure	16b).	In	detail,	the	NSCs	have	been	treated	for	
5	 days	 in	 vitro	 (5	 DIV)	 with	 100	 nM	 of	 the	 selected	 antidepressant	 and	 mood	
stabilizer	compounds	(depicted	in	Figure	16a).		
Specifically,	 using	 a	 high-content	 screening	 apparatus,	 we	 first	 evaluated	 the	
proliferative	 status	 of	 NSCs	 by	 counting	 the	 number	 of	 cells	 versus	 the	 apoptotic	
ones	using	 the	nuclear	dye	DAPI	 (2-(4-amidinophenyl)-1H-indole-6-carboxamidine).	
As	 illustrated	 in	 Figure	17,	 all	 the	 compounds	 showed	a	profile	 very	 similar	 to	 the	
control,	suggesting	that	proliferation	doesn’t	take	place	under	these	conditions.	Only	
for	valproic	acid,	as	the	number	of	cells	decreased,	a	concomitant	slight	increase	of	
apoptosis	has	been	observed.		
			 	
Figure	 17.	 Evaluation	 of	 the	 total	 number	 of	 NSCs	 (left	 panel)	 versus	 the	 apoptotic	 ones	
(right	panel).	
	
Additionally,	we	evaluated	the	differentiation	of	NSCs,	by	assessing	the	percentage	
of	neurons,	astrocytes	and	mature	oligodendrocytes	 (using	β-III-tubulin,	GFAP,	and	
MBP	markers,	 respectively).	 Analysis	 of	 the	data	 reported	 in	 Figure	 18	 showed	no	
significant	increase	of	the	β-III-tubulin	positive	cells	after	treating	with	100	nM	of	all	
the	 tested	 compounds.	 Interestingly,	 SSRI	 S-fluoxetine	 displayed	 an	 increase	 of	
astrocyte	differentiation	(Figure	19	right	panel).	This	is	in	line	with	previous	findings,	
showing	 that	 fluoxetine	 treatment	 enhanced	 the	 expression	 of	 glial	marker	 genes	
following	neural	differentiation	 in	cultured	embryonic	stem	cells.220	By	contrast,	an	
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in	 vivo	 study	 showed	 that	 fluoxetine	 treatment	 counteracted	 the	 stress-induced	
numerical	decrease	of	astrocytes,	but	had	no	effect	on	the	astrocyte	cell	number	in	
control	animals.221	Thus,	astroglial	structural	plasticity	in	response	to	stress	and		
	
Figure	18.	Differentiation	of	NSCs	towards	the	neural	lineage.	
	
		
Figure	19.	Differentiation	of	NSCs	towards	the	astrocyte	lineage.	
	
antidepressant	treatment	support	the	hypothesis	that	glial	changes	may	contribute	
to	 the	 cellular	 actions	of	 antidepressants.	Remarkably,	 in	our	model,	 the	observed	
effect	of	S-fluoxetine	on	astrocyte	resulted	slightly	different	to	that	obtained	for	the	
racemic	 mixture	 or	 its	 R-enantiomer,	 suggesting	 a	 putative	 enantioselective	
mechanism	of	action	(Figure	19,	right	panel).		
Regarding	 oligodendrocyte	 differentiation,	 it’s	 worth	 to	 note	 the	 effect	 shown	 by	
fluoxetine	 racemic	mixture	 (Figure	 20,	 left	 panel).	 This	 is	 consistent	with	 a	 recent	
study	showing	that	adult	mice	treated	with	10	mg/kg	of	racemic	fluoxetine	reduced	
cell	death	of	oligodendrocytes	at	5	days	after	spinal	cord	injury	(SCI).222	 Indeed,	the	
observed	effect	appeared	to	be	greater	than	the	sum	of	effects	displayed	by	the	two	
enantiomers	singularly.	This	might	point	out	to	a	mechanism	of	action	independent	
from	the	SERT	inhibition.		
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Figure	 20.	 Differentiation	 of	 NSCs	 towards	 the	 oligodendrocyte	 lineage	 (left	 panel)	 and	
evaluation	of	dendritic	arborization	(right	panel).	
	
Lastly,	we	have	studied	 the	neuronal	maturation	 in	 terms	of	neuronal	morphology	
and	dendritic	arborization	of	cultured	neurons.	Also	in	this	case,	all	the	compounds	
showed	 a	 behavior	 similar	 to	 the	 control,	 and	 striking	 evidences	 could	 not	 be	
appreciated	(Figure	20,	right	panel).	
Regarding	the	 lack	of	marked	effects,	we	have	to	consider	that	the	studied	cellular	
system	is	highly	complex	and	several	crucial	factors	might	be	involved.	First,	as	noted	
in	 Par.	 4.1.2,	 previous	 studies	 have	 shown	 that	 only	 chronic,	 and	 not	 acute,	
antidepressants	 treatment	 increase	 neural	 cell	 proliferation	 and	 enhance	
differentiation	in	vivo,56,	223	and	in	neural	precursors	derived	from	human	or	mouse	
embryonic	NSCs.224 	
Second,	 the	 ability	 of	 such	molecules	 to	modulate	 neurogenesis	 in	 vitro	 has	 been	
mainly	 observed	 at	 higher	 concentration.172,	 225 Particularly,	 Kusakawa	 et	 al.	
reported	that	8	days	(but	not	6	days)	of	treatment	with	1	µM	fluoxetine	resulted	in	a	
significant	increase	of	the	mRNA	expression	levels	of	glial	marker	genes.220	
Conversely,	 another	 recent	 report	 showed	 that	 1	 μM	 fluoxetine	 (which	 is	
comparable	 to	 therapeutic	 plasma	 concentrations),226	 significantly	 enhanced	 the	
proliferation	of	 embryonic	NPCs,	without	 affecting	 the	differentiation.227	However,	
at	higher	concentration	(20	μM),	fluoxetine	significantly	decreased	cell	proliferation,	
as	 a	 consequence	 of	 cytotoxic	 effects.	 This	 is	 in	 agreement	with	 previous	 findings	
obtained	 in	 primary	 rat	 cerebellar	 granule	 cells228	 and	 hippocampal	 neural	 stem	
cells.229	 Thus,	 the	 concentration	used	 in	 such	experiments	 is	 of	 critical	 importance	
due	to	the	differences	observed	among	in	vitro	studies.		
In	addition,	it	has	been	shown	that	although	the	NSCs	isolated	from	different	species	
and	gender,	or	from	different	CNS	areas	at	several	embryonic	and	postnatal	stages	
share	 common	 features	 (self-renewal	 and	 multipotency),	 but	 they	 also	 show	
significant	 differences	 in	 relation	 to	 their	 culture	 requirements	 and	 drug	
responsiveness,	or	 to	 their	plasticity	and	differentiation	repertoire.230	For	example,	
to	determine	whether	the	antidepressant-induced	up-regulation	of	cell	proliferation	
is	 specific	 to	 the	 hippocampus,	 another	 brain	 region	 known	 to	 contain	 progenitor	
cells	in	adulthood,	the	SVZ,	was	examined.	Notably,	chronic	fluoxetine	treatment	did	
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not	 influence	 the	number	of	BrdU-labeled	cells	of	 this	brain	 region,	demonstrating	
that	 antidepressants	 specifically	 increase	 cell	 proliferation	 in	 the	 hippocampus.56	
This	has	been	further	confirmed	by	Santarelli	et	al.168	 
Furthermore,	 as	already	discussed	at	 the	beginning	of	 this	paragraph,	 it	 should	be	
noted	 that,	when	 comparing	 the	main	 characteristics	 of	NSCs	 in	 vivo	 and	 in	 vitro,	
significant	 differences	 occur.	 Accordingly,	 while	 in	 vivo	 the	 presence	 of	 a	 niche	
stringently	 controls	NSCs	 activity,	 in	 vitro	NSCs	 can	 divide	 and	 differentiate	 in	 the	
absence	of	a	niche.	Likewise,	it	is	evident	that	NSCs	identity	in	vivo	evolves	through	
developmental	 stages;	 in	 contrast,	 in	 vitro	 NSCs	 that	 have	 undergone	 long-term	
expansion,	mainly	 have	 a	 single	 radial	 glia-like	 identity.	 Lastly,	 authentic	 neuronal	
functional	phenotypes	are	acquired	in	vivo,	while	only	partial	functional	maturation	
can	be	achieved	in	vitro.37	
Collectively,	the	obtained	results	and	those	reported	in	the	literature,	might	suggest:	
(i)	 to	 repeat	 such	 experiments	 at	 higher	 compound	 concentration	 (similar	 to	 the	
brain	 therapeutic	 concentration);	 (ii)	 to	 extend	 the	 temporal	 frame	 of	 treatment	
mimicking	 the	 antidepressants	 chronic	 exposure;	 (iii)	 to	 perform	 dose-response	
studies.	
	
	
4.1.3	Target	identification	studies	
	
Despite	their	key	roles	in	therapy	and	as	biological	probes,	7%	of	approved	drugs	are	
claimed	 to	 have	 no	 known	 primary	 target,	 and	 up	 to	 18%	 lack	 a	 well-defined	
mechanism	 of	 action.210 Furthermore,	 37%	 of	 first-in-class	 drugs	 derive	 from	
phenotypic	screens,167	and	consequently,	the	targets	for	some	of	these	drugs	remain	
largely	unknown.210		
Although	 target	 identification	 is	 seen	 as	 an	 important	 and	 almost	 indispensable	
component	of	the	phenotypic	screening	strategy,	it	is,	however,	not	a	critical	step,	in	
the	sense	that	a	project	could	advance	to	lead	optimization	and	in	principle	even	to	
clinical	trials	and	market	approval	without	target	knowledge.		
Nevertheless,	 the	 target	 identification	 represents	 a	 bold	 step	 in	 a	 phenotypic	
screening	pipeline	as	already	pointed	out	for	P7C3	in	Par	1.7.1.	
Generally,	 three	 distinct	 and	 complementary	 approaches	 have	 been	 proposed	 for	
discovering	 the	protein	 target	of	 a	 small	molecule:	direct	biochemical	methods	 (i),	
genetic	interaction	methods	(ii)	and	computational	inference	methods	(iii).231		
Direct	 methods	 (i)	 involve	 labeling	 the	 protein	 or	 small	 molecule	 of	 interest,	
incubation	of	the	two	populaltions	and	direct	detection	of	binding,	usually	following	
some	 type	 of	 wash	 procedure.232	 Genetic	 manipulation	 (ii)	 can	 also	 be	 used	 to	
identify	protein	 targets	by	modulating	presumed	 targets	 in	 cells,	 thereby	 changing	
small-molecule	 sensitivity.233	 Target	 hypotheses,	 in	 contrast,	 can	 be	 generated	 by	
computational	 inference	 (iii),	 using	pattern	 recognition	 to	 compare	 small	molecule	
effects	to	those	of	known	reference	molecules	or	genetic	perturbations.209	
It	should	be	noted	that	mechanistic	hypotheses,	rather	than	targets	per	se,	for	new	
compounds	 emerge	 from	 such	 strategies.	 The	 target	 pathway	or	 protein	of	 a	 new	
small	molecule	is	identified,	but	remains	to	be	confirmed.231		
Here,	we	discussed	opportunities	for	medicinal	chemists	to	make	a	direct	impact	in	
addressing	target	identification	studies	by	using	direct	methods	(i).	
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Among	them,	biochemical	affinity	purification	provides	the	most	direct	approach	to	
finding	 target	 proteins	 that	 bind	 small	 molecules	 of	 interest.231	 Because	 they	 are	
based	on	physical	 interactions	 involving	usually	proteins,	biochemical	methods	can	
lead	 to	 information	about	molecular	mechanisms	of	efficacy	or	 toxicity.	Moreover,	
unbiased	 protein	 identification,	 especially	 from	 lysates	 containing	 intact	 protein	
complexes,	potentially	allows	evaluation	of	polypharmacological	profile.234	
One	 of	 the	 best	 known	 direct	methods	 is	 the	 affinity	 purification,	 which	 involved	
monitoring	chromatographic	fractions	for	enzyme	activity	after	exposure	of	extracts	
to	 compound	 immobilized	 on	 a	 column,	 followed	 by	 elution.	 In	 general,	 such	
approach	 requires	 large	 amounts	 of	 extract	 and	 stringent	 wash	 conditions.	 Such	
approach	has	been	used	with	success	to	identify	certain	protein	targets.234	However,	
these	methods	 seem	best	 suited	 for	 situations	where	a	high-affinity	 ligand	binds	a	
relatively	 abundant	 target	 protein.	 Following	 washes	 can	 indeed	 bias	 proteins	
identified	to	those	with	the	highest-affinity	interactions,	decreasing	the	likelihood	of	
finding	additional	targets	that	might	be	important	in	cellular	contexts.210		
Affinity	purification	experiments	also	involve	the	challenge	of	preparing	immobilized	
affinity	 compounds	 that	 retain	 cellular	 activity,	 so	 that	 target	 proteins	 will	 still	
interact	with	the	small	molecule	while	it	is	bound	to	a	solid	support.	A	related	issue	
is	 the	 identification	of	appropriate	controls	and	tethers.	These	controls	mostly	 rely	
on	 the	 availability	 of	 related	 inactive	 compounds.	 The	 inactive	 analog	 must	 be	
sufficiently	different	from	the	compound	of	interest	to	fail	to	bind	the	target,	raising	
the	 possibility	 that	 it	will	 have	 different	 physicochemical	 properties	 and	 therefore	
different	nonspecific	interactions	with	proteins.	The	choice	of	tether,	influencing	the	
type	of	background	proteins	identified,	also	becomes	a	critical	parameter.231	
Recent	affinity-based	methods	have	attempted	 to	overcome	one	or	more	of	 these	
challenges.	Approaches	based	on	chemical	or	ultraviolet	 light–induced	cross-linking	
use	 covalent	modification	 of	 the	 protein	 target	 or	 small	molecule	 to	 increase	 the	
likelihood	 of	 capturing	 low-abundance	 proteins	 or	 those	 with	 low	 affinity	 for	 the	
small	molecule.213	If	the	first	method	requires	prior	knowledge	of	the	protein	being	
targeted,	 making	 it	 a	 slightly	 biased	 approach,	 the	 second	 one	 is	 still	 completely	
unbiased,	 but	 even	 suffers	 from	 limitations.	 Some	 small-molecule	 libraries	 are	
prepared	for	making	affinity	matrices	after	an	activity	 is	 identified.214 Because	this	
method	 relies	 on	 modification	 of	 the	 compound	 structure,	 it	 requires	 additional	
studies,	 as	 the	 physicochemical	 properties	 of	 the	 starting	 molecule	 have	 been	
significantly	modified.	For	example,	if	a	small	molecule	can	be	fluorescently	labeled,	
it	 can	 be	 used	 to	 probe	 proteins,	 however	 it	 should	 be	 kept	 in	 mind	 that	 it	 can	
establish	different	nonspecific	interactions	with	other	proteins	or,	even	worst,	it	can	
lose	 the	 activity.	 Indeed,	 we	 already	 discussed	 in	 Par.	 1.7.1	 the	 case	 of	 P7C3	
exemplified	the	above-mentioned	limitations.	Accordingly,	all	the	newly	synthesized	
probes	 for	 target	 deconvolution	 studies	 failed	 to	 identify	 the	 putative	 targets	 of	
P7C3.	
Despite	 these	 limitations,	 this	 approach	 has	 been	 successfully	 applied	 to	 small	
molecules	 discovered	 to	 inhibit	 cancer	 cell	 proliferation	 through	 a	 phenotypic	
screening.	 Particularly,	 the	 functionalization	 of	 the	 identified	 hit	 with	 a	
photoreactive	 group	 for	 UV	 light-induced	 covalent	 cross-linking	 to	 interacting	
proteins,	and,	at	 the	same	time,	with	an	alkyne	group	for	reporter	tag	conjugation	
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for	cross-linking,	allowed	to	identify	an	integral	mitochondrial	membrane	protein	as	
target	of	the	starting	hit.	214		
Although	the	potential	of	phenotypic	screens	for	the	discovery	and	characterization	
of	active	compounds	is	high,	target	identification	remains	a	major	challenge	and	only	
the	 integration	 of	 target	 identification	 strategies,	 including	 chemical	 labeling,	
proteomics,	 genomics	 and	 computational	 methods,	 may	 help	 in	 overcoming	 this	
critical	step.		
	
	
4.2	Design	of	TCAs-functionalized	congeners	
	
As	 at	 the	 core	 of	 such	 chemical	 biology	 approach	 is	 developing	 chemical	 tools	 to	
understand	 the	 mechanisms	 and	 the	 neuroregenerative	 potential	 of	 NSCs,	 we	
envisioned	 developing	 different	 set	 of	 functionalized	 congeners	 inspired	 by	 TCAs.	
Indeed,	 the	 functionalized	 congener	 approach	 has	 been	 already	 demonstrated	 its	
applicability	 towards	 different	 types	 of	 congeners	 and	 a	 wide	 range	 of	 GPCRs,	 as	
proposed	by	Jacobson.235	Such	strategy	was	originally	defined	as	the	approach	that	
allows	the	functionalization	of	a	certain	lead	compound	with	known	activity	against	
GPCRs.	 Particularly,	 it	 referred	 to	 a	 derivative	 presenting	 a	 chemical	 reactive	
functional	 group,	 such	 as	 an	 amine	 or	 carboxylic	 acid	 that	 can	 be	 covalently	
conjugated	 through	 a	 spacer	 linker	 to	 a	 position	 structurally	 permissive	 on	 the	
pharmacophore.	 This	means	 that	 the	 insensitivity	 to	 structural	modification	of	 the	
attachment	 site	 is	 an	 essential	 and	 indispensable	 condition	 for	 the	 synthesis	 of	
covalent	conjugates	that	retain	the	activity.	Thus,	the	goals	of	this	approach	focused	
on	both	developing	potential	new	pharmaceutical	agents	in	which	the	activity	of	the	
pharmacophore	may	be	modulated	through	distal	modifications,	and	on	synthesizing	
molecular	probes	useful	to	explore	the	drug	evoked	response	given	by	its	interaction	
with	 the	 target.235	Moreover,	 an	 additional	 advantage	of	 this	 approach	 is	 that	 the	
new	congener	may	improve	the	pharmacological	profile	of	the	starting	molecule	by	
establishing	 secondary	 favorable	 interactions	 with	 the	 target(s).	 Accordingly,	
tethering	different	types	of	functionalized	chain	to	a	pharmacophore	can	provide	a	
wide	variety	of	chemical	probes	depending	on	the	strategy	of	functionalization	that	
includes	 fluorescent	 probes,	 dual-acting	 (multi-target)	 probes,	 conjugation	 to	
carrier/dendrimer,	and	so	forth.170		
Given	 the	 success	 of	 this	 approach	 towards	 understanding	 of	 the	 structural	 and	
functional	significance	of	GPCRs	(discussed	in	the	2nd	part	of	this	thesis),	we	aim	to	
apply	 this	 strategy	 to	develop	different	set	of	 functionalized	congeners	 inspired	by	
TCAs.	 In	 particular,	 in	 the	 following	 paragraphs,	 the	 design	 of	 fluorescent-,	 multi-
target-,	 and	 polyamine-functionalized	 congeners	 inspired	 to	 TCAs	 have	 been	
described.	
	
	
4.2.1	Design	rationale	of	TCAs-functionalized	fluorescent	congeners	
 
As	already	pointed	out,	unfortunately,	 there	 is	not	a	general	streamlined	approach	
to	 target	 identification,	 and	 it	 often	 remains	 a	 major	 bottleneck	 in	 phenotypic	
approach.	 Although	 a	 great	 number	 of	 systematic	 approaches	 capitalizing	 on	
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proteomic	 and	 genomic	 technologies	 have	 been	 developed,	 from	 a	 medicinal	
chemistry	 perspective,	 developing	 properly	 tagged-molecules	 able	 to	 gain	 insights	
on	the	underlying	mechanisms	is	particularly	attractive.200	
On	these	bases,	we	have	developed	a	purposely-functionalized	congeners	library	48-
51	by	conjugating	desipramine	19	and	 its	corresponding	primary	amine	7	 from	the	
focused	chemical	library	with	a	fluorescent	dye	in	order	to	generate	a	selected	set	of	
fluorescent	 probes	 to	 potentially	 be	 used	 for	 further	 target	 identification	 studies	
(Figure	21).12	
	
	
Figure	21.	Design	of	TCA-inspired	fluorescent	congeners	48-51.	
	
Indeed,	 small	molecules	 fluorescent	probes	have	been	widely	used	as	 sensors	and	
probes	 in	 the	 analysis	 of	 a	 variety	 of	molecules	with	 a	 great	 potential	 for	 live	 cell	
imaging.236	An	emerging	field,	involving	the	use	of	small	molecules	with	fluorescent	
properties,	 is	 also	 the	 theranostic	 –	 i.e.	 a	 single	 chemical	 entity	 that	 integrates	
imaging	 and	 therapy.	 Even	 if	 this	 approach	 is	 still	 at	 its	 infancy,	 several	 examples	
validated	this	strategy	against	neurodegenerative	diseases.215	Notably,	the	group	of	
Moore	brilliantly	exemplified	as	the	curcumin-BODIPY	analogue	CRANAD-44	(Figure	
22)	can	be	effective	not	only	to	monitor	Aβ	in	an	AD	mouse	model,	but	also	with	the	
chelating	 pirazole	moiety,	 it	 can	 significantly	 inhibited	 Cu2+-induced	 crosslinking	 of	
Aβ.216		
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Importantly,	 the	 value	 of	 fluorescence-based	 imaging	 grows	 in	 parallel	 to	 the	
development	 of	 sophisticated	 fluorescent	 techniques237	 and	 more	 efficient	
fluorescent	dyes	as	well.238	 Indeed,	the	advancement	of	fluorescence	reagents,	not	
only	 offer	 a	 wide	 range	 of	 new	 fluorophores	 with	 different	 physiochemical	 and	
spectroscopic	 properties	 (such	 as	 excitation	 and	 emission	 wavelengths,	 photo-
bleaching,	 fluorescence	 quantum	 yield,	 stability,	 etc.),	 but	 has	 also	 resulted	 in	 a	
multitude	 of	 more	 complex	 fluorescence	 technologies	 such	 as	 fluorescence	
resonance	 energy	 transfer	 (FRET),	 fluorescence	 activated	 cell	 sorting	 (FACS)	 and	
fluorescence	correlation	spectroscopy	(FCS),	etc.237	
The	 “conventional”	 fluorescent	 probe	 design	 has	 been	 performed	 by	 following	
hypothesis-driven	approach.	It	implies	to	know	the	target	in	advance	and	the	derived	
fluorescent	probes	is	usually	constituted	by	the	recognition	motif	(phamracophore),	
a	 linker	 and	 a	 fluorophore.	 Hence,	 the	 functional	 significance	 of	 such	 probes	 is	
intrinsically	 limited	 by	 the	 available	 knowledge	 of	 the	 target.	 An	 alternative	
approach	 is	 diversity-driven	 approach,	 in	 which	 a	 broad	 range	 of	 fluorescence	
molecules	 are	 constructed	 by	 diversity	 oriented	 fluorescence	 library	 approach	
(DOFLA),	as	a	toolbox	for	unbiased	screening.239		
Remarkably,	the	second	approach	has	already	contributed	to	identify	the	fatty	acid	
binding	protein	7	(FABP7)	as	potential	intracellular	marker	expressed	in	both	human	
and	mouse	NSCs,	 by	 screening	a	DOFLA	 library	on	NSCs.217	 The	 identified	BODIPY-
based	fluorescent	probe	(CDr3,	in	Figure	22)	was	confirmed	to	specifically	label	NSCs	
in	 a	mixed	primary	mouse	brain	 cell	 culture,	 as	well	 as	 human	 cells	 differentiated	
from	ESCs;	and	now	is	sold	as	chemical	probe	to	be	used	in	the	biological	studies	of	
NSCs.192	
	
Figure	22.	BODIPY-based	fluorescent	probes.	
	
Since	its	inception,	several	other	fluorescent	probes	have	been	reported	as	potential	
tool	for	cell-type-specific	labeling.240	On	the	other	hand,	the	deliberate	development	
of	fluorescent	probes	to	gain	insights	of	the	signaling	pathway(s)	modulated	by	the	
selected	 compound	 in	 the	 cellular	 environment	 (i.e.	 NSCs)	 has	 not	 been	 reported	
yet.	Furthermore,	in	such	complex	scenario	where	an	exact	molecular	target	cannot	
be	 identified,	 the	 development	 of	 such	 probes	 cannot	 even	 be	 started	 by	 the	
conventional	method,	as	there	is	no	available	validated	target.		
Furthermore,	in	our	case,	little	is	known	about	the	underlying	mechanism	by	which	
TCAs	enhance	adult	neurogenesis	and	neuroplasticity.241	These	observations	support	
the	hypothesis	that	the	observed	proneurogenic	effect	 is	mediated	by	mechanisms	
that	do	not	only	rely	on	inhibition	of	the	monoamine	reuptake	transporters.241	Thus,	
complex	 and	 oppositely	 directed	 interactions	 between	 neurotransmitter	 systems	
and	 other	 signaling	 pathways/proteins,	 including	 Wnt/β-catenin,	 or	 neurotrophic	
factors,	may	be	involved	in	the	net	effects	displayed	by	TCAs.241		
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Nonetheless,	 the	 profiling	 of	 TCAs	 revealed	 a	 complex	 polypharmacological	multi-
target	profile,	spanning	from	the	interactions	with	amine	transporters	to	related	pre-	
and	post-	synaptic	receptors.233		
On	this	basis,	the	design	of	a	selected	set	of	TCAs	fluorescent	congener	probes	has	
been	 performed,	 as	 fluorescent	 ligands	 have	 proven	 to	 be	 useful	 tools	 also	 in	 a	
cellular	context,	offering	a	wealth	of	information	about	the	mapping	or	identification	
of	 ligand	binding	sites,	 the	movement	and	 internalization	of	molecular	 targets	and	
the	sub-cellular	localization	and	visualization.242	Particularly,	desipramine	19	and	its	
corresponding	primary	amine	7	have	been	conjugated	with	a	BODIPY	fluorescent	dye	
through	 two	different	 linkers	 to	give	 the	TCA-inspired	 fluorescent	congeners	48-51	
(Figure	21),	as	already	described	in	Chapter	3.		
BOBIPY	 dye	 has	 been	 selected	 because	 of	 its	 distinctive	 and	 useful	 features,	
including	 hydrophobicity,	 photochemical	 stability,	 efficient	 uptake	 into	 cell	
membranes,	 high	 extinction	 coefficient	 and	 fluorescence	 quantum	 yield.243	
Moreover	 the	BODIPY	core	has	been	widely	used	as	 fluorescent	 imaging	agent	 for	
Aβ,	reinforcing	our	dye	selection	in	terms	of	cellular	permeability,	stability	and	low	
toxicity.244	
To	assess	if	the	conjugation	modifies	the	spectroscopic	features	of	the	BODIPY	dye,	
we	investigated	the	native	fluorescence	of	TCA-inspired	fluorescent	congeners	48-51	
in	 two	 different	 solvents:	 ethanol	 and	 dichloromethane.	 Notably,	 no	 significant	
changes	 have	 been	 observed	 between	 the	 excitation	 and	 emission	maxima	 in	 the	
different	 solvents	 (Table	 6)	 and	 the	 identified	 wavelengths	 are	 similar	 to	 those	
already	reported	for	this	dye,192	suggesting	that	the	conjugation	did	not	influence	its	
fluorescent	profile.	As	shown	in	Figure	23,	the	excitation	and	emission	spectra	of	48-
51	 in	dichloromethane	(A,	C,	E,	G)	and	in	ethanol	(B,	D,	F,	H)	display	a	small	Stokes	
shift,	 but	 sharp	 excitation	 and	 emission	 peaks.	 This	 latter	 factor	 contributes	 to	
overall	 their	 brightness.	 Additional	 studies	 in	 different	 environments,	 including	
phosphate	 buffered	 saline	 at	 physiological	 pH,	 will	 be	 also	 performed	 to	 assess	
potential	different	behavior	of	48-51.	
	
Table	6.	Excitation	and	emission	maxima	of	compounds	48-51	in	different	solvents.	
	 Dichloromethane	 EtOH	
	 λ(exc)	(nm)	 λ(em)	(nm)	 λ(exc)	(nm)	 λ(em)	(nm)	
48	 504	 507	 501	 503	
49	 502	 503	 500	 503	
50	 505	 507	 501	 503	
51	 505	 507	 505	 506	
	
	
	
Collectively,	the	TCA-inspired	fluorescent	probes	48-51	might	act	as	invaluable	tools	
for	 getting	 initial	 clues	 toward	 identifying	 the	 target(s)	 and	 for	 consequent	
unraveling	the	mechanism	by	which	TCAs	exert	neurogenic	effects.	
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Figure	23.	Fluorescent	spectra	of	48-51	 registered	at	0.5	µM	in	dichloromethane	(A,	C,	E,	G)	and	 in	
ethanol	(B,	D,	F,	H).	
	
4.2.2	Design	rationale	of	TCA-functionalized	multi-target	congeners		
	
Based	 on	 the	 success	 of	 multi-target	 drug	 design	 strategy	 for	 neurodegenerative	
diseases,245 we	have	also	designed	potential	multi-target	 ligands	 towards	NSCs	by	
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combining	in	a	single	chemical	entities	two	pharmacophoric	fragments	belonging	to	
two	molecules	with	different	neurogenic	mechanisms	of	action.		
Indeed,	 due	 to	 the	 resilient	 architecture	 of	 the	 complex	 cellular	 system,	 the	
modulation	 of	 networks	 of	 targets	 through	 a	 well-concerted	 polypharmacological	
approach246	may	 represent	 an	 innovative	 approach	 to	 perturb	 the	 combination	 of	
different	 interconnected	biochemical	networks	orchestrating	the	NSCs	proliferation	
and	differentiation.		
In	addition,	as	previously	discussed	in	Chapter	1,	the	ability	of	defined	“cocktail”	of	
small	molecules	 to	modulate	 specific	 stages	of	NSCs	or	 to	 reprogram	somatic	 cells	
into	specific	 lineages	suggest	that	the	partial	 inhibition	of	a	carefully	selected	small	
number	of	targets	can	be	more	efficient	than	complete	inhibition	of	a	single	target.	
In	principle,	these	goals	can	be	attained	by	either	combination	of	compounds	or	by	
the	use	of	equivalent	multi-target	ligands.246	
In	the	firs	case,	the	combination	of	buspirone	and	melatonin	(Figure	24),	which	has	
already	 completed	 the	 trial	 as	 a	 potential	 mood	 and	 cognitive	 agent	 for	MDD,201	
demonstrated	 that	 both	 enhanced	 neurogenesis	 in	 the	 pre-clinical	 neurogenesis-
based	 in	 vitro	 assays	 and	 antidepressant	 responses	 in	 the	 in	 vivo	 behavioral	 tests	
that	were	equivalent	to	fluoxetine.203	Intriguingly,	buspirone	increased	not	only	the	
number	 of	 neuronal-positive	 cells,	 but	 also	 the	 number	 of	 non-neuronal	 (GFAP	
positive)	cells.	Melatonin	repressed	buspirone-induced	GFAP-positive	cell	formation,	
without	 eliminating	 the	 ability	 of	 buspirone	 to	 promote	 neuronal	 differentiation.	
Melatonin	had	no	effect	alone	suggesting	that	melatonin	works	synergistically	with	
buspirone.	
On	 the	other	 hand,	 the	development	of	multi-target	 ligands	has	 provided	 a	 set	 of	
brilliant	 examples	 to	 support	 this	 concept. One	 of	 the	 most	 appealing	 examples	
came	 from	 the	 group	 of	 Youdim.247	 They	 designed	 and	 synthesized	 a	multi-target	
compound,	 (M30	 in	Figure	24),	possessing	the	neuroprotective	N-propargyl	moiety	
of	 the	 anti-Parkinsonian	 drug,	 monoamine	 oxidase-B	 inhibitor,	 rasagiline	 and	 the	
antioxidant–iron	 chelator	 moiety	 of	 the	 8-hydroxyquinoline	 derivative	 of	 the	 iron	
chelator,	 VK28.	 The	 authors	 also	 demonstrated	 the	 neuroprotective	 and	 the	
neurorestorative	 activity	 of	 M30,	 acting	 against	 multiple	 brain	 targets,	 including	
regulation	 on	 amyloid	 β,	 neurogenesis,	 and	 activation	 of	 hypoxia	 inducible	 factor	
signaling	 pathways.	 The	 diverse	 pharmacological	 properties	 of	 M30	 make	 this	
compound	potential	valuable	for	treating	AD.247		
Given	the	crucial	property	played	by	neurogenesis	for	new	AD-modifying	drugs	and	
considering	 that	 GSK-3β	 inhibition	 has	 been	 reported	 to	 regulate	 and	 increase	
neurogenesis,248	 novel	 BACE-1/GSK-3β	 dual	 triazinone	 inhibitors	 (Figure	 24)	 have	
been	recently	showed	to	exert	remarkable	neuroprotective	and	neurogenic	activities	
and	 no	 neurotoxicity	 in	 cell-based	 assays.	 Moreover,	 displaying	 good	 brain	
permeability	and	pharmacokinetic	properties	 in	mice,	 these	multi-target	 triazinone	
derivatives	might	 emerge	 as	 suitable	 candidates	 for	 the	 development	 of	 effective	
multi-target	drugs	against	AD.249		
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Figure	24.	Multi-target		with	neurogenic	properties.	
	
Conversely,	 Rodríguez-Franco	 et	 al.	 exploited	 the	 neuroregenerative	 properties	 of	
melatonin	by	combining	 it	with	 fragments	showing	 interesting	and	complementary	
features	 to	 provide	 hybrid	 compounds.	 In	 2014,	 the	 melatonin	 framework	 was	
combined	 to	 a	 selected	 protonable	 (N,N-dibenzyl(N-methyl)amine)	 fragment,	
present	 in	 the	 AChE	 inhibitor	 AP2238,	 leading	 to	 new	 melatonin−N,N-dibenzyl(N-
methyl)amine	hybrids	(Figure	24).	These	new	hybrids	show	a	balanced	multi-target	
profile	 spanning	 from	 AChE	 inhibitory	 activity	 to	 antioxidant	 and	 neuroprotective	
properties.	 Importantly,	 they	 promote	 maturation	 of	 NSCs	 into	 a	 neuronal	
phenotype	and	thus,	they	could	contribute	to	CNS	repair.	In	addition,	given	the	low	
cell	toxicity	and	efficient	BBB	permeability,	this	multi-target	profile	highlights	these	
melatonin−N,N-dibenzyl(N-methyl)amine	 hybrids	 as	 useful	 prototypes	 in	 the	
research	of	innovative	drugs	for	AD.250		
In	 a	 following	 paper,	 the	 intriguing	 effect	 of	melatonin	 has	 been	 exploited	 by	 the	
same	author	to	design	merged	melatonin−pinoline	hybrids	(Figure	24).	 In	this	case,	
the	6-methoxy-1,2,3,4-tetrahydro-β-carboline	(pinoline)	is	combined	with	melatonin,	
and	 both	 are	 structurally	 related	 to	 serotonin.	 Their	multi-target	 profile	 has	 been	
evaluated	 and	 included	 serotonergic	 and	 melatonergic	 receptors,	 metabolic	
enzymes	 (monoamine	 oxidases),	 and	 antioxidant	 activity.	 Both,	 pinoline	 and	 2-
acetyl-6-methoxy-1,2,3,4-tetrahydro-β-carboline	 were	 able	 to	 stimulate	 early	
neurogenesis	and	neuronal	maturation	in	an	in	vitro	model	of	NSCs	isolated	from	the	
adult	 rat	 SVZ.	 Such	 effects	 are	 presumably	 mediated	 via	 serotonergic	 and	
melatonergic	stimulations.251		
On	these	bases,	we	developed	multi-target	ligands	towards	NSCs.	The	most	common	
rational	 strategy	 to	 generate	 multi-target	 compounds	 is	 the	 framework	
combination,220	which	 starts	with	 the	 selection	of	 two	structures	or	 sub-structures	
interfering	 with	 two	 distinct	 targets	 relevant	 for	 the	 biological	 process	 under	
investigation.220	In	fact,	multi-target	ligands	arising	from	framework	combination	can	
be	 viewed	 as	 linked,	 fused,	 or	 merged	 depending	 upon	 the	 degree	 to	 which	 the	
frameworks	have	been	integrated.	In	linked	multi-target	compounds,	the	molecular	
fragments	are	joined	by	a	chemical	 linker	(either	cleavable	or	metabolically	stable).	
Fused	multi-target	 ligands	 are	 referred	 to	 compounds	where	 the	 two	 frameworks	
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are	connected	without	a	discernable	linker,	meanwhile	merged	multi-target	ligands	
indicates	 an	 overlap	 of	 a	 common	 chemical	 moiety	 present	 in	 both	 starting	
fragments.220	We	turned	our	attention	to	the	fusing	strategy,	by	amalgamating	into	a	
new	single	molecule	 starting	 fragments	as	much	as	possible	 to	 limit	 the	molecular	
weight	increase.219	To	this	respect,	as	shown	in	Figure	25,	we	conjugated	the	primary	
amines	1-3	and	17-19	of	focused	chemical	library	with	other	small	molecules	active	
on	NSCs	(i.e.	valproic	acid,	52).10	
	
	
Figure	25.	Design	of	multi-target	congeners	53-58.	
	
As	 already	 noted	 in	 Chapter	 1,	 the	 modulation	 of	 neurogenesis	 by	 targeting	
epigenetic	 enzymes	 using	 small	 molecules	 is	 particularly	 attractive.132	 Among	 the	
HDAC	inhibitors,	valproic	acid	52	emerged	to	modulate	neuronal	differentiation	and	
hippocampal	neurogenesis.137	Moreover,	by	also	interacting	with	GSK3,	valproic	acid	
enhanced	 neurogenesis	 by	 activating	 ERK	 pathway-dependent	 cortical	 neuronal	
growth.137		
Given	 the	 intrinsic	 ability	of	 the	 starting	molecules	 to	 simultaneously	 interact	with	
multiple	 targets,	 these	 multi-target	 ligands	 53-58	 may	 provide	 an	 innovative	
approach	 to	 perturb	 the	 combination	 of	 different	 interconnected	 biochemical	
networks	orchestrating	the	NSCs	proliferation	and	differentiation.		
	
	
4.2.3	Design	rationale	of	TCAs-polyamine	congener	
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Since	 polyamines	 have	 been	 considered	 as	 ”privileged	 structures”,252	 the	 last	
conjugation	strategy	of	this	functionalized	congener	approach,	relies	on	developing	
polyamine-based	functionalized	congener	inspired	by	TCA.		
The	 most	 common	 natural	 polyamines,	 such	 as	 putrescine,	 spermidine,	 and	
spermine	 (Figure	 26),	 are	 aliphatic	molecules	with	 amine	 groups	 distributed	 along	
their	structure.	These	polyamines	are	present	in	all	organism	cells,	where	they	play	a	
fundamental	role	 in	cell	proliferation	and	have	both	pro-	and	antiapoptotic	effects.	
252	
	
	
Figure	26.	Some	naturally	occouring	polyamines.	
	
Additionally,	 polyamines	 are	 involved	 in	 many	 signaling	 pathways	 through	 their	
effects	 on	 G	 proteins,	 protein	 kinases,	 nucleotide	 cyclases,	 and	 receptors	 and	
through	 their	 regulation	 of	 the	 expression	 of	 proteins	 involved	 in	 a	 variety	 of	
processes.253 For	 example,	 spermine	 is	 also	 released	 from	 synaptic	 vesicles	 on	
depolarization,	 indicating	 that	 polyamines	 may	 function	 as	 neuromodulators.254	
Moreover,	 polyamines	 influence	 the	 properties	 of	 several	 neurotransmitter	
pathways	 known	 to	 be	 involved	 in	mental	 disorders,	 including	 catecholamines,	 γ-
aminobutyric	acid,	nitric	oxide,	and	glutamate.255		
The	wide	range	of	activities	displayed	by	polyamines	is	clear	evidence	of	how	nature	
exploits	 them	 for	 different	 roles	 at	 different	 targets,	 supporting	 the	 viability	 of	
polyamine	 skeletons	 as	 privileged	 structures.	 And	 indeed,	 polyaminoquinones	
emerged	 as	 readily	 accessible	 and	 easily	 diversified	 scaffolds	 for	 anticancer	 lead	
discovery,256 whereas	 tetraamine-based	 hybrids	 produced	 novel	 inhibitors	 of	
muscular	 nicotinic	 acetylcholine	 receptors257 or	 acetylcholinesterase	 enzyme.258 
However,	 the	 polyamine	 roles	 in	 neurogenesis	 have	 not	 been	 widely	 explored.	
Recent	 evidences	 suggest	 that	 putrescine	 in	 neurosphere	 stimulates	 neural	
progenitor	 proliferation.72	 Furthermore,	 in	 vivo	 depletion	 of	 putrescine	 by	 specific	
and	 irreversible	 inhibition	 of	 ornithine	 decarboxylase,	 the	 first	 key	 enzyme	 of	 the	
polyamine	synthesis	pathway,	induces	a	consistent	decrease	in	neural	progenitor	cell	
proliferation	 in	 the	 two	 neurogenic	 areas,	 the	 DG	 and	 the	 SVZ.72	 Based	 on	 these	
intriguing	 findings,	 the	 authors	 proposed,	 as	 a	 working	 hypothesis	 for	 further	
studies,	that	putrescine	could	be	the	intracellular	link	between	hormonal	and	growth	
factor	 signaling	 pathways	 acting	 on	 neural	 progenitor	 cell.	 However,	 no	 additional	
studies	have	so	far	been	reported	yet.	
Nevertheless,	 the	 demonstration	 that	 the	 conjugation	 with	 polyamine	 not	 only	
increases	 the	 cationic	 character	 of	 the	 starting	 molecule,	 but	 also	 may	 promote	
accumulation	 directly	 into	 the	 mitochondrion,172	 attracted	 our	 attention.	
Accordingly,	 additional	 neuroprotective	 effects	 may	 be	 achieved	 following	 this	
functionalization	 strategy.172	 This	 is	 of	 particular	 importance,	 as	 we	 searched	 for	
compounds	 able	 to	 modulate	 neurogenesis	 and	 to	 exert	 neuroprotective	 effects.	
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Thus,	as	depicted	in	Figure	27,	the	combination	of	desipramine	with	spermidine	has	
been	envisioned	leading	to	polyamine	conger	65.	
	
	
Figure	27.	Design	of	polyamine	congener	65.	
	
To	the	best	of	our	knowledge,	this	represents	the	first	example	of	direct	conjugation	
of	a	known	compound	with	neurogenic	activity	(i.e.	desipramine	19)	to	a	polyamine	
carrier	molecule	(spermidine)	that	may	provide	further	insights	in	the	roles	played	by	
polyamine	in	neurogenesis	and,	hopefully,	to	compounds	endowed	with	a	promising	
neurogenic	and	neuroprotective	profile.	
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Experimental	part	
	
	
General	 information.	All	the	commercial	available	reagents	and	solvents	were	used	
purchased	 from	 Sigma-Aldrich	 (Italy),	 TCI	 chemicals	 (Europe)	 and	 Alfa	 Aesar	
(Germany)	 without	 purification.	 Column	 chromatography	 purifications	 were	
performed	under	"flash	conditions"	using	Sigma-Aldrich	silica	gel	grade	9385,	60	Å,	
230-400	 mesh.	 CEM	 Discover	 SP	 focused	 microwave	 reactor	 was	 used	 for	
microwave-mediated	 reactions.	 Thin	 layer	 chromatography	 (TLC)	 separations	were	
performed	 on	 0.20	 mm	 silica	 gel	 60	 F254	 plates	 (Merck,	 Germany),	 which	 were	
visualized	by	exposure	 to	ultraviolet	 light	 (254	and	366	nm),	 iodine	and	potassium	
permanganate	stains.	Reactions	involving	generation	or	consumption	of	amine	were	
visualized	by	using	bromocresol	green	(0.04%	in	EtOH	made	blue	by	NaOH)	following	
heating	of	 the	plate.	Compounds	were	named	 following	 IUPAC	 rules	as	applied	by	
ChemBioDraw	Ultra	 (version	13.0).	NMR	experiments	were	 run	on	Varian	VXR	400	
(401	MHz	for	1H;	101	MHz	for	13C).	Spectra	were	acquired	at	300	K,	using	CDCl3	and	
CD3OD	as	 solvents.	Chemical	 shifts	 for	 1H	and	 13C	 spectra	were	 recorded	parts	per	
million	 (ppm)	 using	 the	 residual	 non-deuterated	 solvent	 as	 the	 internal	 standard.	
Data	 are	 reported	 as	 follows:	 chemical	 shift	 (ppm),	 multiplicity	 (indicated	 as:	 s,	
singlet;	br	s,	broad	singlet;	exch,	exchangeable	proton	with	D2O;	d,	doublet;	t,	triplet;	
q,	quartet;	p,	pentet;	m,	multiplet	and	combinations	thereof),	coupling	constants	(J)	
in	Hertz	(Hz)	and	integrated	intensity.	
	
	
Procedure	for	the	preparation	of	N-functionalized	acetals	67	and	69:	
	
N-(2,2-dimethoxyethyl)-2,2,2-trifluoroacetamide	(67):	
 To	a	solution	of	2,2-dimethoxyethanamine	(66)	(4.75	mmol,	0.52	mL)	in	THF	(8	mL)	
were	added	trifluoroacetic	anhydride	(TFAA,	5.70	mmol,	0.79	mL)	and	triethylamine	
(5.70	mmol,	0.79	mL)	and	the	mixture	was	stirred	at	room	temperature	for	4	hours.	
After	evaporation	of	the	solvent	under	vacuum	the	reaction	mixture	was	neutralized	
with	saturated	solution	of	NaHCO3	and	diluted	with	DCM.	The	layers	were	separated	
and	 the	aqueous	phase	extracted	with	DCM	(3	x	15	mL).	The	organic	phases	were	
reunited,	washed	with	 brine,	 dried	 over	Na2SO4,	 filtered	 and	 evaporated	 at	 rotary	
evaporator.	 The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (6:4	
petroleum	ether/EtOAc)	affording	67	as	pale	yellow	oil.	Yield	75%.	
1H	NMR	(401	MHz,	CDCl3)	δ	6.58	(br	s,	1H),	4.42	(t,	J	=	5	Hz,	1H,),	3.49	(t,	J	=	5	Hz,	
2H,),	3.41	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	41.2,	54.7,	101.7,	115.8	(q,	J	=285	Hz),	157.4	(q,	 J	=37	
Hz).	
	
N-(3,3-dimethoxypropyl)acetamide	(69):	
To	 a	 solution	 of	 3,3-dimethoxypropionitrile	 68	 (8.7	 mmol,	 0.98	 mL)	 and	 acetic	
anhydride	(17.4	mmol,	1.65	mL)	in	dry	MeOH	(60	mL),	NiSO4	(1.3	g,	8.7	mmol)	was	
added.	To	the	resulting	suspension	NaBH4	(2.3	g,	60.1	mmol)	was	cautiously	added	
over	 30	min	 at	 0°C.	 A	 vigorous	 reaction	with	 the	 formation	 of	 a	 black	 precipitate	
takes	place.	After	 6	h,	 the	 reaction	was	quenched	by	 adding	 saturated	 solution	of	
		 68	
NaHCO3	(5	mL)	 at	 0°C.	 Then,	 the	 obtain	mixture	was	 repeatedly	 filtered	 on	 celite,	
until	 removal	of	 the	black	 solid	 residue.	Then,	 the	 filtrate	was	 concentrated	under	
reduced	pressure	to	give	the	residue	that	was	purified	by	flash	chromatography	(9:1	
DCM/MeOH)	to	give	the	title	compound	69	as	yellow	oil.	Yield	56%.		
1H	NMR	(401	MHz,	CDCl3)	δ	6.10	(br	s,	1H),	4.42	(t,	J=	5.5	Hz,	1H),	3.32	(m,	8H),	1.96	
(s,	3H),	1.81	(q,	J=	5.5,	13	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	169.9,	104.0,	53.4,	35.4,	31.9,	23.2.		
	
	
General	 procedure	 for	 the	 preparation	 of	 N-functionalized	 tricyclic	 scaffolds	 (1b-
12b):	
To	a	solution	of	suitable	tricyclic	scaffold	1a-6a	(1	mmol)	and	acetal	67	or	69	(1.1-1.4	
mmol)	 in	 DCM	 (2	 mL)	 under	 nitrogen,	 were	 added	 trifluoroacetic	 acid	 (TFA,	 13	
mmol)	 and	 triethylsilane	 (TES,	 2.5	mmol)	 and	 the	 resulting	mixture	was	 stirred	 at	
room	 temperature	 for	 2-16	 hours.	 The	 reaction	 was	 cooled	 at	 0°C	 and	 carefully	
neutralized	with	saturated	solution	of	NaHCO3	and	diluted	with	DCM.	The	aqueous	
layer	was	extracted	with	DCM	(3	x)	and	the	combined	organic	phases	were	washed	
with	 brine,	 dried	 over	 Na2SO4	 and	 concentrated	 under	 reduce	 pressure.	 The	
resulting	 residue	was	purified	by	 flash	chromatography	on	silica	gel	using	different	
eluent	mixtures	to	give	the	title	compounds	1b-12b.	
	
N-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-2,2,2-trifluoroacetamide	(1b):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (8:1.5:0.5	
DCM/Tol/EtOAc)	affording	1b	as	white	solid.	Yield	90%.		
1H	NMR	(401	MHz,	CDCl3)	δ	7.20	–	7.09	(m,	6H),	7.04-6.96	(m,	2H),	6.50	(s,	1H,	exch),	
3.95	(t,	J	=	5.9	Hz,	2H),	3.55	(q,	J	=	5.8	Hz,	2H),	3.15	(s,	4H).	
	
N-(2-(5H-dibenzo[b,f]azepin-5-yl)ethyl)-2,2,2-trifluoroacetamide	(2b):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (8:2	 petroleum	
ether/EtOAc)	affording	2b	as	yellow	solid.	Yield	95%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.05-7.35	 (m,	9H),	6.81	 (s,	2H),	3.98	 (t,	 J=	5.5	Hz,	2H),	
3.48	(m,	2H).	
	
N-(2-(9H-carbazol-9-yl)ethyl)-2,2,2-trifluoroacetamide	(3b):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (7:2:1	 petroleum	
ether/DCM/EtOAc)	affording	3b	as	white	solid.	Yield	82%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.09	(d,	J	=	7.8	Hz,	2H),	7.47	(m,	2H),	7.45	–	7.34	(m,	1H),	
7.28	-	7.24	(m,	3H),	6.28	(s,	1H,	exch),	4.56	(t,	J	=	5.9	Hz,	2H),	3.83	(q,	J	=	6.0	Hz,	2H).	
	
2-(10H-phenothiazin-10-yl)-N-(trifluoromethyl)ethan-1-amine	(4b):	
The	 resulting	 residue	was	 purified	 by	 flash	 chromatography	 (7:3	 petroleum	ether/	
EtOAc)	affording	4b	as	pale	yellow	oil.	Yield	88%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.21	(m,	4H),	7.00	(t,	J	=	8.0	Hz,	2H),	6.94	(d,	J	=	7.8	Hz,	
2H),	4.16	(t,	J	=	5.8	Hz,	2H),	3.73	(d,	J	=	5.8	Hz,	2H).	
	
2-(2-chloro-10H-phenothiazin-10-yl)-N-(trifluoromethyl)ethan-1-amine	(5b):	
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The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (8.5:1.5	 petroleum	
ether/	EtOAc)	affording	5b	as	pale	yellow	oil.	Yield	70%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.20	-	7.12	(m,	2H),	7.04	(d,	J	=	8.2	Hz,	1H),	6.98	-	6.79	
(m,	4H),	4.07	-	4.02	(m,	2H),	3.66	(t,	J	=	6.4	Hz,	2H).	
	
N-(trifluoromethyl)-2-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-amine	
(6b):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (8.5:1.5	 petroleum	
ether/	EtOAc)	affording	6b	as	pale	yellow	oil.	Yield	84%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.28	–	7.16	 (m,	4H),	7.10	 (s,	1H),	7.04	–	6.96	 (m,	2H),	
6.74	(s,	1H,	exch),	4.16	(t,	J	=	6.0	Hz,	2H),	3.72	(q,	J	=	5.9	Hz,	2H).	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)acetamide	(7b):	
The	resulting	residue	was	purified	by	flash	chromatography	(7:2:1	petroleum	ether/	
EtOAc/	EtOH)	affording	7b	as	white	solid.	Yield	71%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.17	–	7.01	(m,	6H),	6.92	(t,	J	=	7.3,	2H),	5.57	(br	s,	1H,	
exch),	3.75	(t,	J	=	6.7	Hz,	2H),	3.24	(t,	J	=	6.9	Hz,	2H),	3.14	(s,	4H),	1.87	(s,	3H),	1.85	–	
1.72	(m,	2H).	
	
N-(3-(5H-dibenzo[b,f]azepin-5-yl)propyl)acetamide	(8b):	
The	resulting	residue	was	purified	by	flash	chromatography	(6:3:1	petroleum	ether/	
EtOAc/	EtOH)	affording	8b	as	pale	yellow	solid.	Yield	75%.		
1H	NMR	(CDCl3)	δ	7.33	-	7.29	(m,	2H),	7.11	-	7.07	(m,	2H),	7.05	-	6.98	(m,	4H),	6.84	(s,	
2H),	6.66	(br	s,	1H,	exch),	3.84	(m,	2H),	3.29	(m,	2H),	1.87	(s,	3H),	1.73	(m,	2H).	
	
N-(3-(9H-carbazol-9-yl)propyl)acetamide	(9b):	
The	resulting	residue	was	purified	by	flash	chromatography	(6:3:1	petroleum	ether/	
EtOAc/	EtOH)	affording	9b	as	pale	pink	solid.	Yield	62%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.10	(d,	J	=	7.8	Hz,	2H),	7.49	-	7.42	(m,	4H),	7.23	(t,	J	=	4.0	
Hz,	2H),	4.39	(t,	J	=	6.8	Hz,	2H),	2.61	(t,	J	=	6.9	Hz,	2H),	2.40	(s,	3H),	2.05	(p,	J	=	6.9	Hz,	
2H).	
	
N-(3-(10H-phenothiazin-10-yl)propyl)acetamide	(10b):	
The	resulting	residue	was	purified	by	flash	chromatography	(6:3:1	petroleum	ether/	
EtOAc/	EtOH)	affording	10b	as	pale	yellow	oil.	Yield	82%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.21	-	7.14	(m,	4H),	6.96	-	6.85	(m,	4H),	6.24	(br	s,	1H,	
exch),	3.31	(q,	J	=	6.1	Hz,	2H),	1.98	(q,	J	=	6.1	Hz,	2H),	1.75	(s,	3H).	
	
N-(3-(2-chloro-10H-phenothiazin-10-yl)propyl)acetamide	(11b):	
The	resulting	residue	was	purified	by	flash	chromatography	(6:3:1	petroleum	ether/	
EtOAc/	EtOH)	affording	11b	as	pale	yellow	oil.	Yield	82%.	
1H	NMR	(401	MHz,	CD3OD)	δ	7.11	(t,	J	=	7.9	Hz,	1H)	7.05	-	7.05	(m,	1H),	6.93	(d,	J	=	
8.0	Hz,	1H)	6.90	–	6.79	(m,	4H),	3.81	(t,	J	=	6.7	Hz,	2H),	3.19	(t,	J	=	6.9	Hz,	2H),	1.90-
1.83	(m,	5H).	
	
N-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)acetamide	(12b):	
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The	resulting	residue	was	purified	by	flash	chromatography	(6:3:1	petroleum	ether/	
EtOAc/	EtOH)	affording	12b	as	pale	yellow	oil.	Yield	72%.	
1H	NMR	(401	MHz,	CD3OD)	δ	7.17	–	7.03	(m,	5H),	6.92	–	6.85	(m,	2H),	3.89	(t,	J	=	6.8	
Hz,	2H),	3.27	–	3.17	(m,	2H),	1.95	–	1.81	(m,	5H).	
	
	
General	procedure	for	the	preparation	of	primary	amines	(1-12):	
Method	 A:	 To	 a	 solution	 of	 trifluoroacetamides	 1b-6b	 (1	 mmol)	 in	 a	 mixture	 of	
MeOH:	H2O	(2:1,	3.5	mL),	K2CO3	(7.88	mmol)	was	added	and	the	resulting	mixture	is	
stirred	 at	 rt	 for	 4-6	 h.	 After	 evaporation	 of	 MeOH	 under	 vacuum	 the	 resulting	
aqueous	residues	was	diluted	with	H2O	(10	mL)	and	extracted	with	DCM	(3	x	15	mL).	
The	 organic	 phases	were	 reunited,	washed	with	 brine,	 dried	 over	Na2SO4,	 filtered	
and	evaporated	at	 rotary	evaporator	 to	give	 the	 title	 compounds	1-6,	without	any	
further	purification.		
Method	B:	To	a	solution	of	acetamides	7b-12b	(1	mmol)	in	a	mixture	of	MeOH:	H2O	
(2:1,	 5	 mL),	 KOH	 (7.5	 mmol)	 was	 added	 in	 a	 pressure-tight	 microwave	 tube.	 The	
resulting	mixture	was	submitted	to	microwave	irradiation	for	90	min	at	160°C,	with	
an	irradiation	power	of	150	W.	After	evaporation	of	the	solvents	under	vacuum,	the	
resulting	mixture	was	purified	by	flash	chromatography	using	as	eluent	a	mixture	of	
DCM:	MeOH:	33%	aq.	NH3	solution	(9:1:0.1)	to	give	the	title	compounds	7-12.	
	
2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethan-1-amine	(1):	
The	title	compound	1	was	obtained	as	colorless	oil	by	using	Method	A.	Yield	98%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.11	(m,	6H),	6.93	(t,	J	=	7.3	Hz,	2H),	3.81	(t,	J	=	6.0	Hz,	
2H),	3.18	(s,	4H),	2.86	(s,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.04,	134.23,	129.91,	126.43,	122.70,	120.02,	53.98,	
39.82,	32.27.	
MS(ESI):	m/z	C16H18N2;	calcd.	[M]:	238.33,	found	[M	+	1]:	239,	[M	+	Na+]:	261.	
	
2-(5H-dibenzo[b,f]azepin-5-yl)ethan-1-amine	(2):	
The	title	compound	2	was	obtained	as	yellow	solid	by	using	Method	A.	Yield	98%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.28	–	7.19	 (m,	2H),	7.11	–	6.92	 (m,	6H),	6.73	 (s,	2H),	
3.81	(t,	J	=	1.5	Hz,	2H),	2.81	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.42,	134.13,	132.12,	129.19,	128.84,	123.52,	120.70,	
53.84,	39.31.	
MS(ESI):	m/z	C16H16N2;	calcd.	[M]:	236.32,	found	[M	+	1]:	237,	[M	+	Na+]:	259.	
	
2-(9H-carbazol-9-yl)ethan-1-amine	(3):	
The	title	compound	3	was	obtained	as	pale	yellow	oil	by	using	Method	A.	Yield	97%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.13	(dt,	J	=	7.8,	1.1	Hz,	2H),	7.53	–	7.41	(m,	4H),	7.27	(m,	
2H),	4.35	(t,	J	=	6.2	Hz,	2H),	3.18	(t,	J	=	6.1	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	140.65,	125.77,	122.92,	120.41,	119.07,	108.76,	46.21,	
41.33.	
MS(ESI):	m/z	C14H14N2;	calcd.	[M]:	210.28,	found	[M	+	1]:	211,	[M	+	Na+]:	243.	
	
2-(10H-phenothiazin-10-yl)ethan-1-amine	(4):		
The	title	compound	4	was	obtained	as	colorless	oil	by	using	Method	A.	Yield	98%.	
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1H	NMR	(401	MHz,	CDCl3)	δ	7.17	–	7.10	(m,	4H),	6.96	–	6.84	(m,	4H),	3.96	(t,	J	=	5.9	
Hz,	2H),	3.03	(t,	J	=	5.9	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.21,	127.59,	127.24,	125.87,	122.70,	115.78,	109.98,	
50.51,	38.82.	
MS(ESI):	m/z	C14H14N2S;	calcd.	[M]:	242.34,	found	[M	+	1]:	243,	[M	+	Na+]:	265.	
	
2-(2-chloro-10H-phenothiazin-10-yl)ethan-1-amine	(5):	
The	title	compound	5	was	obtained	as	yellow	oil	by	using	Method	A.	Yield	96%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.17	–	7.12	(m,	2H),	7.02	(d,	J	=	8.2	Hz,	1H),	6.96	–	6.82	
(m,	4H),	3.92	(t,	J	=	5.9	Hz,	2H),	3.03	(t,	J	=	5.9	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.22,	127.61,	127.27,	125.88,	122.73,	115.80,	50.46,	
38.81.	
MS(ESI):	m/z	C14H13ClN2S;	calcd.	[M]:	276.78,	found	[M	+	1]:	277,	[M	+	Na+]:	299.	
	
2-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-amine	(6):	
The	title	compound	6	was	obtained	as	yellow	oil	by	using	Method	A.	Yield	97%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.29	–	7.13	(m,	4H),	7.10	–	7.05	(m,	1H),	7.02	–	6.88	(m,	
2H),	4.02	(t,	J	=	5.9	Hz,	2H),	3.08	(t,	J	=	5.9	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.76,	144.26,	127.72,	127.67,	127.63,	124.87,	123.38,	
119.36,	119.33,	116.15,	112.27,	112.24,	50.66,	38.65.	
MS(ESI):	m/z	C15H13F3N2S;	calcd.	[M]:	310.34,	found	[M	+	1]:	311,	[M	+	Na+]:	333.	
	
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propan-1-amine	(7):	
The	title	compound	7	was	obtained	as	colorless	oil	by	using	Method	B.	Yield	78%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.15	-	7.07	(m,	6H),	6.98	–	6.87	(m,	2H),	3.79	(t,	J	=	6.7	
Hz,	2H),	3.16	(s,	4H),	2.71	(t,	J	=	7.0	Hz,	2H),	1.71	(p,	J	=	6.8	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.27,	134.23,	129.82,	126.34,	122.47,	119.91,	47.94,	
39.90,	32.18,	31.69.	
MS(ESI):	m/z	C17H20N2;	calcd.	[M]:	252.36,	found	[M	+	1]:	253,	[M	+	Na+]:	275.	
	
	3-(5H-dibenzo[b,f]azepin-5-yl)propan-1-amine	(8):	
The	title	compound	8	was	obtained	as	yellow	solid	by	using	Method	B.	Yield	79%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.24	(t,	J	=	7.7	Hz,	2H),	7.07	–	6.92	(m,	6H),	6.71	(s,	2H),	
3.78	(t,	J	=	6.5,	2H),	2.74	(t,	J	=	6.7	Hz,	2H),	1.69	(t,	J	=	6.6	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	188.54,	150.76,	133.85,	132.14,	129.14,	128.80,	123.31,	
120.26,	48.20,	40.05,	30.68.	
MS(ESI):	m/z	C17H18N2;	calcd.	[M]:	250.35,	found	[M	+	1]:	251,	[M	+	Na+]:	273.	
	
3-(9H-carbazol-9-yl)propan-1-amine	(9):	
The	title	compound	9	was	obtained	as	yellow	oil	by	using	Method	B.	Yield	77%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.08	(d,	J	=	7.8	Hz,	2H),	7.49	–	7.38	(m,	4H),	7.27	–	7.17	
(m,	2H),	4.40	(t,	J	=	6.8	Hz,	2H),	2.74	(t,	J	=	6.9	Hz,	2H),	2.01	(p,	J	=	6.9	Hz,	2H),	1.67	(s,	
1H).	
13C	NMR	 (101	MHz,	CDCl3)	δ	140.37,	125.60,	120.32,	118.78,	108.59,	40.44,	39.58,	
32.44.	
MS(ESI):	m/z	C15H16N2;	calcd.	[M]:	224.31,	found	[M	+	1]:	225,	[M	+	Na+]:	247.	
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3-(10H-phenothiazin-10-yl)propan-1-amine	(10):	
The	title	compound	10	was	obtained	as	yellowish	oil	by	using	Method	B.	Yield	98%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.14	-	7.18	(m,	4H),	6.96	–	6.86	(m,	4H),	3.95	(t,	J	=	6.7	
Hz,	2H),	2.82	(t,	J	=	6.8	Hz,	2H),	1.95	(q,	J	=	6.7	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.26,	127.53,	127.25,	125.37,	122.53,	115.58,	53.45,	
44.79,	39.63,	30.09.	
MS(ESI):	m/z	C15H16N2S;	calcd.	[M]:	256.37,	found	[M	+	1]:	257,	[M	+	Na+]:	279.	
	
3-(2-chloro-10H-phenothiazin-10-yl)propan-1-amine	(11):	
The	title	compound	11	was	obtained	as	yellow	oil	by	using	Method	B.	Yield	87%.	
1H	NMR	(401	MHz,	CD3OD)	δ	7.13	(t,	J	=	8.0	Hz,	1H),	7.04	(d,	J	=	8.1	Hz,	1H),	6.97	–	
6.84	(m,	4H),	6.82	(d,	J	=	8.3	Hz,	1H),	3.82	(t,	J	=	6.7	Hz,	2H),	2.67	(t,	J	=	7.1	Hz,	2H),	
1.82	(m,	2H).	
13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 146.64,	 144.45,	 133.00,	 127.58,	 127.31,	 127.02,	
124.86,	123.89,	122.76,	121.98,	115.94,	115.63,	44.64,	38.80,	29.27.	
MS(ESI):	m/z	C15H15ClN2S;	calcd.	[M]:	290.81,	found	[M	+	1]:	291,	[M	+	Na+]:	323.	
	
3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propan-1-amine	(12):	
The	title	compound	12	was	obtained	as	yellowish	oil	by	using	Method	B.	Yield	48%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.20	–	7.03	(m,	4H),	6.93	-	6.87	(m,	3H),	3.94	(t,	J	=	6.7	
Hz,	2H),	2.80	(t,	J	=	6.7	Hz,	2H),	1.89	(t	J	=	6.7	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.69,	144.38,	130.16,	130.02,	129.70,	129.38,	129.06,	
128.21,	 127.65,	 127.59,	 127.51,	 125.51,	 124.25,	 123.13,	 122.81,	 120.11,	 119.16,	
119.12,	119.08,	119.04,	115.93,	111.98,	111.94,	111.90,	111.87,	44.93,	39.51,	30.11.	
MS(ESI):	m/z	C16H15F3N2S;	calcd.	[M]:	324.37,	found	[M	+	1]:	325,	[M	+	Na+]:	347.	
	
	
General	procedure	for	the	preparation	of	secondary	amines	(13-24):	
To	 a	 solution	 of	 formaldehyde	 (1	mmol)	 in	MeOH	 (5	mL),	 20	mg	 of	 clay	 K10	was	
added	 and	 left	 stirred	 at	 rt	 for	 15	min	 in	 a	 pressured-microwave	 tube.	 Then,	 the	
appropriate	primary	amine	1-12	(1.5	mmol)	was	added	to	the	reaction	mixture	and	
was	submitted	to	irradiation	for	30	min	at	80	°C.	A	mixture	of	10	mg	of	clay	K10	with	
sodium	borohydride	(1.5	mmol)	was	then	added	to	the	reaction	after	cooling	down	
to	0°C.	It	was	allowed	to	reach	rt	and	was	irradiated	again	for	10	min	at	80	°C.	It	was	
then	 diluted	 with	 MeOH,	 filtered,	 concentrated	 to	 dryness	 and	 purified	 by	 flash	
chromatography	on	silica	gel	using	a	gradient	of	DCM/MeOH/33%	aq.	NH3	solution	
(from	9.5:	0.5:	0.05	to	9:	1:	0.1)	to	give	secondary	amines	13-24.		
	
2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylethan-1-amine	(13):	
The	title	compound	13	was	obtained	as	yellow	oil.	Yield	37%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.15	–	7.07	(m,	6H),	6.91	(m,	2H),	3.87	(t,	J	=	6.3	Hz,	2H),	
3.15	(s,	4H),	2.75	(t,	J	=	6.3	Hz,	2H),	2.35	(s,	3H).	
13C	NMR	(101	MHz,	CD3OD)	δ	147.44,	134.50,	129.82,	126.42,	123.32,	119.00,	46.72,	
46.42,	32.69,	31.52.	
MS(ESI):	m/z	C17H20N2;	calcd.	[M]:	252.36,	found	[M	+	1]:	253,	[M	+	Na+]:	275.	
	
2-(5H-dibenzo[b,f]azepin-5-yl)-N-methylethan-1-amine	(14):	
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The	title	compound	14	was	obtained	as	yellow	oil.	Yield	42%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.08	–	6.95	(m,	6H),	6.73	(s,	2H),	3.87	(t,	J	=	5.9	Hz,	2H),	
2.70	(s,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.18,	134.02,	132.05,	129.18,	128.92,	123.63,	120.67,	
49.78,	48.64,	35.82.	
MS(ESI):	m/z	C17H18N2;	calcd.	[M]:	250.35,	found	[M	+	1]:	251,	[M	+	Na+]:	272.	
	
2-(9H-carbazol-9-yl)-N-methylethan-1-amine	(15):	
The	title	compound	15	was	obtained	as	yellow	oil.	Yield	31%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.10	(d,	J	=	7.8	Hz,	2H),	7.47	(d,	J	=	4.0	Hz,	4H),	7.25	(q,	J	
=	3.8	Hz,	2H),	4.47	(t,	J	=	6.1	Hz,	2H),	3.08	(m,	2H),	2.42	(s,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	140.52,	125.76,	122.91,	120.36,	119.05,	108.70,	43.15,	
41.33,	29.71.	
MS(ESI):	m/z	C17H18N2;	calcd.	[M]:	224.31,	found	[M	+	1]:	225,	[M	+	Na+]:	247.	
	
N-methyl-2-(10H-phenothiazin-10-yl)ethan-1-amine	(16):	
The	title	compound	16	was	obtained	as	yellow	oil.	Yield	38%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.19	–	7.11	(m,	4H),	6.98	–	6.85	(m,	4H),	4.13	(t,	J	=	6.0	
Hz,	2H),	3.04	(t,	J	=	5.9	Hz,	2H),	2.45	(s,	3H),	2.00	(br	s,	1H,	exch).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.01,	127.41,	127.29,	124.67,	122.50,	115.25,	56.59,	
46.37,	45.83.	
MS(ESI):	m/z	C16H16N2S;	calcd.	[M]:	256.37,	found	[M	+	1]:	257,	[M	+	Na+]:	279.	
	
2-(2-chloro-10H-phenothiazin-10-yl)-N-methylethan-1-amine	(17):	
The	title	compound	17	was	obtained	as	yellow	oil.	Yield	29%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.21	–	7.10	(m,	4H),	6.95	–	6.85	(m,	4H),	4.01	–	3.92	(m,	
2H),	2.75	–	2.67	(m,	2H),	2.34	(s,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	128.75,	128.38,	123.87,	123.22,	116.60,	116.48,	57.43,	
46.78,	31.81.	
MS(ESI):	m/z	C16H15ClN2S;	calcd.	[M]:	290.81,	found	[M	+	1]:	291,	[M	+	Na+]:	313.	
	
N-methyl-2-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-amine	(18):	
The	title	compound	18	was	obtained	as	yellow	oil.	Yield	26%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.24	–	7.09	(m,	5H),	7.01	–	6.91	(m,	2H),	4.06	–	3.98	(m,	
2H),	2.76	–	2.67	(m,	2H),	2.34	(s,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.96,	144.75,	130.40,	128.29,	128.06,	127.93,	126.01,	
124.11,	 123.70,	 123.32,	 119.70,	 119.67,	 116.12,	 112.42,	 112.38,	 110.56,	 57.03,	
47.32,	46.40.	
MS(ESI):	m/z	C16H15F3N2S;	calcd.	[M]:	324.37,	found	[M	+	1]:	325,	[M	+	Na+]:	347.	
	
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine	(19):	
The	title	compound	19	was	obtained	as	pale	yellow	oil.	Yield	44%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.13	–	7.03	(m,	3H),	6.90	(t,	J	=	8.0	Hz,	1H),	3.78	(t,	J	=	6.7	
Hz,	2H),	3.27	(s,	1H,	exch),	3.14	(s,	3H),	2.64	(t,	J	=	7.1	Hz,	1H),	1.84	–	1.76	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.29,	134.23,	129.85,	126.39,	122.49,	119.96,	49.74,	
48.50,	36.35,	32.23,	27.94.	
MS(ESI):	m/z	C18H22N2;	calcd.	[M]:	266.39,	found	[M	+	1]:	267,	[M	+	Na+]:	289.	
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3-(5H-dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine	(20):	
The	title	compound	20	was	obtained	as	yellow	oil.	Yield	36%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.24	(t,	J	=	7.8	Hz,	2H),	7.07	-	6.96	(m,	4H),	6.74	(s,	2H),	
3.80	(t,	J	=	6.4	Hz,	2H),	2.70	(t,	J	=	6.7	Hz,	2H),	2.32	(s,	3H),	1.78	(t,	J	=	6.6	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.40,	133.72,	132.09,	129.17,	128.93,	123.51,	120.17,	
49.61,	48.66,	35.54,	26.03.	
MS(ESI):	m/z	C18H20N2;	calcd.	[M]:	264.37,	found	[M	+	1]:	265,	[M	+	Na+]:	287.	
	
3-(9H-carbazol-9-yl)-N-methylpropan-1-amine	(21):	
The	title	compound	21	was	obtained	as	yellowish	oil.	Yield	35%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.10	(d,	J	=	7.8	Hz,	2H),	7.45	(m,	4H),	7.23	(t,	J	=	7.9,	Hz,	
2H),	4.39	(t,	J	=	6.8	Hz,	2H),	2.61	(t,	J	=	6.9	Hz,	2H),	2.40	(s,	3H),	2.05	(p,	J	=	6.9	Hz,	
2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	140.48,	125.73,	122.89,	120.40,	118.89,	108.72,	49.16,	
40.76,	36.27,	29.01.	
MS(ESI):	m/z	C16H18N2;	calcd.	[M]:	238.33,	found	[M	+	1]:	239,	[M	+	Na+]:	261.	
	
N-methyl-3-(10H-phenothiazin-10-yl)propan-1-amine	(22):	
The	title	compound	22	was	obtained	as	yellow	oil.	Yield	28%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.17	-	7.13	(m,	4H),	6.96	–	6.85	(m,	4H),	3.91	(t,	J	=	7.0	
Hz,	2H),	2.41	(t,	J	=	7.1	Hz,	2H),	2.20	(s,	3H),	2.00	–	1.92	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.90,	145.79,	127.97,	127.73,	125.68,	122.93,	116.05,	
57.70,	46.09,	45.91,	25.76.	
MS(ESI):	m/z	C16H18N2S;	calcd.	[M]:	270.39,	found	[M	+	1]:	271,	[M	+	Na+]:	293.	
	
3-(2-chloro-10H-phenothiazin-10-yl)-N-methylpropan-1-amine	(23):	
The	title	compound	23	was	obtained	as	yellow	oil.	Yield	30%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.19	–	7.10	(m,	2H),	7.03	(d,	J	=	8.7	Hz,	1H),	6.98	–	6.86	
(m,	4H),	3.89	(dd,	J	=	7.7,	6.3	Hz,	2H),	2.41	(t,	J	=	7.0	Hz,	2H),	2.23	(s,	3H),	1.99	–	1.90	
(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	127.84,	127.47,	127.37,	122.83,	122.20,	115.85,	115.78,	
57.00,	45.56,	45.45,	25.06.	
MS(ESI):	m/z	C16H17ClN2S;	calcd.	[M]:	304.84,	found	[M	+	1]:	305,	[M	+	Na+]:	327.	
	
N-methyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propan-1-amine	(24):	
The	title	compound	24	was	obtained	as	yellow	oil.	Yield	24%.	
1H	NMR	(401	MHz,	CD3OD)	δ	7.26	-	7.12	(m,	5H),	7.04	(s,	1H),	6.97	(s,	1H),	4.04	–	3.97	
(m,	2H),	2.68	(m,	2H),	2.31	(s,	3H),	1.95	(m,	2H).	
13C	 NMR	 (101	 MHz,	 CD3OD)	 δ	 145.64,	 144.39,	 127.61,	 127.51,	 127.42,	 123.04,	
119.03,	118.99,	115.84,	111.90,	111.87,	56.99,	45.54,	45.52,	24.99.	
MS(ESI):	m/z	C17H17F3N2S;	calcd.	[M]:	338.39,	found	[M	+	1]:	339,	[M	+	Na+]:	361.	
	
	
General	procedure	for	the	preparation	of	tertiary	amines	(25-36):	
Method	C	To	a	suspension	of	primary	amines	1-3	and	7-9	 (1	mmol)	 in	H2O	(4	mL),	
37%	aq.	formaldehyde	(10	mmol)	and	90%	aq.	formic	acid	(5	mmol)	solutions	were	
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sequentially	added	 in	a	pressure-tight	microwave	 tube	cooled	 to	0 °C.	After	5	min,	
the	 reaction	 was	 allowed	 to	 reach	 rt,	 and	 then	 was	 submitted	 to	 microwave	
irradiation	for	1	h	at	100°C,	with	an	irradiation	power	of	50	W.	The	reaction	mixture	
was	neutralized	with	NaHCO3,	 followed	by	extraction	with	DCM	(3x).	The	collected	
organic	 extracts	were	dried	over	Na2SO4,	 and	evaporated	 in	 vacuum	 to	give	 crude	
products,	 which	 were	 purified	 by	 column	 chromatography	 on	 silica	 gel	 with	 an	
eluent	of	DCM/MeOH/33%	aq.	NH3	solution.	
Method	D	To	a	suspension	of	primary	amines	4-6	and	10-12	(1	mmol)	in	H2O	(4	mL),	
37%	aq.	formaldehyde	(10	mmol)	and	90%	aq.	formic	acid	(5	mmol)	solutions	were	
sequentially	added	in	a	pressure	tube	cooled	to	0 °C.	After	5	min,	the	reaction	was	
allowed	to	reach	rt,	and	then	was	warmed	at	80°C	for	8	h.	The	reaction	mixture	was	
neutralized	 with	 NaHCO3,	 followed	 by	 extraction	 with	 DCM	 (3x).	 The	 collected	
organic	 extracts	were	dried	over	Na2SO4,	 and	evaporated	 in	 vacuum	 to	give	 crude	
products,	 which	 were	 purified	 by	 column	 chromatography	 on	 silica	 gel	 with	 an	
eluent	of	DCM/MeOH/33%	aq.	NH3	solution.	
	
	
2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylethan-1-amine	(25):	
The	title	compound	25	was	obtained	as	colorless	oil	by	using	Method	C.	Yield	56%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.14	–	7.02	(m,	6H),	6.94	–	6.85	(m,	2H),	3.91	–	3.83	(m,	
2H),	3.13	(s,	4H),	2.49	–	2.38	(m,	2H)	2.20	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	146.93,	145.31,	131.47,	129.20,	127.03,	124.85,	53.40,	
40.15,	34.63,	31.89.	
MS(ESI):	m/z	C18H20N2;	calcd.	[M]:	266.39,	found	[M	+	1]:	267,	[M	+	Na+]:	289.	
	
2-(5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylethan-1-amine	(26):	
The	title	compound	26	was	obtained	as	yellow	oil	by	using	Method	C.	Yield	58%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.22	(t,	J	=	7.8	Hz,	2H),	7.04	(m,	J	=	7.1	Hz,	4H),	6.98	(t,	J	=	
7.3	Hz,	2H),	6.71	(s,	2H),	3.89	(t,	J	=	8.1	Hz,	2H),	2.55	(t,	J	=	8.1	Hz,	2H),	2.29	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.74,	133.81,	132.08,	129.11,	128.90,	123.37,	120.18,	
57.22,	49.29,	45.79.	
MS(ESI):	m/z	C18H20N2;	calcd.	[M]:	264.37,	found	[M	+	1]:	265,	[M	+	Na+]:	287.	
	
	2-(9H-carbazol-9-yl)-N,N-dimethylethan-1-amine	(27):	
The	title	compound	27	was	obtained	as	colorless	oil	by	using	Method	C.	Yield	56%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.09	(t,	J	=	7.8	Hz,	1H),	7.52	–	7.35	(m,	4H),	7.30	–	7.13	
(m,	2H),	4.43	(t,	J	=	7.8	Hz,	2H),	2.76	–	2.67	(m,	2H),	2.37	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	125.93,	125.71,	120.59,	119.47,	109.75,	108.64,	57.32,	
46.07,	45.91.	
MS(ESI):	m/z	C16H18N2;	calcd.	[M]:	238.33,	found	[M	+	1]:	239,	[M	+	Na+]:	261.	
	
N,N-dimethyl-2-(10H-phenothiazin-10-yl)ethan-1-amine	(28):	
The	title	compound	28	was	obtained	as	colorless	oil	by	using	Method	D.	Yield	81%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.20	–	7.09	(m,	4H),	6.93	-	6.90	(m,	4H),	4.01	(t,	J	=	7.0	
Hz,	2H),	2.73	(t,	J	=	7.0	Hz,	2H),	2.34	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.01,	127.45,	127.33,	124.70,	122.55,	115.27,	105.58,	
56.55,	46.29,	45.82.	
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MS(ESI):	m/z	C16H18N2S;	calcd.	[M]:	270.39,	found	[M	+	1]:	271,	[M	+	Na+]:	293.	
	
2-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylethan-1-amine	(29):	
The	title	compound	29	was	obtained	as	colorless	oil	by	using	Method	D.	Yield	72%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.26	(s,	1H),	7.21	–	7.08	(m,	2H),	7.01	(d,	J	=	8.1	Hz,	1H),	
6.98	–	6.85	(m,	4H),	4.01	–	3.92	(m,	2H),	2.75	–	2.62	(m,	2H),	2.33	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	128.76,	128.38,	123.87,	123.22,	116.60,	116.48,	57.43,	
47.60,	46.78,	31.81.	
MS(ESI):	m/z	C16H17ClN2S;	calcd.	[M]:	304.84,	found	[M	+	1]:	305,	[M	+	Na+]:	327.	
	
N,N-dimethyl-2-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)ethan-1-amine	(30):	
The	title	compound	30	was	obtained	as	yellowish	oil	by	using	Method	D.	Yield	45%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.19	–	7.08	(m,	4H),	6.96	–	6.90	(m,	3H),	4.03	–	3.95	(m,	
2H),	2.73	–	2.65	(m,	2H)	2.30	(s,	6H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.39,	144.18,	129.83,	127.72,	127.49,	127.36,	125.44,	
123.54,	 123.13,	 122.75,	 119.13,	 119.10,	 115.55,	 111.85,	 111.81,	 109.99,	 56.46,	
46.75,	45.83.	
MS(ESI):	m/z	C16H17	F3N2S;	calcd.	[M]:	338.39,	found	[M	+	1]:	339,	[M	+	Na+]:	361.	
	
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine	(31):	
The	title	compound	31	was	obtained	as	pale	yellow	oil	by	using	Method	C.	Yield	61%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.19	–	6.93	(m,	6H),	6.97	–	6.85	(m,	2H),	3.76	(t,	J	=	6.9	
Hz,	3H),	3.15	(s,	4H),	2.30	(t,	J	=	7.8	Hz,	2H),	2.14	(s,	6H),	1.72	(p,	J	=	7.1	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.28,	134.19,	129.74,	126.32,	122.36,	119.97,	57.63,	
48.82,	45.45,	32.20,	26.11.	
MS(ESI):	m/z	C19H24N2;	calcd.	[M]:	280.42,	found	[M	+	1]:	281,	[M	+	Na+]:	303.	
	
3-(5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine	(32):	
The	title	compound	32	was	obtained	as	yellow	oil	by	using	Method	C.	Yield	64%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.19	(t,	J	=	8.0	Hz,	2H),	7.03	–	6.87	(m,	6H),	6.67	(s,	2H),	
3.70	(t,	J	=	6.9	Hz,	2H),	2.31	(t,	J	=	7.3	Hz,	2H),	2.09	(s,	6H),	1.71	–	1.62	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.89,	133.91,	132.11,	129.11,	128.79,	123.22,	120.40,	
57.35,	48.65,	45.51,	25.71.	
MS(ESI):	m/z	C19H22N2;	calcd.	[M]:	278.40,	found	[M	+	1]:	279,	[M	+	Na+]:	301.	
	
3-(9H-carbazol-9-yl)-N,N-dimethylpropan-1-amine	(33):	
The	title	compound	33	was	obtained	as	yellow	oil	by	using	Method	C.	Yield	56%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.12	–	8.05	(m,	2H),	7.46	-	7.44	(m,	4H),	7.21	(t,	J	=	4.0	
Hz,	2H),	4.43	–	4.34	(t,	J	=	7.0	Hz,	2H),	2.29	(t,	J	=	6.8	Hz,	2H),	2.22	(s,	6H),	2.06	–	1.97	
(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	140.44,	125.56,	122.78,	120.25,	118.71,	108.71,	56.61,	
45.38,	40.65,	26.90.	
MS(ESI):	m/z	C17H20N2;	calcd.	[M]:	252.36,	found	[M	+	1]:	253,	[M	+	Na+]:	275.	
	
N,N-dimethyl-3-(10H-phenothiazin-10-yl)propan-1-amine	(34):	
The	title	compound	34	was	obtained	as	yellow	oil	by	using	Method	D.	Yield	74%.	
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1H	NMR	(401	MHz,	CDCl3)	δ	7.17	–	7.08	(m,	4H),	6.94	–	6.84	(m,	4H),	3.94	–	3.86	(m,	
2H),	2.40	(t,	J	=	7.1	Hz,	2H),	2.19	(s,	6H),	1.94	(p,	J	=	7.0	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	150.35,	145.24,	127.42,	127.17,	125.13,	122.38,	115.49,	
57.14,	45.54,	45.36,	25.21.	
MS(ESI):	m/z	C17H20N2S;	calcd.	[M]:	284.42,	found	[M	+	1]:	285,	[M	+	Na+]:	307.	
	
3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine	(35):	
The	title	compound	35	was	obtained	as	yellow	oil	by	using	Method	D.	Yield	66%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.20	–	7.09	(m,	2H),	7.05	–	6.98	(m,	1H),	6.97	–	6.85	(m,	
4H),	3.88	(t,	J	=	7.7	Hz,	2H),	2.40	(t,	J	=	7.0	Hz,	2H),	2.22	(s,	6H),	2.00	–	1.88	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	146.52,	144.51,	133.21,	127.84,	127.47,	124.82,	123.53,	
122.83,	122.20,	115.85,	115.78,	57.00,	45.56,	45.45,	25.06.		
MS(ESI):	m/z	C17H19ClN2S;	calcd.	[M]:	318.86,	found	[M	+	1]:	319,	[M	+	Na+]:	341.	
	
N,N-dimethyl-3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propan-1-amine	(36):	
The	title	compound	36	was	obtained	as	yellow	oil	by	using	Method	D.	Yield	48%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.18	–	7.05	(m,	5H),	6.95	–	6.89	(m,	2H),	3.92	(t,	J	=	7.0	
Hz,	2H),	2.39	(t,	J	=	7.0	Hz,	2H),	2.19	(s,	6H),	1.96	–	1.88	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	145.64,	144.39,	129.93,	129.40,	127.61,	127.51,	127.42,	
124.05,	123.04,	119.03,	118.99,	115.84,	111.90,	111.87,	56.99,	45.54,	45.52,	24.99.	
MS(ESI):	m/z	C18H19F3N2S;	calcd.	[M]:	352.42,	found	[M	+	1]:	353,	[M	+	Na+]:	375.	
	
	
Procedures	 for	 the	 preparation	 of	 TCA-functionalized	 fluorescent	 congeners	 (44-
47):	
10-(3-Chloropropyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine	(39):		
2,4-Dimethylpyrrole	 37	 (2.0	 mL,	 19	 mmol)	 was	 added	 to	 a	 solution	 of	 4-
chlorobutanoyl	chloride	38	(0.99	mL,	8.8	mmol)	in	dry	DCM	(20	mL)	over	10	min	at	0	
°C.	The	reaction	was	stirred	at	0	°C	for	30	min,	then	warmed	up	to	rt	and	stirred	for	
an	additional	30	min.	Et3N	(3.7	mL,	26	mmol)	was	then	added	in	small	portions	at	0	
°C	and	the	mixture	was	stirred	at	rt	for	10	min.	BF3•OEt2	(5.5	mL,	44	mmol)	was	then	
added	 in	 portions	 and	 the	 mixture	 was	 stirred	 at	 rt	 for	 14	 h.	 The	 reaction	 was	
quenched	with	careful	addition	of	H2O	(20	mL)	and	the	system	was	stirred	vigorously	
for	 15	min.	 The	 aqueous	 layer	 was	 extracted	with	 DCM	 (3	 ×	 10	mL).	 The	 organic	
layers	were	combined	and	washed	with	brine	(10	mL).	The	organic	 layer	was	dried	
over	Na2SO4,	filtered,	and	the	solvent	was	removed	under	reduced	pressure,	taking	
care	 not	 to	 heat	 the	 crude	 mixture.	 The	 brown	 residue	 was	 purified	 by	
chromatography	on	silica	gel	using	as	eluent	(DCM/petroleum	ether/Tol	6:3:1).	The	
resulting	residue	was	further	purified	by	recrystallization	from	toluene	to	yield	0.90	g	
(32	%)	of	39	as	a	red	needles.	1H-NMR	(401	MHz,	CDCl3)	δ	6.04	(s,	2H),	3.68	(t,	J	=	6.0	
Hz,	2H),	3.11	(t,	J	=	8.0	Hz,	2H),	2.50	(s,	6H),	2.42	(s,	6H),	2.09	-	2.04	(q,	J	=	6.4	Hz,	
2H).	 13C-NMR	 (101	 MHz,	 CDCl3)	 δ	 154.13,	 144.40,	 140.30,	 131.39,	 121.84,	 44.70,	
34.00,	16.55,	14.44.	
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10-(3-Azidopropyl)-5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinine	(40):		
Sodium	azide	(240	mg,	3.6	mmol)	was	added	to	a	solution	of	39	(600	mg,	1.9	mmol)	
in	dry	DMF	(36	mL).	The	mixture	was	stirred	at	40	°C	for	36	h.	H2O	(20	mL)	was	then	
added	 and	 the	 suspension	 was	 extracted	 with	 DCM	 (3	 x	 20	 mL).	 The	 combined	
organic	 layers	were	washed	with	 brine	 (20	mL).	 The	 organic	 layer	was	 dried	 over	
Na2SO4,	filtered	and	the	solvent	was	removed	under	reduced	pressure	to	afford	600	
mg	(99	%)	of	40	as	an	orange	solid.1H-NMR	(401	MHz,	CDCl3)	δ	6.02	(s,	2H),	3.43	(t,	J	
=	6.4	Hz,	2H),	2.95	(t,	J	=	8.4	Hz,	2H),	2.49	(s,	6H),	2.36	(s,	6H),	1.87	-	1.82	(q,	J	=	6.4	
Hz,	2H).	13C-NMR	(101	MHz,	CDCl3)	δ	154.20,	144.69,	140.35,	131.32,	121.81,	51.46,	
30.95,	25.52,	16.26,	14.40.	
pent-4-yn-1-yl	4-methylbenzenesulfonate	(42):	
To	a	solution	of	pent-4-yn-1-ol	41	(0.31	mL,	3.34	mmol),	Et3N	(0.56	mL,	4.01	mmol),	
and	4-(dimethylamino)pyridine	 (0.008	mg,	3.07	mmol)	 in	DCM	(10	mL)	at	0	 °C	was	
added	 p-toluenesulfonyl	 chloride	 (0.67	 g,	 3.51	 mmol)	 portion	 wise.	 The	 reaction	
mixture	 was	 brought	 to	 rt	 and	 stirred	 for	 15	 h.	 Aqueous	 NaOH	 (1	 N,	 6	 mL)	 was	
added,	 and	 the	mixture	was	 vigorously	 stirred	 for	 15	min	 at	 rt.	 The	 usual	workup	
(DCM,	brine),	 followed	by	 flash	chromatography	 (petroleum	ether/EtOAc	7:3)	gave	
the	title	compound	42	as	yellow	oil	(88%	yield).	1H-NMR	(401	MHz,	CDCl3)	δ	7.58	(d,	J	
=	8.0	Hz,	2H),	7.17	(d,	J	=	8.0	Hz,	2H),	3.94	(t,	J	=	6.0	Hz,	2H),	2.22	(s,	3H),	2.05	-	2.01	
(td,	J1	=	6.8	Hz,	J2	=	2.8	Hz,	2H),	1.81	(t,	J	=	2.4	Hz,	1H),	1.63	(q,	J	=	6.0	Hz,	2H).		
13C-NMR	 (101	MHz,	 CDCl3)	 δ	 144.85,	 132.71,	 129.88,	 127.67,	 82.14,	 69.73,	 68.85,	
27.54,	21.32,	14.44.	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)but-3-yn-1-amine	(44):	
A	mixture	of	7	 (0.15	 g,	 0.61	mmol),	 4-bromobut-1-yne	43	 (28	µL,	 0.30	mmol)	 in	 a	
mixture	 of	 H2O/CHCl3	 (70:30,	 3	 mL)	 and	 10%	 aq.	 NaOH	 (0.9	 mL)	 was	 placed	 in	 a	
microwave	 tube.	 The	 tube	was	 subjected	 to	MW	 irradiation	 at	 140	 °C	 for	 10	min,	
with	an	irradiation	power	of	200	W.	Removal	of	the	solvent	under	reduced	pressure,	
followed	 by	 column	 chromatography	 on	 silica	 gel	 using	 DCM/MeOH/33%	 aq.	 NH3	
solution	(9.6:	0.4:	0.02)	afforded	final	compound	44	as	colorless	oil	(53%).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.15	-7.08	(m,	6H),	6.93	-	6.90	(m,	2H),	3.81	(t,	J	=	6.8	Hz,	
2H),	3.16	(s,	4H),	2.72	(t,	J	=	6.8	Hz,	2H),	2.66	(t,	J	=	6.8	Hz,	2H),	2.35	-	2.32	(m,	J1	=	
6.4Hz,	J2	=	2.4	Hz,	2H),	1.90	(t,	J	=	2.8	Hz,	1H),	1.77	(q,	J	=	6.8	Hz,	2H).		
13C-NMR	(101	MHz,	CDCl3)	δ	145.70,	131.67,	127.23,	123.77,	119.87,	117.36,	79.83,	
66.92,	45.83,	45.28,	44.44,	29.62,	25.65,	16.91.	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-N-methylbut-3-yn-1-amine	
(45):	
To	a	solution	of	19	(0.07	g,	0.26	mmol)	in	acetone	(8	mL),	Et3N	(0.11	mL,	0.79	mmol),	
4-bromobut-1-yne	 43	 (0.12	 g,	 0.52	 mmol)	 and	 DMAP	 (0.01	 g,	 0.08	 mmol)	 were	
sequentially	added	 in	a	pressure	 tube	and	resulting	mixture	was	 refluxed	 for	72	h.	
Then,	 the	 solvent	 was	 evaporated	 and	 the	 crude	 residue	 chromatographed	 with	
DCM/MeOH/33%	aq.	NH3	solution	(9.6:	0.4:	0.02)	to	afford	45	as	yellow	oil	(40%).	
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1H-NMR	(401	MHz,	CDCl3)	δ	7.14	-	7.07	(m,	6H),	6.92	-	6.89	(m,	2H),	3.77	(t,	J	=	6.4	
Hz,	2H),	3.16	(s,	4H),	2.52	(t,	J	=	7.2	Hz,	2H),	2.42	(t,	J	=	6.8	Hz,	2H),	2.26	(dd,	J1	=	6.8	
Hz,	J2	=	1.6	Hz,	2H),	2.17	(s,	3H),	1.91	(s,	1H),	1.72	(q,	J	=	7.2	Hz,	2H).		
13C-NMR	(100MHz,	CDCl3)	δ	148.28,	134.20,	129.77,	126.33,	122.38,	119.97,	68.90,	
55.98,	55.01,	48.69,	41.98,	32.22,	25.61,	16.87.	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)pent-4-yn-1-amine	(46):	
A	 mixture	 of	 7	 (0.15	 g,	 0.61	 mmol),	 42	 (0.07	 mg,	 0.30	 mmol)	 in	 a	 mixture	 of	
H2O/CHCl3	 (70:30,	 3	mL)	 and	 10%	 aq.	 NaOH	 (0.9	mL)	 was	 placed	 in	 a	microwave	
tube.	 The	 tube	 was	 subjected	 to	 MW	 irradiation	 at	 140	 °C	 for	 10	 min,	 with	 an	
irradiation	 power	 of	 200	 W.	 Removal	 of	 the	 solvents	 under	 reduced	 pressure,	
followed	 by	 column	 chromatography	 on	 silica	 gel	 using	 DCM/MeOH/33%	 aq.	 NH3	
solution	(9.6:	0.4:	0.02)	afforded	final	compound	46	as	colorless	oil	(53%).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.13	-	7.05	(m,	6H),	6.91	-	6.87	(m,	2H),	3.78	(t,	J	=	6.8	
Hz,	2H),	3.14	(s,	4H),	2.64	(t,	J	=	6.8	Hz,	4H),	2.19	(td,	J1	=	7	Hz,	J2	=	2.8	Hz,	2H),	1.89	
(t,	J	=	2.8	Hz,	1H),	1.74	(q,	J	=	7.2	Hz,	2H),	1.63	(q,	J	=	6.8	Hz,	2H).		
13C-NMR	(101	MHz,	CDCl3)	δ	148.26,	134.21,	129.79,	126.32,	122.43,	119.92,	84.02,	
68.49,	48.65,	48.49,	47.50,	32.17,	28.52,	28.24,	16.28.	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-N-methylpent-4-yn-1-amine	
(47):	
To	a	solution	of	19	(0.07	g,	0.26	mmol)	in	acetone	(8	mL),	Et3N	(0.11	mL,	0.79	mmol),	
42	(0.12	g,	0.52	mmol)	and	DMAP	(0.01	g,	0.08	mmol)	were	sequentially	added	in	a	
pressure	 tube	 and	 resulting	mixture	was	 refluxed	 for	 72	 h.	 Then,	 the	 solvent	was	
evaporated	and	the	crude	residue	chromatographed	with	DCM/MeOH/33%	aq.	NH3	
solution	(9.6:	0.4:	0.02)	to	afford	47	as	yellow	oil	(63%).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.12	-	7.07	(m,	6H),	6.92	-	6.88	(m,	2H),	3.76	(t,	J	=	6.8	
Hz,	2H),	3.16	(s,	4H),	2.35	(q,	J	=	6.8	Hz,	4H),	2.15	-	2.13	(td,	J1	=	7Hz,	J2	=	2,4	Hz,	2H),	
2.12	(s,	3H),	1.89	(t,	J	=	2.8	Hz,	1H),	1.71	(q,	J	=	6.8	Hz,	2H),	1.60	(q,	J	=	7.2	Hz,	2H).	
13C-NMR	(101	MHz,	CDCl3)	δ	148.31,	134.18,	129.75,	126.32,	122.33,	119.99,	84.32,	
68.28,	56.33,	55.39,	48.74,	42.24,	32.25,	26.15,	25.71,	16.21.	
	
General	 click	 procedure	 for	 the	 preparation	 of	 TCA-functionalized	 fluorescent	
congeners	(48-51):	
The	alkyne	congener	44-47	 (1.0	mmol)	was	dissolved	 in	a	1:1:1	mixture	of	t-BuOH,	
H2O	and	DCM	 (10	mL).	 To	 this	 solution,	 the	 azide	40	 (1.2	mmol)	was	 added	while	
stirring	 vigorously	 at	 rt.	 Copper	 (II)	 sulfate	 pentahydrate	 (15	 mol%)	 and	 sodium	
ascorbate	 (45	mol%)	were	 then	added	 sequentially	 to	 the	 reaction	mixture,	which	
was	 left	 stirring	 for	 1-2	 h	 under	 nitrogen.	 The	 solvents	were	 then	 removed	 under	
vacuum	and	the	resulting	residue	was	purified	by	column	chromatography	on	silica	
gel	and,	when	needed,	recrystallized	to	afford	compounds	48-51.	
N-(2-(1-(3-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)propyl)-1H-1,2,3-triazol-4-yl)ethyl)-3-(10,11-dihydro-5H-
dibenzo[b,f]azepin-5-yl)propan-1-amine	(48):		
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The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography,	 using	 as	 eluent	
CHCl3/EtOH/33%	aq.	NH3	solution	(9.5:	0.5:	0.05),	and	then	recrystallized	from	EtOH	
and	H2O	to	afford	48	as	orange	needles	(33%	yield).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.15	(s,	1H),	7.12	-	7.03	(m,	6H),	6.89	-	6.86	(m,	2H),	6.01	
(s,	2H),	4.35	(t,	J	=	5.6	Hz,	2H),	3.73	(t,	J	=	6.4	Hz,	2H),	3.12	(s,	4H),	2.93	(t,	J	=	8.4	Hz,	
2H),	2.80	(t,	J	=	7.2	Hz,	2H),	2.57	(t,	J	=	7.2	Hz,	2H),	2.49	(s,	6H)	2.42	(t,	J	=	6.4	Hz,	2H),	
2.16	(m,	9H),	2.08	(q,	2H),	1.71	(q,	J	=	6.4	Hz,	2H).		
13C-NMR	(101	MHz,	CDCl3)	δ	154.48,	148.29,	146.69,	143.78,	140.09,	134.20,	131.25,	
129.81,	 126.31,	 122.41,	 121.92,	 121.47,	 119.90,	 57.09,	 54.98,	 49.78,	 48.41,	 42.07,	
32.30,	32.15,	25.61,	25.54,	23.65,	16.07,	14.45.		
11B-NMR	(128	MHz,	CDCl3)	δ	1.18	(t,	J	=	32.64	Hz,	B-F).		
19F-NMR	(377	MHz,	CDCl3)	δ	-146.60	(m).		
MS(ESI):	m/z	C38H46BF2N7;	calcd.	[M]:	649.64,	found	[M	+	1]:	650,	[M	+	Na+]:	672,	[M	
+	K+	]:	688.	
	
N-(2-(1-(3-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)propyl)-1H-1,2,3-triazol-4-yl)ethyl)-3-(10,11-dihydro-5H-
dibenzo[b,f]azepin-5-yl)-N-methylpropan-1-amine	(49):		
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography,	 using	 as	 eluent	
DCM/petroleum	ether/Tol/MeOH/33%	aq.	NH3	solution	(7.5:	0.5:	1:	1:	0.1),	and	then	
recrystallized	from	toluene	to	afford	49	as	orange	needles	(33%	yield).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.18	(s,	1H),	7.11	-	7.04	(m,	6H),	6.90	-	6.86	(m,	2H),	6.00	
(s,	2H),	4.40	(t,	J	=	6	Hz,	2H),	3.76	(t,	J	=	6.8	Hz,	2H),	3.12	(s,	4H),	2.94	(td,	J1	=	8.4	Hz,	
J2	=	3.2	Hz,	2H),	2.84	(m,	J	=	6.4	Hz,	4H),	2.65	(t,	J	=	6.8	Hz,	2H),	2.48	(s,	6H),	2.16	(s,	
6H),	2.10	(q,	J	=	8.8	Hz,	2H),	1.17	(q,	J	=	6.8	Hz,	2H).		
13C-NMR	(101	MHz,	CDCl3)	δ	154.51,	148.22,	146.43,	143.68,	140.05,	134.20,	131.22,	
129.81,	 126.33,	 122.46,	 121.93,	 121.55,	 119.89,	 49.85,	 48.98,	 48.33,	 47.28,	 32.25,	
32.13,	28.23,	26.02,	25.51,	16.07,	14.44.	
11B-NMR	(128.5MHz,	CDCl3	)	δ	1.19	(t,	J	=	32.6	Hz,	B-F).		
19F-NMR	(377MHz,	CDCl3	)	δ	-146.56	(m).		
MS	(ESI):	m/z	C37H44BF2N7	;	calcd.	[M]:	635.61,	found	[M	+	1]:	636,	[M	+	Na+]:	658,	[M	
+	K+	]:	675.	
	
3-(1-(3-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)propyl)-1H-1,2,3-triazol-4-yl)-N-(3-(10,11-dihydro-5H-
dibenzo[b,f]azepin-5-yl)propyl)propan-1-amine	(50):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography,	 using	 as	 eluent	
DCM/petroleum	ether/Tol/MeOH/33%	aq.	NH3	solution	(7.5:	0.5:	1:	1:	0.1)	to	afford	
50	as	orange	waxy	solid	(38%	yield).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.19	(s,	1H),	7.11	-	7.06	(m,	6H),	6.90	-	6.87	(m,	2H),	6.00	
(s,	2H),	4.43	(t,	J	=	6.4	Hz,	2H),	3.77	(t,	J	=	6.4	Hz,	2H),	3.12	(s,	4H),	2.95	(m,	J	=	8.4	Hz,	
2H),	2.70	(t,	J	=	7.2	Hz,	2H),	2.63	(m,	4H),	2.48	(s,	6H),	2.16	(s,	6H),	2.12	(q,	J	=	6.4	Hz,	
2H),	1.80	(m,	4H).	
13C-NMR	(101	MHz,	CDCl3)	δ	154.48,	148.22,	148.04,	143.70,	140.08,	134.19,	131.24,	
129.79,	 126.35,	 122.46,	 121.93,	 120.95,	 119.90,	 49.86,	 49.03,	 48.46,	 47.50,	 32.27,	
32.15,	29.54,	28.06,	25.52,	23.29,	16.06,	14.44.		
11B-NMR	(128.5Hz,	CDCl3)	δ	1.19	(t,	J	=32.64	Hz,	B-F).		
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19F-NMR	(400MHz,	CDCl3)	δ	-146.53	(m).		
MS	(ESI):	m/z	C38H46BF2N7	;	calcd.	[M]:	649.64,	found	[M	+	1]:	650,	[M	+	Na+]:	672.	
	
3-(1-(3-(5,5-difluoro-1,3,7,9-tetramethyl-5H-4λ4,5λ4-dipyrrolo[1,2-c:2',1'-
f][1,3,2]diazaborinin-10-yl)propyl)-1H-1,2,3-triazol-4-yl)-N-(3-(10,11-dihydro-5H-
dibenzo[b,f]azepin-5-yl)propyl)-N-methylpropan-1-amine	(51):	
The	 resulting	 residue	was	 purified	 twice	 by	 flash	 chromatography,	 using	 as	 eluent	
DCM/petroleum	ether/Tol/MeOH/33%	aq.	NH3	solution	(7.5:	0.5:	1:	1:	0.1)	to	afford	
51	as	orange	waxy	solid	(39%	yield).	
1H-NMR	(401	MHz,	CDCl3)	δ	7.18	(s,	1H),	7.12	-	7.05	(m,	6H),	6.89	-	6.86	(m,	2H),	6.01	
(s,	2H),	4.43	(t,	J	=	6	Hz,	2H),	3.75	(t,	J	=	6.8	Hz,	2H),	3.13	(s,	4H),	2.96	(m,	J1	=	8.4	Hz,	
J2	=	2.8	Hz,	2H),	2.65	(t,	J	=	7.6	Hz,	2H),	2.49	(s,	6H),	2.37	(t,	J	=	6.8	Hz,	2H),	2.31	(t,	J	=	
7.2	Hz,	2H),	2.17	(s,	6H),	2.12	(m,	5H),	1.75	(q,	J	=	6.8	Hz,	2H),	1.70	(q,	J	=	6.8	Hz,	2H).	
13C-NMR	(101	MHz,	CDCl3)	δ	154.48,	148.31,	143.73,	140.09,	134.18,	131.25,	129.75,	
126.32,	 122.34,	 121.93,	 120.85,	 119.96,	 57.07,	 55.42,	 49.83,	 48.71,	 42.25,	 32.32,	
32.21,	27.26,	25.70,	25.54,	23.39,	16.08,	14.44.		
11B-NMR	(128	MHz,	CDCl3)	δ	1.20	(t,	J	=	32.64	Hz,	B-F).		
19F-NMR	(377MHz,	CDCl3	)	δ	-146.55	(m).		
MS	(ESI):	m/z	C39H48BF2N7	;	calcd.	[M]:	663.67,	found	[M	+	1]:	664,	[M	+	Na+]:	686.	
	
General	procedure	for	the	preparation	of	hybrids	(53-58):	
	
A	 solution	 of	 valproic	 acid	 52	 (1.07	 mmol)	 in	 DCM	 (7	 mL),	 Et3N	 (2.92	 mmol),	
hydroxybenzotriazole	 (HOBt;	 1.70	 mmol),	 1-ethyl-3-[3-
(dimethylamino)propyl]carbodiimide	hydrochloride	(EDCI;	2.92	mmol)	was	cooled	to	
0 °C	 and	 stirred	 for	 30	 min.	 A	 solution	 of	 the	 appropriate	 amine	 (1–3	 and	 7-9,	 1	
mmol)	 and	 Et3N	 (2.92	 mmol)	 in	 DCM	 (2	 mL)	 was	 subsequently	 added,	 and	 the	
mixture	was	stirred	overnight	at	rt	under	nitrogen.	The	solvent	was	removed	under	
vacuum,	and	the	obtained	residue	was	purified	by	flash	chromatography	on	silica	gel	
using	as	eluent	a	mixture	of	DCM/MeOH.	
	
N-(2-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)ethyl)-2-propylpentanamide	(53):	
The	 resulting	 residue	was	 purified	 twice	 by	 flash	 chromatography,	 using	 as	 eluent	
DCM/MeOH	(10:	0.05)	and	then	petroleum	ether/EtOAc	(6:	4),	to	afford	53	as	white	
solid	(78%	yield).	
1H	NMR	(401	MHz,	CDCl3)	δ	7.17	–	7.03	(m,	6H),	6.92	(t,	J	=	7.3	Hz,	2H),	5.57	(br	s,	1H,	
exch),	3.88	(t,	J	=	5.8	Hz,	2H),	3.41	(q,	J	=	5.7	Hz,	2H),	3.15	(s,	4H),	1.96	–	1.88	(m,	1H),	
1.54	–	1.42	(m,	2H),	1.35	–	1.21	(m,	2H),	1.21	–	1.07	(m,	4H),	0.78	(t,	J	=	7.3	Hz,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	176.06,	147.55,	134.00,	129.92,	126.65,	122.98,	119.89,	
49.74,	47.87,	37.44,	35.25,	32.29,	20.79,	14.03.	
	
N-(2-(5H-dibenzo[b,f]azepin-5-yl)ethyl)-2-propylpentanamide	(54):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (6:	 4	 petroleum	
ether/EtOAc),	to	afford	54	as	pale	yellow	solid.	Yield	81%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.30	–	7.21	 (m,	2H),	7.11	–	6.96	 (m,	6H),	6.76	 (s,	2H),	
6.02	(br	s,	1H,	exch),	3.90	–	3.82	(m,	2H),	3.37	(t,	J	=	5.4	Hz,	2H),	1.95	–	1.90	(m,	1H),	
1.52	–	1.39	(m,	2H),	1.33	–	1.20	(m,	2H),	1.18	–	1.03	(m,	4H),	0.76	(t,	J	=	7.3	Hz,	3H).	
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13C	NMR	(101	MHz,	CDCl3)	δ	176.10,	149.63,	133.92,	132.10,	129.22,	129.17,	123.92,	
120.71,	49.73,	47.75,	36.31,	35.21,	20.74,	14.03.	
	
N-(2-(9H-carbazol-9-yl)ethyl)-2-propylpentanamide	(55):	
The	 resulting	 residue	was	purified	by	 flash	chromatography	 (10:	0.05	DCM/MeOH)	
affording	55	as	white	solid.	Yield	73%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.08	(d,	J	=	7.8	Hz,	2H),	7.48	–	7.41	(m,	4H),	7.28	–	7.19	
(m,	2H),	5.48	(br	s,	1H,	exch),	4.47	(t,	J	=	6.2	Hz,	2H),	3.72	(q,	J	=	6.2	Hz,	2H),	1.53	–	
1.44	(m,	2H),	1.88	–	1.81	(m,	1H),	1.35	–	1.11	(m,	6H),	0.82	(t,	J	=	7.2	Hz,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	176.60,	140.29,	125.84,	122.93,	120.37,	119.22,	108.68,	
47.42,	42.41,	38.32,	34.90,	20.76,	14.08.	
	
N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-2-propylpentanamide	(56):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (9.8:0.2	 DCM/MeOH)	
affording	56	as	white	solid.	Yield	77%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.16	–	7.01	(m,	6H),	6.91	(t,	J	=	7.3	Hz,	2H),	3.77	(t,	J	=	6.7	
Hz,	2H),	3.28	(q,	J	=	6.7	Hz,	2H),	3.15	(s,	4H),	1.90	(m,	1H),	1.78	(q,	J	=	6.7	Hz,	2H),	
1.59	–	1.43	(m,	2H),	1.36	–	1.07	(m,	6H),	0.82	(t,	J	=	7.1	Hz,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	175.92,	148.05,	134.17,	129.89,	126.41,	122.62,	120.29,	
119.80,	48.01,	37.03,	35.22,	32.16,	27.87,	20.81,	14.08.	
	
N-(3-(5H-dibenzo[b,f]azepin-5-yl)propyl)-2-propylpentanamide	(57):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (9.6:0.4	 DCM/MeOH)	
affording	57	as	white	solid.	Yield	86%.	
1H	NMR	(401	MHz,	CDCl3)	δ	7.31	–	7.22	(m,	2H),	7.08	(m,	2H),	7.00	(m,	4H),	6.78	(s,	
2H),	6.14	(br	s,	1H,	exch),	3.81	(t,	J	=	5.9	Hz,	1H),	3.30	(q,	J	=	5.9	Hz,	1H),	1.95	–	1.87	
(m,	1H),	1.76	(p,	J	=	7.1	Hz,	2H),	1.45	(m,	2H),	1.32	–	1.03	(m,	6H),	0.78	(t,	J	=	7.2	Hz,	
3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	175.96,	150.26,	133.45,	132.29,	129.20,	129.13,	123.64,	
120.10,	49.02,	47.52,	38.17,	35.15,	26.06,	20.75,	14.10.	
	
N-(3-(9H-carbazol-9-yl)propyl)-2-propylpentanamide	(58):	
The	 resulting	 residue	 was	 purified	 by	 flash	 chromatography	 (9.8:0.2	 DCM/MeOH)	
affording	58	as	white	solid.	Yield	97%.	
1H	NMR	(401	MHz,	CDCl3)	δ	8.09	(d,	J	=	8.0	Hz	2H),	7.45	(t,	J	=	7.1,	2H),	7.38	(d,	J	=	8.2	
Hz,	2H),	7.24	–	7.21	(m,	2H),	5.30	(br	s,	1H,	exch),	4.36	(t,	J	=	6.8	Hz,	2H),	3.27	(q,	J	=	
6.6	Hz,	2H),	2.08	(p,	J	=	6.9	Hz,	2H),	1.84	–	1.77	(m,	1H),	1.51	–	1.36	(m,	2H),	1.32	–	
1.04	(m,	6H),	0.82	(m,	3H).	
13C	NMR	(101	MHz,	CDCl3)	δ	176.05,	140.08,	125.80,	122.88,	120.47,	119.06,	108.44,	
47.68,	40.90,	37.33,	35.11,	29.03,	20.78,	14.05.	
	
	
Procedures	for	the	preparation	of	TCA-functionalized	polyamine	congener	(65):	
	
4-[3-Amino-propyl)-tert-butoxycarbonyl-amino]-	 butyl}-carbamic	 acid	 tert-Butyl	
Ester	(60):		
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To	 a	 solution	 of	 1,4-diaminobutane	59	 (0.34	mL,	 0.67	mmol)	 in	 CHCl3	 (5	mL)	was	
added	tert-butyl	dicarbonate	(0.24	mL,	1.03	mmol)	portion	wise	at	0	°C.	The	reaction	
was	 stirred	 at	 0	 °C	 for	 3	 h,	 and	 then	 the	 solvents	 were	 removed	 in	 vacuo.	 The	
resulting	residue	was	washed	with	H2O	(10	mL)	 for	30	min,	and	then	the	 insoluble	
bis-substituted	 product	was	 removed	 by	 filtration.	 The	 filtrate	was	 extracted	with	
DCM	(3	×	10	mL),	and	the	organic	layers	were	combined,	washed	with	brine	(30	mL),	
and	dried	over	Na2SO4.	The	solvents	were	removed	in	vacuo	to	afford	a	pale	yellow	
oil	60	(69%	yield).	
1H-NMR	(401	MHz,	CDCl3)	δ	4.74	(s,	1H),	3.07	(m,	2H),	2.67	(t,	J	=	7.2	Hz,	2H),	1.43	
(m,	4H),	1.38	(s,	9H)	1.33	(s,	2H).		
13C-NMR	(101	MHz,	CDCl3)	δ	155.98,	78.93,	41.73,	40.36,	30.79,	28.37,	27.43.	
	
3-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)(methyl)amino)propan-1-ol	
(62):		
A	mixture	of	19	(0.14	g,	0.54	mmol),	3-bromopropan-1-ol	61	(0.07	mg,	0.54	mmol)	in	
a	mixture	of	H2O/CHCl3	 (70:30,	2	mL)	and	10%	aq.	NaOH	 (0.5	mL)	was	placed	 in	a	
microwave	 tube.	 The	 tube	was	 subjected	 to	MW	 irradiation	 at	 140	 °C	 for	 10	min,	
with	 an	 irradiation	 power	 of	 200	 W.	 Removal	 of	 the	 solvents	 under	 reduced	
pressure,	 followed	by	column	chromatography	on	silica	gel	using	DCM/MeOH/33%	
aq.	NH3	solution	(9.6:	0.4:	0.02)	afforded	final	compound	62	as	colorless	oil	(23%).	
1H	NMR	(401	MHz,	CDCl3)	δ	7.18	–	7.05	(m,	6H),	6.92	(t,	J	=	7.2	Hz,	2H),	3.81	–	3.69	
(m,	4H),	3.16	(s,	4H),	2.50	(t,	J	=	5.7	Hz,	2H),	2.46	–	2.36	(m,	2H),	2.15	(s,	3H),	1.74	(q,	
J	=	7.1	Hz,	2H),	1.69	–	1.58	(m,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.17,	134.17,	129.79,	126.42,	122.46,	119.95,	64.50,	
58.26,	56.04,	48.76,	41.98,	32.23,	27.79,	25.59.	
	
	
3-chloro-N-(3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)-N-methylpropan-1-
amine	(63):	
To	a	solution	of	62	 (0.87	g,	0.27	mmol)	 in	CHCl3	 (3	mL)	was	added	SOCl2	 (0.04	mL,	
0.53	mmol)	dropwise	at	0	 °C.	The	 resulting	mixture	was	stirred	at	 rt	 for	4	h	under	
nitrogen	and	then	was	quenched	by	adding	NaHCO3	saturated	solution	(15	mL).	The	
aqueous	 phase	was	 extracted	with	 DCM	 (3	 x	 10	mL)	 and	 the	 organic	 layers	were	
combined,	washed	with	brine	(30	mL),	and	dried	over	Na2SO4.	The	resulting	residue	
was	purified	by	column	chromatography	to	give	the	title	compound	63	as	colorless	
oil	(45%	yield).	
1H	NMR	(401	MHz,	CDCl3)	δ	7.13	–	7.05	(m,	6H),	6.90	(t,	J	=	7.2	Hz,	2H),	3.76	(t,	J	=	6.7	
Hz,	2H),	3.47	(t,	J	=	6.5	Hz,	2H),	3.15	(s,	4H),	2.37	(q,	J	=	7.0,	5.0	Hz,	2H),	2.11	(s,	3H),	
1.82	(m,	2H),	1.70	(p,	J	=	6.9,	12	Hz,	2H).	
13C	NMR	(101	MHz,	CDCl3)	δ	148.22,	134.15,	129.76,	126.33,	122.34,	119.94,	55.30,	
54.50,	48.54,	43.17,	42.23,	32.23,	30.25,	25.59.	
	
tert-butyl	 (4-((3-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-
yl)propyl)(methyl)amino)propyl)amino)butyl)carbamate	(64):	
A	mixture	of	63	(0.04	g,	0.12	mmol),	60	(0.04	mg,	0.24	mmol)	in	CH3CN	(1.2	mL)	was	
placed	in	a	microwave	tube.	The	tube	was	subjected	to	MW	irradiation	at	110	°C	for	
1	 h,	 with	 an	 irradiation	 power	 of	 50	 W.	 Removal	 of	 the	 solvents	 under	 reduced	
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pressure,	 followed	 by	 column	 chromatography	 on	 silica	 gel	 using	 a	 gradient	 of	
DCM/MeOH/33%	 aq.	 NH3	 solution	 (from	 9:	 1:	 0.1	 to	 8.5:	 1.5:	 0.15)	 afforded	 final	
compound	64	as	yellow	oil	(65%).	
1H	NMR	(401	MHz,	CDCl3)	δ	7.11	–	7.04	(m,	6H),	6.88	(t,	J	=	7.4	Hz,	2H),	4.87	(br	s,	1H,	
exch),	3.73	(t,	J	=	6.6	Hz,	2H),	3.13	(s,	4H),	3.06	(m,	2H),	2.76	(t,	J	=	6.5	Hz,	2H),	2.60	
(t,	J	=	7.3	Hz,	2H),	2.39	(m,	4H),	2.13	(s,	3H),	1.72	(dt,	J	=	27.8,	6.8	Hz,	4H),	1.56	(t,	J	=	
7.4	Hz,	2H),	1.45	(m,	11H).	
13C	NMR	(101	MHz,	CDCl3)	δ	156.06,	148.07,	134.10,	129.80,	126.40,	122.51,	119.91,	
56.67,	55.51,	48.61,	48.27,	48.00,	41.73,	39.85,	32.16,	28.41,	27.35,	25.51,	24.90.	
	
N1-(3-((3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl)(methyl)amino)propyl)-
N4-methylbutane-1,4-diamine	(65):	
To	a	solution	of	the	protected	amine	64	(0.04	g,	0.08	mmol)	in	DCM	(2	mL),	TFA	(93	
µL,	1.21	mmol)	was	added	dropwise	at	0°C.	The	resulting	solution	was	left	to	stir	at	
room	temperature	for	3	h.	The	solvent	was	then	evaporated	under	vacuum	washing	
with	 heptane	 (3	 times)	 to	 remove	 the	 excess	 of	 TFA.	 The	 solid	 residues	 were	
repeatedly	triturated	with	diethyl	ether	and	filtered	to	afford	the	title	compound	65	
as	pale	yellow	solid	(90%).	
1H	NMR	(401	MHz,	CD3OD)	δ	7.25	–	7.14	(m,	6H),	7.05	–	6.94	(m,	2H),	3.93	(t,	J	=	6.5	
Hz,	2H),	3.38	-	3.11	(m,	7H),	3.1	–	3.09	(m,	4H),	3.03	(t,	J	=	7.1	Hz,	2H),	2.80	(s,	3H),	
2.21	–	2.02	(m,	4H),	1.91	–	1.73	(m,	4H).	
13C	NMR	(101	MHz,	CD3OD)	δ	147.70,	134.12,	129.59,	126.27,	122.75,	119.31,	54.52,	
52.57,	46.85,	46.81,	44.22,	39.00,	38.52,	31.71,	24.07,	22.73,	22.18,	20.87.	
	
	
Native	fluorescence	study	of	48-51	
	
General	information	
All	 the	 spectra	were	 recorded	 using	 a	 Jasco	 FP-750	 spectrofluorometer,	 equipped	
with	the	control	and	data	acquisition	software	FP-750.	Both	excitation	and	emission	
slits	were	set	up	at	5	nm	bandwidth,	and	1	cm	quartz	cells	were	employed.	
	
General	procedure		
Accurately	 weighed	 amounts	 of	 the	 studied	 compounds	 were	 dissolved	 using	
ethanol	 or	 DCM	 to	 obtain	 1	mM	 stock	 solutions.	 From	 these	 stocks,	 intermediate	
dilutions	were	prepared	as	required.	The	final	concentration	of	the	compounds	was	
0.5	µM.		
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1.	Introduction	
	
	
1.1	G	protein-coupled	receptors	(GPCRs)	in	drug	discovery	
	
Seven-transmembrane	 (7TM)	 domain	 G	 protein-coupled	 receptors	 (GPCRs)	
constitute	the	largest	integral	membrane	protein	family	in	the	human	genome,	with	
almost	1000	members.1	All	GPCRs	share	the	canonical	fold	of	7TM	helices	embedded	
in	the	membrane	and	linked	by	alternating	intracellular	(I-III)	and	extracellular	loops	
(II-IV).	 The	 extracellular	 loops	 and	 the	 N-termini	 constitute	 the	 ligand-binding	
domain	 for	 the	 class	 A	 GPCRs,	 while	 the	 intracellular	 loops	 and	 the	 C-termini	 are	
involved	 in	 G-protein	 binding	 and	 activation.	 Despite	 these	 similarities,	 several	
differences	 have	 been	 reported	 between	 the	 members	 within	 class	 A	 GPCRs.	
According	 to	 the	 nature	 of	 ligand,	 the	 conformational	 rearrangements	 of	 helices	
produce	 different	 binding	 pockets	 (in	 size,	 shape	 and	 amino	 acid	 interactions	
network),	so	that,	for	example,	the	binding	pocket	of	acetylcholine	in	M2	muscarinic	
receptor	 is	more	 deeply	 embedded	within	 the	 7TM	 segment	 compared	 to	 that	 of	
more	 polar	 nucleosides	 in	 A2A	 receptor	 (see	 detailed	 review2	 on	 this	 argument).	
Striking	 differences	 have	 also	 been	 observed	 between	 the	 binding	 pocket	 of	 an	
agonist	 and	 antagonist	 in	 the	 same	 GPCR.2	 Thus,	 the	 size,	 shape	 and	 interactions	
network	made	by	amino	acids	of	these	binding	pockets	explain	the	ability	of	GPCRs	
to	 discriminate	 between	 diverse	 chemical	 signals,	 that	 can	 be	 translated	 into	 the	
multiple	conformations	adopted	by	GPCR,	each	of	which	is	associated	with	a	specific	
physiological	 response.	 And	 in	 fact,	 given	 these	 peculiar	 properties,	 the	 GPCR	
superfamily	 represents	 the	 major	 transducers	 of	 the	 information	 (including	
responses	 to	 hormones,	 neurotransmitters	 and	 extracellular	 stimuli)	 flow	 into	 the	
cells.	As	such,	GPCRs	are	associated	with	a	multitude	of	diseases	that	make	members	
of	 this	 family,	 important	 pharmacological	 targets.	 Indeed,	 GPCRs	 encompass	 the	
largest	family	of	proteins	targeted	by	drug	discovery	and	their	high	tractability	and	
profitability	 reflect	 the	 fact	 that	GPCRs	 continue	 to	 be	one	of	 the	most	 important	
target	 classes	 (30-50%	 of	 the	 marketed	 drugs)	 in	 the	 portfolio	 of	 the	 majority	 of	
pharma	companies.3		
As	in	2004	Filmore	pointed	out	“It’s	a	GPCR	world”,4	and	undoubtedly	it	is	still	right	
today,	even	though	the	GPCR	drug	discovery	 is	moving	towards	new	paradigms.5	 If	
for	a	 long	time,	 it	was	not	possible	to	understand	the	“GPCR	world”,	because	their	
multi-membrane	 spanning	 structure	makes	 them	difficult	 to	 isolate	and	crystallize,	
the	beginning	of	1980s	provided	a	series	of	breakthroughs	 that	eventually	allowed	
the	detailed	structural	characterization	of	these	proteins.6		
Starting	 from	 the	 crucial	 observation	 made	 by	 Lefkowitz	 that	 the	 cloning	 and	
sequencing	 of	 β2-adrenergic	 receptor	 (β2AR)	 gene	 have	 revealed	 significant	
similarities	 to	 rhodopsins	 (the	 well-characterized	 model	 of	 GPCRs),6	 in	 2000,	
Palczewski	 was	 able	 to	 get	 the	 first	 x-ray	 structure	 of	 rhodopsin.7	 However,	 this	
structure	provided	only	limited	details	of	GPCR	functioning,	due	to	the	relatively	low	
resolution	 and	 low	 sequence	 homology	 to	 most	 druggable	 GPCRs.	 Since	 then,	 a	
plethora	 of	 mutagenesis,	 biophysical	 and	 biochemical	 studies	 with	 the	 goal	 of	
characterizing	 GPCR	 structures	 and	 functions	 have	 been	 developed.	 But,	 only	 in	
2007,	Kobilka	obtained	the	crystal	structure	of	the	β2AR	in	its	inactive	state	thanks	to	
the	manipulation	 and	 stabilization	 of	 GPCR	 structure	with	 an	 antibody	 protruding	
out	of	the	membrane.8	This	structure	shed	light	on	how	antagonists	bind	within	the	
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7TM	hydrophobic	core	of	the	receptor	and	stabilize	the	inactive	conformation.	This	
opens	 new	 possibilities	 and	 new	 collaborations	 in	 the	 field,9	 culminating	 in	 the	
establishment	 of	 the	 first	 structure	 of	 the	 β2AR	 with	 the	 partial	 inverse	 agonist	
carazolol	 at	 2.4	 Å	 resolution	 in	 the	 active	 state,	 a	 state	 that	 had	 previously	
considered	 being	 too	 unstable	 to	 be	 isolated.10	 Indeed,	 by	 using	 T4	 lysozyme	 (a	
highly	crystallizable	protein	at	the	N-terminus	of	the	receptor)	to	stabilize	the	highly	
dynamic	structure	of	β2AR	and	the	development	of	a	new	detergent	 to	enable	 the	
purification	of	the	complex,	the	crystal	structure	in	the	active	state	was	obtained	and	
was	compared	to	the	inactive	one.	This	provided	valuable	insights	into	the	activation	
process,	including	the	identity	of	the	specific	helices	that	move	and	affect	G	protein	
binding.	Finally,	in	2011	Kobilka's	group	published	the	first	ever	structure	of	a	GPCR	
in	the	active	state	with	the	high	affinity	agonist	BI-167107	at	3.5	Å	resolution11	and	
then	bound	to	the	Gs	protein	at	3.2	Å	resolution.12	The	stabilization	of	its	active	state	
with	 a	 nanobody	 has	 again	 led	 to	 unprecedented,	 atomic-level	 understanding	 of	
GPCR	function	including	the	movement	of	the	crucial	helices	and	loops.		
Kobilka's	work	was	also	accompanied	by	pioneering	work	from	the	Stevens	group	at	
Scripps	Research	Institute	(currently	at	University	of	Southern	California),	which	also	
developed	 special	 techniques	 to	 crystallize	 GPCRs.	 Indeed,	 in	 the	 same	 year,	 the	
crystal	 structure	 of	 A2A	 adenosine	 receptor	 was	 also	 solved	 in	 complex	 with	 the	
agonist	UK-432097.13		
The	new	developments	achieved	in	the	GPCR	field	led	to	Lefkowitz	and	Kobilka	being	
awarded	 the	2012	Nobel	 Prize	 in	Chemistry	 and,	 from	 that	moment	on,	 the	GPCR	
research	area14	seemed	to	be	on	the	cusp	of	a	new	era	for	GPCR	drug	discovery.	In	
addition,	 the	 new	 improvements	 obtained	 in	 X-ray	 crystallography	 have	 provided	
tremendous	 insights	 into	 the	molecular	mechanisms	underlying	 ligand	 recognition,	
GPCR	activation	and	constitutive	activity.3	In	fact,	these	breakthroughs	have	opened	
the	way	 to	not	only	a	detailed	dissection	of	 the	mechanism	of	GPCR	 function,	but	
also	 to	 structure-based	 drug	 design,	 substantiating	 how	 the	 GPCR	 structural	
revolution	 is	 impacting	 current	 drug	 discovery.15	 Indeed,	 until	 that	 moment,	 the	
design	of	selective	 ligand	that	 is	able	to	discriminate	among	the	receptor	subtypes	
within	 a	 GPCR	 subfamily	 resulted	 to	 be	 particularly	 difficult,	 if	 not	 impossible.	
Indeed,	when	comparing	members	within	a	subfamily	(i.e.	muscarinic	receptors),	the	
high	 sequence	 similarity	 in	 the	orthosteric	pocket	makes	 the	development	of	 such	
selective	 ligand	extremely	problematic	 to	 accomplish.	 Instead,	 the	diversity	 shown	
within	the	cytoplasmic	loops	and	C	terminus	open	new	possibilities	in	this	context.		
As	 a	 consequence,	 the	 first	 insights	 into	 the	 challenges	 of	 developing	 subtype	
selective	drugs	came	from	the	recently	solved	GPCR	crystal	structures.	These	include	
the	 structure	 of	 the	 human	 M2	 muscarinic	 acetylcholine	 receptor	 bound	 to	 the	
antagonist	3-quinuclidinyl-benzilate,16	as	well	as	the	structure	of	M3	receptor	bound	
to	 the	 bronchodilator	 drug	 tiotropium.17	 These	 works	 revealed	 the	 structural	 and	
functional	diversity	among	the	muscarinic	receptor	subtypes	that	can	be	exploited	to	
design	selective	ligands,	which	would	avoid	the	side	effects	associated	with	the	lack	
of	selectivity	of	the	currently	used	muscarinic	 ligands.	Also	the	crystal	structures	of	
key	opioid	receptors	µ18	and	∂19	have	been	successfully	obtained	in	complex	with	a	
morphinan	 antagonist	 and	naltrindole,	 respectively.	 This	would	 be	of	 fundamental	
importance	 due	 to	 the	 wide	 clinical	 use	 of	 opioid	 ligands	 to	 relieve	 severe	 pain.	
Current	 opioid	 drugs	 indeed	 display	 remarkable	 side	 effects	 (depression	 of	
respiratory	 and	 intestinal	 activity,	 addiction,	 etc.),	 and	 these	 crystal	 structures	
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together	with	structure-based	approaches	may	lead	to	design	more	selective	opioid	
drugs	with	a	better	pharmacological	profile.	
Recently,	 the	 solved	 crystal	 structures	 of	 P2Y12	 receptor	 (P2Y12R)	 in	 complex	 with	
antagonist	 AZD1283	 (antithrombotic	 drug),20	 and	 different	 agonists	 2MeSATP	
(partial)	 and	 2MeSADP	 (full)21	 reveal	 striking	 conformational	 differences	 between	
agonist	and	antagonist	complexes	especially	 in	the	extracellular	regions	resulting	in	
different	 orientations	 of	 the	 ligands	 and	 partially	 overlapped	 binding	 sites.	
Moreover,	 by	 analyzing	 in	 detail	 the	 extracellular	 interface,	 an	 additional	 pocket	
adjacent	to	ligand-binding	region	was	also	identified,	suggesting	that	these	structure	
may	represent	invaluable	starting	points	for	designing	P2Y12R	ligands	with	improved	
pharmacological	properties	and	allosteric	modulators	as	well,	with	potential	clinical	
application	as	antithrombotic	drugs.	However,	the	possibility	to	rationally	design	an	
allosteric	 ligand	 for	 GPCR	 became	 a	 tangible	 reality	 since	 the	 x-ray	 structures	 of	
another	P2Y1	receptor	(P2Y1R)	in	complex	with	a	nucleotide	antagonist	MRS2500	and	
a	 non-nucleotide	 antagonist	 BPTU	 were	 obtained.22	 Remarkably,	 the	 crystal	
structure	in	complex	with	BPTU	is	particularly	significant	as	highlighted	an	allosteric	
pocket	 on	 the	 external	 receptor	 interface	with	 the	 lipid	 bilayer,	making	 BPTU	 the	
first	structurally	characterized	selective	GPCR	 ligand	 located	entirely	outside	of	 the	
orthosteric	binding	site.	Moreover,	recent	reports	showed	that	in	addition	to	P2Y12R,	
also	P2Y1	is	 involved	 in	platelet	aggregation,	 thus,	suggesting	 it	as	a	new	promising	
antithrombotic	target,	which	may	offer	a	better	pharmacological	profile	than	P2Y12R	
inhibitors.23		
Despite	 these	 tremendous	 advances,	 GPCR	 have	 always	 been	 and	 still	 remain	 a	
complex	 target	class.	The	above	discussed	x-ray	 structures	 indeed	show	previously	
unobtainable	details	of	interactions	between	GPCRs	and	ligands,	including	the	roles	
of	lipophilic	regions	and	water	molecules	as	driving	forces	of	binding.	In	addition,	the	
structures	 have	 revealed	 several	 surprising	 ligand-binding	 modes,	 including	 sites	
outside	 the	orthosteric	pocket.	 In	 addition	 to	 the	 structural	 information	about	 the	
ligand-GPCR	 complexes,	 such	 structures	 have	 provided	 insights	 into	 the	 structural	
basis	of	 the	 superfamily's	biochemical	 functions.	GPCRs	can	concomitantly	 interact	
with	 a	 vast	 array	 of	 endogenous	 and	 exogenous	 ligands	 and	 adopt	 multiple	
conformational	states	that	couple	to	different	signaling	pathways.	Several	innovative	
paradigms	of	drug	action	arise	as	a	consequence	of	these	properties	of	GPCRs,	and	
include	 biased	 ligands,	 allosteric	 modulators,	 oligomerization,	 GPCR	 regulation,	
polypharmacology	and	off-targets	evaluation,	and	deorphanisation.5	
Perhaps,	 one	 of	 the	 most	 significant	 discoveries	 in	 this	 context	 has	 been	 the	
observation	that	ligand	binding	produces	conformational	changes	in	GPCR	structure	
that	 is	 associated	 to	 differential	 interaction	 with	 G	 proteins,	 arrestins	 and	 other	
proteins	 inside	 the	 cell,	 thereby	 leading	 to	 different	 physiological	 responses,	 a	
phenomenon	 called	 "functional	 selectivity"	 or	 “biased	 agonism”.24	 This	 concept	
arises	from	the	fact	that	GPCR	exist	as	an	ensemble	of	conformations,	each	of	which	
is	 preferentially	 linked	 to	 specific	 signaling	 effectors	 and,	 once	 ligand	binds	 to	 the	
receptor	in	a	certain	conformation,	this	can	produce	different	biochemical	effects.	As	
recently	proposed,	several	endogenous	peptides	that	activate	the	µ-opioid	receptor	
display	particularly	distinct	bias	profiles.25	Nonetheless,	this	peculiar	ability	of	ligands	
interacting	with	GPCR	has	been	exploited	to	develop	GPCR	biased	agonists	already	in	
the	 clinical	 trials.	 For	example,	µ-opioid	 receptor	Gi-biased	 ligand,	namely	TRV130,	
has	already	 launched	Phase	3	clinical	program	for	postoperative	pain.26	The	typical	
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side	 effects	 associated	 to	 the	 opioid	 drugs,	 such	 as	 the	 unbiased	 morphine,	 are	
avoided	by	eliminating	the	arrestin	pathway	responsible	for	those	adverse	effects.	
Another	 significant	 and	 related	 approach	 to	 selectively	 target	 GPCR	 relies	 on	
allosteric	modulation.	As	discussed	above	for	P2Y1R,	the	allosteric	modulators	do	not	
bind	 to	 the	 orthosteric	 ligand	 binding	 pocket,	 but	 instead	 act	 at	 an	 alternatively	
located	binding	site	(allosteric	site),	structurally	distinct	from	the	orthosteric	site,	to	
either	 potentiate	 (positive	 allosteric	 modulator)	 or	 inhibit	 (negative	 allosteric	
modulator)	 activation	 of	 the	 receptor	 by	 its	 natural	 ligand.	 Compounds	 with	 an	
allosteric	mode	of	action	may	have,	in	principle,	a	number	of	theoretical	advantages	
over	 orthosteric	 ligands.	 For	 example,	 if	 allosteric	 modulators	 do	 not	 display	 any	
agonism,	 they	 are	quiescent	 in	 the	 absence	of	 endogenous	 agonist	 and	only	 exert	
their	 effect	 in	 the	presence	of	 a	 released	orthosteric	 agonist.	 Thus,	 such	 allosteric	
modulators	have	the	potential	 to	maintain	activity	dependence	and	both	temporal	
and	spatial	aspects	of	endogenous	physiological	signaling.	Additionally,	as	previously	
anticipated,	 allosteric	 ligands	 offer	 the	 potential	 advantage	 of	 greater	 receptor	
selectivity,	as	allosteric	pocket	across	receptor	subtypes	are	less	conserved	than	the	
orthosteric	 site.	 Conversely,	 selectivity	 may	 be	 also	 achieved	 by	 combining	 both	
orthosteric	and	allosteric	pharmacophores	within	the	same	molecule	to	yield	a	novel	
class	 of	 ‘bitopic’	GPCR	 ligand.27	 The	promising	 profile	 of	 allosteric	 ligand	has	 been	
employed	 by	 AstraZeneca	 to	 develop	 a	 novel	 metabotropic	 glutamate	 receptor	 2	
(mGluR2)	positive	allosteric	modulator,	AZD8529.	It	 is	able	to	potentiate	the	effects	
of	glutamate	on	mGluR2	with	a	good	selectivity	over	 the	other	glutamate	 receptor	
sub-types	and	is	currently	in	clinical	trials	indicated	for	addiction	treatment.28		
Moreover,	 there	 is	 a	 growing	 appreciation	 that	 GPCR	 regulation	 and	 signaling	 is	
much	 more	 complex	 than	 originally	 envisioned,	 and	 includes	 signaling	 through	 G	
protein	 independent	 pathways,	 signaling	 activated	 after	 agonist-mediated	 GPCR	
internalization,	and	GPCR	oligomerization.	 If	 the	 first	point	 is	well	 recognized	since	
the	 establishment	 that	β-arrestins	 can	 also	 function	 as	molecular	mediators	 of	 G-
protein	 independent	 signaling	by	acting	 to	a	 variety	of	 signaling	proteins	 (i.e.	 ERK-
mitogen-activated	protein	kinase	pathway),29	the	second	point	is	still	under	intense	
investigation	and	will	be	not	discussed	herein	(see	cited	review30	for	details).	On	the	
other	 hand,	 the	 role	 of	 GPCR	 oligomerization	 is	 not	 completely	 clear.	 GPCRs	 do	
indeed	 form	 dimers	 (or	 higher	 order	 oligomers),	 and	 that	 dimerization	 can	 occur	
between	the	same	GPCRs,	close	family	members,	or	distinct	families	of	GPCRs.	It	has	
been	 proposed	 that	 GPCR	 dimerization	 affects	 ligand	 binding,	 receptor	 activation,	
desensitization	and	trafficking,	as	well	as	receptor	signaling.	Moreover,	the	interface	
between	monomers	 can	 cooperatively	 transmit	allosteric	effects.	 For	example,	 the	
heteromeric	assembly	of	mGluR2	and	5-HT2A	receptors	enhances	glutamate-elicited	
Gi	signaling	and	reduces	5-HT-elicited	Gq	signaling.	Interestingly,	antipsychotic	drugs	
invert	 this	 signaling	balance	 through	 the	 complex	 (Gi	 signaling	decreases,	whereas	
Gq	 signaling	 increases),	modifying	 the	 balance	 from	 being	 in	 favor	 of	 Gi	 signaling	
(normal	 complex)	 to	being	 in	 favor	of	Gq	 signaling	 (propsychotic).	 This	arises	 from	
the	modulation	 of	 the	 interaction	 between	 significant	 TM	 residues	 (TM4-5)	 at	 the	
interface	 of	 heteromer,	 induced	 by	 the	 ligand	 binding.	 Accordingly,	 disease	 states	
involving	psychosis,	such	as	schizophrenia,	are	associated	with	a	variable	disruption	
of	 the	 Gi-Gq	 balance	 (i.e.	 decrease	 in	 Gi	 and	 increase	 in	 Gq),	 consistent	 with	 the	
mGluR2	down-regulation	and	5-HT2A	 receptor	up-regulation	observed	 in	untreated	
schizophrenic	 patients.	 Further	 in	 vivo	 experiments	 corroborate	 this	 finding,	
suggesting	 the	potential	 benefits	 of	 combination	 therapy	 involving	mGluR2	 agonist	
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and	5-HT2A	receptor	inverse	agonist	in	the	treatment	of	schizophrenia,	especially	in	
resistant	cases.31	
Mechanistic	 insights	 in	 this	process	would	be	of	pivotal	 importance	because	 some	
GPCRs	are	active	only	in	the	dimeric	state	(i.e.	mGluRs).	Thus,	compounds	specifically	
targeting	 the	heteromeric	 interface	 are	particularly	promising	not	only	 to	 serve	 as	
powerful	 tools	 to	explore	the	significance	of	GPCR	heteromers,	but	also	may	serve	
for	 the	 development	 of	 highly	 selective	 drugs	 for	 the	 treatment	 of	 a	 variety	 of	
disorders.32	
Additionally,	the	design	of	multitarget	ligands	deliberately	targeting	GPCRs	has	been	
recently	 emerged	 as	 suitable	 alternative	 in	 GPCR	 drug	 discovery.	 In	 this	 case,	 the	
authors	 exploited	 the	 multitarget	 profile	 of	 new	 hybrid	 molecules,	 designed	 by	
combining	elements	of	a	known	agonist	of	 the	5-HT4	serotonin	receptor	 (RS67333)	
and	an	inhibitor	of	the	enzyme	acetylcholinesterase	(donepezil).	The	identified	lead	
compound,	 namely	 Donecopride,	 displayed	 both	 acetylcholinesterase	 inhibitory	
effects	and	partial	5-HT4	 receptor	agonist	activity	 in	vitro	 in	nanomolar	 ranges	and	
exhibited	 in	 vivo	 pro-cognitive	 and	 anti-amnesic	 effects,	 resulting	 particularly	
promising	as	multitarget	ligand	for	the	treatment	of	Alzheimer’s	disease.33		
If	drugs	with	multiple	mechanisms	of	action	are	particularly	attractive	and	effective,	
often	 the	 observed	 polypharmacological	 profile	 of	 such	 drugs	 can	 be	 also	
detrimental.	Especially,	when	searching	for	new	small	molecules	that	act	at	GPCRs,	
the	 so-called	 off-targets	 effect	 of	 a	 candidate	 molecule	 should	 be	 carefully	
determined	 in	 broad	 screening	 at	 other	 receptors,	 ion	 channels,	 enzymes,	 and	
transporters.34	 This	 would	 be	 of	 particular	 importance	 in	 the	 de-risking	 process,	
when	 that	 activity	 is	 considered	 undesirable.	 To	 achieve	 this	 goal	 different	
approaches	 have	 been	 developed.	 For	 example,	 Paoletta	 et	 al.	 systematically	
examined	 the	 promiscuity	 of	 a	 set	 of	 adenosine/adenine	 congeners,	 previously	
designed	for	the	treatment	of	neuropathic	pain,	to	reveal	unexpected	interactions	of	
these	ligands	with	numerous	off-target	sites	of	Psychoactive	Drug	Screening	Program	
(PDSP).35	 This	 revealed	 an	 association	 of	 structures	 and	 substructures	 of	 the	
nucleosides	 with	 specific	 interactions	 with	 other	 GPCRs,	 ion	 channels	 and	 a	
transporter	 in	 the	 CNS.	 Interestingly,	 the	 results	 obtained	 showed	 specific	
interactions	 with	 biogenic	 amine	 receptors,	 such	 as	 adrenergic	 receptors	 and	
serotonergic	 receptors.	Moreover,	 after	 selecting	 compounds	with	 a	 Ki	 <	 1	 µM	or	
showing	a	recognition	pattern	within	this	series	of	compounds,	molecular	modeling	
studies	have	been	performed	based	on	x-ray	structures	and	homology	models.	This	
allowed	 an	 improved	 understanding	 of	 the	 structural	 requirements	 for	 these	 off-
target	interactions	with	other	Family	A	GPCRs.	This	systematic	analysis	of	structural	
features	of	the	ligands	with	amino	acid	residues	of	the	binding	site	of	the	receptors	
is	 aimed	 at	 predicting	 promiscuity	 of	 new	 analogues	 within	 a	 ligand	 family	 and	
designing	more	selective	ligands.35	
In	 a	 recent	work,	 a	 chemoproteomic	 platform	 to	 explore	 the	 polypharmacological	
profile	 of	 5-HT1A	 and	 5-HT6	 receptor	 ligands	 has	 been	 developed.	 This	 relied	 on	
synthesizing	 a	 new	 set	 of	 probes	 suitable	 for	 the	 nonbiased	 study	 of	 off-targets	
activities.	Starting	from	high-affinity	ligands	of	these	receptors,	proper	modifications	
with	appropriate	tag(s)	for	covalent	binding	(such	as	benzophenone	and	biotin)	have	
been	 introduced.	 	The	resulting	probes	allow	subsequent	enrichment	of	the	bound	
proteins	 of	 the	 cell	 homogenate	 to	 enable	 protein	 profiling	 by	 using	 mass	
spectrometry.	 In	addition	to	bind	their	cognate	receptor,	several	additional	 targets	
have	been	 identified	 in	proteomic	experiments.	 In	particular,	HSP60	and	prohibitin	
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proteins	have	been	 recognized	as	off-targets	of	5-HT1A	and	5-HT6	 receptor	 ligands,	
respectively.	 	 This	 approach	could	be	extended	 to	other	drugs	of	 interest	 to	 study	
the	targeted	proteome	in	disease-relevant	systems.36	
Lastly,	despite	the	remarkable	progress	in	the	field	of	GPCR	biology	during	the	past	
two	decades,	a	number	of	GPCRs	have	not	yet	been	 linked	to	endogenous	 ligands.	
These	 “orphan”	 receptors	 represent	 a	 large	 part	 (>	 140	 GPCRs)	 of	 the	 genes	
encoding	 for	 GPCRs.37	 In	 this	 respect,	 Pfizer	 created	 a	 novel	 chemical	 probe	
identification	platform	with	the	aim	of	discovering	chemical	probes	for	members	of	
orphan	GPCR.	GPCR-focused	 libraries	were	 screened	against	 a	 set	of	orphan	GPCR	
targets,	 providing	 the	 identification	 of	 the	 first	 small	 molecule	 agonist	 for	 GPR39	
receptor.	 It	 is	 thought	 that	 this	 receptor	 is	 involved	 in	 the	 regulation	 of	 insulin	
secretion	and	preservation	of	β-cells	in	the	pancreas.	As	confirmed	by	functional	and	
biochemical	 assays,	 this	 compound	 stimulated	 intracellular	 Ca2+	 mobilization	 and	
cAMP	signal	transduction	pathways	in	recombinant	cells	overexpressing	GPR39,	but	
not	 in	 parental	 cells.	 However,	 it	 did	 not	 potentiate	 glucose-stimulated	 insulin	
secretion	 in	 human	 islet	 preparations,	 possibly	 because	 the	 compound	 was	 not	
sufficiently	 potent	 or	 efficacious,	 GPR39	 signaling	 through	 the	 Ca2+	pathway	might	
not	be	coupled	to	insulin	secretion,	or	GPR39	was	not	involved	in	insulin	signaling.38		
Thus,	the	deorphanization	of	orphan	GPCRs	is	one	of	the	most	important	missions	in	
GPCR	 research.	 Searching	 for	 ligands	 of	 orphan	 GPCRs	 and	 elucidating	 their	
structure,	 signaling,	 and	 physiological	 and	 pathophysiological	 roles	 shall	 offer	 new	
opportunities	for	discovering	next-generation	medicines.	
These	key	issues	sit	at	the	forefront	of	GPCR	research	and	are	considered	critical	to	
the	future	successful	development	of	new	therapeutic	modalities	and	drugs.	
	
	
1.2	Functionalized	congener	approach	to	explore	GPCR	structure	and	function		
	
In	the	early	1980s,	the	first	reports	appeared	on	the	development	of	“functionalized	
congeners”,	 which	 were	 introduced	 by	 Jacobson	 and	 coworker.39	 Actually,	 two	
papers	were	reported	on	the	same	issue	of	Journal	of	Medicinal	Chemistry,40	which	
dealt	 with	 the	 development	 of	 functionalized	 congeners	 of	 adenosine	 as	 agonists	
and	xanthines	as	antagonists	of	adenosine	receptors.	The	approach	was	conceptually	
expanded	in	1987,	when	Jacobson	et	al	proposed	its	applicability	towards	different	
types	 of	 congeners	 and	 a	 wide	 range	 of	 GPCR.41	 The	 functionalized	 congener	
approach	was	originally	defined	as	the	approach	that	allows	the	functionalization	of	
a	certain	drug	with	known	activity	against	GPCR	(Figure	1).	Particularly,	it	referred	to	
a	 derivative	 presenting	 a	 chemical	 reactive	 functional	 group,	 such	 as	 an	 amine	 or	
carboxylic	 acid	 that	 can	 be	 covalently	 conjugated	 through	 a	 spacer	 linker	 to	 a	
position	 structurally	 permissive	 on	 the	 pharmacophore.	 This	 means	 that	 the	
insensitivity	 to	 structural	 modification	 of	 the	 attachment	 site	 is	 an	 essential	 and	
indispensable	condition	for	the	synthesis	of	covalent	conjugates	that	retain	binding	
affinities	 at	 the	 binding	 site.	 Thus,	 the	 goals	 of	 this	 approach	 focused	 on	 both	
developing	 potential	 new	 pharmaceutical	 agents	 in	 which	 the	 activity	 of	 the	
pharmacophore	may	be	modulated	through	distal	modifications,	and	on	synthesizing	
molecular	probes	useful	to	explore	the	drug	binding	site	and	evoked	response	given	
by	 its	 interaction	 with	 the	 receptor.41	 Moreover,	 an	 additional	 advantage	 of	 this	
approach	is	that	the	new	congener	may	improve	the	pharmacological	profile	of	the	
starting	molecule	by	establishing	secondary	favorable	interactions	with	the	receptor.	
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Indeed,	 tethering	 different	 types	 of	 functionalized	 chain	 to	 a	 pharmacophore	 can	
provide	 a	 wide	 variety	 of	 chemical	 probes	 depending	 on	 the	 strategy	 of	
functionalization	 that	 includes	 spectroscopic	 probes,	 conjugation	 to	
carrier/dendrimer,	dual-acting	probes	and	so	forth.42		
	
Figure	1.	General	representation	of	the	functionalized	congener	approach.	
	
Since	 that	 moment,	 this	 approach	 was	 particularly	 productive	 in	 elucidating	 the	
subtle	differences	among	adenosine	receptor	(AR)	subtypes,	long	before	the	first	x-
ray	structure	of	A2AAR	was	available.		
And	as	confirmed	by	Wikström	in	a	report	named	“Chemical	Biology	in	the	USA”,	the	
brilliant	work	developed	by	Jacobson	was	indeed	regarded	as	“a	typical	example	of	
chemical	 biology	 research	 in	 the	 study	 of	 the	 different	 subtypes	 of	 a	 GPCR	
subfamily”.43		
Indeed,	 by	 applying	 this	 approach,	 Jacobson	 and	 coworkers	 successfully	
characterized	the	adenosine	receptors	and	their	agonists	and	antagonists,	suggesting	
them	as	potential	druggable	 targets.44	At	 that	 time,	adenosine	 receptors	were	 just	
discovered	and	nothing	or	 little	was	known	about	the	physiological	 roles	mediated	
by	these	receptors.	Adenosine	was	considered	a	depressant	neuromodulator	and	its	
involvement	 in	multiple	diseases	and	conditions	 including	 inflammation,	endocrine	
disorders,	 cancer,	 cerebral	 and	 cardiac	 ischaemia	 has	 been	 only	 successively	
demonstrated.44		
Of	 note,	 this	 approach	 has	 been	 successfully	 applied	 to	 a	 wide	 range	 of	 GPCRs,	
including	all	the	adenosine,	P2Y,	muscarinic	acetylcholine	and	adrenergic	receptors.	
To	 provide	 an	 exemplificative	 application	 of	 this	 approach,	 the	 A3AR	 and	 its	
congeners	will	be	selected	to	further	discussion	in	the	following	paragraph.		
	
	
1.2.1	Adenosine	A3	receptor	and	its	congeners:	a	landmark	study	
	
Adenosine	 A3	 receptors	 (A3ARs)	 are	 G	 protein-coupled	 receptors	 coupled	 to	 Gi/Gq	
and	 are	 involved	 in	 a	 variety	 of	 intracellular	 signaling	 pathways	 and	 physiological	
functions.	 A3ARs	 mediate	 a	 sustained	 cardioprotective	 function	 during	 cardiac	
ischemia,	 it	 is	 involved	 in	 the	 inhibition	 of	 neutrophil	 degranulation	 in	 neutrophil-
mediated	 tissue	 injury,	 it	 has	 been	 implicated	 in	 both	 neuroprotective	 and	
neurodegenerative	effects,	and	 it	may	also	mediate	both	cell	proliferation	and	cell	
death.	45	
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The	 main	 approach	 to	 develop	 adenosine	 receptor	 agonists	 basically	 relied	 on	
modifications	of	endogenous	 ligand	 (adenosine)	and	can	be	 schematically	outlined	
as	follows:	modification	of	adenine	by	substituting	N6-,	C2-positions	and	modification	
of	 ribose	 moiety	 by	 C5’-	 and	 4’-substitutions,	 and	 ribose	 ring	 constraint.	 On	 the	
other	 hand,	 adenosine	 constituted	 also	 the	 starting	 point	 to	 design	 A3AR	
antagonists,	having	established	the	boundaries	of	structural	requirements	to	switch	
from	 agonists	 to	 antagonists.46	 It	 should	 be	 mentioned	 that	 chemically	 diverse	
antagonists	have	been	already	developed,	but	they	will	not	be	described	at	this	time	
(see	cited	review47	for	details).		
Indeed,	the	prototypical	A3Rs	agonist	 IB-MECA	(CF101,	1	 in	Figure	2)	and	the	more	
selective	agonist	Cl-IB-MECA	(CF102,	2)	have	been	discovered	in	1994	by	introducing	
a	 3-iodobenzyl	 group	 at	 N6	position	 and	 a	 chlorine	 at	 C2	 (only	 for	 Cl-IB-MECA)	 of	
adenine,	 and	modifying	 the	 C5’	 position	 of	 the	 ribose	moiety	 with	 a	 small	 amide	
group.48	
Once	 the	 structural	 requirements	 for	 obtaining	 A3AR	 selective	 agonists	 have	 been	
confirmed,49	these	compounds	have	been	widely	used,	as	pharmacological	probes	in	
the	elucidation	of	the	physiological	role	of	A3AR	and	IB-MECA	have	been	also	radio-
iodinated,	giving	rise	to	[125I]-I-AB-MECA,	as	a	high-affinity	radioligand	for	A3AR.50	Of	
note,	 IB-MECA	(CF101)	and	Cl-IB-MECA	(CF102),	 sponsored	by	Can-Fite	BioPharma,	
are	 currently	 in	 clinical	 trials	 for	 the	 treatment	 of	 rheumatoid	 arthritis51	 and	
hepatocellular	carcinoma,51	respectively.	
Modifications	at	the	ribose	moiety	first	regarded	the	4ʹ-thio	substitution	that	affects	
AR	 selectivity,	 producing	 several	 highly	 potent	 and	 selective	 A3AR	 agonists	 even	
varying	 the	 size	 of	 substituent	 at	 N6-position,	 such	 as	 compound	 3.52	 This	 can	 be	
easily	 converted	 into	 selective	 antagonist	 4,	 by	 truncating	 4’-thioadenosine	
derivatives	at	the	5’	position.53		
Additionally,	conformational	studies	of	the	ribose	moiety	and	its	equivalents	indicate	
that	the	ring	oxygen	is	not	required	for	A3AR	selectivity	and	that	the	North	(N)	ring	
conformation	 is	 favored	 in	binding	 to	 the	A3AR.	The	conformation	constrain	of	 the	
ribose-like	 ring	 is	 achieved	 by	 using	 the	 bicyclo[3.1.0]hexane	 ring	 system,	 which	
assumes	an	(N)-envelope	conformation	affording	highly	selective	A3AR	agonists	such	
as	MRS3558	 (5)	 (Ki	=	0.29	nM	at	human	A3AR).54	By	contrast,	 the	opposite	 isomer,	
which	maintains	a	South	(S)	conformation	of	the	ribose-like	ring,	was	>100-fold	less	
potent	 at	 the	 A3R.	 A	 further	 conformational	 locking	 of	 ribose-like	 moiety	 can	 be	
obtained	 by	modifying	 the	 5’	 positions	 with	 a	 spirolactam	 that	 produces	 a	 highly	
selective	 antagonist	 6	 toward	 A3AR,	 suggesting	 that	 the	 A3AR	 is	 not	 so	 strictly	
dependent	on	the	5’	region	for	ligand	recognition.46	
Substitutions	at	the	C2	position	encompass	the	introduction	of	rigid	arylalkynyl	group	
in	 full	 agonist	MRS5698	 (7),	 a	 3,4-	 difluorophenyl	 derivative,	 that	 appeared	 to	 be	
better	tolerated	by	the	receptor	both	in	terms	of	affinity	and	selectivity	(Ki	=	3	nM	at	
A3AR).55	To	further	extend	the	SAR	studies,	while	keeping	this	last	modification	at	C2,	
the	 N6	 position	 substitutions	with	 both	 small	 and	 large	 hydrophobic	 groups	 at	 N6	
maintained	the	activity	as	A3R	selective	agonist.55	On	the	other	hand,	truncation	the	
5’	position	of	ribose-like	ring	provided	also	in	this	case	selective	antagonists,	but	only	
with	small	hydrophobic	groups	at	N6	position,	such	as	8.56		
Moreover,	 docking	 studies	 allowed	 to	 identify	 additional	 substitutions	 on	 C2-
phenylethynyl	 and	 particularly	 sulfonate	 group	 substituent	 provided	 N6-3-
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chlorobenzyl-2-(3-sulfophenylethynyl)	derivative	9	(MRS5841)	that	bound	selectively	
to	human	A3R	(Ki	=	1.9	nM)	as	agonist.57		
Agonist	 analogues	 with	 greater	 in	 vivo	 efficacy	 were	 selected	 using	 a	 phenotypic	
screen	 in	 a	 Bennett	 mouse	 model	 of	 chronic	 neuropathic	 pain.	 This	 identified	
derivatives	containing	different	C2-arylethynyl	groups,	such	as	5-chloro-thien-2-yl	 in	
MRS5980	(10,	Ki	=	0.7	nM),	that	were	particularly	effective	in	vivo	compared	to	7.58	
	
	
Figure	2.	Development	of	A3R	congeners.	
	
By	 combining	molecular	modeling	 and	 phenotypic	 screening	 to	 identify	 additional	
nucleoside	derivatives	with	translational	potential,	the	linear	ethynyl	group	at	C2	has	
been	 substituted	 with	 a	 1,2,3-triazol-1-yl	 linker.	 This	 modification	 would	 avoid	
potential	in	vivo	liabilities	of	the	alkyne	group	as	a	Michael	acceptor	for	nucleophiles	
such	 as	 glutathione,	 although	 this	 risk	 was	 later	 shown	 to	 be	 minimal	 in	 a	
metabolomics	 study.59	 This	 modification	 successfully	 provided	 several	 N6-methyl	
derivatives,	 among	 which	 N6-ethyl	 5-chlorothien-2-yl	 analogue	 (11,	 MRS7126)	
preserved	in	vivo	efficacy	(85%	protection	at	1	h)	with	short	duration.60		
In	addition,	N6-small	alkyl	derivatives	were	newly	optimized	for	A3AR	affinity	and	the	
effects	 of	 a	 1-deaza-adenine	 modification	 probed.	 1-Deaza-N6-ethyl	 alkyne	 12	
(MRS7144,	Ki	=	1.7	nM)	was	highly	efficacious	in	vivo.	Thus,	the	presence	of	N1	is	not	
required	 for	nanomolar	binding	affinity	or	potent	 functional	 activity.	Docking	of	1-
deaza	compounds	to	a	receptor	homology	model	confirmed	a	similar	binding	mode		
as	previously	reported	1-aza	derivatives.	This	is	the	first	demonstration	in	non-ribose	
adenosine	analogues	that	the	1-deaza	modification	can	maintain	high	A3AR	affinity,	
selectivity,	and	efficacy.61	
Collectively,	 the	 iterative	 optimization	 process	 of	 adenosine-based	 A3	 ligands	
showed	that	there	is	a	pronounced	interrelationship	of	substitution	at	various	sites	
	 11	
on	the	adenosine	structure	with	respect	to	their	effects	on	A3AR	affinity,	selectivity,	
and	efficacy.	
Another	 alternative	 of	 functionalized	 congener	 approach	 is	 the	 development	 of	
fluorescent	 ligands	 for	 characterization	 of	 adenosine	 receptors	 (ARs),	 which	 hold	
promise	in	drug	discovery.	The	size	of	a	strategically	labeled	AR	ligand	can	be	greatly	
increased	 after	 the	 attachment	 of	 a	 fluorophore,	with	 the	 possibility	 of	 improving	
the	pharmacological	profile	of	the	parent	molecule	via	secondary	interactions	given	
by	 the	 fluorophore.	 Indeed,	 the	 choice	 of	 fluorophore	 (e.g.	 Alexa	 Fluor	 488),	
attachment	point	and	linker	length	can	significantly	alter	the	selectivity	and	potency	
of	 the	 starting	 molecule.	 Fluorescent	 derivatives	 of	 adenosine	 agonists	 and	
antagonists	 (e.g.	 XAC	 and	 other	 heterocyclic	 antagonist	 scaffolds)	 have	 been	
successfully	synthesized	and	characterized.62		
In	 particular,	 several	 previously	 developed	 A3	 agonist	 and	 newly	 synthesized	
congeners	have	been	conjugate	to	a	fluorophore	linked	through	the	C2	or	N6	position	
of	 adenosine-based	 ligands	 presenting	 the	 (N)-methanocarba	 structural	 motif	 for	
enhancing	A3R	selectivity.	Such	fluorescent	derivatives	were	compared	in	radioligand	
binding	affinity	and	selectivity	at	the	human	A3R	in	membranes	of	Chinese	hamster	
ovary	 (CHO)	cells	expressing	 the	receptor.	Two	derivatives	namely	MRS5218	 (13	 in	
Figure	3)	and	MRS5704	(14)	were	the	most	promising	derivatives	and	were	selected	
for	further	studies	in	subsequent	experiments	using	whole	cells.	In	particular,	13	was	
tethered	 to	 the	Cy5	 fluorophore	 (a	 cyanine	dye	 that	 absorbs	 in	 the	orange	 region	
and	 fluoresces	 in	 the	 red	 region),	 by	 a	 flexible	 amide	 chain	 at	 the	 C2	 position.	 In	
contrast,	 14	 was	 conjugated	 to	 the	 rigid	 polycyclic	 1-pyrenyl	 fluorophore	 moiety	
through	an	ethynyl	group	extending	from	the	C2	position.	By	flow	cytometry		
	
	
Figure	3.	Fluorescent	A3R	ligands.	
	
experiments,	the	hydrophobic	C2-(1-pyrenyl)	derivative	14	has	been	showed	to	bind	
non-selectively,	whereas	 C2-tethered	 cyanine5-dye	 labeled	13	 bound	 selectively	 to	
human	A3R	expressed	in	whole	CHO	cells.	The	same	behavior	of	13	was	observed	in	
a	 native	 cell	 line	 expressing	 A3R	 (human	 promyelocytic	 leukemic	 HL-60	 cell	 line).	
These	findings	suggested	that	13	might	be	a	useful	tool	for	characterizing	the	A3AR.63	
The	 functionalized	 congener	 approach	 has	 been	 demonstrated	 to	 be	 feasible	 for	
modulating	 and	even	enhancing	 the	pharmacological	 profile	 of	 a	 ligand	of	 a	GPCR	
based	 on	 conjugation	 to	 a	 biocompatibile	 polyamidoamine	 (PAMAM)	 dendrimers	
designed	 to	 interact	 with	 distal	 extracellular	 regions	 of	 a	 7TM-spanning	 receptor	
without	drug	release	unlike	nanocarrier.64		
Jacobson	 and	 coworker	 have	 reported	 on	 the	 feasibility	 of	 potent	 and	 selective	
activation	of	specific	subtypes	of	ARs	using	multivalent	conjugates	and	the	ability	to	
modulate	the	selectivity	based	on	the	linkage	between	the	pharmacophore	and	the	
polymeric	 carrier.	 Particularly,	 N6-chain	 elongated	 functionalized	 congener	 ADAC	
(N6-[4-[[[4-[[[(2-aminoethyl)amino]carbonyl]methyl]anilino]carbonyl]methyl]-
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phenyl]-adenosine),	A1	congener	has	been	covalently	conjugated	to	polyamidoamine	
(PAMAM)	dendrimers	of	both	generations	2.5	(G2.5)	and	3	(G3)	and	further	linked	to	
AlexaFluor	488	 (AF488)	moiety	 for	 fluorescent	detection.	Depending	on	the	nature	
of	 the	 linker	 moiety,	 the	 G2.5	 multivalent	 conjugates	 led	 to	 unexpected	 high	
selectivity	in	binding	to	the	human	A3AR	with	the	most	selective	G2.5	15	showing	>	
100-fold	selectivity	in	both	radiobinding	(Ki	app	=	2.4	nM)	and	functional	assays	(EC50	=	
1.6	 nM	 in	 inhibition	 of	 adenylate	 cyclase)	 compared	 to	 A1	 and	 A2A	 receptors.	
Moreover,	 since	 residual	 amino	 groups	 on	 dendrimers	 are	 associated	 with	
cytotoxicity,	 the	 G2.5	 dendrimer	 15	 carrying	 an	 unreacted	 terminal	 carboxylate	
groups	 was	 selected	 for	 fluorescent	 microscopy	 studies.	 Intriguingly,	 the	 A3R	
selective	G2.5	dendrimer	15	was	able	to	bind	CHO	cells	expressing	the	A3AR	but	did	
not	bind	cells	that	did	not	express	the	receptor.	However,	the	fluorescent	signal	was	
not	 uniform	on	 the	membrane,	 suggesting	 the	 potential	 existence	 of	 higher-order	
receptor	oligomers	of	A3AR.	Thus,	this	A3AR	selective	conjugate	15	could	be	useful	in	
pharmacological	 models	 of	 tissue	 rescue	 from	 ischemia	 and	 as	 a	 fluorescent	
conjugate	 tool	 to	 characterize	 the	 A3R	 in	 situ	 and	 to	 probe	 the	 existence	 of	 A3AR	
oligomers.65	
In	a	following	example,	again	the	N6-chain	elongated	functionalized	congener	ADAC	
was	 conjugated	 to	 higher	 generation	 (G5.5)	 PAMAM	 dendrimers,	 generating	 high	
molecular	 weight	 (60	 amide-linked	 nucleoside	 moieties),	 multivalent	 AR	 agonist	
acting	 at	 the	 A3AR.	 Additionally,	 an	 amine-functionalized	 derivative	 of	 AF488	 was	
introduced	 to	 the	 dendrimer,	 as	 seen	 previously.	 The	 resulting	 dendrimer	 16	 was	
only	 slightly	 selective	 for	 the	 A3AR	 in	 radiobinding	 assay	 and	 non-selective	 in	 an	
assay	 of	 adenylate	 cylase	 inhibition.	 Despite	 that,	 it	 displayed	 to	 protect	 A3-
transfected	HL-1	cells	using	both	an	LDH	assay	and	an	apoptosis	assay	with	greater	
potency	 (IC50	 =	 35	 nM)	 than	 the	 corresponding	 monomeric	 nucleosides,	 which	
protected	 in	 the	 µmolar	 range.	 Thus,	 a	 multivalent	 conjugate	 not	 only	 has	 been	
demonstrated	 to	 preserve	 binding	 affinity	 at	 the	ARs,	 but	 also	 it	 displayed	 greatly	
enhanced	functional	potency	in	an	in	vitro	model	of	cardioprotection.66		
In	the	search	of	different	linker	moieties	to	use	for	dendrimers-nucleosides	covalent	
coupling,	 Cu(I)-catalyzed	 “click”	 chemistry	 reaction	was	 exploited	 to	 conjugate	 the	
distal	 alkyne	 of	 a	 2-octadiynyl	 nucleoside	 previously	 synthesized	 with	 the	 azide-
derivatized	G4	(fourth-generation)	PAMAM	dendrimers	to	form	triazoles.	The	newly	
synthesized	 triazole-linked	conjugates	 retained	A3AR	activation	with	apparent	Ki	 of	
0.1−0.3	 nM,	 displaying	 selectivity	 and	 enhanced	 A3AR	 affinity	 in	 comparison	 with	
various	amide-linked	dendrimers.	Furthermore,	a	bifunctional	conjugate	17	was	also	
prepared	by	linking	both	A3	(via	triazole-linked	conjugates)	and	P2Y14	receptors	(via	
amide-linked	 uridine-5ʹ-diphosphoglucuronic	 acid)	 pharmacophores.	 17	 represents	
the	 first	 example	 of	 multivalent	 dendrimer	 conjugate	 able	 to	 simultaneously	
targeting	two	different	GPCRs	with	selectivity	over	other	ARs	and	P2Y	receptors	that	
can	be	useful	to	evaluate	the	formation	of	heteromeric	GPCR	aggregates.	Moreover,	
this	 polypharmacological	 profile	 may	 exert	 synergistic	 effects	 useful	 in	 disease	
treatment.67	
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Figure	4.	Functionalized	A3R	congeners	conjugated	to	PAMAM	dendrimers.	
	
Hence,	 the	 functionalized	 congener	 approach,	 including	 both	 small	molecules	 and	
macromolecular	 conjugates	 development,	 has	 been	 brilliantly	 applied	 for	 studying	
the	chemical	and	biological	properties	of	GPCRs,	thus	having	the	potential	to	provide	
useful	tools	in	GPCRs	research	and	also	in	some	cases	useful	therapeutics.	
	
	
1.3	P2Y14	receptor	as	drug	target	
	
Despite	the	well-characterized	adenosine	and	purinergic	receptors	discussed	earlier,	
only	about	fifteen	years	have	elapsed	since	the	first	characterization	of	the	orphan	
gene	GPR105,68	subsequently	named	P2Y14	receptor	(P2Y14R).69	This	receptor	is	a	Gi-
coupled	 receptor	 potently	 activated	 by	 UDP-glucose	 (UDPG,	 18	 in	 Figure	 5)	 that,	
even	 sharing	 important	 structural	 similarities	 with	 members	 of	 the	 P2Y	 receptor	
family,	displays	a	significantly	different	pharmacological	response	profile.	
The	P2Y	receptors	(P2YR)	are	a	group	of	eight	molecularly	defined	GPCRs	that	can	be	
divided	in	two	subfamilies,	according	to	the	primary	sequence	identity	and	to	the	G-
coupled	protein.	The	P2Y1R,	P2Y2R,	P2Y4R	and	P2Y6R	activate	Gq/phospholipase	C-β	
and	 can	 be	 grouped	 into	 a	 P2Y1R-like	 subfamily	 of	 P2YR.	 The	 P2Y12R,	 P2Y13R	 and	
P2Y14R	 exhibit	 45–50%	 homology	 and	 comprise	 a	 second	 group	 of	 P2YR,	 the	 so-
called	 P2Y12R-like	 subfamily	 that	 activate	 the	 G	 protein	 of	 the	 Gαi/o	 and	 inhibit	
adenylyl	cyclase	activity.70		
P2Y14R	 identified	 as	 the	 most	 recently	 discovered	 receptor	 among	 the	 other	
members	of	P2Y	family,	 is	now	well	known	that	 is	activated	not	only	by	UDPG,	but	
also	other	nucleotide	sugars	with	a	relative	potency	order	(in	a	concentration	range	
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0.1-1.0	μM):	UDP-glucose	(18)	>	UDP-galactose	(19)	>	UDP-glucuronic	acid	(UDPGA,	
20)	 >	 UDP-N-acetylglucosamine	 (21).71	 Moreover,	 following	 studies	 revealed	 that	
also	UDP	is	a	potent	agonist	of	P2Y14R.72	
Given	its	peculiar	feature	to	be	the	only	known	P2Y	subtype	to	be	activated	by	UDP-
glucose,	P2Y14R	adds	diversity	to	the	P2Y	family69	and	stimulated	a	flurry	of	studies	
not	 only	 concerning	 its	 role	 in	 health	 and	 diseases,	 but	 also	 regarding	 the	
physiological	functions	of	UDP-sugars,	which	have	long	been	considered	exclusively	
as	activated	carriers	of	sugar	moieties	in	the	metabolism	of	carbohydrates.71			
The	 widespread	 distribution	 of	 P2Y14R	 was	 observed	 in	 adipose	 tissue,	 stomach,	
intestine,	 some	 brain	 regions,	 skeletal	 muscles,	 spleen,	 lung,	 and	 heart	 and	 it	 is	
associated	with	immune	and	inflammatory	cells	as	well	as	many	epithelia	suggesting	
a	pivotal	role	in	immune	and	inflammatory	responses.73		
Indeed,	 P2Y14R	 expression	 and	 UDP-glucose	 were	 up-regulated	 following	
inflammatory	 injury	 in	 mast	 cell-like	 cell	 lines,	 suggesting	 that	 the	 P2Y14R	 is	 a	
mediator	of	degranulation	 in	these	cells.	Accordingly,	the	potent	P2Y14R	agonist,	2-	
thio-UDP-glucose,	 enhanced	 the	 release	 of	 β-hexosaminidase,	 an	 indicator	 of	
granule	 secretion.74	 Using	 siRNA	 to	 knock	 down	 the	 P2Y14R	 also	 reduced	
hexosaminidase	 secretion.	 Similar	 results	 were	 reported	 using	 the	 human	 bone	
marrow-derived	mast	cell	line	LAD2,	and	incubation	of	these	cells	with	the	selective	
antagonist	PPTN	(10	μM)	resulted	in	reduced	UDP-sugar-potentiated	C3a-promoted	
hexaminidase	secretion.75		
UDP-glucose	 also	 promoted	 Rho	 kinase-dependent	 chemotaxis	 of	 human	
neutrophils,76	 and	 adding	 the	 P2Y14R	 antagonist	 PPTN	 to	 a	 polymorphonuclear	
neutrophils	suspension	abolished	this	effect.77	
In	addition	to	promoting	recruitment	of	circulating	neutrophils,	UDP-glucose	induced	
the	mobilization	and	enhanced	re-location	of	bone	marrow	stem	cells.78	Particularly	
P2Y14R-mediated	hematopoietic	 stem	cell	mobilization	provides	 a	potential	 tool	 to	
improve	 the	 efficiency	 and	 outcome	 of	 hematopoietic	 peripheral	 stem	 cell	
transplantation.	 Furthermore,	 primitive	 hematopoietic	 stem	 cells	 lacking	 P2Y14R	
displayed	 impaired	 ability	 to	 restore	 hematopoiesis	 in	 irradiated	 mice,	 suggesting	
that	 the	 P2Y14R	 on	 progenitor	 stem	 cells	 promotes	 regenerative	 responses	 after	
injury.79	
Functional	 studies	 regarding	 the	high	expression	 levels	 in	 the	gastrointestinal	 tract	
revealed	 an	 influence	 of	 P2Y14	 in	 gastric	 motility	 function;	 however	 Bassil	 et	 al.	
demonstrated	 that	 some	 effects	 of	 UDP-glucose	 were	 independent	 of	 P2Y14R	
signaling.80	 P2Y14R	 has	 also	 been	 identified	 as	 one	 of	 the	 293	GPCRs	 expressed	 in	
human	pancreatic	islets.81	It	is	known	that	GPCRs	play	a	critical	role	in	regulation	of	
hormones	secretion	from	pancreatic	islets.	Depending	on	their	presence	in	different	
islet	cells	(α-,	β-,	or	δ-	cells),	a	certain	GPCR	have	a	different	impact	on	the	release	of	
glucagon,	insulin	or	somatostatin.	Interestingly,	a	recent	study	suggests	contribution	
of	the	P2Y14R	to	this	process.82	Particularly,	it	pointed	out	that	UDP-glucose	released	
from	 liver	 cells	 in	 obese	 states,	 acts	 as	 a	 chemo-attractant	 to	 recruit	
monocytes/macrophages,	 leading	 to	 liver	 inflammation	 and	 insulin	 resistance.	
Indeed,	 P2Y14R	 knockout	 mice	 were	 protected	 from	 high	 fat	 diet	 (HFD)-induced	
glucose	 intolerance,	 and	 exhibited	 improved	 systemic	 insulin	 sensitivity	 and	
enhanced	 insulin	 action	 in	 adipose	 tissue,	 liver	 and	 skeletal	muscles.	 Furthermore,	
P2Y14R	 knockout	 mice	 exhibited	 a	 reduced	 number	 of	 macrophages	 in	 the	 liver	
compared	to	wild	type	and	the	plasma	levels	of	UDP-glucose	were	4-fold	elevated	in	
HFD-fed	animals	compared	to	controls.82	
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Notably,	a	recent	report	that	is	in	apparent	conflict	with	the	results	described	above	
showed	 no	 differences	 in	 insulin	 sensitivity	 between	western	 diet	 (rich	 in	 fat	 and	
cholesterol)-fed	wild	 type	and	P2Y14R-deficient	mice.83	Meister	and	coworkers	also	
found	 that	 insulin	 immunostaining	 of	 pancreatic	 tissue	 was	 similar	 in	 both	
genotypes,	 but	 glucose-promoted	 insulin	 secretion	 and	 serum	 insulin	 levels	 in	
perfused	 islets	were	markedly	 reduced	 in	 P2Y14R-deficient	mice.	 Perfusion	 of	wild	
type	 islets	with	UDP-glucose	did	not	 increase	 insulin	 secretion,	 supporting	 the	 fact	
that	the	P2Y14R	regulates	functions	necessary,	but	not	sufficient	to	promote	insulin	
granule	 exocytosis.	 Additionally,	 transcriptome	 analysis	 of	 pancreatic	 islets	
demonstrated	 that	 P2Y14R	 deletion	 led	 to	 the	 down	 regulation	 of	 >300	 genes,	
including	 the	 glucose	 transporter	 SLC2A2	 and	 several	 GPCR-modulated	 insulin	
release	pathways.83	
The	discrepancy	highlighted	by	 these	 two	studies	may	be	ascribed	 to	 the	different	
contributions	 of	 liver	 inflammation	 in	 insulin	 sensitivity	 between	 the	 two	 mouse	
models;	but	also	suggest	 that	 the	physiological	 relevance	of	P2Y14R	still	 remains	 to	
be	defined	in	more	detail.	
Taken	together	these	experimental	evidences	support	the	 idea	that	P2Y14R	may	be	
an	attractive	target	for	the	treatment	of	diabetes	and	other	inflammatory	diseases.	
However,	 to	 date,	 the	 P2Y14R	 has	 not	 been	 widely	 explored	 from	 a	 medicinal	
chemistry	 perspective.	 Concerning	 the	 agonists,	 the	 structure-activity	 relationships	
(SAR)	of	analogues	of	the	native	ligands	have	been	evaluated	by	Jacobson’s	group.	
The	P2Y14R	receptor	seems	to	be	the	most	structurally	restrictive	member	of	the	P2Y	
family,	at	least	with	respect	to	modification	of	the	nucleobase,	ribose	and	phosphate	
moieties	of	agonist	ligands.	Nonetheless,	the	demonstration	that	also	UDP	activates	
P2Y14R,	 suggest	 that	 the	 glucose	 moiety	 is	 amenable	 to	 modification	 and	 is	 not	
required	 for	 activation	 of	 the	 P2Y14R.	 Indeed,	 following	 studies	 support	 the	 initial	
hypothesis	that	the	glucose	moiety	of	UDPG	can	be	modified.		
The	first	SAR	study	was	directed	to	explore	modifications	of	the	nucleobase,	which	
led	to	the	identification	of	2-thio-UDP-glucose	(MRS2690,	22	 in	Figure	5)	displaying	
7-fold	greater	potency	for	the	P2Y14R	than	does	UDP-glucose.84	Several	analogues	of	
UDP	 also	 have	 been	 developed	 that	 exhibit	 high	 potency	 and	 selectivity	 at	 the	
P2Y14R,	 by	 replacing	 glucose	with	 other	 sugars,	 substitution	 of	 hydroxyl	 groups	 of	
glucose	 with	 fluorine,	 and	 chain	 extension.	 Indeed,	 docking	 studies	 based	 on	 the	
previously	 developed	model	 of	 P2Y14R,85	 suggest	 that	 the	 hexose	moiety	 of	UDPG	
interacts	with	multiple	H-bonding	and	charged	resides	and	therefore	may	provide	a	
suitable	region	for	agonist	modification.86	 Indeed,	the	carboxylate	group	of	UDPGA	
can	be	extended	via	an	amide	linkage	to	a	flexible	chain	(i.e.	2-acylaminoethylamides	
derivatives),	 without	 loosing	 P2Y14R	 activity.	 Molecular	 modeling	 explained	 that	
retain	 the	 activity	 because	 of	 predicting	 the	 close	 proximity	 of	 this	 chain	 to	 the	
second	extracellular	 loop	of	 the	receptor.	 In	addition,	 replacement	of	glucose	with	
other	 sugars	 did	 not	 significantly	 affect	 P2Y14R	 potency.	 Accordingly,	 elective	
monofluorination	of	the	glucose	moiety	highlighted	the	importance	for	the	2’’-	and	
6’’-hydroxyl	groups	in	receptor	recognition.	All	the	other	attempts	to	modify	ribose	
such	as	abolished	the	activity.86		
Based	 on	 these	 findings,	 the	 structural	 permissive	 site	 was	 further	 modified	 by	
removing	or	substituting	with	smaller	phosphoester	groups,	which	were	tolerated	at	
this	 receptor.	 Simple	 alkyl	 esters	 at	 this	 position	 and	 analogues	 of	 UDP	 displayed	
highly	 potent	 agonist	 activity	 at	 the	 P2Y14R.	 The	 effects	 of	 these	modifications	 to	
preserve	 and	 enhance	 potency	 at	 the	 P2Y14R	 were	 additive	 with	 the	 previously	
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identified	 2-thio	 substitution	 of	 the	 uracil	 moiety,	 affording	 compounds	 with	
nanomolar	and	subnanomolar	potency.	These	include	α,β-difluoromethylene-UDP	
	
	
Figure	5.	P2Y14R	agonists,	antagonists	and	fluorescent	antagonist	probe.	
	
	(MRS2802,	 23)	 and	 α,β-methylene-2-thio-UDP	 (MRS2905,	 24).	 Notably,	 these	
molecules	 also	 displayed	 high	 selectivity	 for	 activation	 of	 the	 P2Y14R	 at	
concentrations	 that	 are	 inactive	 at	 the	 UDP-activated	 P2Y6	 receptor	 as	 well	 as	 at	
other	P2Y	receptors.87		
On	the	other	hand,	non-nucleotide	antagonists	of	the	P2Y14R	have	been	discovered	
trough	 high-throughput	 screens	 by	 the	 Merck	 Frosst	 company,	 leading	 to	 the	
identification	 of	 Black	 and	 coworkers	 applied	 high-throughput	 screens	 to	 identify	
naphthoic	 acid	 (25)88	 and	 dihydropyridopyrimidine	 (26)89	 compounds	 as	 potential	
P2Y14R	 antagonists	 with	 pIC50	values	 of	 2.2	 and	 8.4,	 respectively.	 Analogs	 of	 each	
type	of	molecule	subsequently	were	synthesized.	Whereas	dihydropyridopyrimidine	
derivatives	 (26)	appeared	to	be	noncompetitive	antagonists	of	 the	P2Y14R,	 the	4,7-
disubstituted	 naphthoic	 acid	 derivative	 (PPTN,	 25	 in	 Figure	 5)	 inhibited	 [3H]-UDP	
binding	 suggesting	 antagonist	 of	 the	 orthosteric	 site	 of	 the	 receptor.	 Even	 though	
PPTN	shows	a	promising	pharmacological	profile,	not	 inhibiting	up	 to	10	μM	PPTN	
the	other	Gq/i-linked	P2YRs,	but	unfortunately,	it	displays	low	oral	bioavailability,	and	
additional	P2Y14R	antagonists	will	be	needed.		
Additionally,	 few	selective	 radioligands	 for	P2YRs	are	available,	 thus	 improved	and	
more	versatile	affinity	probes	are	needed.90	
To	this	end,	Kiselev	et	al.	designed	the	first	fluorescent	ligand	of	the	P2Y14R,	i.e.	the	
AF488-labeled	 antagonist	 MRS4174	 (27).91	 This	 compound	 contained	 a	
functionalized	 chain	 at	 the	 secondary	 nitrogen	 of	 the	 piperidine	 ring,	 selected	 as	
suitable	 for	 tethering	 fluorophore	 on	 the	 basis	 of	 docking	 studies	 at	 a	 P2Y14R	
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homology	model.	An	azide-bearing	AF488	was	conjugated	to	the	alkyne	congener	of	
25	 by	 [2	 +	 3]	 click	 cycloaddition	 reaction.	 Flow	 cytometry	 showed	 high	 specific	
P2Y14R	 binding	 of	 MRS4174	 (27)	 with	 exceptionally	 high	 affinity	 (Ki	 =	 80	 pM)	 in	
antagonizing	UDPG-induced	cAMP	inhibition	in	P2Y14R-expressing	CHO	cells.		
Collectively,	 the	 development	 of	 P2Y14R	 fluorescent	 probes	 and	 small	 molecules	
agonists	and	antagonists	both	as	pharmacological	tools	and	as	potential	therapeutic	
agents	may	lead	to	considerable	progress	for	further	supporting	and	expanding	the	
previous	pharmacological	investigations.	
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2.	Aims	and	objectives	
	
Since	 the	 introduction	 of	 fluorescent	 ligands	 in	 the	 mid	 1970s,92	 they	 have	 been	
widely	applied	as	powerful	 tools	 to	monitor	 the	 structure	and	dynamics	of	GPCRs.	
The	success	of	such	approach	lies	on	the	fact	that,	in	comparison	to	isotope-labeled	
methods,	 fluorescence-based	technology	represents	a	safe	and	 inexpensive	way	to	
“watch”	 receptors	 in	 living	 cells	 because	 of	 its	 biocompatibility,	 affordability,	 and	
feasibility	in	a	variety	of	strategies.93		
Notably,	 the	 value	 of	 fluorescent	 probes	 for	 receptors	 grows	 in	 parallel	 to	 the	
development	 of	 sophisticated	 fluorescent	 techniques94	 and	 more	 efficient	
fluorescent	dyes	as	well.95	 Indeed,	 the	advancement	of	 fluorescence	 reagents,	 not	
only	 offer	 a	 wide	 range	 of	 new	 fluorophores	 with	 different	 physiochemical	 and	
spectroscopic	 properties	 (such	 as	 excitation	 and	 emission	 wavelengths,	 photo-
bleaching,	 fluorescence	 quantum	 yield,	 stability,	 etc.),	 but	 has	 also	 resulted	 in	 a	
multitude	 of	 more	 complex	 fluorescence	 technologies	 such	 as	 fluorescence	
resonance	 energy	 transfer	 (FRET),	 fluorescence	 activated	 cell	 sorting	 (FACS)	 and	
fluorescence	correlation	spectroscopy	(FCS),	etc.94	
Moreover,	as	already	discussed,	the	versatility	of	this	approach	allows	its	application	
to	 a	wide	 range	 of	molecules	 including	 small	molecules,	 antibodies,	 proteins,	 and	
dendrimers.	 Among	 these	 probes,	 fluorescent	 ligands	 efficiently	 consent	 the	 real-
time	monitoring	of	ligand−receptor	interactions,	the	visualization	and	localization	of	
GPCRs,	 their	 internalization	 and	 trafficking.	 On	 the	 other	 hand,	 fluorescent	
antibodies,	proteins,	 and	amino	acids	mostly	 contribute	 to	 receptor-based	 studies,	
such	 as	 receptors	 oligomerization.96	 Importantly,	 fluorescent	 probes	 play	 also	 a	
pivotal	role	in	studying	orphan	GPCRs.		
Currently,	 the	 main	 strategy	 to	 rationally	 design	 fluorescent	 ligands	 relies	 on	
conjugating	an	agonist	or	antagonist	of	the	GPCRs	to	various	fluorophores.	By	using	
this	 strategy,	GPCR	 fluorescent	 ligands	with	high	 affinity	 and	 selectivity	have	been	
reported,	as	seen	for	A3R	receptor.62	However,	some	key	issues	must	be	addressed	
in	 probe	 design,	 especially	 including	 physicochemical	 properties	 and	
pharmacological	 activities	 of	 the	 final	 probes.	 Because	 of	 the	 large	 mass	 of	
fluorophores,	 their	 conjugation	 to	 ligands	 or	 pharmacophores	 targeted	 at	 GPCRs	
may	have	a	big	impact	on	the	properties	of	the	final	conjugate,	especially	the	affinity	
and	selectivity	to	the	receptor.	Thus,	the	choice	of	a	fluorophore	is	perhaps	the	most	
critical	 step	 in	 the	 rational	 design	 of	 fluorescent	 probes.93	 Accordingly,	 numerous	
factors	are	implicated	in	its	biological	functionality,	and	these	include	excitation	and	
emission	 wavelengths,	 fluorescence	 quantum	 yield,	 fluorescence	 life-time,	 photo-
stability	 and	 size.	 This	 latter	 factor	 is	 of	 fundamental	 importance	 because	
significantly	 impacts	 on	 the	 physicochemical	 properties	 of	 fluorescent	 conjugates,	
especially	 in	 the	 case	 of	 small	 molecule-based	 probes,	 often	 causing	 nonspecific	
binding.95	
Another	important	aspect	to	consider	is	the	positional	attachment	of	a	fluorophore	
to	the	ligand	structure.		It	must	be	particularly	suitable	to	minimize	the	influence	on	
receptor	binding	affinity.	
Furthermore,	 the	 linker	 should	 provide	 the	 proper	 spacing	 between	 the	
pharmacophore	 and	 fluorophore	 in	 order	 to	maintain	 the	pharmacological	 activity	
and	hopefully	improved	solubility,	stability	and	affinity.	Usually,	the	linker	is	a	carbon	
chain	that	ends	with	heteroatoms	such	as	nitrogen	atoms.	The	terminal	heteroatom	
groups	 are	 used	 to	 couple	with	 the	 fluorophores	 or	 pharmacophores.	 It	 has	 been	
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reported	 that	 the	 high	 lipophilicity	 would	 increase	 the	 nonspecific	 binding	 of	 a	
fluoroligand.	 Therefore,	 polyamide,	 polyethylene	 glycol,	 and	 peptide	 hydrophilic	
linkers	are	being	preferred.93	
Compared	with	peptide,	antibodies,	proteins,	and	amino	acids	-based	probes,	small-
molecule	probes	have	become	more	promising	tools	for	the	study	of	GPCRs,	owing	
to	their	tremendous	advantages	in	stability,	solubility,	reasonable	cell	permeability,	
subtype	selectivity,	and	application	in	high-throughput	screening.	
The	 development	 of	 such	 probes	 started	 with	 the	 selection	 of	 a	 known	 ligand	 or	
drug.	This	ligand	must	have	a	high	affinity	and	selectivity	to	the	receptor,	as	well	as	a	
structurally	 permissive	 site	 for	 further	 modification	 in	 its	 chemical	 structure.62	 A	
reactive	 group,	 such	 as	 amine,	 hydroxyl,	 alkynyl,	 or	 carboxyl	 group,	 is	 generally	
introduced	into	the	ligand	molecules	and	following	condensation	and	click	reactions	
at	 this	 site	 are	 performed	 to	 conjugate	 the	 pharmacophores	 and	 linkers	 or	
fluorophores.	
In	 light	 of	 these	 considerations,	 the	 functionalized	 congener	 approach	 aimed	 at	
developing	 fluorescent	 probes	 targeting	 P2Y14	 is	 particularly	 attractive	 because	 of	
the	limited	knowledge	of	its	structure	and	physiological	responses.		
As	previously	mentioned,	 in	a	 recent	paper,	 Jacobson	and	coworker	have	reported	
on	the	structure	of	the	first	P2Y14	fluorescent	antagonist	probe	structurally	derived	
from	 the	 potent	 and	 highly	 selective	 PPTN	 antagonist	 (25).97	 This	 molecule	
selectively	 labeled	 the	 P2Y14R	 in	 live	 cells	 as	 quantified	 by	 flow	 cytometry.	 It	 has	
been	 designed	 based	 on	 the	 docking	 studies	 performed	with	25	 showing	 that	 the	
piperidine	 moiety	 is	 suitable	 for	 tethering	 fluorophores.	 Click	 chemistry	 has	 been	
used	 to	 conjugate	 functionalized	 an	 alkyne	 derivative	 of	25	 and	 the	 azide	 bearing	
AlexaFluor488.	However,	the	previously	reported	synthesis	of	fluorescent	antagonist	
MRS417497	(27)	suffered	from	a	low	yield	in	the	final	click	cycloaddition	step	to	link	
the	azide-functionalized	fluorophore	and	the	alkyne-functionalized	pharmacophore.	
Given	 the	 remarkably	 high	 affinity	 of	 27	 and	 its	 low	 nonspecific	 character,	 we	
explored	an	alternate	synthesis	of	 this	compound.	This	was	necessary	 to	provide	a	
sufficient	supply	of	this	fluorescent	probe	to	be	use	in	displacement	assay.98	
In	parallel,	 the	design	of	 fluorescent	agonist	probes	has	been	envisioned	based	on	
previous	 SAR	 studies	 of	 UDP	 analogues.	 Particularly,	 the	 terminal	 sugar	moiety	 of	
UDPG	has	been	identified	as	structurally	permissive	for	further	modification	without	
losing	 the	 activity.	 In	 particular,	 the	 amide	 derivatives	 at	 the	 glucose	 C6	 position	
have	 been	 found	 to	 retain	 the	 activity	 toward	 P2Y14R.	 Thus,	 for	 designing	
fluorescent-agonist	 probes	 at	 P2Y14R,	 the	 UDPGA	 has	 been	 selected	 as	 suitable	
starting	 point.	 Particularly,	 UDPGA	 has	 been	 conjugated	 to	 different	 boron-
dipyrromethene	 (BODIPY)	 dyes	 with	 the	 reactive	 amine	 linkers	 of	 varying	 length.	
Importantly,	the	longer	chain	analogue	MRS4183	retains	the	activity	and	served	as	a	
tracer	for	microscopy	and	flow	cytometry,	displaying	minimal	nonspecific	binding.99	
Additionally,	thanks	to	the	recent	human	P2Y14R	homology	model	based	on	human	
P2Y12R	X-ray	structures100	as	 template	 to	conduct	docking	and	molecular	dynamics	
simulations,	 the	 development	 of	 non-nucleotide	 based	 antagonists	 has	 been	
envisaged	 starting	 from	 the	 structure	 of	 25.	 The	 immediate	 goal	 was	 to	 suggest	
bioisosteric	substitutions	to	the	hydrophobic	and	bulky	naphthalene	ring	of	25	that	
would	 maintain	 a	 similar	 orientation	 of	 the	 piperidine	 and	 4-(trifluoromethyl)-	
phenyl	 substituents	when	 bound	 to	 the	 receptor	 and	 therefore	 preserve	 receptor	
affinity.	 Along	 this	 line,	 we	 aim	 at	 simultaneously	 reducing	 both	 the	 molecular	
weight	 and	 the	 high	 lipophilicity	 of	 25	 that	 contributes	 to	 its	 low	 solubility	 and	
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difficulty	 of	 purification.	 On	 these	 bases,	 the	 design	 and	 synthesis	 of	 structural	
analogues	of	25	have	been	developed	by	replacing	one	phenyl	ring	of	naphthoic	acid	
core	of	25	with	an	alkyne	or	a	triazole.	In	particular,	I	was	involved	in	the	first	part	of	
the	development	of	 triazolyl	derivatives,	enabling	 to	set	up	 the	synthetic	 route	 for	
achieving	3	of	the	overall	40	triazole	compounds.98,	101	
To	sum	up,	given	the	 increasing	 interest	 in	developing	fluorescent	 ligand	probes	as	
pharmacological	tools	for	characterizing	GPCRs,	a	new	synthetic	route	to	obtain	the	
previously	synthesized	fluorescent	antagonist	probe	27	has	been	reported.	The	main	
goal	consists	of	improving	the	reaction	yield	as	27,	which	has	proved	to	be	a	highly	
potent	and	selective	in	situ	tracer	of	P2Y14R	in	whole-cell	binding	assays.	In	parallel,	
the	development	of	P2Y14R	 fluorescent	congeners	has	provided	 the	opportunity	 to	
get	 additional	 insights	 to	 further	 study	 the	 role	 and	 distribution,	 as	 well	 the	
structural	feature	of	the	binding	site	of	this	receptor.	
As	a	further	step,	the	development	of	non-nucleotide	antagonists	makes	possible	to	
achieve	 compounds	 with	 better	 physicochemical	 properties	 compared	 to	 the	
liabilities	of	nucleotide-based	ligands	and	the	low	bioavailability	of	25.	
Collectively,	 such	 fluorescent	 congeners	 and	 non-nucleotide	 antagonists	 may	 be	
powerful	tools	in	expanding	the	SAR	of	P2Y14R,	which	still	lacks	chemical	diversity	in	
its	collective	ligands.	
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3.	Chemistry	
	
	
3.1	Alternative	synthesis	of	fluorescent	P2Y14	antagonist		
	
The	previously	developed	synthesis	of	27	suffered	from	a	low	reaction	yield	(4%)	in	
the	final	click	cycloaddition	step	to	link	the	azide-functionalized	fluorophore	29	and	
the	alkyne-functionalized	pharmacophore	28	(Scheme	1).97	
	
	
Scheme	 1.	 Reagents	 and	 conditions:	 CuSO4	 (7.5%	 aqueous	 solution),	 sodium	
ascorbate	(1	M	aqueous	solution),	tBuOH,	H2O,	25°C	(4%). 
	
Thus,	we	explore	a	more	efficient	 route	 that	consisted	of	 forming	an	amide	as	 the	
ultimate	 step	 (Schemes	 2A	 and	 2B).98	 In	 details,	 to	 provide	 the	 functionalized	
congener	 28,	 the	 synthetic	 pathway	 started	 with	 the	 formation	 of	 the	 two	 parts	
composing	the	triazole	linker	chain.	In	particular,	the	functionalized	alkyne	chain	32	
has	been	synthesized	from	compound	hex-5-yn-1-ol	30,	which	was	subjected	to	two	
substitution	 reactions,	 involving	 first	 the	 formation	 of	 the	 tosylate	 31	 and	 its	
following	replacement	with	a	bromine.	Next,	6-amino-1-hexanol	33	was	reacted	with	
HBr	to	afford	its	bromine	derivative	34,	substituted	again	to	afford	the	chain	bearing	
the	 azide	 functionality	35.	 Once	 formed	 the	 key	 intermediates	32	 and	35,	32	was	
conjugated	to	the	pharmacophore	of	25,	previously	protected	at	carboxylic	function	
as	 ethyl	 ester	36,	 yielding	 functionalized	 congener	 37.	 To	 provide	 the	 triazole	 38,	
click	 chemistry	 reaction	 was	 exploited	 involving	 the	 azide	 35	 and	 the	 alkyne	
functionalized	 congener	 37	 (Scheme	 3A).102	 The	 functionalized	 congener	 38,	
containing	 the	 preformed	 triazole	 chain	with	 a	 terminal	 amino	 function,	was	 then	
converted	 to	 the	 corresponding	 carboxylic	 acid	 derivative	 39	 by	 using	 LiOH	 to	
hydrolyze	the	ester.		
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Scheme	2A.	Reagents	and	conditions:	a.	TsCl,	NEt3,	DMAP,	CH2Cl2,	r.t.,	15	h;	b.	LiBr,	
DMF,	r.t.,	12	h;	c.	HBr	48%	sol.,	80	°C,	20	h;	d.	NaN3,	H2O,	reflux,	12	h;	e.	SOCl2,	EtOH,	
0	 °C	 to	 r.t.,	 10	 h;	 f.	 K2CO3,	 DMF,	 ;	 g.	 35,	 CuSO4	 (15	mol%),	 sodium	 ascorbate	 (45	
mol%),	t-BuOH:H2O:	CH2Cl2;	h.	LiOH	0.5	M,	MeOH,	H2O.	
	
Then,	 the	 coupling	 of	 AlexaFluor488	 fluorophore	 40	 and	 pharmacophore	 was	
attempted	 by	 two	 parallel	 strategy:	 1)	 condensation	 of	 the	 fluorophore	 as	 a	 4-
carboxylic	acid	40	to	the	ethyl	ester-protected	derivative	38	of	the	pharmacophore	
followed	 by	 ester	 saponification;	 or	 2)	 by	 reaction	 of	 the	 fluorophore	 that	 was	
activated	in	situ	as	a	N-succinimidyl	ester	41	with	the	amino	derivative	39,	having	a	
deprotected	carboxylic	acid	(Scheme	2B).	However,	the	failed	attempt	(1)	provided	
only	traces	of	the	desired	compound	as	confirmed	from	the	mass	analysis,	while	the	
second	 synthetic	 route	 resulted	 more	 promising,	 providing	 compound	 27	 with	
improved	reaction	yield	(10%)	compared	to	the	previous	synthetic	method	(4%).91	
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Scheme	2B.	Reagents	and	conditions:	b.	TSTU,	DIPEA,	DMF,	0	°C	for	1	h	then	r.t.	for	
2h;	c.	39,	DIPEA,	DMF,	overnight.	
	
	
3.2	Synthesis	of	fluorescent	P2Y14	agonist		
	
As	 depicted	 in	 Scheme	 3,	 the	 synthesis	 of	 derivative	 44	 (MRS4183)	 was	
accomplished	 using	 standard	 coupling	 conditions	 involving	 the	 commercially	
available	primary	amine	of	the	BODIPY	dyes	(42)	and	the	carboxylate	group	of	UDP-
glucuronic	acid	43.99	
	
	
Scheme	3.	Reagents	and	conditions:	COMU	(1.5	equiv),	DIPEA	(2	equiv),	DMF,	0	°C,	
0.3%	yield.	
	
Before	establishing	this	synthetic	protocol,	different	conditions	were	tried	(Table	1)	
to	increase	the	reaction	yield	and	simplify	the	purification	process.	Indeed,	the	first	
attempt	 (condition	 A)	 to	 synthetize	 44	 resulted	 in	 an	 impure	 product	 even	 after	
several	 successive	 purification	 attempts,	 due	 to	 an	 impurity	 co-eluting	 with	 the	
desired	product.	The	higher	reactivity	of	a	different	coupling	agent,	[[(Z)-(1-cyano-2-
ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium	
hexafluorophosphate	 (COMU,	 conditions	 B	 and	 C),	 compared	 to	 HATU	 led	 to	 the	
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formation	 of	 numerous	 side	 products	 during	 the	 reaction	 that	 complicated	 the	
purification	process	(2	or	3	purifications)	without	leading	to	a	significant	detectable	
amount	of	title	compound.	Nevertheless,	the	best	performing	procedure	(condition	
D),	 using	 excess	 of	43	 (1.5	 equiv),	 COMU	 (1.5	 equiv)	 as	 coupling	 agent	 and	DIPEA	
(2	equiv)	 as	 base,	 provided	 the	 desired,	 pure	 product	 after	 one	 purification	 step	
using	a	C18	HPLC	column,	however,	in	a	very	low	yield	(0.3%).99	
	
Table	1.	Different	conditions	used	for	obtaining	derivative	44.	The	solvent	used	was	
dry	DMF.	Condition	D	gave	the	best	results.		
Condition	 Bodipy	 TR-cadaverine.HCl	
(42)	
UDP-glucuronic	
acid.Na+3	(43)	
Coupling	agent	 Base	
A	 1	eq	 1.5	eq	 HATU	1.5	eq	 NEt3	1	eq	
B	 1.2	eq	 1	eq	 COMU	1.5	eq	 DIPEA	1.5	eq	
C	 1	eq	 1.5	eq	 COMU	1.5	eq	 DIPEA	1.5	eq	
D	 1	eq	 1.5	eq	 COMU	1.5	eq	 DIPEA	2	eq	
Abbreviations:	 COMU,	 [[(Z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-
ylmethylidene]-dimethylazanium	hexafluorophosphate;	HATU,	 1-[bis(dimethylamino)methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium	3-oxid	hexafluorophosphate;	DIPEA,	diisopropylethylamine.		
	
	
3.3	Synthesis	of	P2Y14	antagonists	
	
Based	 on	 the	 recently	 developed	 hP2Y14R	 homology	 model	 built	 on	 the	 agonist-
bound	 hP2Y12R	 X-ray	 structure	 and	 refined	 by	molecular	 dynamics,100	 the	 docking	
pose	of	PPTN	25	suggested	two	bioisosteric	alternatives	to	the	naphthoic	acid	core.	
The	 first	 relies	 on	 replacing	 one	 phenyl	 ring	 of	 naphthoic	 acid	 core	 of	25	 with	 an	
alkyne	 group	 (synthesis	 not	 showed,	 see	 Results	 and	 Discussion).	 However,	 this	
modification	 provided	 derivative	 148	 displaying	moderate	 potency	 and	 it	 was	 not	
selected	as	lead	compound.	On	the	other	hand,	the	second	alternative	proposed	to	
replace	one	phenyl	ring	of	naphthoic	acid	core	of	25	with	a	triazole,	that	can	interact	
favorably	with	the	amino	acid	residues	in	P2Y14R	binding	site,	almost	overlapping	the	
binding	pose	of	25.	
Thus,	a	versatile	synthetic	approach	was	used	for	introducing	arylacetylene	moieties	
in	the	form	of	1,2,3-triazoles98,	101	by	click	coupling	with	an	azido	group	present	on	
the	core	of	the	molecule	by	copper-catalyzed	[2+3]	cycloaddition.102	
As	 depicted	 in	 Scheme	 4,	 the	 triazolyl	 derivative	 106	 and	 its	 analogues	 were	
synthesized	 starting	 from	 the	 3-amino-5-bromobenzoic	 acid	 45	 and	 4-(4-
bromophenyl)piperidin-4-ol	49.	The	carboxylic	group	of	45	was	first	converted	to	the	
methyl	ester	46,	and	then	the	amine	function	was	protected	to	give	Boc-derivative	
47a.	A	di-Boc	side	product	47b	accompanied	the	product	that	was	initially	isolated,	
and	this	 impurity	 reverted	to	 the	desired	mono-Boc	product	47a	upon	heating	 the	
mixture	in	refluxing	MeOH	in	the	presence	of	dilute	K2CO3.	The	palladium-catalyzed	
condensation	 of	 arylbromide	 47a	 with	 bis(pinacolato)-diboron	 under	 basic	
conditions	afforded	dioxaborolane	48.	The	acid-catalyzed	dehydration	of	49	yielded	
derivative	 50,	 which	 was	 reduced	 to	 provide	 compound	 51.	 Derivative	 52	 was	
obtained	 by	 coupling	48	 with	 compound	51	 under	 Suzuki	 conditions.103	 Then,	 the	
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conversion	 of	 the	 amino	 group	 of	 52	 to	 a	 trifluoroacetamide	 derivative	 53	 was	
accomplished	by	using	 trifluoroacetamide	anhydride	 in	 the	presence	of	base.	After	
removing	the	N-Boc	protecting	group	of	53	to	give	compound	54,	aryl	azide	55	was	
formed	from	an	arenediazonium	tosylate	that	was	generated	in	situ	and	subsequent	
addition	of	 sodium	azide.104	 The	1,2,3-triazolyl	 derivative	57	was	 synthesized	 via	 a	
click	 reaction	 involving	aryl	 azide	55,	 4-(trifluoromethyl)phenylacetylene,	Cu(II)	 salt	
and	 sodium	 ascorbate,102	 followed	 by	 the	 one-pot	 hydrolysis	 of	 the	
trifluoroacetamide	 and	 the	 ester	 in	 the	 presence	 of	 potassium	 hydroxide	 to	 yield	
107.		
	
	
Scheme	4.	Regents	and	conditions:	
a.	CH3OH,	SOCl2,	0	to	23	°C	(98%);	b.	1)	Boc2O,	NEt3,	DMAP,	CH2Cl2;	2)	K2CO3,	MeOH,	
reflux	(70%);	c.	PdCl2(dppf),	AcOK,	DMF,	95	°C	(74%);	d.	F3CCO2H,	90	°C	(97%);	e.	H2,	
Rh/C,	100	psi	(98%);	f.	Pd(Ph3P)4,	K2CO3,	DME,	85	°C	(71%);	g.	(CF3CO)2O,	NEt3,	Et2O;	
h.	 F3CCO2H,	 CH2Cl2	 (70%);	 i.	 1)	 Ts-OH,	 NaNO2,	 H2O/acetonitrile;	 2)	 NaN3,	 (83%);	 j.	
CuSO4,	sodium	ascorbate	(1M	aq.)	k.	KOH	(1M	aq.).	R	defined	in	Tables	3	in	Results	
and	discussion	section.	
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4.	Results	and	Discussion	
	
	
4.1	Biological	evaluation	of	P2Y14	fluorescent	agonists	
	
Although	nucleotide	analogs	of	 endogenous	P2Y14R	agonist	UDP	 suffer	 from	a	 low	
bioavailability	and	chemical	stability,	the	possibility	arisen	from	previous	SAR	studies	
to	modify	at	C6	position	of	the	glucose	ring	of	UDPGA	(20)	attracted	our	attention.87	
In	 fact,	 that	 SAR	 study	 reported	 that	 several	 amide	 derivatives	 at	 the	 glucose	 C6	
have	been	constructed,	and	most	of	 these	derivatives	retained	agonist	activity.87	 It	
was	 also	 found	 that	 P2Y14R	 agonist	 activity	was	 retained	with	 attachment	of	 large	
groups	 such	 as	 unprotected,	 as	 well	 as	 acetyl-	 and	 Boc-protected	
aminoethylamides,87	and	G3	PAMAM	dendrimers	attached	to	the	C6	carbon.67	
Following,	 docking	 studies	on	 a	 validated	P2Y14R	homology	model100	 based	on	 the	
recently	 reported	 structures	of	 the	hP2Y12R,21	 revealed	 indeed	 that	 this	position	 is	
amenable	 to	 further	 modification	 without	 compromising	 the	 recognition	 at	 the	
receptor.	 Accordingly,	 it	 occupied	 a	 subpocket	 of	 the	 binding	 site,	 suggesting	 the	
suitability	of	the	site	of	attachment	and	the	dependence	of	potency	on	the	length	of	
the	 spacer	 chain.	 Therefore,	 two	 fluorescent	 derivatives	 of	20	 were	 designed	 and	
prepared	(Figure	6)	based	on	predictions	from	computational	modeling	of	P2Y14R		
	
	
Figure	6.	Chemical	structures	of	P2Y14R	agonist	20	and	fluorescent	probes	147	and	44.	
	
agonist	 binding.99	 Particularly,	 two	different	 linker	 chains	were	 exploited,	 but	 only	
the	 longer	 chain	 analogue	 44	 retains	 the	 activity	 at	 P2Y14R	 (EC50	 =	 0.96	 nM	 for	
inhibition	of	cAMP	production	in	hP2Y14R-expressing	CHO	cells).		
	
Table	 2.Inhibition	 of	 P2Y14R	 binding	 in	 whole	 cells	 by	 known	 ligands	 of	 P2Y14R	 using	 44	 as	 a	 FCM	
tracer.	
Compound	
hP2Y14R	 cAMP	 assay	 (EC50	or	
IC50,	μM)	
FCM	binding	at	hP2Y14R	(Ki,	
μM)	
P2Y14	ligands	
UDP	 0.160	 0.63	±	0.03	
UDP-glucose	 0.261	 2.23	±	0.2	
MRS2690	 0.011	 0.34	±	0.04	
43	 UDP-glucuronic	
acid	
0.370	 5.3	±	0.4	
25	PPTN	 0.00043	 0.0019	±	0.0001	
	
Accordingly,	as	depicted	 in	Figure	7,	44	exhibited	strong	specific	binding	to	P2Y14R-
CHO	cells	in	flow	cytometry	(FCM).	We	also	quantified	saturation	of	binding	curve	of		
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Figure	7.	Inhibition	of	binding	of	44	in	P2Y14R-CHO	cells	by	antagonist	PPTN	25	and	agonists	UDP	and	
UDP-glucose	(10	µM),	analyzed	by	flow	cytometry.	Incubation	of	cells	for	30	min	with	antagonist	25	or	
agonist	UDP	and	UDP-glucose	(all	at	10	µM)	followed	by	incubation	with	44	(50	nM)	for	30	min	was	
performed.	
	
44	 to	 P2Y14R-expressing	 cells	 by	 using	 FCM,	 which	 provided	 an	 apparent	 binding	
constant	of	21.4	±	1.1	nM,	and	the	kinetics	of	binding	as	well,	showing	a	t1/2	=	23.9	
min	 at	 50	nM	of	44.	 Competition	experiments	 for	 fluorescent	binding	with	 known	
P2Y14R	ligands	have	been	also	reported.		As	showed	in	Table	2,	the	obtained	results	
followed	the	expected	rank	order	of	P2Y14R	potency	(25≫MRS2690	>UDP	>	UDPG	
>UDPGA).	
The	specific	labeling	of	P2Y14R-CHO	cells	by	44	has	been	also	confirmed	by	confocal	
fluorescence	microscopy	studies	(Figure	8).	As	expected,	the	fluorescent	labeling	was	
inhibited	 in	 the	 presence	 of	 antagonist	 25	 and	 it	 is	 irregularly	 distributed	 on	 the	
surface	 of	 the	 cells	 and	 partially	 internalized.	 This	 is	 in	 line	with	 previous	 reports	
showing	the	internalization	of	fluorescent	agonists	of	other	P2YRs	and	GPCRs.105		
	
	
Figure	8.	Fluorescence	confocal	microscopy.	Cells	were	incubated	using	a	fixed	concentration	of	44	
(200	nM)	at	different	times	30	min	(A,	B)	or	120	min	(C,	D)	of	incubation	in	the	absence	(A,	C)	or	
presence	(B,	D)	of	antagonist	25	(10	µM).	
Herein,	 a	 useful	 fluorescent	 probe	 44,	 pharmacologically	 complementary	 to	 the	
previously	reported	non-nucleotide	fluorescent	antagonist	27,	has	been	developed.	
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The	 utility	 of	 this	 probe	 to	 specifically	 label	 P2Y14R	 using	 flow	 cytometry	 and	
fluorescence	microscopy	was	also	demonstrated.	 It	may	allow	to	 further	 study	 the	
role	 and	 distribution	 of	 this	 receptor,	 and	 its	 structural	 requirements	 to	 design	 a	
more	potent	P2Y14R	ligands.	
	
	
4.2	Biological	evaluation	of	P2Y14	antagonists	
	
As	 already	 pointed	 out,	 only	 few	 non-nucleutide	 P2Y14R	 antagonists	 are	 currently	
known.	 Black	 and	 coworkers	 applied	 high-throughput	 screens	 to	 identify	
dihydropyridopyrimidine89	 and	 naphthoic	 acid88	 compounds	 as	 potential	 P2Y14R	
antagonists.	 Analogs	 of	 each	 type	 of	 molecule	 subsequently	 were	 synthesized.	
Whereas	 dihydropyridopyrimidine	 derivatives	 appeared	 to	 be	 noncompetitive	
antagonists	of	the	P2Y14R,	the	naphthoic	acid	derivatives	inhibited	[3H]-UDP	binding	
suggesting	 antagonism	 of	 the	 orthosteric	 ligand	 binding	 site	 of	 the	 receptor.	
Problems	with	high	affinity	binding	to	serum	proteins	observed	with	several	of	these	
naphthoic	acid	analogs	were	partially	circumvented	in	the	analogue	PPTN	25	that	is	
able	to	retain	the	activity,	even	showing	low	oral	bioavailability.	A	prodrug	based	on	
PPTN	also	was	developed	to	improve	its	pharmacological	profile.106		
To	date,	25	 is	the	most	potent	and	selective	P2Y14R	non-nucleotide	antagonist,	but	
its	liabilities	precluded	to	further	develop	a	drug	candidate.	
Motivated	 by	 these	 findings,	 we	 searched	 for	 different	 scaffolds,	 which	 may	
resemble	the	structural	features	and	the	activity	profile	of	25	toward	the	P2Y14R.	
To	 this	end,	a computational	pipeline	was	 implemented	based	on	a	human	P2Y14R	
homology	 model100	 built	 on	 the	 recently	 reported	 structures	 of	 the	 hP2Y12R,21	 in	
order	to	suggest	alternatives	to	the	hydrophobic	and	bulky	naphthalene	ring	of	25.	
Thus,	 by	 means	 of	 docking	 and	 molecular	 dynamics	 simulations,	 the	 suitable	
alternatives	relied	on	replacing	one	of	the	phenyl	ring	of	naphthalene	core	of	25	with	
groups	able	to	maintain	the	interactions	pattern	with	this	receptor	and	hopefully	to	
improve	the	physiochemical	properties	as	well.	In	particular,	as	shown	in	Figure	9,		
	
	 	
Figure	9.	Design	strategy	to	analogues	of	PPTN	25.	
through	 isosteric	 replacement	 of	 the	 phenyl	 ring	 of	 naphthoic	 acid	 core	 with	 an	
alkyne	and	a	triazole,	we	developed	compounds	148	and	107,	respectively.98	
These	compounds	were	then	evaluated	for	the	binding	profile	at	P2Y14R	using	flow	
cytometry.	 Particularly,	 thanks	 to	 the	 improved	 synthetic	 route	 for	 obtaining	 27,	
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which	provide	a	sufficient	supply	of	this	fluorescent	probe	to	be	use	in	displacement	
assay,	a	novel	flow	cytometry	competition	assay	using	whole	cells	expressing	P2Y14	
receptor	and	fluorescent	antagonist	27	as	a	tracer	was	developed.	The	p-F3C-phenyl-
triazole	 derivative	 (107,	 MRS4217,	 IC50	 =	 32	 nM)	 was	 more	 potent	 than	 a	
corresponding	 alkyne	 148	 and	 was	 further	 selected	 as	 lead	 compound.	 Thus,	
employing	 different	 substituted	 alkynes	 to	 obtain	 the	 triazole	 core	 led	 to	 the	
development	of	a	focused	library	(∼40	members).	The	synthesized	compounds	were	
first	 prioritized	 thanks	 to	 docking	 studies	 and	 then	 assayed	 in	 the	 flow	 cytometry	
competition	 assay	 (Table	 3).	 Interestingly,	 the	 compounds	 that	 at	 3	 μM	 displayed	
inhibition	 of	 >80%	 of	 fluorescent	 PPTN	 analogue	 27	 were	 also	 evaluated	 in	 the	
fluorescent	assay	with	full	concentration-response	curves	(results	not	shown).	With	
these	data	 in	hand,	we	can	conclude	 that	 the	 IC50	values	 for	 the	 selected	 triazoles	
ranged	 from	 31.7	 nM	 (107)	 to	 481	 nM	 (120)	 compared	 to	 the	 IC50	 6.0	 nM	 of	 the	
reference	of	PPTN	antagonist	25;	and	the	potencies	were	in	the	rank	order	of:	25	>	
107	 >	 119	 >	 117	 >	 113,	 124,	 126	 >	 121,	 132,	 112	 >	 120.	 Importantly,	 as	 clearly	
emerged	from	the	SAR	analysis,	P2Y14R	allowed	to	accommodate	 in	 its	binding	site	
compounds	para-substituted	on	the	aromatic	ring	with	hydrophobic	group	(such	as	
121	 contains	 a	 tert-butyl	 group,	 whereas	 117	 presents	 a	 5-bromothiophen-2-yl	
group).	The	only	 compounds	 showing	a	3,4-difluorophenyl	group	 is	derivative	132,	
that	may	give	the	opportunity	of	developing	metabolically	stable	compounds.	
To	 reveal	 unexpected	 interactions	 of	 these	 ligands	with	 numerous	off-target	 sites,	
the	 Psychoactive	 Drug	 Screening	 Program	 (PDSP)	 has	 been	 used	 to	 test	 specific	
interactions	 with	 other	 GPCRs,	 ion	 channels	 and	 a	 transporter	 in	 the	 CNS.	
Interestingly,	both	compounds	25	and	148	showed	only	a	few	off-target	interactions	
at	<10	μM.	In	particular,	the	measured	Ki	values	(μM)	of	25	were	6.79	(D3	dopamine	
receptor)	and	2.75	(δ-opioid	receptor),	whereas	the	Ki	values	(μM)	of	148	were	1.46	
(σ1	 receptor)	 and	 3.60	 (σ2	 receptor).	Notably,	 a	 representative	 triazole	 derivative	
(116)	showed	no	off-target	interactions	at	the	same	concentration.		
Despite	 the	 lack	 of	 information	 about	 the	 P2Y14R	 X-ray	 structure,	 the	 predictive	
power	 of	 the	 P2Y14R	 homology	 model	 herein	 demonstrates	 to	 enable	 GPCR	 drug	
discovery.	 Indeed,	 the	 high	 affinity	 derivatives	 together	with	 the	 lack	 of	 off-target	
interactions	 in	 these	 chemical	 series	 offers	 powerful	 tools	 to	 improve	 our	
understanding	of	P2Y14R	pharmacology	and	potentially	could	lead	to	clinically	useful	
drug	candidates	for	inflammatory	and	endocrine	diseases.	
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Table	3.	Chemical	structures	of	compounds	106-146	and	%	inhibition	of	P2Y14R.	
	
	
	
Compound	
	
R	=	
	
P2Y14R	affinity,	
	
%	 inhibition	at	3	µMa	
25	
	
	
92.6±1.2%	
	
106	
	
	
30.1±2.1%	
	
107	
	
	
92.3±0.5%	
	
108	
	
	
67.2±2.2%	
	
109	
	
	
14.5±2.1%	
	
110	
	
	
21.1±2.9%	
	
111	
	
	
26.5±5.2%	
	
112	
	
	
82.7±1.5%	
	
113	
	
	
88.8±0.8%	
	
114	
	
	
67.3±2.5%	
	
115	
	
	
44.2±1.9%	
	
116	
	
	
66.2±2.0%	
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117	
	
	
93.1±0.8%	
	
118	
	
	
75.1±2.8%	
	
119	
	
	
91.5±0.3%	
	
120	
	
	
87.1±0.5%	
	
121	
	
	
88.9±4.6%	
	
122	
	
	
79.0±2.2%	
	
123	
	
	
39.6±7.4%	
	
124	
	
	
85.2±0.8%	
	
125	 	
	
13.7±3.1%	
	
126	
	
	
86.7±1.0%	
	
127	
	
	
65.3±4.5	
	
128	 	
	
49.9±2.2%	
	
129	
	
	
65.2±1.2%	
	
130	
	
	
37.3±4.6%	
	
131	
	
	
42.2±4.3%	
	
132	
	
	
85.0±0.6%	
	
133	 	
	
76.2±1.7%	
	
134	
	
	
33.4±1.3%	
	
135	
	
	
35.7±0.7%	
	 32	
	
136	
	
	
69.3±3.8%	
	
137	
	
	
33.6±3.5%	
	
138	
	
	
11.6±1.2%	
	
139	 	
	
14.0±5.1%	
	
140	 	
	
13.1±2.6%	
	
141	
	
	
18.1±5.8%	
	
142	
	
	
32.4±2.7%	
	
143	
	
	
73.4±3.1%	
	
144	 	
	
6.0±1.3%	
	
145	 	
	
53.1±2.0%	
	
146	 	
	
50.1±1.9%	
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Experimental	part	
	
Reagents	and	instrumentation.		
The	proton	and	carbon	nuclear	magnetic	resonance	spectra	were	recorded	using	a	
Bruker	400	MHz	NMR	spectrometer.	Purification	of	final	compounds	was	performed	
by	preparative	HPLC	(Column:	Luna	5	µm	C18(2)	100	Å,	LC	Column	250	x	4.6	mm).	
Method	A	Eluent:	 0.1%	TFA	 in	water-CH3CN	 from	100:0	 to	70:30	 in	45	min	with	a	
flow	rate	of	5	mL/min.	Method	B	Eluent:	10	mM	TEAA	buffer-CH3CN	from	80:20	to	
20:80	in	40	min	with	a	flow	rate	of	4	mL/min.	Purities	of	all	tested	compounds	were	
≥95%,	 as	 estimated	 by	 analytical	 HPLC	 (Column:	 Zorbax	 Eclipse	 5	 µm	 XDB-C18	
analytical	column,	150	X	4.6	mm;	Agilent	Technologies,	Inc).	Peaks	were	detected	by	
UV	 absorption	 (254	 nm)	 using	 a	 diode	 array	 detector.	 All	 derivatives	 tested	 for	
biological	 activity	 showed	 >95%	 purity	 in	 the	 HPLC	 systems.	 Analytical	 thin-layer	
chromatography	was	carried	out	on	Sigma-Aldrich®	TLC	plates	and	compounds	were	
visualized	with	UV	 light	at	254	nm.	Silica	gel	 flash	chromatography	was	performed	
using	230-400	mesh	silica	gel.	Unless	noted	otherwise,	 reagents	and	solvents	were	
purchased	 from	 Sigma-Aldrich.	 Low-resolution	 mass	 spectrometry	 was	 performed	
with	 a	 JEOL	 SX102	 spectrometer	with	 6-kV	 Xe	 atoms	 following	 desorption	 from	 a	
glycerol	 matrix	 or	 on	 an	 Agilent	 LC/MS	 1100	 MSD,	 with	 a	 Waters	 (Milford,	 MA)	
Atlantis	 C18	 column.	 High-resolution	 mass	 spectroscopic	 (HRMS)	 measurements	
were	 performed	 on	 a	 proteomics	 optimized	 Q-TOF-2	 (Micromass-Waters)	 using	
external	calibration	with	polyalanine.	
Hex-5-yn-1-yl	 4-methylbenzenesulfonate	 (31).	 To	 a	 solution	 of	 hex-5-yn-1-ol	 30	
(0.84	 mL,	 7.64	 mmol),	 triethylamine	 (1.28	 mL,	 9.17	 mmol),	 and	 4-
(dimethylamino)pyridine	(20	mg,	0.15	mmol)	 in	DCM	(25	mL)	at	0	°C	was	added	p-
toluenesulfonyl	chloride	(1.53	g,	8.02	mmol)	in	three	portions.	The	reaction	mixture	
was	brought	to	r.t.	and	stirred	for	15	h.	Aqueous	NaOH	(1	N,	15	mL)	was	added,	and	
the	mixture	was	vigorously	stirred	for	15	min	at	r.t.	The	usual	workup	(DCM,	brine)	
gave	the	title	compound	(1.68	g,	88%)	as	a	yellowish	oil.	1H	NMR	(400	MHz,	CDCl3)	δ:	
1.42-1.48	(2H,	m),	1.65-1.68	(2H,	m),	1.84	(1H,	J	=	4,	t),	2.05-2.09	(2H,	m),	2.31	(3H,	
s),	3.96	(2H,	J	=	6,	t),	7.26	(2H,	J	=	8.0,	d),	7.69	(2H,	J	=	8.0,	d).	13C	NMR	(100	MHz,	
CDCl3)	δ:	17.7,	21.6,	24.2,	27.7,	69.0,	69.9,	83.4,	127.0,	129.9,	133.0,	144.8.		
6-Bromohex-1-yne	(32).	LiBr	(1.7	g,	19.6	mmol)	was	added	to	a	stirred	solution	of	31	
(1.64	g,	6.52	mmol)	in	dry	DMF	(20	mL).	After	the	exothermic	reaction,	the	mixture	
was	stirred	at	room	temperature	for	24	h.	Then,	water	(25	mL)	was	added	and	the	
aqueous	phase	extracted	with	Et2O	(3	x	25	mL).	The	collected	organic	fractions	were	
dried	over	Na2SO4,	 filtered	and	concentrated	 in	vacuo.	The	residue	was	purified	by	
flash	chromatography	using	as	eluent	Hex:	EtOAc	(5:1)	to	afford	a	colorless	oil	(0.86	
g,	82%).	1H	NMR	(400	MHz,	CDCl3)	δ:	1.66-1.70	(2H,	m),	1.90-1.98	(3H,	m),	2.24	(2H,	
m),	3.59	 (2H,	 J	=	6.4,	 t).	13C	NMR	(100	MHz,	CDCl3)	δ:	19.7,	29.4,	29.7,	45.6,	69.2,	
83.8.	
6-Bromohexan-1-amine	hydrochloride	 (34).	6-Aminohexanol	33	 (0.5	g,	4.27	mmol)	
was	slowly	added	to	a	stirring	48%	hydrogen	bromide	solution	(5.1	mL)	at	0	°C	and	
the	resulting	mixture	was	stirred	at	80	°C	for	20	h.	The	mixture	was	neutralized	by	
adding	 NaOH	 2N	 (20	 mL)	 and	 extracted	 with	 EtOAc	 (3	 x	 20	 mL).	 The	 combined	
organic	fraction	was	washed	with	water	(50	mL)	followed	by	brine	(50	mL)	and	then	
dried	over	Na2SO4,	filtered	and	concentrated	in	vacuo.	The	obtained	viscous	oil	was	
then	dissolved	in	4M	hydrogen	chloride	solution	in	dioxane	to	give	a	sticky	solid	that	
is	washed	with	Et2O	and	then	filtered	for	affording	to	a	yellowish	solid	(0.55	g,	61%).	
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1H	NMR	(400	MHz,	MeOD)	δ:	1.42–1.46	(4H,	m),	1.59–1.70	(2H,	m),	1.74–1.82	(2H,	
m),	2.86	(2H,	J	=	8,	t),	3.39	(2H,	J	=	4,	t).	13C	NMR	(100	MHz,	MeOD)	δ:	25.2,	27.0,	
27.2,	32.2,	32.8,	44.2.		
6-Azidohexan-1-amine	(35).	To	a	solution	of	34	(0.55	g,	2.54	mmol)	in	water	(25	mL),	
NaN3	(0.49	g,	7.69	mmol)	was	added	and	the	resulting	mixture	was	heated	at	100°C	
for	 12	 h.	 After	 cooling,	 37%	 ammonia	 solution	 was	 added	 until	 a	 basic	 pH	 was	
reached,	and	 the	aqueous	phase	was	extracted	with	Et2O	 (3	x	20	mL).	The	organic	
fractions	were	 collected,	 dried	over	Na2SO4	 and	 filtered,	 and	 the	 solvent	 removed	
under	vacuum	to	give	a	yellow	oil	(0.29	g,	80%).	1H	NMR	(400	MHz,	CDCl3)	δ:	1.29–
1.34	(4H,	m),	1.35–1.40	(2H,	m),	1.50–1.54	(2H,	m),	2.15	(2H,	br	s),	2.62	(2H,	J	=	4,	t),	
3.18	(2H,	J	=	8.0,	t).	13C	NMR	(100	MHz,	CDCl3)	δ:	26.4,	26.6,	28.8,	33.1,	41.8,	51.4	
Ethyl	 4-(4-(piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-naphthoate	 (36).	
To	a	solution	of	25	 (0.50	g,	1.57	mmol)	 in	EtOH	(50	mL),	thionyl	chloride	(1.37	mL,	
18.84	mmol)	was	carefully	added	over	30	min	at	0°C.	The	 reaction	was	allowed	to	
warm	up	at	rt	and	stirred	overnight.	The	resulting	mixture	was	quenched	by	adding	
5%	solution	NaOH	(25	mL)	until	basic	pH.	Then,	 the	solvent	was	evaporated	under	
vacuum	and	 the	 aqueous	 residue	 extracted	with	 EtOAc	 (3	 x	 20	mL).	 The	 collected	
organic	 fractions	were	 dried	 over	Na2SO4,	 filtered	 and	 the	 solvent	 removed	under	
reduced	 pressure.	 The	 residue	 was	 purified	 by	 chromatography	 using	 as	 eluent	
DCM/MeOH/NH4OH	 (7:	 3:	 0.3).	 The	 title	 compound	was	 obtained	 as	 a	white	 solid	
(0.61	g,	78%).	1H	NMR	(400	MHz,	MeOD)	δ:	1.35	(3H,	J	=	4	Hz,	t),	1.65-1.69	(2H,	m),	
1.81-1.84	(2H,	m),	2.73-2.79	(3H,	m),	3.15-3.19	(2H,	m),	4.35	(2H,	J	=	8	Hz,	q),	7.33-
7.37	(4H,	m),	7.69	(2H,	J	=	8	Hz,	d),	7.76-7.79	(1H,	m),	7.83-7.90	(4H,	m),	8.26	(1H,	s),	
8.58	 (1H,	 s).	m/z	 (ESI,	MH+)	504;	ESI-HRMS	 (MH+)	 calcd.	 for	C31H29F3NO2	504.2150,	
found	504.2150.	
Ethyl	4-(4-(1-(hex-5-yn-1-yl)piperidin-4-yl)phenyl)-7-(4-(trifluoromethyl)phenyl)-2-
naphthoate	 (37).	 K2CO3	 (0.12	 g,	 0.9	mmol)	was	 added	 to	 a	 stirring	 solution	 of	36	
(0.15	g,	0.3	mmol)	 in	dry	DMF	(15	mL)	and	the	resulting	mixture	left	stirring	for	20	
min.	 Compound	 32	 (0.06	 g,	 0.6	 mmol)	 was	 subsequently	 added	 and	 the	 reaction	
mixture	was	firstly	stirred	at	rt	for	2h	and	then	at	50°C	for	2.5h.	After	cooling	at	rt,	
NaHCO3	 saturated	 solution	 (15	 mL)	 was	 added	 and	 the	 aqueous	 phase	 extracted	
with	 EtOAc	 (3	 x	 20	 mL).	 The	 collected	 organic	 fractions	 were	 dried	 over	 Na2SO4,	
filtered	and	the	solvent	removed	under	reduced	pressure.	The	residue	was	purified	
by	chromatography	using	as	eluent	DCM/MeOH/NH4OH	(9.5:	0.5:	0.05).	The	desired	
compound	was	 obtained	 as	 a	 colorless	 oil	 (0.16	 g,	 92%).	m/z	 1H	NMR	 (400	MHz,	
CDCl3)	δ:	1.38	(3H,	J	=	4	Hz,	t),	1.51-1.55	(2H,	m),	1.65-1.69	(2H,	m),	1.90-1.99	(4H,	
m),	2.06-2.17	(5H,	m),	2.40-2.44	(2H,	m),	2.56-2.59	(1H,	m),	3.10-3.13	(2H,	m),	4.38	
(2H,	J	=	8	Hz,	q),	7.33	(2H,	J	=	8	Hz,	d),	7.38	(2H,	J	=	8	Hz,	d),	7.67-7.70	(3H,	m),	7.71-
7.76	(2H,	m),	7.91-7.95	(2H,	m),	8.15	(1H,	s),	8.60	(1H,	s)	 (ESI,	MH+)	584.	13C	NMR	
(101	MHz,	 CDCl3)	 δ	 14.42,	 18.35,	 25.69,	 25.77,	 26.49,	 29.71,	 32.99,	 42.33,	 54.27,	
58.31,	61.26,	68.58,	84.31,	125.89,	126.65,	126.99,	127.11,	127.44,	127.94,	128.03,	
129.55,	130.07,	130.61,	133.30,	137.61,	140.47,	143.91,	166.56.	(ESI,	MH+)	584;	ESI-
HRMS	(MH+)	calcd.	for	C37H37F3NO2	584.2783,	found	584.2776	
Ethyl	4-(4-(1-(4-(1-(6-aminohexyl)-1H-1,2,3-triazol-4-yl)butyl)piperidin-4-yl)phenyl)-
7-(4-(trifluoromethyl)phenyl)-2-naphthoate	 (38).	 To	 a	 solution	 of	37	 (50	mg,	 0.09	
mmol)	 in	DCM:	 t-BuOH:	H2O	 (1:1:1)	 (2	mL),	 compound	35	was	added,	 followed	by	
copper	 (II)	 sulfate	 pentahydrate	 (15	mol%)	 and	 sodium	 ascorbate	 (45	mol%).	 The	
reaction	mixture	was	stirred	for	24h	at	rt.	The	solvents	were	removed	under	vacuum	
and	the	residue	rinsed	with	37%	ammonia	solution	(5	mL)	and	extracted	with	EtOAc	
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(3	x	8	mL).	The	collected	organic	fractions	were	dried	over	Na2SO4,	filtered	and	the	
solvent	 removed	 under	 reduced	 pressure.	 The	 residue	 was	 purified	 by	
chromatography	 using	 as	 eluent	 a	 gradient	 of	 DCM/MeOH/NH4OH	 (from	 9.5:	 0.5:	
0.05	to	7:	3:	0.3).	The	title	product	was	obtained	as	a	white	solid	 (32	mg,	51%).1H	
NMR	 (400	MHz,	 CDCl3)	 δ:	 1.35-1.39	 (7H,	m),	 1.58-1.65	 (6H,	m),	 1.83-1.88	 (6H,	m),	
2.04-2.07	(2H,	m),	2.39-2.42	(3H,	m),	2.65-2.71	(6H,	m)	3.09-3.17	(2H,	m),	4.23-4.26	
(2H,	m),	4.38	(2H,	J	=	8	Hz,	q),7.21-7.23	(1H,	m),	7.30-7.33	(2H,	m),	7.38-7.40	(2H,	m),	
7.66-7.70	(3H,	m),	7.73-7.76	(2H,	m),	7.96-7.99	(2H,	m),	8.15	(1H,	s),	8.62	(1H,	s).(ESI,	
MH+)	726;	ESI-HRMS	(MH+)	calcd.	for	C43H51F3N5O2	726.3984,	found	726.3995.	
4-(4-(1-(4-(1-(6-Aminohexyl)-1H-1,2,3-triazol-4-yl)butyl)piperidin-4-yl)phenyl)-7-(4-
(trifluoromethyl)phenyl)-2-naphthoic	acid	(39).	To	a	solution	of	38	(32	mg,	44	µmol)	
in	MeOH	(1	mL),	a	solution	of	0.5	M	LiOH	(1	mL)	was	added	and	the	resulting	mixture	
was	 heated	 at	 60°C	 and	 stirred	 overnight.	 After	 cooling,	 the	 solvents	 were	
evaporated	 and	 the	 residue	 purified	 by	 preparative	 HPLC	 (Rt	 =	 31.08	 min).	 The	
product	was	obtained	as	a	white	solid	by	freeze	drying	(6.5	mg,	21%).1H	NMR	(400	
MHz,	MeOD)	δ:	 1.26-1.33	 (4H,	m),	 1.52-1.64	 (6H,	m),	 1.81-1.86	 (6H,	m),	 2.19-2.25	
(2H,	m),	2.46-2.50	(2H,	m),	2.66-2.70	(3H,	m),	2.79	(2H,	J	=	8	Hz,	t),	3.09-3.12	(2H,	m),	
4.30	(2H,	J	=	8	Hz,	t),	7.32	(2H,	J	=	8	Hz,	d),	7.38	(2H,	J	=	8	Hz,	d),	7.66-7.70	(3H,	m),	
7.70-7.72	(4H,	m),	7.89-7.94	(4H,	m),	8.27	 (1H,	s),	8.49	 (1H,	s).	 (ESI,	MH+)	698;	ESI-
HRMS	(MH+)	calcd.	for	C41H47F3N5O2	698.3690,	found	698.3682.	
6-Amino-9-(2-carboxy-4-((6-(4-(4-(4-(4-(3-carboxy-6-(4-(trifluoromethyl)phenyl)-
naphthalen-1-yl)phenyl)piperidin-1-yl)butyl)-1H-1,2,3-triazol-1-
yl)hexyl)carbamoyl)-phenyl)-3-iminio-5-sulfo-3H-xanthene-4-sulfonate	 (27).	 To	 a	
solution	of	AlexaFluor	488	40	 (4.44	mg,	7.08	µmol)	and	N,N-diisopropylethylamine	
(1.34	µL,	7.72	µmol)	in	dry	DMF	(400	µL),	TSTU	(2.42	mg,	7.72	µmol)	was	added	at	0	
°C.	The	resulting	mixture	was	allowed	to	warm	up	at	rt	and	stirred	for	2-3	h.	Then,	a	
solution	 of	 39	 (4.5	 mg,	 6.44	 µmol)	 and	 N,N-diisopropylethylamine	 (1.30	 µL,	 7.08	
µmol)	in	dry	DMF	(300	µL)	was	added,	and	the	reaction	was	stirred	overnight	at	r.t.	
After	removal	of	the	solvent,	the	residue	was	purified	by	preparative	HPLC	(Method	
A,	Rt	=	24.9	min).	The	product	27	was	obtained	as	an	orange	solid	after	lyophilization	
(0.8	mg,	10	%).	MS	(ESI,	m/z)	1212	[M-H]-;	ESI-HRMS	calcd.	m/z	for	C62H57F3N2O12S2	
1212.3462,	found	1212.3459	[M-H]-.	HPLC	purity	96.1%	(Rt	=	5.7	min).	
6-amino-9-(2-carboxy-4-((6-(4-(4-(4-(4-(3-(ethoxycarbonyl)-6-(4-
(trifluoromethyl)phenyl)naphthalen-1-yl)phenyl)piperidin-1-yl)butyl)-1H-1,2,3-
triazol-1-yl)hexyl)carbamoyl)phenyl)-3-iminio-5-sulfo-3H-xanthene-4-sulfonate.	
To	 a	 solution	 of	 AlexaFluor	 488	 40	 (1.2	 mg,	 1.93	 µmol)	 and	 N,N-
diisopropylethylamine	 (0.4	µL,	2.12	µmol)	 in	dry	DMF	(100	µL),	TSTU	(0.7	mg,	2.12	
µmol)	was	added	at	0	 °C.	The	resulting	mixture	was	allowed	to	warm	up	at	 rt	and	
stirred	 for	 30	 min.	 Then,	 a	 solution	 of	 38	 (1.2	 mg,	 1.6	 µmol)	 and	 N,N-
diisopropylethylamine	(0.4	µL,	2.12	µmol)	 in	dry	DMF	(100	µL)	was	added,	and	the	
reaction	was	monitored	by	LC/MS,	showing	only	traces	of	desired	compound	after	5	
h.	
	
Preparation	of	44	(MRS4183):		
Uridine	5ʹ-diphosphoglucuronic	 acid	 trisodium	 salt	 (8.9	mg,	 13.8	µmol)	was	
stirred	in	dry	DMF	(300	µL)	with	ice	cooling	before	the	sequential	addition	of	DIPEA	
(9.3	 µL,	 9.2	 µmol)	 and	 (1-cyano-2-ethoxy-2-oxoethylidenaminooxy)dimethylamino-
morpholino-carbenium	hexafluorophosphate	 (COMU,	 Sigma	Aldrich,	 St.	 Louis,	MO,	
5.9	mg,	 13.8	 µmol).	 After	 20	min,	 a	 solution	 of	 5-(((4-(4,4-difluoro-5-(2-thienyl)-4-
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bora-3a,4a-diaza-s-indacene-3-yl)phenoxy)acetyl)amino)-pentylamine,	hydrochloride	
(BODIPY	 TR	 cadaverine,	 Life	 Technologies,	 Grand	 Island,	 NY,	 5	mg,	 9.2	 µmol)	 and	
DIPEA	(9.3	µL,	9.2	µmol)	in	dry	DMF	(300	µL)	was	added.	The	resulting	mixture	was	
allowed	to	warm	up	and	stirring	continued	at	room	temperature	for	6	h	in	the	dark.	
After	 evaporation	 of	 the	 solvent	 under	 vacuum,	 the	 residue	 was	 purified	 by	
preparative	 HPLC	 (Column:	 Luna®	 5	 µm	 C18(2)	 100	 Å,	 LC	 Column	 250	 x	 4.6	 mm,	
Phenomenex,	 Inc.,	Torrance,	CA);	Eluent:	10	mM	TEAA	buffer-CH3CN	from	90:10	to	
40:60	in	35	min	and	then	from	40:60	to	30:70	in	5	min	with	a	flow	rate	of	5	mL/min.,	
Rt	33.7	min).	The	product	11	was	obtained	after	 lyophilization	as	a	dark	blue	solid	
(di-triethylammonium	salt,	35	µg,	determined	using	the	extinction	coefficient	at	590	
nm	 of	 64,000,	 0.3%	 yield).	 ESI-HRMS	 (M+H+)-	 calcd.	 for	 C41H46BF2N6O19P2S2-	
1069.2078,	 found	 C41H46BF2N6O19P2S2-	 1069.2075;	 HPLC	 purity	 (Column:	 Zorbax	
Eclipse	5	µm	XDB-C18	analytical	column,	150	X	4.6	mm,	Agilent	Technologies,	Santa	
Clara,	CA);	Eluent:	10	mM	TEAA	buffer-CH3CN	from	80:20	to	40:60	in	15	min	with	a	
flow	rate	of	1	mL/min,	retention	time	5.6	min)	was	determined	to	be	95.7%.		
	
Smiles	notation	for	44	(MRS4183):		
O[C@@H]1[C@H](O)[C@@H](COP(OP(O)(O[C@H]2O[C@H](C(NCCCCCNC(COC3=CC=C(C=C3)C4=[N+]
5[B](F)(F)N6C(C7=CC=CS7)=CC=C6C=C5C=C4)=O)=O)[C@@H](O)[C@H](O)[C@H]2O)=O)(O)=O)O[C@H
]1N(C=CC(N8)=O)C8=O	
	
Methyl	 3-amino-5-bromobenzoate	 (46).	3-Bromo-5-aminobenzoic	 acid	45	 (1.0	 g,	
4.62	mmol)	was	 stirred	 in	methanol	 (15	mL)	with	 ice	 cooling	 before	 addition	 of	
thionyl	chloride	(4.00	mL,	55.0	mmol)	dropwise	over	20’.	The	resulting	mixture	was	
allowed	 to	 warm	 up	 at	 r.t.	 and	 left	 stirring	 overnight.	 The	 solvent	 was	 then	
removed	under	vacuum	and	the	residue	was	suspended	in	ethyl	acetate	(200	mL),	
before	washing	with	0.2M	NaOH	(2×100	mL)	and	brine	(100	mL),	drying	(Na2SO4)	
and	concentrating	to	afford	the	title	compound	as	a	white	solid	(1.08	g,	98%).	1H	
NMR	(400	MHz,	CDCl3)	δ:	3.85	(2H,	br	s),	3.90	(3H,	s),	7.00	(1H,	s),	7.27	(1H,	s),	7.53	
(1H,	 s).	 13C	 NMR	 (100	 MHz,	 CDCl3)	 δ:	 52.3,	 114.6,	 121.6,	 122.3,	 122.9,	 132.6,	
147.7,	166.0.	m/z	(ESI,	MH+)	231.	
Methyl	 3-bromo-5-((tert-butoxycarbonyl)amino)benzoate	 (47a).	 To	 a	 solution	 of	
46	 (0.85	 g,	 3.7	mmol)	 and	 trimethylamine	 (1.87	mL,	 11.1	mmol)	 in	 DCM	 (35	mL),	
Boc2O	 (0.97	g,	 4.44	mmol)	 and	DMAP	 (0.37	g,	 3.7	mmol)	were	 sequentially	 added	
with	ice	cooling	bath.	The	resulting	mixture	was	allowed	to	warm	up	at	r.t.	and	left	
stirring	 overnight.	 The	 solvent	 was	 removed	 under	 reduced	 pressure	 and	 the	
resulting	 residue	 was	 purified	 by	 silica	 gel	 chromatography	 using	 as	 eleuent	
Hex/EtOAc	 (8:	 2)	 to	 afford	 the	 title	 compound	 as	 a	 yellow	 solid	 (0.96	 g,	 70%).	 1H	
NMR	(400	MHz,	MeOD)	δ:	1.45	 (9H,	s),	3.83	 (3H,	s),	7.64	 (1H,	s),	7.84	 (1H,	s),	7.93	
(1H,	s).	13C	NMR	(100	MHz,	MeOD)	δ:	27.2,	51.5,	117.5,	121.9,	124.7,	125.4,	132.1,	
141.3,	153.3,	165.6.	m/z	(ESI,	MH+)	331.	
Methyl	 3-((tert-butoxycarbonyl)amino)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-
2-	yl)benzoate	 (48).	 A	 solution	 of	 47a	 (0.25	g,	0.76	mmol),	bis(pinacolato)diboron	
(0.21	g,	0.84	mmol),	KOAc	(0.21	g,	2.20	mmol)	in	dry	DMF	(8	mL)	was	degassed	with	
N2	 for	 30’.	 Then,	 PdCl2(dppf)	 (0.06	 g,	 0.1	 mmol)	 was	 added	 while	 continuing	
degassing	for	additional	5’.	The	reaction	mixture	was	heated	at	95	⁰C	and	left	stirring	
overnight.	After	 cooling	down,	 the	 resulting	mixture	was	diluted	with	H2O	 (15	mL)	
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and	extracted	with	EtOAc	(3x15	mL).	The	organic	fractions	were	collected,	dried	over	
Na2SO4	 and	 filtered.	 The	 solvent	 was	 removed	 under	 reduced	 pressure	 to	 give	 a	
brown	residue	which	was	purified	by	silica	gel	chromatography	using	a	gradient	of	
Hex:	EtOAc	(from	90:	10	to	50:	50).	The	title	compound	was	obtained	as	a	white	solid	
(0.16	g,	56%).	1H	NMR	(400	MHz,	CDCl3)	δ:	1.25	(12H,	s),	1.44	(9H,	s),	3.82	(3H,	s),	
6.57	(1H,	br	s),	7.85	(1H,	s),	8.05	(1H,	s),	8.06	(1H,	s).	13C	NMR	(100	MHz,	CDCl3)	δ:	
24.9,	28.3,	52.1,	84.1,	122.2,	128.9,	130.0,	138.2,	152.6,	166.9.	m/z	(ESI,	MH+)	378.	
4-(4-Bromophenyl)-1,2,3,6-tetrahydropyridine	 (50).	4-(4-Bromophenyl)piperidin-4-
ol	49	 (1.0	g,	3.90	mmol)	was	carefully	added	to	CF3COOH	(2.99	mL,	39	mmol)	and	
the	resulting	mixture	was	heated	at	90	⁰C	for	3	h.	After	cooling	down,	the	solvent	
was	removed	under	vacuum	to	give	the	title	product	as	a	white	solid	(0.90	g,	97%).	
1H	NMR	(400	MHz,	MeOD)	δ:	2.68-2.72	(2H,	m),	3.38	(2H,	t,	J	=	6.1),	3.76-3.77	(2H,	
m),	 6.10	 (1H,	 s),	 7.31	 (2H,	 J	 =	 8.0,	 d),	 7.44	 (2H,	 J	 =	 8.0,	 d).	 13C	 NMR	 (100	MHz,	
MeOD)	δ:	23.3,	40.7,	42.0,	116.4,	121.7,	126.6,	131.4,	134.6,	138.1.	m/z	(ESI,	MH+)	
239.	
4-(4-Bromophenyl)piperidine	 (51).	 To	 a	 solution	 of	 4-(4-bromophenyl)-1,2,3,6-	
tetrahydropyridine	 50	 (0.90	 g,	 3.78	 mmol)	 in	 dry	 MeOH	 (20	 mL)	 was	 added	 a	
spatula	 of	 Rh/C	 catalyst.	 The	 resulting	 reaction	 mixture	 was	 stirred	 at	 r.t.	 in	 a	
hydrogen	atmosphere	(100	psi)	for	17	h.	The	mixture	was	filtered	through	a	cake	of	
celite	and	the	filtrate	was	concentrated	to	give	the	title	compound	as	a	pale	yellow	
solid	(0.91	g,	98%).	1H	NMR	(400	MHz,	MeOD)	δ:	1.55-1.59	(2H,	m),	1.61-1.70	(2H,	
m),	2.55-2.56	(1H,	m),	2.64-2.70	(2H,	m),	3.09-3.06	(2H,	m),	7.13	(2H,	J	=	8.0,	d),	7.31	
(2H,	J	=	8.0,	d).	13C	NMR	(100	MHz,	MeOD)	δ:	32.7,	41.4,	45.6,	119.4,	126.4,	128.2,	
128.5,	131.2,	145.3.	m/z	(ESI,	MH+)	241.	
Methyl	 5-((tert-butoxycarbonyl)amino)-4'-(piperidin-4-yl)-[1,1'-biphenyl]-3-
carboxylate	(52).	A	solution	of	52	(0.11	g,	0.29	mmol),	48	(0.09	g,	0.32	mmol),	K2CO3	
(0.12	 g,	 0.87	 mmol)	 in	 dry	 DMF	 (4.5	 mL)	 was	 degassed	 with	 N2	 for	 30’.	 Then,	
Pd(Ph3P)4	(0.017	g,	0.015	mmol)	was	added	to	the	resulting	mixture	while	flushing	N2	
for	additional	5’.	The	reaction	was	heated	at	85⁰C	for	6	h.	after	cooling	down,	H2O	
(10	mL)	was	added	and	 the	aqueous	phase	was	extracted	with	EtOAc	 (3	x	15	mL).	
The	collected	organic	fractions	were	dried	over	Na2SO4,	filtered	and	the	solvent	was	
removed	 under	 reduced	 pressure.	 The	 residue	 was	 purified	 by	 silica	 gel	
chromatography	using	a	 gradient	of	DCM:	MeOH:	NH4OH	 (from	9:	 10:	 0.1	 to	8:	 2:	
0.2)	to	afford	to	the	title	compound	as	a	yellowish	solid	(0.07	g,	71%).	1H	NMR	(400	
MHz,	CDCl3)	δ:	1.47	(9H,	s),	1.85-1.90	(4H,	m),	2.65-2.68	(1H,	m),	2.78-2.83	(2H,	m),	
3.28-3.37	(2H,	m),	3.85	(3H,	s),	6.67	(1H,	br	s),	7.04-7.06	(1H,	m),	7.24	(2H,	J	=	8,	d),	
7.52	(2H,	J	=	8,	d),	7.84	(2H,	m).	13C	NMR	(100	MHz,	CDCl3)	δ:	28.4,	29.7,	33.8,	42.3,	
42.7,	46.7,	52.2,	61.1,	118.0,	122.6,	126.2,	126.8,	127.3,	128.4,	128.6,	131.5	137.9,	
139.3,	142.1,	146.0,	152.8,	166.9.	m/z	(ESI,	MH+)	411.	
Methyl	 5-((tert-butoxycarbonyl)amino)-4'-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-
[1,1'-biphenyl]-3-carboxylate	(53).	To	a	suspension	of	52	(0.04	g,	0.11	mmol)	in	THF	
(2.5	mL),	NEt3	(45	µL,	0.32	mmol)	and	TFAA	(22	µL,	0.16	mmol)	were	added	and	the	
resulting	mixture	was	 stirred	 for	 3	 h.	 A	 saturated	 solution	 of	 NaHCO3	 (2	mL)	 was	
gradually	added	and	then	the	organic	solvent	was	removed	under	reduced	pressure.	
The	 aqueous	 layer	 was	 extracted	 with	 DCM	 (3	 x	 5	 mL).	 The	 collected	 organic	
fractions	 were	 dried	 over	 Na2SO4,	 filtered	 and	 the	 solvent	 was	 removed	 under	
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reduced	pressure	to	give	a	yellow	oil	that	is	used	in	the	next	step	without	any	further	
purification.	m/z	(ESI,	MH+)	507.	
Methyl	5-amino-4'-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1'-biphenyl]-3-	
carboxylate	 (54).	 To	a	 solution	of	53	 (0.06	g,	0.11	mmol)	in	DCM	(2	mL),	TFA	(170	
µL,	 2.28	 mmol)	 was	 added	 and	 the	 resulting	 mixture	 was	 stirred	 overnight.	 A	
saturated	solution	of	NaHCO3	(2	mL)	was	gradually	added	and	the	aqueous	layer	was	
extracted	 with	 DCM	 (3	 x	 5	 mL).	 The	 collected	 organic	 fractions	 were	 dried	 over	
Na2SO4,	filtered	and	the	solvent	was	removed	under	reduced	pressure.	The	residue	
was	purified	by	silica	gel	chromatography	with	40%	of	EtOAc	in	Hex	to	give	a	yellow	
oil	 (0.27	 g,	 65%).	 (ESI,	MH+)	 407.	 1H	NMR	 (400	MHz,	 CDCl3)	 δ:	 1.63-1.72	 (2H,	m),	
1.93-1.97	(1H,	m),	2.78-2.83	(2H,	m),	3.16-3.22	(1H,	m),	3.81	(3H,	s),	6.99	(1H,	s),	7.1-
7.20	(2H,	m),	7.27	(1H,	s),	7.47	(2H,	J	=	8,	d),	7.58	(1H,	s).	13C	NMR	(100	MHz,	CDCl3)	
δ:	32.6,	33.6,	42.1,	44.2,	46.4,	52.1,	61.0,	76.7,	77.0,	77.3,	114.8,	117.8,	118.7,	127.1,	
127.4,	131.6,	138.9,	142.1,	143.7,	146.7,	167.1.		
Methyl	 5-azido-4'-(1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-[1,1'-biphenyl]-3-
carboxylate	(55).	To	a	solution	of	54	(0.121	g,	0.29	mmol)	in	a	3:7	mixture	of	H2O	
and	acetonitrile	(10	mL),	p-toluenesulfonic	acid	(0.509	g,	2.6	mmol)	was	added,	and	
the	mixture	was	stirred	for	5	min.	NaNO2	(0.184	g,	2.6	mmol)	was	then	added,	and	
the	yellow	solution	was	stirred	at	room	temperature.	 The	 course	 of	 the	 reaction	
was	 followed	 by	 TLC	 (hexane:	 ethyl	 acetate	 =60:40),	 and	 the	 reaction	 was	
allowed	 to	 continue	 until	 the	 starting	 material	 disappeared.	 NaN3	 (0.030	 g,	
0.47	 mmol)	 was	 added	 at	 room	 temperature,	 and	 the	 reaction	 mixture	 was	
stirred	 overnight.	 Et2O	was	 added,	 and	 the	 phases	were	 separated.	 The	 organic	
phase	 was	 dried	 over	 Na2SO4,	 filtered	 and	 concentrated	 under	 reduced	
pressure	 to	 give	 an	 orange	 oil	 that	 was	 purified	 by	 silica	 gel	 chromatography	
using	 as	 eluent	 hexane	 :	 ethyl	 acetate	 (70:30)	 to	 afford	 the	 title	 compound	as	 a	
yellow	oil	 (0.11	g,	83%).	1H	NMR	(400	MHz,	CDCl3):	δ	(ppm)	=	8.03	(t,	 J	=	1.6	Hz,	
1H),	7.68	(t,	J=	1.6	Hz,	1H),	7.56	(d,	J	=	8.3	Hz,	2H),	7.37	(t,	J	=	1.6	Hz,	1H),	7.30	(d,	J	
=	 8.3	 Hz,	 2H),	 4.80	 –	 4.63	 (m,	 1H),	 4.17	 (dd,	 J	 =	 3.1,	 14.2	 Hz,	 1H),	 3.96	 (s,	 3H),	
3.27	(td,	J	=	2.4,	13.3,	13.7	Hz,	1H),	2.90	(td,	J	=	4.2,	12.5	Hz,	2H),	2.02	(d,	J	=	14.2	
Hz,	2H),	1.76	(qd,	J	=	4.2,	12.5	Hz,	2H).	13C	NMR	(100	MHz,	CDCl3):	δ	(ppm)	=	166.6,	
155.9	 ,	144.9	 ,	143.2	 ,	141.5	 ,	138.1	 ,	132.7	 ,	127.8	 ,	125.1	 ,	122.1	 ,	118.7	 ,	52.9	 ,	
46.8	,	44.6	,	42.5	,	34.0	,	33.0.	
General	procedure	for	the	click	cycloaddition	reaction:	
To	a	solution	of	aryl	azide	55,	1	eq)	and	aryl	alkyne	(1.5	eq)	in	2	mL	of	THF:	water	
(1:1),	 sodium	ascorbate	 (freshly	 prepared	1	M	aqueous	 solution)	 and	CuSO4	 (0.5	
eq)	were	sequentially	added.	The	resulting	reaction	was	vigorously	stirred	for	12	h	
at	r.t.	The	reaction	mixture	was	then	concentrated	 in	vacuo	and	purified	by	 flash	
chromatography	(hexane:	ethyl	acetate	=	6	:	4).	
Methyl	 5-(4-phenyl-1H-1,2,3-triazol-1-yl)-4'-(1-(2,2,2-trifluoroacetyl)piperidin-4-
yl)-	[1,1'-biphenyl]-3-carboxylate	(56).	Yellow	solid.	MS	(ESI,	m/z)	535	[M+H]+;	ESI-
HRMS	calcd.	for	C29H26F3N4O3	535.1952,	found	535.1957	[M+H]
+.	
Methyl	 5-(4-(4-(trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4'-(1-(2,2,2-	
trifluoroacetyl)piperidin-4-yl)-	 [1,1'-biphenyl]-3-carboxylate	 (57).	 Orange	 solid	
6.9	 mg	 (99	 %).	 MS	 (ESI,	 m/z)	 603	 [M+H]	 +;	 ESI-HRMS	 calcd.	 for	 C30H25F6N4O3	
603.1825,	 found	603.1831	[M+H]	+.	
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Methyl	 5-(4-(5-chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4'-(1-(2,2,2-
trifluoroacetyl)-	 piperidin-4-yl)-[1,1'-biphenyl]-3-carboxylate	 (95).	 Brown	 solid.		
MS	 (ESI,	 m/z)	 575	 [M+H]	+;	 ESI-HRMS	 calcd.	 for	 C27H23F3N4O3SCl	 575.1131,	 found	
575.1132	[M+H]	+.	
Methyl	 5-(4-cyclohexyl-1H-1,2,3-triazol-1-yl)-4'-(1-(2,2,2-trifluoroacetyl)piperidin-
4-yl)-	[1,1'-biphenyl]-3-carboxylate	(62).	Yellow	solid	5.4	mg	(87	%).	MS	(ESI,	m/z)	
541.2	[M+H]	+;	ESI-HRMS	calcd.	for	C29H32F3N4O3	541.2427,	found	541.2419	[M+H]
+.	
5-(4-Phenyl-1H-1,2,3-triazol-1-yl)-4'-(piperidin-4-yl)-[1,1'-biphenyl]-3-carboxylic	
acid	(106).	To	a	solution	of	56	 (9	mg,	17	µmol)	in	2	mL	of	MeOH:	H2O	(1:1),	KOH	
(9.5	mg,	170	µmol)	was	added,	and	the	resulting	mixture	was	heated	at	50	°C	for	
12	 h.	 After	 removing	 the	 solvents	 under	 reduced	 pressure,	 the	 mixture	 was	
purified	 by	 preparative	 HPLC	 (Method	 B,	 Rt	 =	 25.7	 min).	 The	 product	 was	
obtained	 as	 a	 white	 solid	 by	 lyophilization	 (1.9	 mg,	 26	 %).	 MS	 (ESI,	 m/z)	 425	
[M+H]	+;	 ESI-HRMS	calcd.	 for	C26H25N4O2	 425.1978,	 found	425.1980	[M+H]
+.	HPLC	
purity	97	%	(Rt	=	8.9	min).	1H	NMR	(400	MHz,	MeOD):	δ	(ppm)	=	8.94	(s,	1H),	8.29	
(d,	 J	=	8	Hz,	2H),	7.88	 (d,	 J	=	8	Hz,	2H),	7.68	 (d,	 J	=	8	Hz,	2H),	7.39-7.43	 (m,	2H),	
7.31-7.35	(m,	3H),	2.90-2.96	(m,	5H),	1.94-1.97	(m,	2H),	1.77-1.80	(m,	2H).	
5-(4-(4-(Trifluoromethyl)phenyl)-1H-1,2,3-triazol-1-yl)-4'-(piperidin-4	 yl)-[1,1'-
biphenyl]-3-carboxylic	acid	 (107).	To	a	solution	of	57	 (6.3	mg,	10	µmol)	in	2	mL	of	
MeOH:	H2O	 (1:1),	 KOH	 (5.6	mg,	 100	 µmol)	was	 added,	 and	 the	 resulting	mixture	
was	heated	at	50°C	for	12	h.	After	removing	the	solvents	under	reduced	pressure,	
the	 mixture	 was	 purified	 by	 preparative	 HPLC	 (Method	 B,	 Rt	 =	 30.2	 min).	 The	
product	 was	 obtained	 as	 a	 white	 salt	 by	 lyophilization	 (0.5	 eq	CH3CO2H-salt,	 6.01	
mg,	99	%).	MS	(ESI,	m/z)	493.1	[M+H]+;	ESI-	HRMS	calcd.	for	C27H24F3N4O2	493.1851,	
found	 493.1853	 [M+H]+.	 HPLC	 purity	 99	 %	 (Rt	 =12.6	 min).	 1H	 NMR	 (600	 MHz,	
DMSO-d6):	δ	 (ppm)	=	9.66	 (s,	1H),	8.39	 (t,	 J	=	1.6	Hz,	1H),	8.28	 (t,	 J	=	1.6	Hz,	1H),	
8.22	(d,	J	=	8.1	Hz,	2H),	8.15	(t,	J	=	1.6	Hz,	1H),	7.88	(d,	J	=	8.1	Hz,	2H),	7.75	(d,	J	=	8.3	
Hz,	2H),	7.41	(d,	J	=	8.3	Hz,	2H),	3.20	–	3.15	(m,	2H),	2.76	(td,	J	=	3.2,	12.1	Hz,	 3H),	
1.88	 (s,	 1.5	 Hacetate),	 1.77	 (qd,	 J	 =	 4.2,	 12.9	 Hz,	 4H).	 13C	 NMR	 (150	 MHz,	
DMSO-d6):	 δ	 (ppm)	 =	 167.1,	 146.5,	 145.9,	 143.9,	 140.7,	 137.1,	 136.5,	 134.4,	
128.4,	 128.2,	 127.4	 (2C),	 127.2,	 126.9	 (2C),	 126.0	 (2C),	 125.9	 (2C),	 125.2,	 121.1,	
119.2,	117.9,	55.0,	46.1	(2C),	41.7,	40.0,	33.4	(2C).	
5-(4-(5-Chlorothiophen-2-yl)-1H-1,2,3-triazol-1-yl)-4'-(piperidin-4-yl)-[1,1'	
biphenyl]-3-	carboxylic	acid	(116).	To	a	solution	of	95	(8.3	mg,	14	µmol)	in	2	mL	of	
MeOH:	H2O	(1:1),	KOH	(7.9	mg,	140	µmol)	was	added,	and	the	resulting	mixture	
was	heated	at	60	°C	for	6	h.	After	removing	the	solvents	under	reduced	pressure,	
the	 mixture	 was	 purified	 by	 preparative	 HPLC	 (Method	 B,	 Rt	 =	 28.6	 min).	 The	
product	was	obtained	as	 a	white	 solid	by	lyophilization	(0.5	eq	CH3CO2H-salt,	2.8	
mg,	38%).	MS	(ESI,	m/z)	465	[M+H]	+;	ESI-HRMS	calcd.	for	C24H22N4O2SCl	465.1152,	
found	 465.1151	 [M+H]+.	 HPLC	 purity	 98	 %	 (Rt	 =	 10.6	min).	 1H	 NMR	 (400	MHz,	
DMSO-d6):	δ	(ppm)	=	9.34	(s,	1H),	8.25	(d,	J	=	2.4	Hz,	1H),	8.19	(s,	1H),	8.02	(d,	J	=	
2.4	Hz,	1H),	7.65	 (d,	 J	=	8.1	Hz,	2H),	7.36	–	7.29	 (m,	3H),	7.13	 (d,	 J	=3.8	Hz,	1H),	
3.12	(d,	J	=	12.0	Hz,	2H),	2.76	–	2.63	(m,	3H),	1.83	–	1.61	(m,	5H).	
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Conclusions	and	Perspectives		
	
	
Chemical	probes	-i.e.	small	molecules	that	specifically	bind	and	modulate	the	activity	
of	 a	 cellular	 target-	 are	 powerful	 tools	 that	 allow	 the	 precise	 molecular-level	
interrogation	 of	 biological	 targets	 and	 their	 associated	 pathways.1	 Furthermore,	
chemical	probes	provide	small	molecule	tools	for	validating	clinical	target	candidates	
and,	 at	 the	 same	 time,	 offering	 chemical	 starting	 points	 that	 can	 be	 further	
optimized	by	medicinal	chemistry	for	drug	development.2	
Chemical	 biology	 efforts	 over	 the	 past	 decade	 have	 targeted	 numerous	 protein	
classes	 and	 biological	 pathways.1	 However,	 there	 is	 still	 a	 compelling	 need	 to	
develop	valuable	strategies	to	discovery	high-quality	chemical	probes.	
In	 this	 thesis,	 we	 advocated	 two	 chemical	 biology	 approaches	 in	 two	 distinct	
endeavors.	 The	 first	 part	 of	 this	 thesis	 dealt	 with	 the	 development	 of	 chemical	
probes	 for	modulating	 neural	 stem	 cells	 (NSCs)	 biology	 and	 its	 neuroregenerative	
potential	 for	 the	 treatment	of	neurodegenerative	diseases.	 In	 the	second	part,	 the	
recently	 discovered	 P2Y14	 receptor	 was	 deeply	 investigated	 by	 designing	 new	
chemical	 probes,	 useful	 in	 dissecting	 the	 structure	 and	 function	 of	 this	 receptor,	
which	 has	 been	 found	 to	 be	 involved	 in	 inflammatory,	 endocrine	 and	 other	
pathological	conditions.	
As	 highlighted	 in	 part	 I	 of	 this	 thesis,	 the	 initial	 isolation	of	NSCs	 has	 led	 to	 large,	
systematic	 efforts	 to	 identify	 and	 manipulate	 molecular	 mechanisms	 of	 NSCs	
proliferation,	cell	fate	determination,	and	differentiation.	While	many	of	the	genetic	
and	biochemical	pathways	underlying	these	processes	are	beginning	to	be	disclosed,	
currently	 there	are	no	validated	 targets	 to	 finely	control	NSCs	 fate.	Moreover,	 few	
small	molecule	probes	for	specifically	studying	and	controlling	these	mechanisms	are	
available.	 Potentially,	 NSC-based	 chemical	 assays,	 which	 can	 be	 used	 to	 identify	
compounds	 that	 produce	 a	 phenotype	 of	 interest,	 provide	 suitable	 strategy	 for	
identifying	such	small	molecules.	Accordingly,	in	part	I,	we	fostered	two	parallel	and	
complementary	approaches	to	identify	small	molecule	probes	for	NSCs.	Particularly,	
we	were	drawn	to	knowledge-based	phenotypic	(i)	and	functionalized	congeners	(ii)	
strategies.	 The	 first	 approach	 (i)	 is	 based	 on	 a	 priori	 knowledge	 that	 some	 known	
drugs	 and	 drug	 candidates	 (i.e.	 tricyclic	 antidepressants,	 TCAs	 and	 P7C3)	 have	
already	been	shown	to	display	neuroregenerative	effects.	Thus,	a	focused	chemical	
library	 (1-36)	 inspired	 by	 TCAs	 and	 P7C3	 has	 been	 designed	 and	 synthesized.	 This	
focused	 library	 has	 been	 then	 preliminarily	 evaluated	 for	 its	 safety	 profiles	 in	
neuronal	and	hepatic	cell	models	(CGNs	and	HepG2	cells,	respectively).	Notably,	all	
the	 compounds	 resulted	 particularly	 promising	 from	 this	 primary	 screening,	
displaying	low	toxicity	only	at	high	concentrations	(25-50	µM).	This	is	not	surprising,	
because	 our	 library	 design	 relies	 on	 approved	 drugs	 (TCAs).	 With	 the	 aim	 to	 use	
these	cell	 cultures	as	a	preliminary	 screening	 to	 filter	out	compounds	with	 toxicity	
liabilities,	we	identified	16,	19-21,	29	and	33	with	optimal	safety	profiles,	which	were	
selected	for	further	studies.	These	involved	the	assessment	of	their	neuroprotective	
effects	 in	 a	 low-serum	 neuronal	 model	 of	 cell	 death	 and	 the	 evaluation	 of	 their	
potential	neurogenic	effects	in	a	proliferation	BrdU-based	assay	in	primary	neurons.	
While	 these	 experiments	 are	 still	 ongoing,	 in	 parallel,	 we	 started	 to	 set	 up	 the	
phenotypic	NSCs-based	assay	 that	will	be	used	 to	 test	 the	differentiation	ability	of	
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such	 compounds	 toward	 specific	 lineages	 (i.e.	 neurons,	 astrocytes	 and	
oligodendrocytes).	 Preliminary	 data	 regarding	 selected	 reference	 compounds	 have	
been	generated.	
At	the	same	time,	the	exploitation	of	functionalized	congener	approach	to	TCAs	has	
allowed	 the	 development	 of:	 (a)	 fluorescent,	 (b)	 multi-target,	 and	 (c)	 polyamine-
based	congeners.	Among	them,	the	small	set	of	novel	fluorescent	probes	inspired	to	
TCAs	imipramine	and	desimipramine	(48-51)	may	be	used	to	potentially	identify	the	
subcellular	 localization	of	 these	known	neuroregenerative	drugs	 in	NSC.	The	multi-
target	(53-58)	and	polyamine	(65)	congeners	may	interfere	with	two	or	more	targets	
of	the	complex	NSCs	signaling	network,	thereby	in	principle	providing	a	novel	set	of	
chemical	 probes.	 In	 particular,	 polyamine	 congener	 65	 could	 also	 exploit	 the	
polyamine	 transporter	 for	 a	 facilitated	 entry	 to	 the	 CNS	 and	 accumulation	 in	 the	
mitochondria.		
Collectively,	 these	 results	 represent	 the	 starting	 point	 of	 a	 phenotypic	 approach	
aimed	 at	 identifying	 small	molecule	 probes	 that	 can	 contribute	 to	 elucidate	 NSCs	
biology.	 Further,	 they	 may	 inspire	 the	 design	 of	 neuroregenerative	 drugs	 against	
neurodegenerative	diseases.	
In	part	II	of	this	thesis,	the	functionalized	congener	approach	was	applied	to	develop	
fluorescent	probes	and	antagonists	to	characterize	the	P2Y14	receptor.	This	receptor	
has	been	found	to	be	involved	in	a	variety	of	inflammatory	and	endocrine	processes,	
emerging	as	an	attractive	drug	target.3	Despite	that,	to	date,	the	P2Y14	receptor	has	
not	been	widely	explored	from	a	medicinal	chemistry	perspective.	Additionally,	few	
selective	 radioligands	 are	 available,4	 thus	 improved	 and	 more	 versatile	 chemical	
probes	are	needed.	
Over	 the	 past	 decades,	 fluorescent	 probes	 that	 target	 GPCR	 have	 provided	
significant	 advances	 in	 exploring	 their	 functions	 and	 structures.5	 Although	 many	
GPCR	 crystal	 structures	 have	 been	 resolved	 during	 the	 last	 decade,6	 information	
acquired	 at	 molecular	 level	 by	 fluorescent	 probes	 still	 offered	 an	 undeniable	
potential.	Not	only	 they	allow	to	study	 receptor−ligand	 interactions,	but	also,	 such	
fluorescent	probes	enable	to	monitor	and	visualize	the	dynamic	processes	of	GPCR	
at	cellular	 level	(e.g.	oligomerization	and	internalization).	Further,	these	probes	are	
also	 successfully	 used	 in	 high-throughput	 screening,	 searching	 for	 novel	 GPCR	
agonists	or	antagonists.5	
In	light	of	this	considerations,	based	on	the	structural	template	of	P2Y14	receptor,	Dr.	
Jacobson	 and	 coworkers,	 starting	 from	 the	 previously	 characterized	 antagonist	 25	
(PPTN),	 developed	 the	 first	 high-affinity	 antagonist-based	 fluorescent	 congener	27	
(MRS4174).7	 MRS4174	 displayed	 highly	 favorable	 properties	 when	 employed	 as	 a	
tracer	 in	 whole-cell	 binding	 assays	 of	 P2Y14	 receptor	 using	 flow	 cytometry:	
pharmacological	 selectivity	 over	 the	 other	 member	 of	 P2Y	 receptors	 family,	 an	
exceptional	 high	 receptor	 affinity	 (Ki	 of	 80	 pM),	 and	 strikingly	 low	 nonspecific	
binding.7	However,	its	chemical	synthesis	suffered	from	a	low	yield,	limiting	its	use	as	
tracer	in	displacement	assay.	Thus,	an	improved	synthetic	route	was	developed	and	
this	 enables	 quantification	 of	 antagonist	 affinity	 using	 a	 novel	 flow	 cytometry	
displacement	assay	of	P2Y14	receptor-expressing	CHO	cells.		
In	addition,	we	reported	on	the	design,	preparation,	and	biological	evaluation	of	the	
agonist-based	 fluorescent	 probe	 44	 (MRS4183).8	 Again,	 by	 exploiting	 the	 P2Y14	
receptor	homology	model,	the	first	P2Y14	agonist-based	fluorescent	probe	has	been	
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designed,	based	on	 the	previously	 characterized	P2Y14	agonist	UDP-glucuronic	acid	
(22).	The	conjugation	with	the	BODIPY	fluorophore	affords	44,	which	retained	P2Y14R	
potency	 with	 an	 EC50	 value	 of	 0.96	 nM.	 It	 also	 effectively	 served	 as	 a	 tracer	 for	
microscopy	and	flow	cytometry,	displaying	minimal	nonspecific	binding.8	
Furthermore,	these	promising	results	have	already	led	to	the	development	of	a	new	
series	 of	 P2Y14R	 antagonists	 based	 on	 3-(4-aryl-1H-1,2,3-triazol-1-yl)-biphenyl)	
scaffold.7a,	 9	 Particularly,	 all	 the	 triazole	 derivatives	 106-146	 were	 evaluated	 in	 a	
novel	flow	cytometry	competition	assay	using	whole	cells	expressing	P2Y14	receptor	
and	 fluorescent	 antagonist	 27	 as	 a	 tracer.	 This	 led	 to	 the	 identification	 of	 the	 hit	
compound	107	(MRS4217),	which	displays	an	IC50	of	32	nM.	
Collectively,	 all	 this	 results	 allowed	 expanding	 the	 SAR	 at	 this	 receptor,	which	 still	
lacks	chemical	diversity	in	its	ligands.	Moreover,	the	synthesized	probes	could	aid	in	
unveiling	the	pharmacological	potential	of	this	receptor,	and	could	 inspire	clinically	
useful	 drug	 candidates	 for	 inflammatory,	 endocrine	 and	 other	 pathological	
conditions.	
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Appendix:	Representative	spectra	
	
	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
Representative 1H-NMR and high-resolution mass spectra of compound 106 
 
				
			 	
Representative 1H-NMR and high-resolution mass spectra of compound 107 
 
 
 
 
 
 
  
Representative 1H-NMR and high-resolution mass spectra of compound 116 
 
 
 
 
 
 
 
 
  
Representative	HPLC	trace	of	compound	44	(MRS4183):	
	
	
	
Representative	MS	spectrum	and	High-resolution	mass	spectrum	of	compound	44	
(MRS4183)	
	
	
	
	
	
Figure	S1.	Fluorescent	excitation	spectrum	of	44,	MRS4183,	indicated	a	lmax	value	at	
590	 nm	 (extinction	 coefficient	 for	 Bodipy-TR	 =	 64,000	 cm-1M-1,	 from	
www.lifetechnologies.com),	as	measured	in	solution	(6.25	µM	in	water)	in	a	cuvette	
(path	length	=	1	cm)	using	a	SpectraMax	M5	reader	(Molecular	Devices,	Sunnyvale,	
CA).	Emission	Wavelength	for	11	was	determined	to	be	616±4	nm.		
	
